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Introduction
Hungary is carrying a heavy burden of cervical cancer.
Regarding mortality, it may be found in the list of mortali-
ties in the last quarter among the European countries (Fig-
ure 1). Cervical screening, as a public health policy, has
proved its effectiveness in terms of reduction of morbidity,
and mortality from the target disease in the target popula-
tion (Figure 2) [1], and a wide application of morphology-
based cervical cytology (Pap smear) as screening tool is
strongly recommended by international bodies [2, 3]. Hun-
gary (a Central-Eastern European country, population ten
million, one of the “countries in transition” which joined
the European Union in 2004), cervical screening had un-
dergone several developmental stages [4]. 
History of cervical screening on Hungary
In Hungary, the history of opportunistic cervical screen-
ing dates back to the late 1950s. At the beginning, the
screening tool was colposcopy alone, sporadically applied
by gynaecologists engaged in practicing oncological gy-
naecology. In 1954, a ministerial decree was issued, de-
claring that “mass screening must be conducted in such a
way that each woman over 30 years of age be screened by
colposcopy” (MOH 8834/31/1954). There are no data on
its effect.
In the meantime, exfoliative cytology has been extensively
investigated, as a method of early detection of potentially
pre-cancerous lesions (cervical intraepithelial neoplasia
[CIN I-III.]), and early cancer of the uterine cervix, with
particular attention to those located in the transformation
zone and endocervical canal. Since mid 1960s more and
more cytology laboratories – based on pathology depart-
ments – had been set up in Hungary. In 1972, a “School of
Cytotechnologists” to provide regular training for “pre-
screeners” was established, and the system of “pre-screen-
ing” introduced. By the end of 1970s, the sufficient capacity
to meet the demands of three-yearly cytology screening of
entire eligible population was in place [5].
By the end of 1970s, more and more gynaecologists be-
came experienced in the practice of colposcopy. In 1976, a
joint deliberation by the Board of Gynaecology and Board
of Oncology was issued saying that “every gynaecological
examination should be performed as screening”, and, “no
cervical screening without cytology” [6]. Colposcopy com-
pleted by cytology had become the screening protocol: the
smear-taking by gynaecologists as well as colposcopy had
been carried out as part of a complete gynaecological ex-
amination. In fact, the gynaecologists have monopolised
the cervical screening, and “gynaecological cancer screen-
ing instead of “cervical screening” had been the widely
recognised practice in the country. 
During the 1980s, a country-wide opportunistic “cervical
screening programme” had taken place. The annual number
of smears analysed exceeded one million, the clinical stage
of the detected cervical cancers had favourably shifted,
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“Gynaecological cancer screening” or “cervical screening?” 
The case of Hungary
L. Döbrőssy1, R. Koiss2
1 Ofﬁce of Chief Medical Ofﬁcer, Budapest; 2 St. Stephen’s Hospital, Obstetrics and Gynecology, Oncology Department, Budapest (Hungary)
Summary
In Hungary, “gynaecological cancer screening” by gynaecologists having interest in oncology has had a long history. The screening
tool was colposcopy alone embedded in complete gynaecological examination. Later on smear-taking for cytology has been added.
This screening protocol has survived until now both in the gynaecological community and public. In the meantime, as it proved its ef-
fectiveness, cytological examination has been internationally recommended,\ as sole method of organized cervical screening; in case
of non-negative test result, gynaecological examination including colposcopy is justified. Smear-taking can be undertaken by trained
paramedical personnel. The authors have made an attempt to argue the use of “cervical screening” instead of “gynaecological cancer
screening”, which is deeply entrenched into both professional and public consciousness in Hungary. 
Key words: Cervical screening; Colposcopy; Cytology; Health visitors.
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however the mortality rates had not decreased, but did level
off at a rather high level (8-10/10
5 
population). It has been
admitted that the “cervical screening programme” had
failed [7]. The reason for failure was obviously the lack of
individual identification of women to be screened: only the
number of smears analysed was registered, and not the
women screened. As a result, certain self-selected women
(approximately 30% of the eligible ones) had been screened
with unnecessary frequency, while the majority of the
women had never been screened. 
In the mid 1990s, as part of “secondary prevention of
cancer” sub-component of the “Close the gap” programme”
Figure 1. — Cervical
cancer: incidence and
mortality in the European
Countries.
Figure 2. — Mortality
from cervical cancer in the
Nordic Countries, as func-
tion of intensity of screen-
ing strategy. Source:
Nygård M.: “Screening
for cervical cancer: when
theory meets reality”.
BMC Cancer. 2011, 11,
240.
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co-sponsored by the World Bank, a “model” cervical
screening programme was implemented on a limited scale,
with the aim of introducing elements of “organized screen-
ing”, as recommended by WHO/IARC and UICC [8], and
to adopt the recommendation to the local needs and oppor-
tunities [9]. The pilot programme has created a favourable
policy-environment for integration of organized cervical
screening as a core function of the healthcare system.
In 2003, as a component of the National Public Health
Programme launched by the Government, a country-wide
National Cervical Screening Programme has been estab-
lished, with the National Chief Medical Officer’s Office in
charge. All requirements of “supply side” of organised
screening have been met [10]. The programme was a na-
tion-wide, provider-initiated, invitation-based organised
screening, supported by a National Screening Registry. Its
objective was to three-yearly screen the asymptomatic
women of 25-64 years of age by cytological analysis of cer-
vical smears, and to refer those with abnormal (non-nega-
tive) cytology to gynaecological services to further
diagnostic procedure including colposcopy and appropri-
ate treatment. Notwithstanding, the gynaecological com-
munity has continued the traditional practice and they
remained in the driver’s seat of cervical screening. Fur-
thermore, they insisted on a bimanual pelvic examination
complemented with colposcopy, in addition to smear-tak-
ing. All the women eligible for screening received invita-
tion letter, however, the majority of women – without
waiting for invitation, or even having received it – have re-
ported themselves for “gynaecological screening” by their
“own” (private) gynaecologists, and, these screening ex-
aminations had not been registered by the National Screen-
ing Registry. As a result, the coverage of screening (i.e.
proportion of women who rejected the invitation and turn
up for screening outside the organised programme) has
been rather high (approximately 60%), but compliance
rates (proportion of those women who accepted the invita-
tion, screened inside the programme, and registered by the
screening registry have remained unacceptably low (8-
10%), and a significant proportion of the female popula-
tion has never been screened. 
The analysis of the reasons for non-attendance at the of-
fered screening showed that one of the main difficulties to
overcome is the limited access to the smear-taking gynae-
cological service, particularly in rural areas where gynae-
cological services are not available locally. According to
the reimbursement data provided by the National Health
Insurances Fund, much more smears were taken and
analysed outside as compared to inside the programme. 
The question presented itself as to whether what is called
“population cervical screening” was really a health policy
and service-based screening programme, or a widespread
clinical exercise? In the view of gynaecological commu-
nity (and to certain extent in the conscience of the public at
large, too) it seemed to be the latter one. There was an ur-
gent need to reconsider and reorganise the screening prac-
tices going by the “state-of-the-art” screening strategy in
Hungary, to erase the term of “gynaecological screening”
form the consciousness of the women at large.
Efforts to reorganise the screening practices: the role of
“health visitors” 
2008 was a turning point. The Hungarian National Audit
Office carried out an investigation “about the utilisation of
the financial resources expended for screening pro-
grammes”, and as a result they made proposals to the health
government to reorganise the cervical screening pro-
grammes in line with the international recommendations,
practically to apply cytology as sole screening test, to bring
closer the provision of organised cervical screening to pri-
mary care practices; furthermore, the smears be taken by
primary care personnel and non-negative cases be referred
to gynaecological services for further clarification [10].
Following these recommendations, the health government
(Ministry of Human Resources) decided to improve access
to screening facilities by intensifying the involvement of
primary care personnel, particularly the “health visitors” in
the screening process. 
Education and training of the health visitors
The “health visitors” are the public health nurses, who
are ubiquitous, and qualified to provide preventive services
to the female population in the country. They are profes-
sionals receiving higher education, i.e. a four-year course
following the secondary high school graduation. Their ac-
tivities have been organized at the primary care level, work-
ing in close cooperation with local primary care physicians.
They have personal contact with virtually all invited
women, and they seem suitable for taking the cervical
smear, and have easy access to those who have difficulties
in seeking gynaecological services [11].
Their new task as smear-takers would have remarkable
implication for education and training [12]. First of all,
proper communication skill is required when counselling,
and providing pre-screening information, while answering
questions of the women to be screened. Then, they must
have some basic knowledge in epidemiology, anatomy,
physiology, and pathology of cervical cancer and precur-
sors. They have to be familiar with the theory and strategies
of cervical screening, classification of smears, psycholog-
ical side-effects, and ways to prevent them. They must
know the referral routes to the gynaecological services. In
addition, they must have skills in asking the women about
their general health, provide information, and gain in-
formed consent. Most importantly, they have to be skilful in
taking smears from the uterine cervix and the endocervical
canal, transfer of cellular material onto the glass slide, fix-
ation and label of the sample, and its transportation to cy-
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tological laboratory. Having all these in mind, a curriculum
had been designed, approved, and accredited by the rele-
vant authority. It consisted of three elements. The first
phase includes a 40-hour theoretical course, presenting all
the knowledge as set out above; second, a two-day session
on communication with the women to be screened; and
third, under supervision of a gynaecologist, a period of
training in smear-taking, until they achieved the necessary
skill. One is pronounced skillful enough if 30 good quality
smears are obtained, as judged by a competent cytopathol-
ogist. After having completed the course, the candidates
take a final examination, and receive “certificate of com-
petency” that authorises them to carry out cervical screen-
ing in their localities according to the screening protocol.
Pilot programmes of involving the “health visitors” are
promising. In the near future, the knowledge and skill re-
quired by cervical screening would be included in the cur-
riculum of graduate education and training of the would-be
health visitors, and their screening activities extended na-
tion-wide. 
Discussion
By definition, screening aims to early detect cancer and
its precursors by means of regular examination of predom-
inantly asymptomatic individuals of appropriate age with-
out any complains, using evidence-based screening tests.
[13]. It has the potential to significantly reduce the burden
of target disease in the population, and to detect malignant
tumours, as well as precursor lesions earlier than it would
be the case without screening, and to refer them for appro-
priate diagnostic procedure and treatment. 
According to the valid “state-of-the-art recommenda-
tions”, cervical screening means “microscopic analysis of
the sample obtained by after visualising the cervix, taken
from the ectocervix, transformation zone, and endocervix”
[3]. Cervical screening reduces the incidence of cervical
cancer and its precursor lesions, and mortality from cervi-
cal cancer, and improves quality of life. The degree of re-
duction of lesions in question seems to be proportional to
the intensity of screening strategy, i.e. the age range, fre-
quency, and interval between consecutive screening
episodes (Figure 2) [1]. Cytological screening every three
to five years can potentially prevent up to four out of five
cases of cervical cancer, and can reduce cervical cancer in-
cidence up to 80% at population level [14]. Such benefits
can only be achieved if screening is provided in organized,
population-based programmes with quality assurance at all
levels [15]. Establishment of screening registries, and link-
age of individual screening data with cancer registry data,
taking into account appropriate data protection standards
and methods, are essential tools of monitoring and evalua-
tion.
In Hungary, gynaecologists traditionally have a key role to
play in cervical screening process by taking cervical smears
themselves, in addition to assessment by colposcopy and bi-
manual pelvic examination. In the current “gynaecological
screening protocol” physical examination of breasts has been
added, that is obviously not suitable for detecting “small”
lumps in the breasts which is the ultimate aim of breast
screening [16], however, it has been admitted by highly com-
petent gynaecologists that the aim of a “gynaecological can-
cer screening” is nothing but “cervical screening” [17]. 
In the beginning, the screening test applied was col-
poscopy alone. Since Hinselmann first described the basic
colposcopic equipment and its use establishing the foun-
dation for the practice of colposcopy [18], this optical
method was becoming widespread throughout the coun-
tries, particularly those under German influence, such as
Hungary, and since the 1960s it has been widely used over-
sees, too. Colposcopy is a diagnostic procedure to examine
an illuminated, magnified view of the cervix. Many pre-
malignant and malignant lesions in this area have dis-
cernible characteristics which can be detected through the
examination, allowing the colposcopist to visually distin-
guish normal from abnormal appearing tissue and take di-
rected biopsies for further pathological examination
[19-21]. However, when colposcopy is evaluated for pri-
mary screening, it has been accompanied by simultaneous
cytology. The rationale beyond this combined testing ap-
proach is that it decreases false negative and false positive
rates associated to cytology alone, and also reduces the
need for call-back for repeat cytology, being used as a guide
for collection of the cytology specimen [14]. 
The unbiased assessment of the accuracy of colposcopy
requires the independent verification with a gold standard,
which usually relies on histology. Without histological con-
firmation, colposcopically negative cases are very often
considered as truly negative, and in case of endocervical
location of the squamo-columnar junction, or glandular cer-
vical lesions, colposcopy may be really false negative. The
sensitivity of colposcopy directed biopsy for CIN2+ in
women with satisfactory colposcopy was 57-81% [22, 23]. 
Constraints limiting the application of colposcopy to pri-
mary screening include its high costs relative to cytology,
the availability and accessibility of trained colposcopist hav-
ing long enough experience to acquire expertise in recogni-
tion of specific patterns in the epithelium of surface of
cervix, and – last but not least – the lower ability to detect
endocervical lesions. The expert colposcopist may be able to
predict the histological diagnosis quite accurately, but in
general, the coloscopic-histological correlation is only mod-
erate [24]. 
Colposcopy continues to be used routinely as standard
gynaecological diagnostic throughout Europe provided the
availability of the instruments and trained colposcopists.
The most common reason for referral of women for col-
poscopy is abnormal cervical cytology discovered as a re-
sult of cytological screening. It is important that all women
with high-grade abnormalities (CINII-III) be referred im-
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mediately for diagnostic colposcopy. Colposcopy is widely
used as a clinical diagnostic procedure, but definitely not
recommended as a primary screening tool, particularly not
as method for population-oriented mass screening.
The other element of “gynaecological screening” is the
bimanual pelvic examination, i.e. palpation to assess the
position, size, mobility, lumpiness, tenderness of uterus, as
well as the annexes. However, the palpation is obviously
not sensitive enough to recognise any lesions of endome-
trial layer of uterine corpus and the ovaries. This procedure
might be clinically justified, but does not bring closer at all
to the aims of cervical screening, and does not fit in the
public health agenda [25]. 
The current “gynaecological cancer screening” protocol
prescribes a complicated multistep diagnostic procedure
performed by medical specialist [16]. Conversely, a screen-
ing test as a public health procedure, by definition, should
be simple, i.e. easy to perform and interpret acceptable, ac-
curate, reliable, sensitive, and specific [13]. It follows that
to link a mass screening examination as a public health
measure to clinical diagnostic setting, and to a complex
clinical examination, is an obvious fallacy and nonsense.
Gynaecologists have an important, nothing to replace
with, role in “second step” of screening: to clarify a case
with abnormal cytology, women need to be referred to a
gynaecologist who can exclude or confirm the suspicion of
malignancy suggested by the cytological examination, in
other words, he/she establishes the diagnosis. However,
“screening” which takes place opportunistically in the gy-
naecological practice, on the initiative of the individual
woman or her doctor, by colposcopy and pelvic examina-
tion in clinical settings, should be discouraged. (Of course,
this recommendation does not contradict the necessity of
the periodical gynaecological check-up which can be rea-
sonably advised to and expected from each health-con-
scious woman). Bimanual pelvic examination must not be
undertaken as a routine part of sample-taking in asympto-
matic women. Such “screening practice” results in high
coverage in self-selected individuals who are screened too
frequently; at the same time in a low coverage of other pop-
ulation groups. Its effectiveness is limited and cost-effec-
tiveness is poor. 
The task of smear-taking for cytology and referring those
with abnormal cytology to gynaecological services fits very
well in the traditional preventive role of “health visitors”.
They can personally contact each woman who has been in-
vited by the National Screening Registry, and encourage
them to accept the offered screening. They can pay particu-
lar attention to those who have never attended a screening
test, and to the less educated ones of lower socioeconomic
status. They can easily provide pre-screening information on
both the benefits and potential harms of screening, while as-
sisting them to gain informed decision to participate. They
can arrange mutually suitable appointment. Most impor-
tantly, they can take the cervical smears for cytology, and
send it to cytology laboratories. After acquiring the test re-
sults, they can reassure the woman if the test is negative, and,
in case of non-negative result, they can explain what “ab-
normality” means, and must refer the woman to gynaeco-
logical services for further examination (including
colposcopy). Last but not least, they can offer psychological
support to those who receive “bad news”.
Ultimately, one can conclude that for the time being, cy-
tology has remained the standard method of population
screening for cervical cancer in Hungary. However, not
only the strengths but also the limitations of cytology for
cervical cancer screening must be recognised. 
As far as the value of conventional cytology is con-
cerned, there is room for criticism. Cytology is a subjec-
tive test, and in programmes without quality assurance, it is
impossible to achieve and maintain its proper performance.
Cytology is labour intensive; a great number of trained pre-
screener cytotechnologists and cytopathologists are re-
quired to be employed to meet the needs of a country-wide
mass screening. Despite the low cost of consumables, high-
quality cytology is expensive in absolute terms and may
not be the most cost-effective option for screening [26].
Furthermore, as opposed to conventional cytology, liquid-
based cytology has logistical and operational advantages
(interpretation at higher speed, lower rate of unsatisfactory
smears, and possibility of ancillary molecular testing using
remnant fluid), but is more expensive, and neither more
sensitive nor more specific than conventional cytology with
respect to detection of histologically confirmed high-grade
CIN [27]. 
Finally, the needs of populations vaccinated against HPV-
16/18 have to be taken in consideration. In this case, we
should anticipate that the positive predictive value (PPV) of
cervical screening will be reduced because there will be
fewer high-grade lesions among women with cytological
abnormalities. It is therefore rational to develop multiple
modalities for cervical cancer prevention, including meth-
ods that achieve similar or better screening performance
than cytology alone, but also meet the demands of under-
served populations, such as low cost, the need for fewer
visits (i.e. cytology, diagnostic colposcopy, and treatment)
in each screening cycle, and fewer interventions in a life-
time due to a grater negative reassurance of a single screen-
ing intervention [28].
Conclusion 
The current state of conventional, morphology-based cer-
vical screening as a public health measure calls for a “shift
of paradigm of screening” for the sake of the female popu-
lation. The insistence by the gynaecological community on
their “historical role” seems to be a major obstacle. The
“bad habits die hard”. The notion of “gynaecological can-
cer screening” needs to be dismissed forever (because of
negative psychological connotation of mentioning “can-
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cer”), and instead become “cervical screening” which
should come into general use. It is hoped that higher com-
pliance with the offered screening would be attained
through the involvement of the country-wide network of
health visitors into the organized screening, and the ulti-
mate aim of cervical screening programme: the improve-
ment of women’s health in the country be achieved in
Hungary. 
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Introduction
Recurrent ovarian carcinoma is generally incurable [1],
and, therefore, several treatments including chemotherapies,
selected surgery, and radiation are combined for each pa-
tient. However, the effects of these treatments on progres-
sion-free survival (PFS) have not been evaluated. Therefore,
the outcomes of each treatment for women with recurrent
or advanced epithelial ovarian carcinoma previously treated
with paclitaxel plus platinum-based chemotherapy were
evaluated.
Materials and Methods
All women with a histologically confirmed diagnosis of ep-
ithelial ovarian cancer who were referred to the present center
from January 2007 to December 2011 were included in a data-
base of treatment and outcome variables. The charts of patients
who progressed while receiving or after completion of at least
three cycles of paclitaxel plus platinum-based chemotherapy or
discontinued treatment early because of toxicity were reviewed
to update their follow-up. The follow-up period was ended in De-
cember 2012. All patients had measurable lesions that conformed
to the Response Evaluation Criteria in Solid Tumors (RECIST)
criteria, and tumor response evaluation was performed according
to the RECIST v1.0 guidelines [2].
Whether and how a patient should be treated in cases of relapse
were up to the investigator’s discretion, and the documented ther-
apies were independently assigned to the following groups. For
platinum-resistant patients whose recurrence was documented
within six months of platinum-based therapy, the regimen of
chemotherapy was a non-platinum regimen as second-line treat-
ment. The chemotherapeutic choices included pegylated liposo-
mal doxorubicin (PLD), irinotecan (CPT-11), gemcitabine, and
docetaxel. For platinum-sensitive patients whose recurrence was
documented for more than six months after the completion of plat-
inum-based therapy, platinum-based chemotherapy was used
again. Among carefully selected patients, secondary surgery with
complete cytoreduction (no visible residual disease) or irradiation
was also performed.
The disease-control rate (DCR) was defined as either tumor re-
sponse (CR/PR) or stable disease (SD). DCR was compared and
subjected to univariate analysis. PFS was determined from the
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Summary
Aim: The outcomes of treatment for women with recurrent or advanced epithelial ovarian carcinoma previously treated with pacli-
taxel plus platinum-based chemotherapy were analyzed. Materials and Methods: Retrospective analysis was performed in a total of 65
series of treatments provided for 35 patients with a history of paclitaxel plus platinum-based chemotherapy. The chemotherapy regimens
used were classified into the following four types for analysis: conventional paclitaxel plus carboplatin therapy (TC arm), pegylated li-
posomal doxorubicin-containing regimens (PLD arm), CPT-11-containing regimens (CPT-11 arm), and others. Disease-control rates
(DCRs) were compared and subjected to univariate analysis. Progression-free survival (PFS) was determined from the date of the first
cycle of each chemotherapy with the Kaplan-Meier method, and comparisons were performed using the log-rank test. Results: DCR was
80%, 71%, and 26% for the TC, PLD, and CPT-11 arms, respectively. The median PFS was 286, 372, and 76 days for the TC, PLD, and
CPT-11 arms, respectively. There was no discernible difference in PFS between the TC and the PLD arm. In contrast, PFS of the CPT-
11 arm was significantly shorter than that of the TC and PLD arms. In addition, three of seven (42.9%) treatments in the PLD arm
maintained a progression-free period for longer than one year, while only one of 25 (4%) treatments in the TC arm maintained a pro-
gression-free period for more than one year. Conclusions: The PFS of PLD is similar to that of TC. PLD-containing regimens might
have a potential benefit with a higher PFS over one year than the TC regimen.
Key words: CPT-11; Disease control rates; Ovarian carcinoma; Pegylated liposomal doxorubicin; Progression-free survival.
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of chemotherapy for recurrent or advanced epithelial
ovarian carcinoma in patients previously treated
with paclitaxel plus platinum-based chemotherapy
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date of the first cycle of each chemotherapy to first disease pro-
gression and, thereafter, from one progression to the subsequent
one or the last contact date that the patient was still known to be
progression-free. The Kaplan-Meier method and the log-rank test
were used to analyze PFS, and a Bonferroni correction was then
used for comparisons of multiple groups. Differences were con-
sidered significant if the p-value was < 0.05. Statistical analysis
was performed using MedCalc version 12.7.5.
Results
Eighty-nine patients with histologically confirmed ep-
ithelial ovarian cancer were referred to the present center
from January 2007 to December 2011. In 35 patients, at
least one relapse was reported after first-line therapy (Fig-
ure 1). Three patients refused further treatment, and one
patient was lost to follow-up. Information on subsequent
therapies after the first recurrence was evaluable in 31 pa-
tients. The patients’ characteristics are shown in Table 1. A
total of 67 treatments was documented. These treatments
comprised of different modalities such as chemotherapy
(n=60, 89.6%), surgery (n=2, 3.0%), and radiotherapy
(n=5, 7.5%). The most commonly used chemotherapeutic
regimen was a combination of paclitaxel plus platinum-
based chemotherapy (n=25, 41.7%; TC arm), followed by
CPT-11 containing regimens (n=19, 31.7%: monotherapy
with CPT-11 n=2, combination of CPT-11 and docetaxel
n=16, combination of CPT-11 and platinum n=1; CPT-11
arm), and PLD-containing regimens (n=7, 11.7%:
monotherapy with PLD n=5, combination of PLD and car-
boplatin n=2; PLD arm). Two patients with platinum-re-
sistant recurrent ovarian cancer underwent secondary
cytoreductive surgery. In one case, splenectomy was per-
formed for isolated splenic metastasis. The patient had a
179-day remission before the next recurrence of her dis-
ease. In the other case, for a local recurrence in the right
retroperitoneal space and brain metastasis in the cerebel-
Figure 1. — Study design. TC
arm, carboplatin and paclitaxel;
PLD arm, pegylated liposomal
doxorubicin-containing regi-
mens; CPT-11 arm, CPT-11-
containing regimens.
Table 1. — Patients’ clinical characteristics (n=35).
Characteristic No. (%)
Mean age Years 60.9
Range (41-83)
Stage I 5 (14)
II 1 (3)
III 22 (63)
IV 7 (20)
Tumor histology/cytology Serous 24 (69)
Mucinous 3 (9)
Endometrioid 0 (0)
Clear cell 6 (17)
Others 2 (6)
Table 2. — Treatment response, duration of exposure, and
discontinuation of treatment.
TC CPT-11 PLD Others
(n=25) (n=19) (n=7) (n=9)
DCR 80% 26% 71% 33%
Median PFS (days) 286 71 372 78
PFS > 1 year 4%* 0% 42.9%* 0%
Duration of 117 62 167 74 
exposure (days) (3-175) (5-210) (42-372) (19-127)
Discontinuation due 2 2 
to AE (8%) (10.5%)
0 0
TC: carboplatin and paclitaxel;
PLD: pegylated liposomal doxorubicin-containing regimens;
CPT-11: CPT-11-containing regimens;
DCR: disease-control rate; PFS: progression-free survival; AE: adverse event.
*p < 0.05.
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lum, excision of tumor from the pelvic peritoneum and of
the brain metastasis was performed. She survived with no
evidence of recurrent disease (CR) for about 32 months.
These two cases of cytoreductive surgery were excluded
from the analysis due to their small number. Five cases of
irradiation due to palliative administration for recurrent
ovarian cancer were also excluded.
DCR was 80% for the TC arm (CR n=7, PR n=9, SD
n=4), 71% for the PLD arm (CR n=1, PR n=1, SD n=3),
26% for the CPT-11 arm (PR n=2, SD n=3), and 30% for
others (PR n=1, SD n=2) (Table 2). The median PFS of
each chemotherapeutic regimen is shown in Figure 2. The
median PFS was 286 days for the TC arm, 372 days for
the PLD arm, 71 days for the CPT-11 arm, and 78 days
for others. A Kaplan-Meier analysis of patients in the PLD
arm and the TC arm showed no significant difference in
PFS (p = 0.28). On the other hand, PFS was longer in pa-
tients in the TC arm than in the CPT-11 arm (p < 0.001).
PFS of patients in the PLD arm was also significantly
longer than that of patients in the CPT-11 arm (p = 0.002).
Exploratory analyses examining the impact on PFS of the
number of previous lines of chemotherapy, histologic
classification of tumor cells, and chemotherapeutic regi-
men were performed using Cox proportional hazards re-
gression. PFS was significantly shorter in the TC arm and
the PLD arm than in the CPT-11 arm in the multivariate
Cox regression model (data not shown). In addition, with
the limitation inherent from the small numbers, 42.9% (n=3
of 7) in the PLD arm significantly maintained a progres-
sion-free period for longer than one year, while only 4%
(n=1 of 25) in the TC arm maintained a progression-free
period for more than one year (p > 0.05) (Table 2). Treat-
ment discontinuation because of adverse events (AEs) oc-
curred with four treatments (28.6%), two of which occurred
in the TC arm and the two of which occurred in the CPT-
11 arm.
Discussion
Once diseases recur, patients with relapses six months
after completion of initial platinum-based therapy are con-
sidered platinum/taxane-sensitive. Chemotherapy with
platinum is a standard treatment, and patients were treated
with TC or carboplatin and PLD [3-5].
Patients with no response or responses lasting less than
six months are platinum/taxane-resistant and are best
treated with agents that lack cross-resistance to the TC reg-
imen. Most common chemotherapeutic choices for plat-
inum/taxane resistance included PLD, CPT-11, and
gemcitabine [6-10].
In this trial, PFS was similar between the PLD and TC
arms, and PFS was significantly longer for the TC arm/PLD
arm than for the CPT-11 regimen or other regimens. In the
CALYPSO Trial, PFS for PLD with carboplatin (CD) was
significantly superior to that of TC [6]. The PLD arm in
this study consisted of five monotherapy and two CD reg-
imens. In the present study, though most of the cases were
monotherapy, the PLD arm had prolonged PFS, as did the
Figure 2. — Kaplan-Meier esti-
mates of progression-free sur-
vival (PFS). HR: hazard ratio;
TC arm: carboplatin and pacli-
taxel; PLD arm: pegylated lipo-
somal doxorubicin-containing
regimens; CPT-11 arm: CPT-11-
containing regimens.
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TC arm. Thus, on the basis of a median PFS of 372 days,
PLD performed better than expected in terms of PFS.
Gorden et al. reported that a median PFS of PLD
monotherapy in patients with epithelial ovarian carcinoma
that recurred after or that did not respond to first-line plat-
inum-based chemotherapy was 19.1 weeks, and the overall
response rate for PLD was 19.7% [7]. In Japan, Katsumata
et al. reported that the median time to progression of PLD
monotherapy in Japanese patients with Müllerian carci-
noma previously treated with platinum-based chemother-
apy was 166 days [11].
With respect to PFS of longer than one year, PLD was
superior to TC. One of the reasons was that the duration of
treatment was longer in the PLD arm than in the TC arm
(167 vs. 117 days in the median duration of exposure to
chemotherapy, respectively) due to lower toxicity.
As for toxicity, in the HeCOG trial, the rate of discontin-
uation due to toxicity was significantly higher in the pacli-
taxel group (13.5% in CP vs. 3% in CLD, p = 0.020) [12].
In the CALYPSO trial, fewer patients discontinued treat-
ment early for toxicity with PLD than with TC regimens
(6% vs. 15%; p < 0.001) [6]. In the present study, PLD was
used for extended periods of time with very minimal toxi-
cities. Several RCTs failed to show an improvement of sur-
vival for patients with recurrent ovarian carcinoma who
received extended therapy [13]. However, some reports
suggested that continuous PLD treatment in patients who
achieved a response to PLD might delay time to disease
progression. Collins et al. reported that two patients were
maintained on PLD with stable disease for 18 and 34
months, respectively [14]. These cases demonstrated that
PLD can be used for extended periods of time without car-
diotoxicity.
Although a small number of cases was presented, the
present data support the clinical efficacy and tolerability of
PLD-containing regimens for the treatment of recurrent
ovarian cancer. PLD can be used for extended periods of
time with very minimal toxicities. These characteristics of
PLD allow extended chemotherapy and might delay time to
disease progression. PLD may be a promising agent in re-
current ovarian carcinoma.
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Introduction
Epithelial ovarian cancer (EOC) has the highest mortal-
ity rate of all gynecological cancers. There were an esti-
mated 21,880 new cases resulting in 13,850 deaths in 2010
[1].  EOC accounts for approximately 90% of all cases of
ovarian cancer and debulking surgery following six courses
of platinum-based chemotherapy is the standard first-line
treatment which results in complete clinical remission
(CCR) in up to 75% of cases [2]. Despite high response
rates, the recurrence and mortality rates are high [3, 4].
Proofs have shown that increasing cycles of chemotherapy
is of little survival benefit but increases the adverse side ef-
fects [5, 6]. In 2003, Southwest Oncology Group (SWOG)
reported a phase-III randomized trial of 12 versus three
months of maintenance paclitaxel in patients with advanced
ovarian cancer after complete response to platinum and pa-
clitaxel-based chemotherapy [7]. Data showed the median
progression-free survival (PFS) was 21 and 28 months in
the three-cycle and 12-cycle paclitaxel arms, respectively.
The p value was less than 0.005 in favor of the 12-cycle
arm. The trial discontinued because of the protocol-speci-
fied early termination boundary of p = 0.005. As of the date
of study closure, there was no difference in OS between the
treatment arms. However, this result was encouraging to
evoke a number of studies about maintenance therapy for
EOC with different drugs and agents. Maintenance or con-
solidation chemotherapy for advanced EOC refers to the
therapy given after the women have achieved CCR or
pathological complete remission (PCR) following debulk-
ing surgery and induction chemotherapy[7, 8].  Currently
the effectiveness of maintenance chemotherapy has been
assessed but there is insufficient evidence to prove any drug
is more beneficial than observation alone [9-12].  Mainte-
nance radiotherapy may improve the five-year PFS [13,
14], however, because of the intolerable side effects, it is
rarely recommended . 
Immunotherapy is one of the novel therapeutic strategies
for ovarian cancer. It aims to induce or enhance active im-
mune responses directed towards the tumour and to con-
solidate anti-tumour effects of standard therapy, delay, and
possibly prevent progression of disease. Within the last few
years, different immunotherapies based on tumor-specific
antibody, immunogenic peptides or vaccines have been de-
veloped [15]. CA125, also known as MUC16, is a large
membrane-associated mucin protein which is over ex-
pressed in more than 80% of EOC. The soluble molecule
secreted in patient blood is used as a marker for tumor iden-
tification and progression. Due to its poor immunogenic-
ity, the host organism is not able to mount an adequate
immune response against it alone. When the targeted anti-
body binds to the CA125, the complex can bind to the anti-
gen-processing cells more readily than CA125 alone.
During the past 20 years, many phase I/II clinical trials had
studied the CA125-targeted antibodies like oregovomab,
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Summary
Objectives: To assess the effect and toxicity of CA125-targeted antibody used as maintenance therapy for advanced epithelial ovarian
cancer (EOC). Materials and Methods: Two reviewers searched PubMed, Medline, Embase, VIP databases, and the references of selected
articles for randomized controlled trials comparing maintenance CA125-targeted  antibody treatment with placebo/observation. One -,
two-, three-, and five-year overall survival (OS) and progression free survival (PFS) were collected. Incidence and severity of adverse
events were extracted.  Meta-analysis of combined risk ratio (RR) for OS , PFS, and toxicity were conducted. Results: Four trials including
1,259 women were identified. Meta-analysis showed the combined RR was 1.02 (95% CI, 0.85−1.22) for three-year OS and 0.98 (95%
CI, 0.70−1.39) for the three-year PFS. This review found that abagovomab and oregovomab caused toxicity no more than placebo.  Con-
clusions: CA125-targeted antibody used as maintenance therapy alone is not more effective than placebo but they were safe as mainte-
nance therapy.
Key words: CA125-targeted antibody; Epithelial ovarian cancer; Maintenance therapy; Meta-analysis.
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ACA125, and abagovomab in newly diagnosed or recur-
rent advanced ovarian cancer, which showed that they
could cause specific immune response resulted in longer
survival [16-21].  These trials evoked to imagine how they
would act when used as the maintenance therapy. Further
more, it is important for the gynecologists and women with
EOC to assess the potential benefits and adverse effect of
CA125-targeted antibodies, however, currently there have
not been any systematic reviews published on this topic.
This systematic review aimed to evaluate the effective-
ness, toxicity, and impact on the quality of life (QoL) of an-
tibody-based CA125-targeted immunotherapy as
maintenance therapy for EOC.
Materials and Methods
Eligibility criteria
Women with EOC, fallopian tube cancer (FTC) or primary
peritoneal cancer (PPC) who have achieved CCR after debulk-
ing surgery and first-line chemotherapy. The patients were ≥
18 years and have no other concurrent malignancies. The study
design was a randomized controlled trial comparing mainte-
nance CA125-targeted antibody treatment with observation,
placebo or other treatment. Maintenance CA125-targeted anti-
body combined with the other treatment versus the other treat-
ment alone is also included. The PFS rate, OS rate, incidence
and severity of adverse events or QoL score were the primary or
secondary outcomes of the original studies.
Searches
Two reviewers searched MEDLINE (from 1948 to 2014), EM-
BASE (from 1980 to 2014) , PubMed (up to October 2014), and
VIP (1989 to October 2014) independently. It was designed to
identify all published trials in English or Chinese.The aforemen-
tioned databases were searched using the keywords: immunother-
apy,  bioimmunotherapy, CA125, MUC16, oregovomab, abago-
vomab, ACA125, ovarian cancer, and maintenance/consolidation
therapy . VIP was searched using the same keywords in Chinese.
In addition, the authors reviewed the references of selected arti-
cles to identify studies missed through our databases searching.
They also searched the relative websites for ongoing trials.
Two reviewers scanned the titles and abstracts from the initial
search to exclude those articles which did not meet the eligibility
criteria. Then the full text of potentially relevant studies were ob-
tained and assessed by both review authors independently. Any
disagreements were resolved through discussion with a third re-
view author.
Data collection and analysis
The authors extracted OS and PFS after one, two, three, and five
years from the included studies. The incidence and severity of ad-
verse events such as nausea-vomiting, diarrhea, rash, back pain,
myalgia, arthralgia, and flu-like syndrome were also abstracted. The
published QoL scores were collected. The authors pooled the re-
sults of similar trials into a meta-analysis. Revman 5.2 was used to
conduct the meta-analysis and calculate the combined RR and its
95% confidence interval (CI) for OS, PFS, and adverse events.
The authors also assessed the risk of bias of each trial in terms
of randomisation process, allocation concealment, blinding, in-
complete outcome data, selective outcome reporting, and other
possible sources of bias and classified them as low , high or un-
clear risk according to the guidelines of Cochrane Handbook for
Systematic Reviews of Interventions [22].
Results
Data search and quality of the included studies
The search identified 631 trials and initially 600 were ex-
cluded because of duplication and obvious ineligibility after
reading the titles and abstracts. Full text were obtained for
the remaining 31 trials for further scrutiny and 25 ineligible
trials were excluded. Two trials [20, 23] were initially iden-
tified as potentially eligible for inclusion but were subse-
quently found to be ineligible and therefore excluded (Figure
1). In the end, four trials (1,259 patients) were included in
this review. Three trials compared oregovomab [3, 24, 25]
with placebo and the other one compared abagovomab [26]
with placebo. Berek et al. 2008 [24] is a five-year follow-
up survey of Berek et al. 2004 [3]. Berek et al. 2009 [25] re-
Figure 1. — Flowchart of studies screening.
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ported the same trial but the included subjects were 226 more
than Berek et al. 2004 and the primary end point was time to
relapse. The baseline of the four studies was balanced and
there was no significant heterogeneity between them (Table
1). All the four studies were randomly allocated and used
blinding method. None of the trials have any attrition bias or
reporting bias so the included studies had low risk of bias.
Effect  of  CA125-targeted antibody 
Sabbatini et al. [26] reported the median estimated time
to recurrence was 403 days in abagovomab group and 402
days in placebo group. At the end of the double-blind ob-
servation period, the hazard ratio (HR) of OS for the treat-
ment group was 1.150 (95% CI, 0.872−1.518; p = 0.322).
Berek et al. [3, 24, 25] reported the median survival was
57.5 months for oregovomab and 48.6 for placebo but the
p-value was 0.28. The median time to relapse was 10.3
months (95% CI, 9.7− 13.0 months) for oregovomab and
12.9 months (95% CI, 10.1−17.4 months) for placebo (p =
0.29). Data from 1,033 patients was combined and the RR
for three-year OS was 1.02 (95% CI, 0.85−1.22), while the
combined RR for three-year PFS was 0.98 (95% CI,
0.70−1.39) (Figure 2). Therefore, there was no significant
benefit of using CA125-targeted antibody alone as main-
tenance therapy.
Toxicity of antibody against CA125 
For CA125-targeted antibodies, diarrhea was the only side
effect which was recorded more in the abagovomab group
(p = 0.031)[26], but the meta-analysis found that the com-
bined RR for diarrhea was 1.36 (95% CI, 0.94−1.96) so
there was no significant difference between two arms re-
garding diarrhea, which was the same with back pain, fa-
tigue, and arthralgia, et al. (Figure 3). According to Berek et
al.’s study [25], 13.7% of oregovomab group and 18.6% of
placebo group had a serious adverse event but there was not
significant difference between them (p = 0.218). Berek et
al. [3] used European Organization for Research and Treat-
ment of Cancer Quality of Life Questionaire C30 (EORTC
QLQ-C30) to assess the overall health and overall QoL and
found the QoL was similar in the oregovomab group and
the control group. These results indicated that the abagov-
omab and oregovomab were safe and had little impact on
the QoL as maintenance therapy for ovarian cancer.
Discussion
This meta-analysis is based on 1,259 women from four
RCTs that used different antibodies against CA125 as
maintenance therapy for advanced EOC. A number of
methods were employed to identify all trials to minimize
Table 1. — The included studies of CA125-targeted antobody as maintenance therapy for EOC.
Study Study Design Patients Outcome Duration of follow-up Comment 
Berek et al., RCT n=145 Median TTR was 13.3 months Insufficient information
2004 [3] for oregovomab and 10.3
Oregovomab EOC of Stage III/IV months for placebo (p = 0.71).
vs. placebo (1:1) achieved CCR
Median age: 60 in treatment
62 in placebo group  
Berek et al., RCT n=145 Median survival was 57.5 months 5 years A 5-year 
2008 [24] for oregovomab and 48.6 months follow-up 
Oregovomab EOC of Stage III/IV for placebo (p = 0.28) survey of 
vs. placebo (1:1) achieved CCR Berek 2004
Median age: 60 in treatment
62 in placebo group 
Berek et al., RCT n=371 Median TTR was 10.3 months 5 years The same 
2009 [25] for oregovomab and 12.9 months trial of 
Oregovomab EOC of Stage III/IV for placebo (p = 0.29). Berek 2004
vs. placebo (2:1) achieved CCR
Median age:  58.8 in treatment 
59.6 in placebo group
Sabbatini RCT n=888 HR of RFS was 1.099 24 months after random 
2013 [26] (95%CI, 0.919 to 1.315) assignment of the last
Abagovomab EOC/FTC/PPC of Stage patient.
vs. placebo (2:1) III/IV achieved CCR HR of OS was 1.150
(95%CI, 0.872 to 1.518).
Median age: 56.3 in treatment 
56 in placebo group
Abbreviations: RCT: randomized controlled trial; EOC: epithelial ovarian cancer; FTC: fallopian tube cancer; PPC: primary peritoneal cancer; TTR: time to relapse;
RFS: relapse free survivalHR: hazard ratio; OS: overall survival.
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Figure 2. — For-
est plot of sur-
vival analysis of
CA125-targeted
antibody.
Figure 3. — For-
est plot of ad-
verse side effect
of CA25-tar-
geted antobody.
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the influence of publication bias. There were no serious
inconsistency, indirectness, imprecision or publication
bias; this meta-analysis currently provides a reliable as-
sessment of the average effect of CA125-targeted anti-
body maintenance therapy among women with advanced
EOC. Overall, the quality of the evidence was moderate
due to low number of studies and further researches may
change the estimate.
There was no benefit of maintenance CA125-targeted
monoimmunotherapy settings, the drugs, however, were
well-tolerated. The adverse events were similar between
treatment groups and were not life-threatening. Does it re-
ally mean maintenance CA125-targeted immunotherapy of
advanced EOC is of little survival benefit? Perhaps it is too
arbitrary to draw the conclusion. First of all, the included
four studies had different interval between the last cycle of
first-line chemotherapy and the beginning of maintenance
therapy. Berek et al. [3, 24, 25] started oregovomab therapy
within ten weeks after the last cycle of chemotherapy while
Sabbatini et al. [26] began abagovomab therapy within 12
weeks, which was less than six months. As a consensus, the
phase of CCR or PCR of platinum-sensitive cases is usually
longer than six months and the prognosis and biological
characteristics are totally different between platinum-sen-
sitive and platinum-resistant cases. If maintenance therapy
is initiated earlier than six months, the platinum-resistant
cases would be included, which may impair the effect of
the treatment.
Secondly, different studies used different criteria for
judging disease relapse. Berek et al. [3, 24, 25] defined
recurrence as identification of new intraperitoneal lesion
not previously seen or a retroperitoneal lesion on CT scan
greater than 2 × 2 cm. Sabbatini [26] assessed disease
progression as a 20% increase in sum of longest diame-
ters compared to baseline or appearance of any new le-
sions (RECIST version 1.0). Although randomization and
blinding may balance the bias between the treatment and
controlled arms, however the heterogeneity caused by
different criteria would bring error into the meta-analysis
results, especially when the weight of each study is dif-
ferent. As we know, second-line treatment starts usually
based on an increase in serum CA125 level only, with-
out imaging evidence for ovarian cancer because the in-
crease of serum CA125 level occurs usually much earlier
than appearance of objective disease progression. A
working group of the Gynecologic Cancer Intergroup has
developed definitions of CA125 progression to comple-
ment the definitions of objective disease progression in
ovarian cancer [27]. It is supported that doubling in
CA125 from the upper limit of normal reliably predicts
objective progression. For those patients whose CA125
never fell to the normal range, a doubling from the nadir
has been shown to predict progression. In an effort to ad-
dress this issue in a consistent manner, the present au-
thors suggest that the date of progression should be the
date of the earlier of the two events when both the RECIT
and Intergroup criteria were documented.
Braly et al. [17] reported a phase-II trial in which 40 pa-
tients with Stage III/IV EOC were randomized to receive a
two-mg oregovomab infusion either the same day (simul-
taneous infusion arm) or one week after standard carbo-
platin-paclitaxel chemotherapy at cycles 1, 3, and 5, then
quarterly for up to 11 antibody doses. Humoral immunity
occurred more rapidly (p = 0.0033) and with greater mag-
nitude in the simultaneous infusion arm. They came to the
conclusion that the front-line chemotherapy has immune
adjuvant properties when combined with oregovomab im-
munotherapy. Therefore combined strategies of chemother-
apy with oregovomab or other CA125-targeted agents
should be further studied as maintenance therapy.
Conclusions
In summary, there is insufficient evidence which ade-
quately supports the use of antibody against CA125 as
maintenance therapy alone to improve the OS or PFS for
advanced EOC, however, they are safe and tolerable. The
sufficient interval of CCR (> six months) before mainte-
nance therapy and more precise unified criteria of as-
sessing for progression may diminish the bias which
would impair the results. For further study, combining
the immunotherapy with the traditional chemotherapy
may be a new topic.
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Introduction
Ovarian carcinoma is currently the second most common
cause of deaths for genital cancer in the Western countries.
Standard management of ovarian carcinoma consists in
combination of surgery and chemotherapy [1, 2]. Recur-
ring ovarian carcinoma is associated with poor prognosis,
with overall survival (OS) following a relapse being de-
pendent on the overall condition of patients, histopatho-
logical type of tumor, size and number of relapse lesions, as
well as time from last platinum-based chemotherapy [3]. 
Most common recurrence locations include pelvis, peri-
toneum, pleura, liver, lungs, lymph nodes, and central nerv-
ous system [3, 4]. About 70% patients with advanced-stage
ovarian carcinoma respond to the first chemotherapy regi-
men; unfortunately, most of these patients experience disease
recurrence, with median time to progression of about 18
months and median OS of about 24 months. The efficacy of
chemotherapy delivered to these patients is lower than that of
the first-line treatment; this means that only a small percent-
age of patients actually benefits from subsequent chemother-
apy [5]. Currently, radiation therapy plays a less significant
role, being used mainly as a next-line or palliative treatment.
The aim of this retrospective study was to assess the re-
sults of radiotherapy in ovarian carcinoma patients.
Materials and Methods
The study was conducted in ovarian carcinoma patients under-
going radiation therapy in the Department of Teleradiotherapy of
the Oncology Center in Bydgoszcz between January 2009 and De-
cember 2013. The analysis covered patients with all stages of
ovarian carcinoma, i.e. FIGO and TNM Stages I-IV (Table 1). The
patients age ranged from 35 to 67 years. The most common can-
cer type as determined in histopathological assessment was ade-
nocarcinoma and its histological variants. Lymph node metastases
were confirmed in 22 patients while N0 Stage was identified in 18
patients. Tumor differentiation Grades G2 and G3 were deter-
mined in 12 and 18 patients, respectively (Table 2). Eleven pa-
tients underwent radiotherapy twice; three patients were irradiated
three times while one patient underwent radiation treatment as
many as five times. Radiotherapy was delivered to the pelvis in 25
patients, para-aortic lymph nodes in 12 patients, local lesions in 11
patients, and metastases in 13 patients; patients had a history of
multiple surgical and/or systemic treatments.
Patients were treated in line with the accepted management
standard; in most cases, this included combination treatment. Sur-
gical treatment was undertaken in all 47 patients; of these, three
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Summary
Relapses of ovarian cancer have poor prognosis, overall survival (OS) after recurrence depends on patient’s performance status, his-
tological cell type, size and number of the relapse, and duration of the platinum-free interval. Pelvis, peritoneum, pleural effusion, liver,
lung, lymph nodes, and central nervous system are the most frequent sites of relapse. The standard treatment for ovarian cancer is a com-
bination of surgery and chemotherapy. This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic
factors of patients with ovarian cancer underwent radiotherapy. Results: In 47 with ovarian cancer underwent radiotherapy. Treatment
modalities were radiotherapy 8- 56 Gy. After optimal treatment the authors observed complete remission in seven patients, and pro-
gression and/or metastases in 40 patients. The present study confirmed that patients with low advancement stage had better prognoses
than patients with advanced disease, as confirmed by OS rates in groups T1 vs. T3 (p = 0.066) and T3 vs. T4 (p = 0.066). What was in-
teresting was that the disease-free survival (DFS) in the group of patients with T3 cancer was longer than in the group of patients with
T1 cancer. Time to marker progression (Ca 125) was longer in groups with FIGO Stage I vs. II and I vs. III (p = 0.016, p = 0.044), while
the time to progression in FIGO Stage II cancer patients was shorter than in FIGO Stage III cancer patients. An interesting result was
also obtained in the analysis of 36-month survival where a larger number of patients without the disease symptoms had T3 Stage can-
cer. New prospective studies, designed to include the aspects of target volumes, total doses and fraction doses, together with the use of
state of the art planning techniques, and therapeutic instrumentation are required. 
Key words: Cancer; Ovary; Radiotherapy; Brachytherapy.
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patients required no adjuvant systemic treatment. The remaining
patients received chemotherapy, most commonly platinum-based
regimens in combination with taxoids. 
Disease recurrence was experienced by 44 patients, all of whom
required combination treatment including next-line chemotherapy
and/or radiotherapy and/or surgery. External beam irradiation was
delivered at doses of 8-56 Gy in 47 patients, including 13 patients
who received palliative radiation therapy for metastases. Radiother-
apy consisted of irradiation of the tumor with appropriate margin at
doses of 8-20 Gy in one to five fractions as part of palliative therapy. 
In patients with confirmed metastases into the lymph nodes or
pelvis or patients with local recurrence, target volume most com-
monly included the area from the L1 segment to the obturator foram-
ina, laterally two cm from the pelvic walls on both sides, from 1/3
of pubic symphysis to the S2/S3 intervertebral joint in anteroposte-
rior projection so as to include para-aortic, common iliac, external
iliac, internal iliac presacral, and obturator lymph nodes. 
In patients with confirmed metastases into para-aortic lymph
nodes, target volumes most commonly spanned from the upper
edge of the 12
th
thoracic vertebra down to the L5/S1 intervertebral
joint, including a healthy tissue margin. The treatment was deliv-
ered at total doses of 30-56 Gy, with daily fraction dose of two to
three Gy using six and 15 MeV energy sources. High-dose rate
(HDR) brachytherapy was performed in seven patients at doses
of 10-30 Gy divided into one to four fractions.
Repeated surgery was required by 32 patients, including six pa-
tients who were subjected to at least three surgical procedures.
After completion of the treatment, response was observed in seven
patients, with 40 patients experiencing progression and/or distant
metastases. M1 stage was developed in 31 patients; 22 died of the
disease while the fates of another three patients are unknown. Fol-
low-up visits were held at four weeks after completion of radio-
therapy and then at three-month intervals. Patient follow-up lasted
at least 12 months. Three patients did not report to follow-up vis-
its; further course of their disease remains unknown.
Statistical analysis
Statistical analysis of the was performed using Statistica, ver-
sion 10.0. The association between OS rate, DFS rate, progres-
sion free survival rate, and prognostic factors was estimated
using Kaplan-Mayer model. Differences between categorized
groups were assessed with using the log-rank and Cox-Mantel
tests. Proportions of survivors at 24 and 36 months were as-
sessed using Chi-square test. Statistical significance was con-
sidered at p < 0.05.
Results
OS
Parameters affecting the likelihood of survival were an-
alyzed in the entire group, including: T-staging, FIGO clas-
sification, tumor differentiation grade G, lymph node status,
treatment history including surgery, first, second, third,
next-line chemotherapy, induction chemotherapy, pelvic ra-
diotherapy, local radiotherapy, para-aortic lymph node ra-
diotherapy, radiotherapy of metastases, and brachytherapy.
Log-rank test demonstrated borderline statistical signifi-
cance for longer OS in patients with tumor advancement
stage T1 as compared to T3 (p = 0.066) and higher OS rates
in patients with T3 cancer as compared to patients with T4
cancer (p = 0.064) (Figure 1). A trend towards higher sur-
vival rates was also observed in patients with differentiation
grade G2 as compared to patients with differentiation grade
G3 (p = 0.071). No evidence was provided for N1 Stage
(presence of lymph node metastases) having a negative im-
pact on the survival as compared to N0; likewise, no effect
of distant metastases was observed.
Log-rank and Cox-Mantel tests revealed no significant
effects of the second-, third- and next-line chemotherapy
on OS. The next stage of statistical analysis included the
assessment of the effect of radiation therapy on ovarian car-
cinoma patients. No effect on OS was observed for pelvic
radiotherapy, para-aortic lymph node radiation therapy
(Figure 2), and brachytherapy (p > 0.05). 
A trend towards shorter OS times was observed in pa-
tient undergoing local radiotherapy as compared to patients
not subjected to such treatment (p = 0.079), particularly
with respect to long-term survival (Figure 3). 
In the entire study group, statistical significance (log-rank
test) was determined for the effect of metastases radiother-
apy on OS; patients undergoing such treatment were char-
acterized by longer OS times than patients not subjected to
the metastases-targeted radiotherapy (p = 0.18) (Figure 4).
Table 1. — Patient’s TNM and FIGO Stage.
TNM Stage Number of patients FIGO Stage Number of patients
T1 10 (21.2%) I 7 (14.89%)
T2 13 (27.65%) II 11 (23.40%)
T3 16 (34.04%) III 23 (48.93%)
T4 2 (4.25%) IV 4 (8.51%)
Tx 6 (12.7%) X 2 (4.25%)
Table 2. — Characteristics of patients with ovarian carci-
noma.
Number of patients
Lymph node status
Without lymph node involvement - N0 18 (38.29%)
With lymph node metasases - N1 22 (46.80%)
Unknown status - Nx 7 (14.89%)
Histopathological assesment
Folliculoma 2 (4.25%)
Granulosa cell tumor 1 (2.12%)
Epitheliolid carcinoma 1 (2.12%)
Adenocarcinoma 12 (25.53%)
Adenocarcinoma endometroides 3 (6.38%)
Adenocarcinoma papillare serosum 3 (6.38%)
Adenocarcinoma serosum 1 (2.12%)
Adenocarcinoma clarocellulare 4 (8.51%)
Cystoadenocarcinoma 12 (12.53%)
Infitrartio carcinoma 3 (6.38%)
Carcinoma papillare 2 (4.25%)
Carcinoma serosum 1 (2.12%)
Carcinoma mucinosum 1 (2.12%)
Tumor differentation Grade
Grade 2 12 (25.53%)
Grade 3 18 (38.29%)
Unknown status Gx 17 (36.17%)
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The number of surgical procedures also affected OS at
borderline statistical significance (p = 0.06, lower 95% CI
limit -1.29235; upper 95% CI limit 0.04119). 
DFS
The analysis of DFS time included the assessment of var-
ious parameters using the log-rank test to demonstrate that
DFS was significantly longer in patients with tumor stage
T3 as compared to patients with tumor stage T1 (p=0.03,
lower 95% CI limit -2.62712, upper 95% CI limit
0.104210). Correlation of DFS with lymph node involve-
ment proved to be very interesting. Statistically longer
DFS times were observed in patients with confirmed
lymph node metastases as compared to patients with clin-
ical stage N0 (p = 0.046). Statistical evaluation was also
performed for tumor differentiation grade confirming that
Figure 1. — Overall survival in pa-
tients with ovarian cancer in TNM
stage.
Figure 2. — Overall survival in pa-
tients with ovarian cancer with
para-aortic lymph node radiother-
apy vs. without radiotherapy.
Figure 3. — Overall survival in pa-
tients with ovarian cancer with local
radiotherapy vs. without radiother-
apy.
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the DFS was longer in patients with tumor grade G2 as
compared to patients with tumor grade G3 (p = 0.27). 
With the Cox-Mantel test, a significant effect on DFS
was demonstrated for first-line chemotherapy vs. no sys-
temic treatment (p = 0.007). Patients treated with induc-
tion chemotherapy were characterized by shorter DFS as
compared to patients not subjected to this treatment (p =
0.002). 
The study did not demonstrate any effect of the
second-, third-, and next-line chemotherapy on longer DFS;
similarly, no effects were observed for pelvic radiation ther-
apy, para-aortic node radiation therapy or local radiother-
apy. A trend towards shorter DFS times was observed in
the group of patients undergoing palliative radiation ther-
apy for distant metastases as compared to patients not sub-
jected to radiation therapy (p = 0.08) (Figure 5). 
Figure 4. — Overall survival in pa-
tients with ovarian cancer with
metastases radiotherapy vs. without
radiotherapy.
Figure 5. — Disease-free survival in
patients with ovarian cancer with
metastases radiotherapy vs. without
radiotherapy. 
Figure 6. — Disease-free survival in
patients with ovarian cancer with
brachytherapy vs. without brachy-
therapy.
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The next stage of statistical analysis included the assess-
ment of the effect of brachytherapy on ovarian carcinoma
patients. No effect on the DFS was observed (p > 0.05)
However, curves in the Kaplan-Meier graph reveal a sig-
nificant effect on local tumor control, particularly in the ini-
tial months, although no statistical significance has been
reached (Figure 6). DFS time was longer in the group with
minimum one surgical procedure as compared to no surgi-
cal procedures, with the difference at the border of statisti-
cal significance (p = 0.055). 
Time until Ca125 marker progression
The next stage of the study included the analysis of time
until Ca125 marker progression. The analysis revealed
longer times until Ca125 marker progression in patients with
FIGO stage I cancer as compared to patients with FIGO
stage II cancer (p=0.016) as well as in patients with FIGO
stage I cancer as compared to patients with FIGO stage III
cancer (p=0.044). What is interesting, as shown in the graph,
patients with FIGO stage II cancer had shorter times to pro-
gression than patients with FIGO stage III cancer, although
the differences were not statistically significant). 
The next step of the statistical analysis made use of the
log-rank and Cox-Mantel tests to determine the effects of
pelvic, para-aortic nodes radiotherapy, local radiation ther-
apy, brachytherapy and metastases-targeted radiotherapy in
ovarian carcinoma patients. Shorter times to marker pro-
gression were observed in patients receiving palliative ra-
diotherapy for distant metastases as compared to patients
who were not subjected (did not require) such treatment; the
result was at the border of statistical significance (p=0.060). 
None of the other parameters subject to the analysis, such
as first-, second,- or next-line chemotherapy had any sig-
nificant effect on the time to Ca125 marker progression. 
24- and 36-month survival
Spearman's analysis was employed to analyze OS and
DFS 24 and 36 months after treatment. The study showed
that in the group of patients who survived 36 months with-
out any symptoms of the disease, Stage T3 was more com-
mon than Stage T1 or T2 (p = 0.03). The study showed that
the group of patients who survived 24 and 36 months with-
out disease recurrence included more patients with base-
line confirmation of node metastases as compared to
patients with N0 Stage (p = 0.25 and p = 0.25, respec-
tively). Further analysis revealed that in the group of pa-
tients who survived 36 months without any symptoms of
the disease, Stage G2 was more common than Stage G3,
and the result was at the border of statistical significance (p
= 0.062). A borderline significance trend was observed to-
wards a higher percentage of patients who survived 36
months without any symptoms of the disease and who had
not been subjected to metastases-targeting radiation therapy
(p=0.073). Statistical analyses of OS of 24 months after the
baseline treatment revealed that a higher number of patients
survived in the group not subjected to local radiation ther-
apy as compared to patients who underwent local radio-
therapy (p=0.01). A similar situation was observed in
relation to surgical treatment: a higher percentage of pa-
tients survived 24 and 36 months after the baseline treat-
ment if they had undergone surgery, as compared to patients
not subjected to surgery (p = 0.01 and p = 0.036, respec-
tively).
Discussion
Recent years have witnessed a return to radiotherapy as
adjuvant treatment of ovarian carcinoma. That was due to
the dynamic advances in the techniques involving the plan-
ning and delivery of radiation beam treatments. The goal
of radiotherapy is to treat the largest possible volume within
the abdominal cavity with possibly lowest risk of early or
delayed radiation-induced reactions and good protection of
critical organs. 
Treatment of ovarian carcinoma poses a significant chal-
lenge to radiotherapist as no standards are available re-
garding irradiation, including total dose, fraction doses or
target volume outlines. This is particularly important as the
number of reports on the subject is limited and dates back
to 1980s and 1990s or is based on small patient groups
and/or short follow-up periods [6-12].
The present study confirmed that patients with low ad-
vancement stage had better prognoses than patients with
advanced disease as confirmed by OS rates in groups T1
vs T3 (p = 0.066) and T3 vs. T4 (p = 0.066). What is inter-
esting, the DFS in the group of patients with T3 cancer was
longer than in the group of patients with T1 cancer. Time to
marker progression (Ca 125) was longer in groups with
FIGO Stage I vs. II and I vs. III (p = 0.016, p = 0.044), while
the time to progression in FIGO Stage II cancer patients
was shorter than in FIGO Stage III cancer patients. An in-
teresting result was also obtained in the analysis of 36-
month survival where a larger number of patients without
the disease symptoms had T3 Stage cancer. 
The obtained results regarding cancer staging could have
been affected by the number of patients in the study group;
however, in the present Author's opinion, the difference in
management protocols for patients with low FIGO and
TNM stage cancers and advanced cancer patients might be
of importance here. In addition, ovarian carcinoma is diffi-
cult to diagnose and stage which might significantly affect
the obtained results.
Another parameter subject to the analysis was the lymph
node involvement status. The study revealed longer disease-
free progression times in N(+) patients as compared to N0
patients; in addition, the analysis could not confirm that
lymph node metastases contributed to longer survival. This
might confirm errors in the accuracy of disease staging
and/or presence of micrometastases in N0 patients. The role
of lymphadenectomy in patients with advanced ovarian car-
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cinoma is unclear. Some authors recommend intraopera-
tional removal of pelvic and para-aortic lymph nodes, high-
lighting that lymph node metastases are observed in 50-70%
of ovarian carcinoma patients. The researchers point out that
this is the only way allowing for actual disease staging, as
well as for the removal of bulky lymph nodes, thus signifi-
cantly affecting the PFS, although having no effect on OS,
as studies show. One should remember that besides lymph
node metastases that accompany the disease spread, isolated
lymph node metastases are also possible. In these cases,
consideration of different therapeutic approaches, including
radiotherapy, is recommended [13, 14].
An important result was the lack of the effect of the next-
line chemotherapy on the OS as well as on the DFS, indi-
cating therapeutic nihilism and the need to search for novel
methods for the treatment of ovarian carcinoma. While ra-
diotherapy of the entire abdominal cavity is controversial,
the use of radiation in recurrent cancer and/or palliative
treatment seems to be the main indication for the use of this
technique in ovarian carcinoma patients [15, 16]. On the
other hand, the only randomized trial that confirmed an in-
crease in the OS and the PFS, as well as a reduction in the
rate of recurrences, was the study conducted by Sorbe in
which patients with advanced ovarian carcinoma after in-
duction chemotherapy were subjected to radiotherapy of
the entire abdominal cavity with higher doses targeted to
the pelvic region [17].
The present study could not confirm the effect of radio-
therapy on OS; however, it revealed good local control and
positive impact on the DFS, particularly when the irradia-
tion volume included para-aortic lymph nodes. The study
results might have been affected by the total doses deliv-
ered during the treatments: some authors recommend doses
as high as 45-60 Gy being delivered to bulky lymph node
tumors in salvage therapy, while suggesting that even these
doses might be insufficient [7, 10, 18, 19]. 
Blanchard et al. [13] analyzed a group of 640 ovarian
carcinoma patients, 27 (4.2%) of whom developed isolated
recurrences in lymph nodes. In 23 patients, the recurrence
was correlated with an increase in the level of the Ca125
cancer marker. Most commonly, the recurrence was ob-
served in retroperitoneal lymph nodes, followed by supra-
clavicular, mediastinal, mesenteric, and axillary lymph
nodes. The treatment of recurrence episodes was varied. In
48% of cases, the disease recurrence was observed more
than two years after cancer diagnosis. Mean OS was 68
months (12-210 months), while mean OS after lymph node
recurrence was 26 months. Authors demonstrated no dif-
ferences in two-year survival rates following a lymph node
recurrence in the group of early recurrences (< 24 months)
vs. the group of delayed recurrences (> 24 months) (59%
and 47%, respectively). According to the authors, patients
benefit most from radiotherapy in cases of isolated recur-
rence or recurrence in lymph nodes, particularly para-aor-
tic lymph nodes [13].
Fujiwara et al. [20] assessed a group of isolated or multi-
ple recurrences after disease spread was ruled out. The mean
number of recurrences per patient was two (1-5), with a total
of 44 recurrence foci in 20 patients. Patients were qualified
to radiotherapy with total doses of 40-68 Gy administered in
1.6-2.0 Gy fractions. Tumor regression was observed im-
mediately after treatment completion in 42 recurrences, with
39 recurrences responding within two to three months after
the start of radiotherapy. The percentage of tumor regres-
sions was higher in patients with lesions smaller than five
cm and in cases when recurrences occurred in lymph nodes.
However, according to the authors, disease progression out-
side radiation target volume occurred in most patients. 
The study conducted by Tinger et al. [16] included 80 pa-
tients with ovarian carcinoma remission after at least one
laparotomy and chemotherapy including one to 20 cycles of
platinum-based agents. Some patients were subjected to ra-
diotherapy targeting more than one site of recurrence and/or
metastasis; in 64 patients, radiation was delivered to ab-
dominal cavity, while 11 brain metastases and five metas-
tases into other organs were also observed. Authors were
able to achieve therapeutic response in 73% of patients, with
complete resolution of symptoms, i.e. tumor mass and/or Ca
125 levels in 28% of patients. Partial response was observed
in 45% of patients, while 11% of patients experienced pro-
gression during radiotherapy. Survival rates over periods of
one, two, three, and five years after diagnosis were 89%,
73%, 42%, and 33%, respectively. Respective survival rates
after completion of radiotherapy were 39%, 27%, 13%, and
10%, according to authors' estimates [16]. 
Many studies unambiguously point to the important role
of radiotherapy in palliative treatment of ovarian carci-
noma, particularly in metastases to the brain, bones, and
lymph nodes [21]. Clinical symptoms may be related to re-
currence within pelvis minor, as well as to metastases to
the brain, lungs, and other locations. In their analysis of
available literature, Delaney et al. [21] estimated that dis-
ease spread is observed in 38% of patients, with palliative
radiotherapy indicated in 11% of patients. As shown by the
studies, complete resolution of complaints is achieved after
irradiation in 50-70% of patients [12, 15, 16, 20]. In about
one-third of patients, the effect is maintained for about one
year. The recommended total dose is about 30-45 Gy, de-
pending on the general condition of the patient, cancer type
and treatment history [3, 22]. 
Many authors recommend radiotherapy in palliative
treatment of e.g. brain metastases, incidence of which has
increased in recent years. Whole brain irradiation increases
survival in ovarian carcinoma patients [3, 13]. 
Corn et al. [15] applied this treatment in 32 patients,
demonstrating clinical response in 23 individuals. Of those,
the response was maintained until death in 71% of cases.
The present study confirmed the importance of radiother-
apy in palliative treatment, as patients subjected to this type
of treatment had longer survival, although their DFS times
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were shorter than in patients not subjected to radiotherapy
due to distant metastases, obviously due to the stage of the
disease. In addition, the study suggested that the control of
24-month survivals was better in the group of patients un-
dergoing palliative radiotherapy, as compared to patients
subjected to local radiotherapy. This indicates better radio-
therapeutic control in the treatment of metastases as com-
pared to local disease. The outcome might have been
impacted by the fact that patients undergoing local treatment
had history of multiple failures of other therapies (either sur-
gical or systemic), where the treatment of metastases using
irradiation was usually a primary treatment, commonly ad-
ministered as a part of combination therapy. 
The present study could not confirm the effect of
brachytherapy on DFS. On the other hand, brachytherapy
helped to achieve good local control, particularly within the
first months after initiation of the treatment. The outcome
might have been affected by the number of subjects, as clin-
ical experience demonstrated an important role of
brachytherapy in the treatment of ovarian carcinoma, par-
ticularly in advanced diseases including infiltration of uter-
ine body and/or cervix and/or vaginal wall, as well as in
helping to achieve good local control of the disease and/or
antihemorrhagic effect [23]. 
The results presented herein as well as those reported by
other authors suggest an important impact of adjuvant treat-
ment in ovarian carcinoma patients, while indicating that
radical surgery remains the imperative treatment goal as
having an important effect on local control of the disease
and increase in survival. 
The results obtained in the present study should be sub-
jected to further analyses in larger groups of patients; how-
ever, they may reflect inaccurate staging of the disease in
patients in whom clinical presentation suggested a low
stage and thus affected the extent of the procedure and im-
pacted the overall survival and DFS.
Introduction of novel techniques of radiation planning fa-
cilitates irradiation of the largest possible volume within
the abdominal cavity with the possibly lowest risk of early
or delayed radiation-induced reactions in critical organs.
The available techniques of intensity-modulated radiation
therapy (IMRT), RapidArc, or tomotherapy may provide
maximum protection of critical organs such as kidneys,
liver, and intestines while ensuring precision and short
treatment times when combined with image-guided radia-
tion therapy (IGRT) [24-27]. 
It seems that the views on the role of radiotherapy in ovar-
ian carcinoma treatment should be revised. The marginal
use of radiotherapy should be extended by indications in the
treatment of residual disease, post-surgery or post-
chemotherapy residues, isolated inoperable metastases, re-
currences, as well as in irradiation of the entire abdominal
cavity in patients not qualified and/or resistant to chemo-
therapy or not consenting for other treatment methods. It
should also be kept in mind that this treatment may be com-
bined with intraoperative radiotherapy (IORT) in an in-
creasing number of sites, providing an interesting alternative
in the treatment of this disease [22, 26, 28]. 
Conclusion
In conclusion, the main limitation of the present study
was the fact of its being a retrospective study in a small
group of ovarian carcinoma patients. On the other hand, ac-
cording to the Author’s knowledge, this is one of few stud-
ies dealing with the role of radiotherapy in the treatment of
ovarian cancer.
New prospective studies, designed to include the aspects
of target volumes, total doses, and fraction doses, together
with the use of state of the art planning techniques and ther-
apeutic instrumentation are required. Other problems re-
maining to be solved are to determine the time point at
which radiotherapy should be considered, whether the treat-
ment should be administered in a standalone or combined
fashion (together with chemotherapy and/or IORT and/or
surgery), and what would be the appropriate order of thera-
peutic actions. 
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Introduction
Cervical cancer, the malignant neoplasm of the cervix
uteri, is the second most common cancer among women
worldwide [1]. Cervical intraepithelial neoplasia (CIN) is
considered a precursor of cervical cancer. Development of
cervical cancer goes through several premalignant stages,
from low-grade CIN (CIN I) through high-grade CIN (CIN
II/ III) to cervical cancer [2]. These lesions have the ability
to progress from hyperplasia to cervix, to preinvasive car-
cinoma, and ultimately to invasive carcinoma [3]. There is
a general agreement that either ablation or excision of CIN-
II, III could reduce the incidence and mortality caused by
invasive cervical cancer in women with these lesions [4]. 
Numerous studies have been obtained in exploring the
pathological mechanism underlying CIN development. Mi-
croRNA (miRNA) has been found to play a key role in the
CIN progression. MiRNAs are a class of 19 to 23 nu-
cleotide single-stranded RNA molecules [5] and are epige-
netic factors that regulate cell proliferation, tumor cell
growth, cancer formation, and metastasis by regulating
tumor suppressor genes or oncogenes [6]. Martinez et al.
reported that miR-218 levels in patients with high-risk CIN
were lower than those with low-risk CIN and therefore,
downregulated miR-218 may be involved in the pathogen-
esis of cervical cancer [7]. In addition, tumor suppressor
genes such as p16 and retinoblastoma proteins played roles
in the neoplastic changes of CIN [8]. Previous studies
showed that vascular endothelial growth factor (VEGF) ex-
pression was associated with the progression of CIN [9].
Using microarray gene expression data and bioinformatic
analysis, Prashant et al. suggested that transcription factor
(TF) family E2F played an important role in cervical car-
cinogenesis [10]. Moreover, apolipoprotein A1, a truncated
form of transthyretin and a cleavage fragment of inter-α-
trypsin inhibitor heavy chain H4 were identified to be po-
tential biomarker [11]. Although many factors have been
found in CIN development, the pathogenic mechanisms of
CIN are still not clearly demonstrated, and it is lack of ef-
fective markers for CIN treatment. 
In this study, the authors applied biological informatics
methods to identify the feature genes and miRNAs between
CIN III and normal samples. Additionally, the miRNA-
mRNA regulatory network was constructed and the func-
tional enrichment analysis was performed. The authors
aimed to explore the molecular mechanism and discover
the potential target genes and key miRNAs of CIN.
Materials and Methods
Microarray data 
The data of GSE51993, which was deposited by Mo et al. on
2013, were downloaded from GEO (Gene Expression Omnibus)
(http://www.ncbi.nlm.nih.gov/geo/) database based on the plat-
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Summary
Purpose: The objective of this study was to predict potential target genes and key miRNAs for cervical intraepithelial neoplasia (CIN)
by bioinformatics analysis. Materials and Methods: The microarray data of GSE51993 were downloaded from Gene Expression Omnibus
(GEO) database. Total 30 chips data from two platforms (each platform including eight CIN III samples data and seven normal cervix
samples data) were used to identify the feature miRNAs and genes between CIN III and normal samples, respectively. Then the miRNA-
mRNA regulatory network was constructed using Cytoscape software. Gene Ontology (GO) function and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway enrichment analysis were performed for all target genes with the Database for Annotation, Visualization
and Integrated Discovery (DAVID) online tool. Transcription factors (TFs) and cancer-related genes were analyzed. Results: Total 21 pu-
tative target miRNAs and 361 putative target mRNAs were gained. The miRNA-mRNA regulatory network results showed that miR-338-
5p, miR-193a-5p, and miR-216b were top three hub nodes. GO terms significantly enriched were extracellular region (p = 0.004191) and
embryonic skeletal system (p = 0.004742). No significantly enriched KEGG pathway term was found in this study. PBX1 (pre-B-cell
leukemia transcription factor 1) and LAMC2 (laminin subunit gamma-2) were cancer-promoting genes and also, PBX1 was TF. Conclu-
sions: PBX1 and LAMC2 may be target genes for CIN. MiR-338, and miR-216 may be key miRNAs in CIN development.
Key words: Cervical intraepithelial neoplasia; Bioinformatics; miRNA-mRNA regulatory network.
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form of GPL8179 (Human v2 microRNA expression beadchip)
and GPL10558 (Human HT-12 V4.0 expression beadchip). Total
30 chips data from platforms of GPL8179 (15 chips data) and
GPL10558 (15 chips data) were used for the development of the
genome wide expression profiles of both miRNAs and mRNAs
data, including eight CIN III samples data and seven normal
cervix samples data, respectively. The data were normalized with
robust multi-array average (RMA) [12] algorithm and subjected
to logarithmic transformation.
Feature miRNAs and genes analysis
Probe sets were mapped to miRNAs and genes, respectively.
Nonspecific probes were filtered. When multiple probe sets were
mapped to the same miRNA or gene, the average expression value
was calculated to represent the miRNA or gene expression level.
The feature miRNAs and genes between CIN samples and nor-
mal samples were analyzed. At first, interquartile range (IQR) [13]
was used to filter miRNAs or genes based on gene expression lev-
els distribution. All miRNAs or genes whose variability less than
1/5 overall IQR were eliminated. Then, ANOVA analysis was per-
formed, and feature miRNAs or genes were filtered based on ran-
dom forest [14]. 
TaLasso online analysis and miRNA-mRNA regulatory network
The TaLasso is both website (http://talasso.cnb.csic.es/) and the
algorithm [15]. It has been tested with two datasets with matched
miRNA and mRNA expression data.
The authors converted names of mRNAs and miRNAs which
were screened from gene expression data into ensemble names.
Then, data without ensemble name were deleted and the remain-
ing data of mRNAs and miRNAs were put into TaLasso. The union
of TarBase, miRecords, and miRWalk databases [15] were used
for putative target genes. Cytoscape [16] is a software for visual-
izing complex networks and integrating networks between genes.
With the application of Cytoscape software, the miRNA-mRNA
regulatory network was constructed with these target genes. 
Functional enrichment analysis
Gene Ontology (GO) database [17] is a collection of a large
number of gene annotation terms. Kyoto Encyclopedia of Genes
and Genomes (KEGG) knowledge database [18] is applied to
identify the functional and metabolic pathway. Database for An-
notation, Visualization and Integrated Discovery (DAVID) [19] is
a gene functional enrichment analysis tool to understand the bio-
logical meaning for investigators. GO and KEGG pathway en-
richment analysis were conducted with DAVID. A p-value < 0.05
was the cut-off criterion for the gene enrichment analysis. 
Transcription factors and cancer related genes analysis
The Transcription Factors Database (TFD) [20] is a specialized
database focusing on TFs and their properties. TFs, the target
genes, were selected and identified from target genes based on
TFD. 
The tumor-associated gene (TAG) database [21] (http://
www.binfo.ncku.edu.tw/TAG/) is designed to utilize information
from well-characterized oncogenes and tumor suppressor genes to
facilitate cancer research. Tumor suppressor genes (TSG) database
[22] is a literature-based resource of tumor suppressor by inte-
grating genomic data of mutations, gene expressions, regulations,
methylations, and interactions. The cancer-promoting genes were
extracted from TAG database, and tumor suppressor genes were
extracted from TAG database and TSG database.
Figure 1. — Regu-
latory network of
miRNAs and their
target genes. Yel-
low nodes repre-
sent miRNAs; red
nodes represent
target genes related
to miRNA.
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Results
Feature miRNAs and genes selection
Total 25 feature miRNAs were selected, including hsa-
miR-338-5p, hsa-miR-193a-5p, hsa-miR-216b, hsa-miR-204,
hsa-miR-21*, hsa-miR-887, hsa-miR-323-3p, hsa-miR-887,
hsa-miR-1294, and so on. 
Total 1,143 feature mRNAs were selected, including pre-
B-cell leukemia transcription factor 1 (PBX1), laminin sub-
unit gamma-2 (LAMC2), FBJ murine osteosarcoma viral
oncogene homolog (FOS), chromodomain helicase DNA
binding protein 1-like (CHD1L), chemokine (C-C motif)
ligand 28 (CCL28), nicotinamide nucleotide transhydroge-
nase (NNT), nuclear receptor subfamily 0, group B, mem-
ber 1 (NROB1), and so on.
TaLasso online analysis and miRNA-mRNA regulatory net-
work
For putative target miRNAs and genes, 21 miRNAs and
361 mRNAs were gained. The miRNA-mRNA regulatory
network was established with the 596 unique miRNA-tar-
get gene pairs (Figure 1). The degree of each miRNA in the
network was then calculated and the top six were hsa-miR-
338-5p (42), hsa-miR-193a-5p (38), hsa-miR-216b (37),
hsa-miR-887 (35), hsa-miR-204 (35), and hsa-miR-21*
(35).
Functional enrichment analysis
GO enrichment analysis were carried out for all target
genes. The top five GO terms are shown in Table 1. The
most significant term of cellular component (CC) was ex-
tracellular region (p = 0.004191), and that of biological
process (BP) was embryonic skeletal system (p =
0.004742). 
Transcription factors and cancer related genes analysis
In this study, 15 target genes, such as PBX1, homeobox
D9 (HOXD9), homeobox B8 (HOXB8), and hepatocyte
nuclear factor 4, gamma (HNF4G), were TFs. Five cancer-
promoting genes including PBX1, LAMC2, FOS, CHD1L,
and spalt-like transcription factor 4 (SALL4), as well as 14
tumor suppressor genes such as protein tyrosine phos-
phatase, non-receptor type 6 (PTPN6), microseminoprotein
(MSMB), lactotransferrin (LTF), and histidine triad nu-
cleotide binding protein 1 (HINT1) were detected. 
Discussion 
CIN is the leading cause of death among gynecological
malignancies and represents the second-leading cause of
cancer-related deaths in women worldwide [23]. Regard-
less of the fact that some genes have been reported in the
progression of CIN or cervical cancer, there is a lack of de-
tailed molecular pathogenesis mechanism. In this study, the
authors identified the feature miRNAs and mRNAs be-
tween normal cervix samples and CIN III samples using
bioinformatics analysis. Total 21 putative target miRNAs
and 361 putative target genes were identified. TF analysis
results showed that 15 TFs were associated with the regu-
lation of CIN. Among these factors, PBX1 and LAMC2
were cancer-promoting genes. The miRNA-mRNA net-
work was constructed, and miR-338-5p, miR-193a-5p, and
miR-216b were hub nodes in this regulatory network. 
PBX1 encodes a nuclear protein that belongs to the PBX
homeobox family of transcriptional factors. PBX was a
cofactor for HOX-class homeobox proteins [24]. Previ-
ous studies had shown that HOX and PBX genes were in-
volved in oncogenic processes, such as chromatin
binding, cell cycle control, proliferation, apoptosis, an-
giogenesis, and cell-cell communications [25-28].
Richard et al. reported that disrupting the interaction be-
tween HOX proteins and their co-factor PBX will retard
tumour growth in vivo [24]. Thus, HOX/PBX interaction
may be a potential target in cervical cancer therapy. In this
study, PBX1 was a feature gene and cancer-promoting
gene, suggesting that it was possibly involved in onco-
genic processes in the CIN. The miRNA-mRNA regula-
tory network results also showed that PBX1 was regulated
by miR-193a-5p which was the second hub node in the
network. Previous study found that miR-193 regulated
cell growth through the transforming growth factor-
β (TGF-β) pathway by regulating Smad3 in glioma [29].
In addition, Chen et al. reported that miR-193b, another
member of the miR-193 family, repressed cell prolifera-
tion and regulates cyclin D1 expression in melanoma [30].
Taking these factors into account, the present authors sug-
gested that PBX1 may play an important role in CIN de-
velopment and miR-193a-5p targeting PBX1 expression
may be a critical event in CIN development. As well as
PBX1, LAMC2 is a cancer-promoting gene. It belongs to
the laminin family, which is an epithelial basement mem-
brane protein. It has been shown that LAMC2 was in-
volved in a wide variety of biological processes including
cell adhesion, differentiation, migration, and tumor inva-
sion [31-33]. Immunohistochemical analysis revealed that
Table 1. — Gene ontology analysis.
GO category GO GO term Observed p-value
ontology
GO:0005576 CC Extracellular region 57 0.004191
GO:0048706 BP
Embryonic skeletal
system development
7 0.004742
GO:0006959 BP
Humoral immune
response
7 0.005376
GO:0048562 BP
Embryonic organ
morphogenesis
9 0.005796
GO:0045087 BP
Innate immune
response
9 0.0072
Note: CC: cellular component; BP: biological process.
Observed: number of the observed target genes in the category.
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LAMC2 protein was highly expressed in cervix carcino-
mas [34] and was a marker to predict the risk of progres-
sion of CIN lesions [35]. Therefore, LAMC2 may be a
key gene in CIN development.
Aside from miR-193a-5p, several other miRNAs such as
miR-338 and miR-216b may be important in the develop-
ment of CIN. It was reported that miR-338 suppressed the
gastric cancer progression through PTEN-AKT signaling
by targeting phosphatidylinositol-3,4,5-trisphosphat e-de-
pendent Rac exchange factor 2 (P-REX2a) [36], as well as
its role as a suppressor of the Smoothened-independent sig-
naling pathways [37]. Furthermore, miR-216b was reported
to suppress tumor growth and invasion by targeting KRAS
(kirsten rat sarcoma viral oncogene homolog) in nasopha-
ryngeal carcinoma [38]. Kim et al. showed that miR-216b
promoted cellular senescence through the p53–
p21
Cip1/WAF1
pathway in colon cancer [39]. In this study,
miR-338 and miR-216b were hub nodes in miRNA-mRNA
regulatory network. Thus, the present authors speculated
that miR-338 and miR-216b may be key regulators in CIN
development. 
In order to predict potential target genes for CIN treat-
ment, only CIN III and normal samples, not CIN II or CIN
I, were analyzed. In conclusion, the genes of PBX1 and
LAMC2 may play an important role in CIN development.
These genes showed potential perspective in treatment of
CIN. MiR-338 and miR-216 may be the key miRNAs in
CIN development. They may be used to predict the risk of
progression of CIN lesions. However, further experiments
are still needed to confirm the present results.
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Introduction
Carcinoma of endometrium is the most common cancer
of the female genital tract and 2-3% of all women seem to
have endometrial cancer during their life span [1]. Its is di-
agnosed in 10% of patients with postmenopausal bleeding
[2]. Because bleeding is the earliest symptom, all women
with postmenopausal bleeding must be evaluated [3].
Transvaginal ultrasonography (TVUSG) is used as the first
step because it is a safe, rapid, highly effective, and non-in-
vasive method [4]. However the cut off level is still contro-
versial [5].
The authors aimed to review the role of TVUSG to pre-
dict the risk of endometrial malignancy. 
Materials and Methods
In this study, the authors retrospectively reviewed the data of
129 postmenopausal women, referred to the present hospital in a
period of 27 months, between July 2010 and September 2012. The
patients were between the ages of 46-83 years with the absence of
menstruation for at least one year, provided that the amenorrhea
was not explained by pregnancy, medication or disease.
A total of 129 women were included in the present study. Sub-
jects were divided into two groups as 100 symptomatic patients
(patients with the symptom of bleeding) and 29 patients with the
endometrial thickness detected incidentally (asymptomatic pa-
tients ). Patients with the symptom of bleeding were divided in
three subgroups according to endometrial thickness calculated by
using TVUSG (subgroup 1: < 5 mm, subgroup 2: ≥ 5 mm ≤ 15
mm, subgroup 3: ≥ 15 mm). Asymptomatic patients were divided
into two subgroups (subgroup 1: ≥ 5 mm ≤ 15 mm, subgroup 2:
≥ 15 mm ). Detailed physical and gynecological examinations of
the patients were performed. Dilatation and curettage was per-
formed in all subjects.
Peri- or premenopausal patients, the patients with the history
of endometrial cancer or hyperplasia, and also the patients on hor-
monal replacement therapy or with the history of use were ex-
cluded. The authors also excluded the patients on tamoxifen
therapy and the patients with the history of use.
TVUSG (with a high-frequency vaginal transducer of 6.5 MHz
) was performed in all women. The cut off level was accepted as
five mm. All women with postmenopausal bleeding, irrespective
to their endometrial thickness, and asymptomatic women with
thickened endometrium of five mm and more than five mm, were
accepted as pathologic.
Histological materials were obtained by dilatation and curet-
tage. Samples were kept in 10% formaldehyde solution and sent
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Summary
Objective: The purpose of the study was to assess the reliability of transvaginal ultrasound (TVUSG) in endometrial pathologies by
comparing the ultrasonographic and histopathologic findings in symptomatic and asymptomatic postmenopausal women. Materials
and Methods: In this retrospective study the data of 129 postmenopausal women that underwent dilatation and curettage was reviewed
by dividing them two groups as symptomatic and asymptomatic. Symptomatic group was divided into subgroups according to the value
of endometrial thickness obtained by TVUSG. Results: Among all subjects the cancer rate was found statistically 3.043 times higher in
patients with the endometrial thickness of 15 mm and greater and atrophic endometrium rate was 75% in patients with the endometrial
thickness of less than five mm. Endometrial thickness was found significantly higher in cancer patients than the others (p < 0.05).
Among the patients with endometrial thickness of 15 mm and greater, the cancer rate was found higher in symptomatic group than in
the asymptomatic group. The cancer rate was found statistically higher in patients with bleeding compared to asymptomatic ones with
the endometrial thickness between 5−14.99 mm (p < 0.05). Cancer was not detected in any of the symptomatic patients with the en-
dometrial thickness of less than five mm. Conclusion: Postmenopausal patients with the symptom of bleeding should undergo detailed
gynecological and ultrasonographic examination. The authors believe that this study may be a strong support to the success of TVUSG
as a screening method in both symptomatic and asymptomatic postmenopausal women. Furthermore if the patient is symptomatic with
a thick endometrium, to exclude the malignancy, endometrial biopsy must be performed.
Key words: Postmenopausal bleeding; Transvaginal ultrasonography; Endometrial thickness; Endometrium cancer; Menopause.
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to pathology laboratories. They were assessed with an automatic
tissue follower device for 13 hours. In this procedure, tissues
were exposed to formaldehyde twice for 30 minutes each, to al-
cohol six times for 60 minutes, to xylene three times for 60 min-
utes, to paraffine once for 60 minutes, and twice for 80 minutes,
respectively. After that sections with the thickness of two mi-
crons were dyed with Hematoxylin and Eosin. Sections were in-
spected by the same pathologist. The pathology results were
reported as atrophic endometrium, irregular endometrial prolif-
eration, polyp, simple hyperplasia without atypia, complex hy-
perplasia without atypia, complex hyperplasia with atypia, and
cancers.
Statistical analysis
In this study SPSS (Statistical Package for Social Sciences) pro-
gramme version 15.0 and GraphPad InStat demo version were used
for the statistical analysis of the data. Beside the descriptive statisti-
cal methods, Chi-square test and Fischer exact test were used for the
analyses of comparisons of the groups. Student's t-test and Mann
Whitney U test were used for analyses of the comparison of two
groups, and Kruskal Wallis test was used for the comparison of more
than two groups. Dunn's test was used for the paired comparisons
and Pearson correlation test was used for correlations. Confidence
interval was 95% and significance level was accepted as p < 0.05.
Results
The mean age was 56.66 ± 8.68 years and the mean en-
dometrial thickness was detected as 11.12 ± 6.02 (2.30-
29.00) mm. The endometrium thickness was less than five
mm in 9.3% (n=12), between five and 14.99 mm in 65.1%
(n=84), and > 15 mm in 25.6% (n=33) of the patients
(Table 1).
Among all subjects, atrophic endometrium was found
in 42 patients (32.6%) and irregular endometrial prolifer-
ation was found in 20 patients (15.5%). In 34 patients
(26.4%) there was a polyp, in seven patients (5.4%) sim-
ple hyperplasia without atypia, and in three (2.3%) com-
plex hyperplasia without atypia. Only one patient (0.8%)
had complex hyperplasia with atypia. Twenty-two patients
(17.1%) were reported as cancer in the present study
(Table 2).
The endometrial thickness was less than five mm in 12
patients, between 5−14.99 mm in 62 patients, 15 mm and
greater in 26 patients in the group with the symptom of
bleeding. The endometrial thickness was between
5−14.99 mm in 22 patients and 15 mm and greater in
seven patients in asymptomatic group. When all the pa-
tients were divided into three groups according to their
endometrial thickness (< 5 mm, between 5−14.99 mm,
and ≥ 15 mm) the cancer rate was found statistically
higher in patients with the endometrial thickness of 15
mm and greater, compared to the other two groups (p <
0.05). The cancer rate was 3.043 times more (95% Cİ: 1,
1.68−7.930) in patients with an endometrial thickness of
Table 1. — Symptoms and findings of the patients and en-
dometrial thickness.
N %
Findings
Vaginal bleeding 100 77.5
Thickened endometrium 29 22.5
Endometrial thickness
< 5 mm 12 9.3
5-14.99 mm 84 65.1
≥ 15 mm 33 25.6
Table 2. — Pathology results.
n %
Pathology result
Atrophic endometrium 42 32.6
Irregular endometrial proliferation 20 15.5
Polyp 34 26.4
Simple hyperplasia without atypia 7 5.4
Complex hyperplasia without atypia 3 2.3
Complex hyperplasia with atypia 1 0.8
Endometrioid adenocarcinoma 16 12.4
Serous papillary carcinoma of endometrium 1 0.8
Mixed type: 70% squamous cell ca.
1 0.8
30% adenocarcinoma
Adenocarcinoma with papillary differentiation 1 0.8
Squamous cell carcinoma in situ of cervix 1 0.8
Clear cell carcinoma 1 0.8
Breast cancer with metastasis 1 0.8 
Cancer
Undiagnosed 107 82.9
Diagnosed 22 17.1 
Table 3. — Clinical features according to endometrial
thickness.
< 5 mm 5−14.99 mm ≥ 15 mm
n % n % n %
Findings
Bleeding 12 100.0 62 73.8 26 78.8
Thickened
endometrium 0 0.0 22 26.2 7 21.2
Pathology result
Atrophic
endometrium
9 75.0 31 36.9 2 6.1
Irregular endometrial
proliferation
2 16.7 14 16.7 4 12.1
Polyp 1 8.3 22 26.2 11 33.3
Simple hyperplasia
without atypia
0 0.0 3 3.6 4 12.1
Complex hyperplasia
without atypia 
0 0.0 2 2.4 1 3.0
Complex hyperplasia
with atypia 
0 0.0 0 0.0 1 3.0
Cancer 0 0.0 12 14.3 10 30.3
Cancer
Undiagnosed 12 100.0 72 85.7 23 69.7
Diagnosed 0 0.0 12 14.3 10 30.3
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15 mm and greater, than in ones with the thickness less
than 15 mm (Table 3).
The authors examined the relation of cancer and bleed-
ing by dividing the patients into three groups according
to the endometrial thickness (< 5 mm, between 5-14,99
mm, and ≥ 15 mm). They compared the symptomatic pa-
tients with with asymptomatic ones with the same en-
dometrial thickness. The cancer rate was found to be
higher in patients with bleeding compared to asympto-
matic ones with the endometrial thickness of  ≥ 15 mm.
Cancer diagnosis rate was found statistically higher in
bleeding patients compared to asymptomatic ones with an
endometrial thickness between 5-14.99 mm (p < 0.05)
(Table 4). Cancer was not detected in the symptomatic pa-
tients with an endometrial thickness of < 5 mm. Although
endometrial thickness was found to be lower in patients
with symptom of bleeding compared to asymptomatic pa-
tients, it was not found to be statistically significant (p >
0.05).
Discussion
The authors assessed the reliability of TVUSG in en-
dometrial pathologies by comparing the ultrasonographic
and histopathologic findings in symptomatic and asymp-
tomatic postmenopausal women in this study. According
to the results they found that the cancer rate was statisti-
cally 3.043 times (95% CI: 1.168−7.930) higher in pa-
tients with an endometrial thickness of  ≥ 15mm. There
were no cancer detected in the group of patients with the
endometrial thickness of ≤ 5 mm.
Postmenopausal bleeding is an important sign of both
cervical and endometrial pathologies which should be
kept in mind in differential diagnosis. Cervical cancer
screening methods widely used all over the world how-
ever still do not include a widely accepted screening
method for the endometrial pathologies. The high inci-
dence of endometrial cancer in postmenopausal patients
with bleeding requires a simple diagnostic method with a
high accuracy rate. In postmenopausal women en-
dometrium becomes atrophic and the thickness of en-
dometrium is measured as 2.3 ± 1.8 mm as a result of hor-
monal changes [6]. Hence endometrial thickness is also a
suspicious sign in postmenopausal women. TVUSG is
used as the first step method of examination because it is
cheap, reliable, and non-invasive [4].
There are several studies in the literature similar to the
present one. Gull et al. followed 339 women who had post-
menopausal bleeding for ten years and 39 of them had en-
dometrial cancer and five had hyperplasia with atypia. They
found the ratio of relative risk of endometrial cancer in
women who were referred with postmenopausal bleeding
as 64. None of the endometrial cancer cases were missed
when the endometrial thickness cut-off value was taken as
four mm. They concluded that TVUSG was an excellent
tool for the determination of whether endometrial biopsy
was necessary [7]. They explained these high figures of en-
dometrial cancer during the observational period of 10
years, by the fact that some of the initial biopsy results were
actually false negative which made the incidence too high.
In the present study, 34.6% of the symptomatic patients
with an endometrial thickness > 15 mm were diagnosed as
cancer. According to the present study it can be stated that
one-third of symptomatic patients with endometrial thick-
ness > 15 mm was detected as cancer. This high ratio of
cancer in the present clinic depends on the fact that the
hospital is tertiary centre and these patients with the
higher probability of cancer might have been referred to
the present clinic.
It is proper to accept the cut-off value of endometrial
thickness as five mm [4]. Haller et al. measured the dou-
ble layer endometrial thickness of 81 patients by TVUSG
one day prior to hysteroscopy and curettage. They showed
that TVUSG detected 46 of 48 pathologic conditions in-
cluding all cases of endometrial carcinoma when the cut-
off value was five mm (sensitivity 95.8%, specificity
45.5%) [8]. The present authors also consider cut-off
value as five mm as in the mentioned studies. Atrophic
endometrium was found in 75% of the patients with an
endometrial thickness of less than five mm in the present
study and none of them were cancer. In a multi-centric
study in which 1,168 patients were followed in eight dif-
ferent clinics of four Nordic countries, none of the pa-
tients with an endometrial thickness of less than five mm
were detected as cancer. They also suggested that curet-
tage should not be performed in  these patients [4]. 
When the present authors divided the patients into three
groups according to endometrial thickness, they found a
higher cancer rate in symptomatic (bleeding) group than
the asymptomatic ones who had ≥ 15 mm and statistically
higher rate in the group of 5−14.99 mm endometrial thick-
ness (p < 0.05). This result shows that cancer rate is much
higher in the patients with bleeding symptom than in the
asymptomatic ones with the same endometrial thickness.
Thus, bleeding should seriously alert the physician.
Table 4. — The relationship between bleeding and cancer
according to endometrial thickness.
No cancer Cancer present
n % n %
< 5 mm
without bleeding 0 0.0 0 0.0
with bleeding 12 100.0 0 0.0
5−14.99 mm
without bleeding 22 100.0 0 0.0
with bleeding 50 80.6 12 19.4
≥ 15 mm
without bleeding 6 85.7 1 14.3
with bleeding 17 65.4 9 34.6
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Goldstein suggested that postmenopausal bleeding was
cancer until proven otherwise. He pointed out that, the
risk of malignancy of a thin endometrium was so small
like one in 917. The rate of asymptomatic endometrial
thickening was at least 10% in postmenopausal women
and polyps were the reason in most of the cases. He also
mentioned that the risk of malignancy in polyps was
0.1%. Complication incidence in such postmenopausal
women was not negligible (1.3−3.6%). Hence interven-
tion in such women without any high risk status was not
logical [9]. Unlike his suggestion, in the present study the
authors found cancer rate to be statistically 3.043 times
(95% CI: 1.168−7.930) higher in patients with the en-
dometrial thickness of ≥ 15 mm. Depending on this result
the present authors would like to point out that a thick en-
dometrium of a postmenopausal woman may be a poten-
tial sign of endometrial cancer and should be taken
seriously; if the endometrial thickness is found to be five
mm or greater, biopsy should be performed even if the pa-
tient is asymptomatic.
As a result, the postmenopausal patients with symptom
of bleeding should undergo detailed gynecological exam-
ination and TVUSG should be performed. Furthermore if
the patient is symptomatic with a thick endometrium, en-
dometrial biopsy must be performed in order to exclude
malignancy. TVUSG is an effective and non-invasive
method for the diagnosis and follow up of the patients
who are at high risk of endometrial cancer. The present
authors think that this study may be further strong sup-
port to the success of TVUSG as a screening method in
both symptomatic and asymptomatic postmenopausal
women.
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Introduction
Patients appear to trust information on the Internet as
much as from other media [1]. Thus it is unsurprising that
the Internet and Social Media have become an accessible
source of health-related information for patients and other
interested parties [2]. Almost 80% of Internet users, which
comprised almost 60% of all American adults, use the In-
ternet to seek medical information [3, 4]. This highlights
the importance of assessing the quality and validity of such
information. The importance of the internet within obstet-
rics and gynecology was predicted in 1997 [5] and is likely
to continue [6]. However, studies of the quality of onco-
logical health information published on the Internet have
found it restricted, variable, and overwhelming - patients
may be faced with millions of results for a simple term
search [7-9]. 
Patients and doctors are confronted with a confusing
array of educational, promotional, and even complication-
oriented websites regarding diseases and treatment options
in oncology [10,11]. However, the content of internet re-
sources and video forums is largely unregulated without the
rigor that is applied to scientific publications [12]. There is
a danger of misinformation leading to a negative impact on
patient’s understanding, expectations, choice of therapy,
choice of care, and ultimately quality of life [8, 13, 14]. On-
cology poses other interesting challenges for patients. For
example, if the cancer is endometrial, they may search for
‘endometrial cancer’ but equally may choose alternate
terms such as ‘uterine’, ‘endometrial adenocarcinoma’ or
even ‘womb cancer’. The choice of descriptive terms for a
type of cancer has been found to make a difference with
the quality of information presented by an internet search
[9]. Furthermore, information quality differs based on lan-
guage [7-9, 15-17] which is of importance in multicultural
societies and non-English speaking countries. 
Clinicians are also placed in difficult situations when con-
fronted with internet resources and need tools to identify
quality information for themselves and to direct patients [8,
9]. Several systems have been developed to help identify
quality and reliable health information [7, 8, 16]. The Health
on the Net (HON) Foundation is a not-for-profit accreditation
body supported by the World Health Organization (WHO)
that is multilingual and has the goal of accrediting health
websites using key principles of authority, complementarity,
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Summary
Background: Oncological internet information quality is considered variable, but no comprehensive analysis of gynecological malig-
nancies exists. The present authors’ objectives were to compare the quality of common malignancy websites and to assess for language
or disease differences; and secondly, to perform a quality comparison between medical and layperson terminology. Materials and Meth-
ods: World Health Organization (WHO) Health on the Net (HON) principles may be applied to websites using an automated toolbar func-
tion. Using a search engine (www.Google.com) 8,400 websites were assessed using keywords ‘endometrial, ‘uterine’, ‘cervical’, ‘ovarian’,
‘vaginal’, ‘vulvar’, plus ‘cancer’, in English, French, German, and Spanish; repeated for alternate terms e.g. ‘cervix’, ‘womb’. Results:
Searches for “vaginal’ ‘uterine’, ‘cervical’, and ‘endometrial’ each returned millions of websites. The total percentage of all assessed
HON-accredited sites was notably low across all search terms (median 15%; range 3-19%). Significant differences by malignancy type
(p < 0.0001), language (p < 0.0001), and tertiles (thirds) of the first 150 websites returned (p < 0.0001). French language had most ac-
credited websites. Using alternate terms demonstrated significant differences (p < 0.001) in accredited websites for most gynecological
cancers. Conclusions: Internet data on gynecological malignancies is overwhelming. Further, a lack of validation of the majority of gy-
necological oncologic sites should be appreciated with discrepancies in quality and number of websites across diseases, languages, and
also between medical and layperson terms. Physicians should encourage and more importantly their professional bodies should partici-
pate in the development of informative, ethical, and reliable health websites on the internet and direct patients to them.
Key words: Gynecology; Neoplasms; Internet; Patient education; Women.
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confidentiality, attribution, justifiability, transparency of au-
thorship, sponsorship, and advertising [8, 18]. 
The present authors’ objective was to compare the quality
of gynecological oncology websites based on the HON prin-
ciples and to assess for language or disease differences across
Western languages being English, French, German, and Span-
ish. A further aim was to perform a quality comparison be-
tween search results when medical rather than layperson
terminology or even alternate terms are used for a particular
malignancy. 
Materials and Methods
Internet searching for websites
The authors’ methodology has been previously described and
utilised in previous publications [8, 9]. Using the Google search
engine (www.Google.com), in February 2014, the authors per-
formed internet searches for 15 terms associated with gynecolog-
ical oncology (e.g. endometrial and uterine cancer, Table 1) and
assessed 8,400 websites. English and equivalent terms in French,
German, and Spanish (translated from English through use of
medical translation services and confirmed by laypersons and doc-
tors having the non-English primary language as their primary
language for term accuracy) were utilised.
Internet searching for accredited websites
Based on the observation that patients rarely access more than
the first page of search results [19], the first 150 websites yielded
by each search were then identified and sequentially screened for
quality as defined by the HON Foundation. This was done by ap-
plying HON principles through the HONcode toolbar function [18]
for use on any personal computer and automatically activates or
“lights-up” toolbar if a website is accredited by the HON founda-
tion). The HON function has been used and assessed in several stud-
ies and was thus deemed to be a valid and high calibre tool [8, 20]. 
Analysis of accredited websites likelihood of being viewed
A secondary analysis of the first 150 websites encountered for
each tumor type was undertaken as previously described [8, 16,
21]. Firstly, all returned websites for each cancer were divided
into tertiles (first, middle, and last 50). The proportion of accred-
ited sites in each organ and language was then analysed and com-
pared using the Chi-square test. The purpose of this analysis was
to determine where accredited websites were appearing preferen-
tially i.e. in the pages least likely (last 50) versus the most likely
to be viewed (first 50). 
Quality control
For quality control, an English search (‘cervical carcinoma’),
had non-accredited sites within the first 150 discovered websites
manually evaluated using the HON criteria to determine their
HON status to ascertain if they fulfilled the criteria despite not
being “officially” accredited.
Logistic regression examining variables associated with HON status
This was conducted using the three major variables of search
term, language, and tertiles of the first 150 returned. The referent
groups for each variable were the English version and the first 50
websites respectively as these had the highest percentage and/or
number of HON accredited websites. 
Analysis of website sponsors
For all organ groups, an analysis was undertaken from English
language websites to determine the website sponsors (individual or
Table 1. — Results of the total websites returned for each term and also the percentage of HON accredited sites (po-
HONA). Also, the poHONA according to for websites in tertiles (first, second, and third 50) for each search returned is
also indicated. Total websites and percentage of HON-accredited sites by treatment options.
Terminology Term searched Total websites HON accredited (600 per term)
b
Total PoHONA (%) p value
returned
a
HONCODE + HONCODE  -
Endometrial cancer Endometrial cancer 1,320,00 111 489 600 19
Endometrial adenocarcinoma 321,000 86 514 600 14
Womb cancer 1,150,000 87 513 600 15
Uterine cancer 2,400,000 92 508 600 15
TOTAL (median*, sum^) 1,235,000* 376^ 2024^ 2400^ 15* 0.173
Cervical Cancer Cervical cancer 16,939,000 112 488 600 19
Cancer cervix 12,939,000 113 487 600 19
Cervical intraepithelial neoplasia 570,440 55 545 600 9
TOTAL (median*, sum^) 12,939,000* 280^ 1520^ 1800^ 19* < 0.001
Ovarian cancer Ovarian cancer 15,100,000 80 519 600 13
Ovary cancer 2,010,000 94 506 600 16
Ovarian carcinoma 1,250,000 85 515 600 14
TOTAL (median*, sum^) 2,010,000 259^ 1540^ 1800^ 14* 0.501
Vaginal Cancer Vaginal cancer 1,660,000 103 497 600 17
Vaginal SCC** 410,000 84 516 600 14
Vulvar cancer 441,000 98 502 600 16
Vulvar SCC** 215,000 82 518 600 14
Total (median*, sum^) 425,500* 367^ 2033^ 2400^ 15* 0.15
Grand total (median*, sum^) 1,622,500 1066^ 5964^ 8400^ 15* (3-19)
a – total web sites returned = total of four languages: English, French, German, and Spanish; b – Total of 600 per term = four languages x 150 web sites searched;
**SCC = squamous cell carcinoma.
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organization responsible for the website) and each was categorized
according to prior studies of quality of websites on the internet [7,
8]. In summary, the sites were deemed sponsored by (1) lawyers;
(2) non-profit organizations; (3) government organizations /edu-
cational institutions; (4) commercial; (5) surgeons/ physicians (and
their professional organizations); (6) other health professionals; or
(7) other. Sponsorship was determined independently by two ex-
aminers firstly by web page retrieved; if sponsorship was not ob-
viously apparent, the website was explored until sponsorship could
be determined. The concept of sponsorship is not to be confused
with the Google terminology of “sponsored links” either high-
lighting pages at the start of retrieved search or appearing on the
side of the page under a banner. As in prior analysis, such pages
were not included throughout the entirety of this study [8]. 
Statistical analysis
Comparisons of proportions across types of cancer and language
were performed using the Chi-square test (or Fisher’s exact tests
when cell counts were less than 5). All statistical tests were two-
sided and significance was defined as p < 0.05. Odds ratios and
95% confidence intervals (CI) were also calculated from the logis-
tic regression analysis. Analyses were performed using SAS 9.1.
Results
Internet search results for accredited websites
The total number of websites for each disease term was
variable (Table 1). The terms ‘vaginal’ ‘uterine’, ‘cervical’,
and ‘endometrial’ each returned millions of websites. ‘Cer-
vical cancer’ the most around 17 million, closely followed
by ‘ovarian cancer’ at 15 million, while ‘vulvar squamous
cancer’ had the fewest - around 200,000. 
Including all languages, the total percentage of all as-
sessed HON-accredited (poHONA) sites was notably low
across all search terms (median 15%; range 3-19%, Table
1). Most search terms did record at least 10% poHONA but
this is still very modest. The quality control analysis of
English language for ‘cervical carcinoma’ revealed further
4% of websites that would likely be of a standard equiva-
lent to HONcode accredited sites but have yet to apply for
accreditation.
In regards to linguistic differences (Table 2), French (me-
dian 26%; range 11-35%), had the greatest percentage of
HON-accredited sites across all disease search terms, fol-
lowed by English (21%; 12-34%), Spanish (15%; 8-29%)
and German (9%; 3-19%). 
When analysing by tertiles to determine where HON-ac-
credited sites were more likely to appear, it appears that
HON-accreditation was significantly more common in the
sites that appear in first tertile (Figure 1).
Finally the ORs were calculated demonstrating signifi-
cant differences with search terms, language or between
groups (Table 3). Indeed it appeared an Internet search was
almost equally likely to be accredited provided the key term
for that malignancy was used. However, the first tertile was
Table 2. — Differences in HON accreditation of websites by term and language. PoHONA = percentage of HON accredited
sites. The p values refer to comparison within each terminology/treatment group.
Terminology/ Treatment English French German Spanish p value
HON HON Po HON HON Po HON HON Po HON HON Po
CODE+ CODE- HONA CODE+ CODE- HONA CODE+ CODE- HONA CODE+ CODE- HONA
Uterine cancer < 0.0001
Uterine cancer 24 126 19 33 117 28 20 130 15 15 135 11
Endometrial cancer 33 117 28 39 111 35 13 137 9 26 124 21
Endometrial adenocarcinoma 26 124 21 33 117 28 6 144 4 21 129 16
Womb cancer 19 131 15 33 117 28 20 130 15 15 135 11
TOTAL 102 498 20 138 462 30 59 541 11 77 523 15
Cervical carcinoma < 0.0001
Cervical cancer 37 113 33 42 108 39 10 140 7 23 127 18
Cancer cervix 38 112 34 42 108 39 10 140 7 23 127 18
Cervical intraepithelial neoplasia 25 125 20 15 135 11 4 146 3 11 139 8
TOTAL 100 350 29 99 351 28 24 426 6 57 393 15
Ovarian carcinoma < 0.0001
Ovarian cancer 23 126 18 31 119 26 8 142 6 18 132 14
Ovary cancer 37 113 33 31 119 26 8 142 6 18 132 14
Ovarian carcinoma 22 128 17 29 121 24 10 140 7 24 126 19
TOTAL 82 367 22 91 359 25 26 424 6 60 390 15
Vaginal squamous cell carcinoma < 0.0001
Vaginal cancer 24 126 19 23 127 18 22 128 17 34 116 29
Vaginal SCC* 26 124 21 23 127 18 18 132 14 17 133 13
Vulvar cancer 35 115 30 20 130 15 13 137 9 30 120 25
Vulvar SCC* 16 134 12 26 124 21 24 126 19 16 134 12
Total 101 499 20 92 508 18 77 523 15 97 503 19
Grand total (median*) 385 1714 20.5* 420 1680 26* 186 1914 8* 291 1809 15*
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Figure 2. — Graph of the results of the analysis of website spon-
sors by organ malignancy (or alternate term) across the English
language sites only. Statistical analysis for differences within each
malignancy group is highlighted in the total columns.
Table 3. — Results of the logistic regression analysis com-
paring across gynecological oncology terminology, likelihood
of an accredited website based on first, second, and third 50
websites returned and by language. Referents were chosen
based on the term cervical carcinoma and its alternate terms
being the standard; the first tertile returned because of this
having the greatest percentage of HON accredited websites
and English as the most common language.
Effect on HONCODE status Odds ratio 95% confidence
limits
Category
Cervical carcinoma 1.00 (referent)
Ovarian carcinoma 0.909 0.754 - 1.096
Uterine carcinoma 1.009 0.849 - 1.198
Vaginal/vulval carcinoma 0.963 0.782 - 1.185
Websites^ 
1
st
tertile (0-50) 1.00 (referent)
2
nd
tertile (51-100) 0.501 0.435 - 0.577
3
rd
tertile (101-150) 0.349 0.299 - 0.408
Language 
English 1.00 (referent)
French 1.117 0.956 - 1.306
German 0.427 0.354 - 0.516
Spanish 0.710 0.600 - 0.840
^Of the first 150 websites examined, the first third or 50 (five pages) were
reference group compared to second third and last third.
Figure 1. — Graph of the results of
the percentage of HON accredited
sites (poHONA) by organ group.
Also, the percentage of HONCODE
+ accredited websites (poHONA) ac-
cording to tertiles (first, second, and
third fifty sites) for each search re-
turned is also indicated. Statistical
analysis of differences within each
organ malignancy for tertiles is di-
splayed in the total column.
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more likely to return an accredited site over the second (OR
0.50) and third (0.31). Comparing to English language,
French sites were slightly more likely to return an accred-
ited site (OR 1.12) while least likely in German (OR 0.43)
with Spanish between (OR 0.71).
Analysis of website sponsors
The sponsor analysis of the 150 Websites in English lan-
guage revealed (Figure 2) that the most commonly en-
countered sponsors were commercial sites (51%) followed
by Government organisations or educational institutions
(29%) and non-profit organisations (23%). Other sponsors
(15%), other health professionals (4%), surgeons/physi-
cians (4%) sponsored far less sites and lawyer–sponsored
sites were rarely if ever encountered.
Discussion 
The Internet is a tool that assists health providers and pa-
tients daily. Data exists that women and their families are
seeking information specifically on the Internet and via so-
cial media [22, 23]. Interestingly they may even be asking
questions on the internet that they find too private to even
discuss with their doctors [24, 25]. It has been recognised
that the internet has been utilised to improve colorectal can-
cer screening and this could be translated into ovarian or cer-
vical cancer screening [26]. This adds to the logic that as
physicians we need to direct patients to reliable information. 
General gynecological related resources have demon-
strated a pattern of poor quality [27, 28]. Website content
for gynecological malignancies has never been specifi-
cally studied until now. The quality may appear low in
this study but is in fact is similar to that found in surgical
and urologic oncology where routinely around 20% or
fewer websites are HON accredited [8, 9]. Gynecological
malignancies are somewhat similar to breast (23%) [9]
but performing similar to prostate cancer (16%) [8] on
available data. Language differences exist regarding Web-
site quality [7, 8, 15]. In the present study, French-lan-
guage searches overall had more Website listings and
ultimately had more HON-accredited sites as compared
to English, German, and Spanish. At best, just over a quar-
ter of French were HON-accredited and at worst, under
one-tenth of German websites were HON-accredited. It is
interesting that French again outperformed English as was
the case with multiple common non-gynecological and
non-urologic malignancies in a previous study [9]. Eng-
lish only outperformed French and others languages with
urologic malignancies [8]. Combining this with the dif-
ferences between malignancies suggests differing regional
interest and resource allocation to specific malignancies
based not just on incidence but other factors. 
The incidence and prevalence of cancers as well as their
“public profile” are all likely to be factors influencing the
number of websites available to consumers. When search-
ing the different gynecological malignancies, ‘layperson
terms’ generally performed worse than the correct medical
terminology. This was also demonstrated in other organ on-
cological website searches attesting to the importance of
gynecological oncology [29]. Teaching patients and their
support groups how to search the Internet is important and
adhering to medical terminology is an important finding for
health providers and patients. Advising them of how to ac-
cess the free HONcode toolbar to “screen” websites of
higher quality would also be prudent.
The Internet although a wonderful “free” and “open ac-
cess” resource is increasingly being subjected to commer-
cialisation [16]. This is often at the expense of considered,
well-balanced opinion. Website sponsorships which are
often not obviously disclosed as well as the creation of hid-
den metrics for search retrieval means there may be biases
in what information is returned. This study highlights the
paucity of good quality comprehensive, multilingual in-
formation on available on the Internet and confirms com-
mercial sponsors to be the greatest providers of such
information.
There are a number of limitations of the study. The In-
ternet is dynamic with Websites constantly being developed
and uploaded. Thus search results may vary depending on
time and location. Furthermore other search engines are
available apart from ‘Google’, hence future analyses could
investigate if alternate internet filter systems would signif-
icantly alter the quality of websites retrieved. 
Internet data on gynecological malignancies is over-
whelming. A lack of validation of the majority of gynecol-
ogical oncologic sites should be appreciated with
discrepancies in quality and number of websites across dis-
eases, languages and also between medical and ‘layperson’
terms. Interestingly, the quality found is similar for onco-
logical internet searches for other disease groups. Physi-
cians should encourage and participate in the development
of informative, ethical, and reliable health websites on the
internet and direct patients to them. Importantly, profes-
sional bodies need to act swiftly to become “trusted
sources” that physicians and patients may rely upon in an
increasingly “digital world’.
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Introduction
Nowadays, cervical cancer is the only cancer that has the
potential to be destroyed. Persistent infection of high-risk
human papilloma virus (HR-HPV) has been recognized as a
major risk factor for cervical cancer [1]. The clear pathogenic
factors of cervical cancer and the slow development of the
disease offer a valuable opportunity for mass screening and
treatment. A large number of clinical practices show that cer-
vical precancerous lesions can be found by screening and that
they can be blocked before the occurrence of cervical cancer.
The ThinPrep cytologic test (TCT) combined with HPV de-
tection is recommended as the first screening method. How-
ever, cytological examinations should be performed by
experimental cytologists and include continuous quality con-
trol, which is difficult in regions without adequate medical
resources. HPV detection for cervical cancer and precancer-
ous lesions has high sensitivity and good repeatability, sta-
bility, and objectivity, which is suitable for cervical cancer
screening in regions without adequate medical resources. The
effectiveness of cervical cancer screening depends on the high
sensitivity of HPV DNA detection methods.
For women, in terms of incidence, cervical cancer ranks
second among malignant tumors worldwide. Particularly in
developing countries and regions, it ranks first [2, 3]. The in-
cidence of cervical cancer and death in Xinjiang is the high-
est in Xinjiang in China. In Xinjiang, especially in Southern
Xinjiang, cervical cancer is the leading cause of death in
Uyghur women. Its prevalence and mortality are much
higher in Uyghur women than in women of other ethnicities
living in the same region, and the onset age is also lower than
that in other ethnic populations. Among all the minorities in
China, Uyghur women have the highest mortality due to cer-
vical cancer [4]. Thus, an economical and effective screen-
ing method for cervical cancer is of great significance for the
rural areas of the Xinjiang Uyghur Autonomous Region. The
cervical cancer screening program in Bachu County was sup-
ported by the National Natural Science Foundation of China
and the Chinese Cancer Foundation. This program was in
cooperation with the Maternal and Child Health Hospital of
Bachu County. In this program, a series of commonly used
cervical cancer screening technologies were systemically
evaluated. The Cervista
®
HPV HR test was used in this study
for screening HR-HPV in Uyghur women in the Bachu
County of Xinjiang in order to explore its diagnostic value in
detecting cervical cancer and precancerous lesions in Uyghur
women. Additionally, the test could provide a scientific basis
for the differential diagnosis of patients with a cytological
diagnosis of atypical squamous cells of undetermined sig-
nificance (ASCUS).
Materials and Methods
Subjects
Among the 5045 Uyghur women who attended the screening
program in Bachu County, any woman who tested positive for the
care HPV test, TCT, or acetate/iodine staining was recalled for col-
poscope examination and cervical biopsy of suspicious lesions.
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Summary
Objective: This study aims to evaluate the diagnostic value of the Cervista® human papilloma virus (HPV) high-risk (HR) test in cer-
vical cancer and precancerous lesion screening in Xinjiang Uyghur women. Materials and Methods: Three hundred and seventy three
Uyghur women from Bachu County underwent the Cervista
®
HPV HR test, ThinPrep cytologic test, and cervical biopsy under a col-
poscope. Then the relationship between the infection rate of high-risk human papilloma virus (HR-HPV), the cytological results, and
the histological results was analyzed. Results: With increasing cytological and pathological classification, the HR-HPV infection rate
also increased and reached 100% in patients with cervical cancer. The highest proportion of the pathologically positive group consisted
of patients with group A9 HPV infection as compared to patients infected with group A5/A6 or A7 HPV. Conclusion: HR-HPV is
closely correlated with cervical cancer and precancerous lesions. Group A9 HPV has a high predictive value in cervical disease screen-
ing in Uyghur women. When cytological examination shows atypical squamous cells of undetermined significance (ASCUS), the
Cervista
®
HPV HR test can provide a sensitive differentiation method.
Key words: Cervical cancer; Cervista HPV HR test; ThinPrep cytologic test.
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Among the patients who underwent a colposcope examination, 373
patients were randomly selected to undergo the Cervista
®
HPV HR
DNA test. The patients were 20 to 65 years old, with a mean age of
39.25 ± 8.65 years. This study was conducted in accordance with
the declaration of Helsinki. This study was conducted with approval
from the Ethics Committee of Xinjiang Medical University. Writ-
ten informed consent was obtained from all participants.
Diagnosis using the TCT
Diagnosis using TCT results was based on the new Bethesda
system classification standards recommended by the National
Cancer Institute in 2001. According to the severity of cell atypia,
the specimens could be classified as normal cells, inflammation,
or ASCUS, including the atypical squamous cells of highly squa-
mous intraepithelial lesions (ASCH), low-grade squamous in-
traepithelial lesions (LSIL), highly squamous intraepithelial
lesions (HSIL), and squamous cell carcinoma (SCC).
Cervista® HPV HR test
The 14 kinds of HR-HPV that could be detected by the
Cervista
®
HPV HR test, could be divided into the following three
groups: group A5/A6 (HPV51, HPV56, and HPV66), group A7
(HPV18, HPV39, HPV45, HPV59, and HPV68), and group A9
(HPV16, HPV31, HPV33, HPV35, HPV52, and HPV58). DNA
extraction and the Cervista
®
HPV HR test were carried out ac-
cording to the manufacturer’s instructions.
Pathological grading
Cervical biopsies could be diagnosed histologically as chronic
cervicitis, cervical intraepithelial neoplasia grade I (CIN I), CIN
grade II (CIN II), CIN grade III (CIN III), and cervical SCC (cer-
vical cancer I and infiltrating carcinoma).
Statistical analysis
All results were analyzed using SPSS 18.0 software. The posi-
tive rates of HR-HPV in the different grades of cervical lesions
were compared using the Chi-square and rank sum tests. A value
of α = 0.05 was used as the test standard, and p < 0.05 was con-
sidered statistically significant.
Results
Cytological diagnosis by TCT
Among the 373 samples, there were 265 normal speci-
mens (71.0%), 25 cases of ASCUS (6.7%), ten cases of
ASCH (2.7%), 52 cases of LSIL (13.9%), and 21 cases of
HSIL (5.6%). A total of 108 patients (29%) displayed
ASCUS or further cytological changes.
Relationship between HR-HPV infection and the cytologi-
cal grades
Among the 265 cytologically normal samples, there were
210 (79.2%) HR-HPV-positive cases. Among the 25 cases
of ASCUS, 21 (84%) were HR-HPV positive, while among
the patients with ASCH, nine (90%) were HR-HPV posi-
tive. In patients with LSIL and HSIL, the HR-HPV infection
rates were 100%. The HR-HPV infection rate in the sam-
ples with different cytological grades showed a statistically
significant difference (c
2 
= 20.958, p < 0.05; Table 1). The
HR-HPV infection rate increased with the cytological
grades.
Relationship between cytological abnormalities and the in-
fection rates of different HR-HPV groups
According to the Cervista
®
HPV HR test results, there
were 102 cases of group A5/A6 HPV infection (26.8%), 63
cases of group A7 HPV infection (16.6%), and 215 cases of
group A9 HPV infection (56.6%). The infection rate of
group A9 HPV was prominently higher than that of the
other two groups, including single infection and coinfec-
tion with two or three groups. The infection rates of group
A9, A5/A6, and A7 HR-HPV in the ASCUS, LSIL, and
HSIL cases showed a statistically significant difference
(c
2 
= 19.544, p < 19.544; Table 2).
Association of HR-HPV infection rates with pathological
grades
Based on the histological results, 373 patients were classi-
fied into the chronic cervicitis (n = 247), CIN I (n = 68), CIN
II (n = 26), CIN III (n = 22), and cervical cancer (n = 10)
groups. The positive rate of HR-HPV in the chronic cervicitis
group was 78.1% (193/247), significantly lower than the rates
in the CIN I, CIN II, CIN III, and cervical cancer groups, re-
spectively (95.6% [65/68], 100.0% [26/26], 100% [22/22], and
100% [10/10], respectively; [p < 0.05]; Table 3). The HPV in-
fection rate increased with the increase in the pathological
grade. Among the 315 HR-HPV-positive cases, chronic cer-
vicitis, CIN I, CIN II, CIN III, and cervical cancer accounted
for 61.3% (193/315), 20.6% (65/315), 8.3% (26/315), 7.0%
(22/315), and 3.2% (10/315) of cases, respectively. The HR-
HPV-positive cases included single infection and mixed in-
fection. The infection rates for group A5/A6, group A7, and
group A9 HR-HPV were 26.8%, 16.6%, and 26.8%, respec-
Table 1. — HR HPV infection rates in different cytological
grades of samples.
Cytological Cases (n) HR HPV-positive Positive rate of
diagnosis (cases) HR HPV
Normal 265 210 79.2%
ASCUS 25 21 84.0%
ASCH 10 9 90.0%
HSIL 21 21 100.0%
LSIL 52 52 100.0%
Total 373 315 84.5%
Table 2. — The infection rates of group A9, A5/A6, and A7
HR HPV in the different grades of cytological abnormali-
ties.
Groups A5/6 (cases) A7 (cases) A9 (cases) Total (cases)
ASCH 1 1 8 10
ASCUS 8 1 16 25
HSIL 7 2 19 28
LSIL 12 4 42 58
Normal 74 55 130 259
Total 102 63 215 380
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tively. In the chronic cervicitis, CIN I, CIN II, CIN III, and
cervical cancer groups, the infection rate of group A9 HR-
HPV was markedly higher than the infection rates of the other
groups (c
2 
= 16.288, p < 0.05; Table 4).
Discussion
HPV infection is highly associated with the occurrence and
development of CIN and cervical cancer. It has been proven
that the HPV infection rate is almost 100% in the cervical tis-
sues of cervical cancer patients. Currently, there are many
methods for HPV detection, among which hybrid capture 2
(HC2) HPV DNA detection was the first method to be ap-
proved by the Food and Drug Administration. The HC2 HPV
DNA test can detect 13 types of HR-HPV. However, it has
some limitations, such as false negatives due to a low level of
virus infection or uncorrected sampling, potential cross-cont-
amination, cross-reaction of the HR type probe with the low-
risk type probe, high cost, complex operation, large time
requirements, and so on. The Cervista
®
HPV HR DNA test is
a new HPV detection method that has also been approved by
the Food and Drug Administration recently. It uses Invader
chemistry, a signal amplification method for detecting special
nucleic acid sequences, rather than the polymerase chain re-
action, so that the amplification of erroneous signals can be
avoided. Two synchronous isothermal reactions run at the
same time, which can improve the specificity and anti-inter-
ference capability. Cervista
®
is the only method with an inter-
nal control, which can reduce false-negative results caused by
insufficient sample DNA, and has no cross-reaction with low-
risk HPV types, which reduces the chance of false positives.
Cervista
®
detects the L1 and E6/7 regions of HPV simultane-
ously, significantly improving the specificity, and avoiding the
false-negative results of methods that only detect the L1 re-
gion. It has been reported that there is no significant difference
between the HPV-positive rates in the HC2 and Cervista
®
HPV
HR assays, when a population with no intraepithelial lesions
or malignant lesions is screened [5-8]. The Cervista
®
HPV HR
test was approved for clinical use by China’s State Food and
Drug Administration in November 2011. Researchers com-
pared the Cervista
®
HPV HR test with gene sequencing for
HPV detection and got good consistency [9].
Worldwide, the distribution and genotype of HPV differs
from region to region and nationality to nationality. Currently,
HPV16 is the main type of HPV found in cervical tissues
worldwide, followed by HPV18. HPV16/18, HPV31, 33, 35,
45, 52, and 58 are the other subtypes found in cervical cancer
[10, 11]. Chinese women have much higher HPV16 infection
than in other countries, accounting for 79.6% of all cervical
cancers. However, the positive rate of other important HPV
types differs in different regions [12, 13]. The distribution of
HPV infection also differs according to gender [14]. It has
been reported that HPV16 is the most common type of in-
fection in Tibetan and Yao women [15, 16], but the other types
have a different distribution in Tibetan and Yao women. For
instance, HPV33 and HPV58 rank second and third, respec-
tively, in Tibetan women, but in Yao women, HPV52 and
HPV58 are the second and third most common infections, re-
spectively. Previous findings regarding cervical cancer
showed that HPV16 is the most common infection type in
Uyghur women, followed by HPV58 [17]. This study showed
that the HR-HPV infection rate increased with the increasing
grade of cytological diagnosis and reached 100% in cervical
cancer, further confirming the important role of HR-HPV in
the development of cervical cancer. The present findings also
showed that the infection rate of group A9 HPV was the high-
est, followed by group A5/A6. The present results were con-
sistent with the results reported [18-22], suggesting that group
A9 HR-HPV has high pathogenicity and a high risk of caus-
ing cervical cancer. The high infection rate of group A9 HPV
in the cervical lesions of Uyghur women may be related to
the high infection rates of HPV16 and HPV58 in Uyghur
women, which are both in group A9. Thus, attention should
be paid to the Uyghur women infected with HR-HPV, espe-
cially with the types in group A9, and early intervention
should be taken.
ASCUS presents with more obvious cytomorphological
changes than reactive changes, but does not reach the level
of squamous intraepithelial neoplasia. It can be a benign le-
sion with active proliferation or a potential malignant lesion
[23]. The treatment of ASCUS is always difficult using the
standard treatment of cervical lesions, resulting in excessive
or insufficient treatment or delayed diagnosis and treatment.
Einstein et al. pointed out that in women with cytomorpho-
logical ASCUS [24], HR-HPV has a sensitivity of 92.8% and
negative predictive value of 99.1% for CIN2+ and a sensitiv-
Table 3. — HR-HPV infection in patients with different
pathologic grades.
Histologic grades Number of cases HR-HPV positive Positive rate
Cervical cancer 10 10 100.0%
CIN III 22 22 100.0%
CIN II 26 26 100.0%
CIN I 68 65 95.6%
Chronic cervicitis 247 193 78.1%
Total 373 315 84.5%
Table 4. — The distribution of HR-HPV positive cases in
different pathologic grades.
Groups A5/6 A7 A9 HPV- HPV-
(cases) (cases) (cases) positive negative
(cases) (cases)
Chronic cervicitis 73 45 118 236 54
CIN I 18 13 46 77 3
CIN II 5 3 22 30 0
CIN III 5 2 20 27 0
Cervical cancer 1 0 9 10 0
Total 102 63 215 380 57
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ity of 100% and positive predictive value of 100% for CIN3+.
However, its specificity for CIN2 and CIN3 were only 44.2%
and 43%, respectively [24]. The Cervista
®
HPV HR assay
showed that group A9 HPV has high pathogenicity, which
can be used as a sensitive differential diagnosis method for
the cervical cytomorphological examination. For patients
with cytomorphological ASCUS, the Cervista
®
HPV HR test
should be performed. If the specimen is group A9-positive, a
colposcopy and cervical biopsy should be performed imme-
diately in order to make a clear diagnosis and provide effec-
tive treatment in time. Patients without HR-HPV infection
can have regular cytological examinations. It does not only
save medical resources and reduce the unnecessary cervical
injury caused by colposcopy examination, but also reduces
the economic and psychological burden of the patients.
Conclusion
In this study, Cervista® HR HPV DNA test is firstly used
to screen cervical lesions in Xinjiang Uyghur Women. The
authors aimed to discuss predictive value and found A9
group has high level of pathogenicity, which provides a sen-
sitive shunt method for cervical cytology examination. Fur-
ther study will focus on consistency of Cervista® HR HPV
DNA and HC2, and further validate accuracy of the method.
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Introduction
Currently, taxane is widely used for treatment of a vari-
ety of malignant tumors throughout the world. The stan-
dard therapy for ovarian cancer is combined administration
of paclitaxel with carboplatin every three weeks [1]. The
response rate of paclitaxel and carboplatin administrated
was 63-87% [2-4], and a high efficacy of the therapy has
been shown in advanced or recurrent endometrial carci-
noma. However, neurotoxicity, which is one of the side ef-
fects caused by paclitaxel, sometimes becomes severe and
interferes with the treatment [5, 6].
Docetaxel exerts its anticancer effect by binding to mi-
crotubules and inhibiting depolymerization of the micro-
tubules in the same manner as paclitaxel. In a
comparative study of combined administration of pacli-
taxel with carboplatin and combined administration of
docetaxel with carboplatin every three weeks as the first-
line chemotherapy for patients with ovarian carcinoma,
no significant differences were found in the progression-
free survival (PFS) and response rate (58.7% vs. 59.5%)
[7]. With regards to side effects of docetaxel and carbo-
platin administrated, however, notable strong myelosup-
pression and grade 3-4 neutropenia occurred (94% vs.
84%) compared to combined administration of paclitaxel
with carboplatin. On the other hand, occurrence rates of
neurotoxicity were 45% and 78% for neurosensory (p <
0.001) and 9% and 16% for neuromotor (p < 0.001), and
were significantly mild [7].
Meanwhile, mitigation of side effects is expected with
weekly administration of taxane and platinum, compared
to a concomitant use of taxane and platinum with admin-
istration every three weeks, which is the standard admin-
istration. A number of clinical trials have been conducted
to examine the efficacy of the weekly administration [8-
11]. However, the weekly administration requires frequent
office visits, which is inconvenience for patients and ex-
pected to increase healthcare costs. Results of some stud-
ies indicate that concomitant use of docetaxel and
carboplatin by biweekly administration show favorable
tolerability in patients with lung cancer [12, 13]. How-
ever, no study has been conducted to assess the efficacy
and safety of biweekly administration of docetaxel and
carboplatin for ovarian carcinoma and endometrial carci-
noma, which would be very meaningful. Thus the present
authors designed a phase I/II trial to examine efficacy and
safety of biweekly administration of docetaxel and car-
boplatin for advanced or recurrent endometrial and ovar-
ian carcinomas.
Materials and Methods
Patients
Twenty patients with ovarian carcinoma and 22 patients with
endometrial carcinoma who gave their written agreement between
April 2003 and October 2006 were included in this study. The me-
dian age of the patients with ovarian carcinoma and patients with
endometrial carcinoma was 55.8 (35-69) years and 63.2 (49-74)
Revised manuscript accepted for publication March 2, 2015
EJGO European Journal ofGynaecological Oncology
7847050 Canada Inc.
www.irog.net
Eur. J. Gynaecol. Oncol. - ISSN: 0392-2936
XXXVII, n. 4, 2016
doi: 10.12892/ejgo3000.2016
Biweekly administration of docetaxel and carboplatin for
advanced or recurrent endometrial and ovarian carcinomas
D. Nakayama, H. Nishi, R. Kato, Y. Sagawa, F. Terauchi, K. Isaka
Department of Obstetrics and Gynecology, Tokyo Medical University, Shinjuku-ku, Tokyo (Japan)
Summary
Objective: To examine efficacy and safety of biweekly administration of docetaxel and carboplatin for advanced or recurrent en-
dometrial and ovarian carcinomas. Material and Methods: The recommended doses were determined in the phase I study. In the phase
II feasibility study, the primary end-point was safety, and the secondary end-point was response rate and progression-free survival
(PFS). Results: The recommended doses of docetaxel and carboplatin were determined to be 45 mg/m2 and AUC 3.0, respectively, in
phase I study. In phase II feasibility study, no treatment-related death was observed. Most non-hematotoxicity cases were mild or mod-
erate. Grade 4 neutropenia was confirmed in 13 patients (31.0%), whereas all cases showed tolerability with 2.6 days delay of anticancer
drugs administration in both groups. Response rate was 55.0% in the ovarian carcinoma group, and average PFS was 8.7 months. In the
endometrial carcinoma group, response rate was 50.0% and average PFS was 32.0 months. Conclusion: The present results showed that
biweekly administration of docetaxel and carboplatin for advanced and recurrent endometrial and ovarian carcinomas results in ac-
ceptable side effects, response rate, and PFS.
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years, respectively. ECOG Performance Status was 0 for seven pa-
tients, 1 for nine patients, and 2 for four4 patients in the ovarian
carcinoma group and 0 for 11 patients, 1 for six patients, and 2 for
five patients in the endometrial carcinoma group. According to the
classification of International Federation of Gynecology and Ob-
stetrics, two patients (10.0%) were classified as Stage IC, 16 pa-
tients (80.0%) as Stage IIIC, and two patients (10.0%) as Stage IV
for advanced stages at the initial diagnosis in the ovarian carci-
noma group, and eight patients (36.4%) were classified as Stage
IB, five patients (22.7%) as Stage II, three patients (13.6%) as
Stage IIIA, one patient (4.5%) as Stage IIIB, two patients (9.1%)
as Stage IIIC1, and three patients (13.6%) as Stage IVB for ad-
vanced stages at the initial diagnosis in the endometrial carcinoma
group. All of 20 patients with ovarian carcinoma were recurrent
cases, four patients were determined as recurrent because the
CA125 value became two times higher than the upper limit of the
reference value, the others had measurable disease. Nineteen of 22
patients with endometrial carcinoma were recurrent cases, and all
cases, included three advanced cases (Stage IVB), had measurable
disease.
Methods
To examine efficacy and safety of biweekly administration of
docetaxel with carboplatin therapy, recommended dose were de-
termined in the phase I study; in the phase II feasibility study,
the primary end-point was safety, and the secondary end-point
was response rate and PFS. Of recurrent and advanced epithelial
ovarian carcinoma and recurrent and advanced endometrial car-
cinoma cases, patients who were 20 years and older and below 75
years of age, whose ECOG Performance Status was 0-2, who
maintained major organ functions, and who gave written agree-
ment were included in the study. Intravenous drip infusion was
conducted biweekly, and dose-limiting toxicity (DLT) was grade
4 hematotoxicity and Grade 3 non-hematotoxicity. As premed-
ication, eight mg of dexamethasone and antiemetic agent (5HT3
antagonist) were dissolved into 100 ml of saline and adminis-
tered by intravenous drip infusion 30 minutes before the doc-
etaxel administration. Docetaxel was dissolved into 250 ml of
5% glucose solution or saline, and administered by intravenous
drip infusion over 60 minutes. Carboplatin was dissolved into
100 ml of saline, and administered by intravenous drip infusion
over 60 minutes.
Initial dose was 40 mg/m
2
for docetaxel and AUC 3.0 for car-
boplatin (level 1). Docetaxel and carboplatin were 35 mg/m
2
and
AUC 3.0 for level 0, 45 mg/m
2
and AUC 3.0 for level 2, and 50
mg/m
2
and AUC 3.0 for level 3, respectively. Table 1 shows dose-
escalation scheme. First, one cycle of level 1 administration was
given to three patients, and the presence or absence of adverse
drug reaction in each patient at each administration level was ob-
served. The adverse reaction was evaluated according to the Na-
tional Cancer Institute - Common Toxicity Criteria (NCI-CTC
Version 3.0) [14]. Anticancer drugs at a dose determined at level
1 were administered in three patients, and the incidence of side
effects was observed. The level was increased one level when no
DLT occurred, and maximum-tolerated dose (MTD) was deter-
mined as the dose one level lower than the level at which DLT
occurred in all three patients. When DLT occurred only in one or
two of three patients, the same amount was administered in three
new patients again, and the level was further increased if DLT oc-
curred in two patients or less in six patients. If DLT occurred in at
least three patients, MTD was determined as the dose one level
lower.
Phase II feasibility study was conducted based on the recom-
mended dose obtained in phase I. Toxicity was evaluated in all
patients who received the treatment at every cycle. NCI-CTC
Version 3.0 was used for the evaluation [14]. Response evalua-
tion was conducted as follows for patients with a lesion available
for two-dimensional measurement. The evaluation was con-
ducted two times with at least four week intervals. Complete re-
sponse (CR) was defined as CR of all measurable lesions and
evaluable lesions determined by two separately conducted deter-
minations. Partial response (PR) was defined as at least 50% de-
crease in the sum of the product of the vertical diameter of an
evaluable lesion. Progressive disease (PD) was defined as a 25%
or greater increase in the sum of the product of the vertical di-
ameter of an evaluable lesion or appearance of new lesions. NE
was defined as changes was not evaluable. Stable disease (SD)
was defined as changes that do neither correspond to CR, PR,
PD nor not evaluable (NE).
When no evaluable pathological changes were observed and re-
currence was determined because of increase of CA125 value over
the upper limit of the reference value or at least two times increase
of the nadir level, efficacy was determined according to the
CA125 criteria [15].
Results
Determination of recommended dose
No DLT was observed in three cases at level 1 or level 2.
The recommended doses of docetaxel and carboplatin were
determined to be 45 mg/m
2
and AUC 3.0 at level 2, re-
spectively, in phase I study, because DLT was observed in
all three cases at level 3.
Toxicity
No treatment-related death was observed. Hematotoxicity
results of ovarian carcinoma group and endometrial carci-
noma group are summarized in Tables 2 and 3, respectively.
Table 1. — Dose-escalation scheme.
DOC (mg/m2) CBDCA AUC
Level 0 35 3.0
Level 1 40 3.0
Level 2 45 3.0
Level 3 50 3.0
Table 2. — Hematologic toxicity of ovarian cancer group.
Hematologic G3 G4 Grade 4 (%)
Neutropenia 3 6 6 (30.0)
Febrile neutropenia 0 0 0
Anemia 3 1 1 (5.0)
Thrombocytopenia 2 0 0
Table 3. — Hematologic toxicity of endometrial cancer group
Hematologic G3 G4 Grade 4 (%)
Neutropenia 4 7 7 (31.8)
Febrile neutropenia 0 0 0
Anemia 3 0 0
Thrombocytopenia 3 0 0
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Anemia caused as a side effect of the treatment was con-
firmed in three patients (15.0%) for grade 3 and one patient
(5.0%) for grade 4 in the ovarian carcinoma group. Anemia
in either patient was improved by blood transfusion, but an-
ticancer drug administration was delayed for three days and
dose was reduced to the amount of level 1 for the latter pa-
tient. On the other hand, in the endometrial carcinoma
group, anemia was confirmed in three patients (15.0%) for
grade 3. Neutropenia was confirmed in seven patients
(16.7%) for grade 3 and 13 patients (31.0%) for grade 4;
however, administration of anticancer drugs was conducted
after an average of 2.6 days of postponement because of ad-
ministration of recombinant human granulocyte colony-
stimulating factor (rhG-CSF). No patient developed febrile
neutropenia in both groups. Non-hematotoxicity results of
ovarian carcinoma group and endometrial carcinoma group
are summarized in Tables 4 and 5, respectively. Most non-
hematotoxicity cases were mild or moderate, and were tran-
sient with the exception of one case of endometrial
carcinoma in which the treatment was discontinued because
of anaphylactic shock during the third course of the treat-
ment and one case of frequent diarrhea. In addition, the
color of the nails of nine patients changed into dark brown
(grade 1), and one patient experienced deformation and loss
of nails (grade 2). Neuropathy was observed in three pa-
tients at grade 1 and in two patients at grade 2.
Response and survival
On average, administration was conducted 8.3 times
(ovarian carcinoma group, 7.8 (1-15) times; endometrial
carcinoma group, 8.6 (4-12) times). Response rate was
55.0% in the ovarian carcinoma group (CR: eight cases, PR:
three cases, SD: one case, PD: three cases, NE: one case),
and average PFS was 8.7 months. In the endometrial carci-
noma group, response rate was 50.0% (CR: five cases, PR:
six cases, SD: one case, PD: three cases, NE: three cases)
and average PFS was 32.0 months. Table 6 shows the re-
sponse rate.
Discussion
Taxane anticancer agents have previously indicated effi-
cacy against ovarian and endometrial carcinomas. It is re-
ported that the response rate of paclitaxel alone for
advanced or recurrent endometrial carcinoma is 27-36%
[16, 17], and 21-34% for docetaxel [18-20]. Doxorubicin
plus cisplatin therapy (AP) and cyclophosphamide, dox-
orubicin, and cisplatin therapy (CAP) have been used for
endometrial carcinomas since the 1980s [21, 22]. It was
shown that AP therapy is superior to doxorubicin alone for
advanced or recurrent endometrial carcinoma by two ran-
domized controlled trials of European Organization for Re-
search and Treatment of Cancer and Gynecologic Oncology
Group [23, 24].
Recently, TAP therapy (concomitant use of paclitaxel
160 mg/m
2
, doxorubicin 45 mg/m
2
, and cisplatin 50
mg/m
2
, G-CFS), which is a three-drug combination-
chemotherapy including paclitaxel in addition to AP ther-
apy, was examined in a randomized controlled trial (GOG
177). Response rate, PFS and OS of the TAP therapy were
all significantly superior, but toxicity of TAP therapy, es-
pecially neuropathy, was more severe than that of AP ther-
apy [25]. Based on these results, AP therapy is used as the
first-line therapy  for endometrial carcinoma in general
community hospitals. However, doxorubicin has car-
diotoxicity. It is reported that administration of doxoru-
bicin at 550 mg/m
2
or higher caused significantly higher
rate of congested heart failure [26]. Therefore, adminis-
tration of doxorubicin at 550 mg/m
2
or higher was asso-
ciated with a great risk even if the patient was determined
as doxorubicin sensitive. Combination therapies of plat-
Table 5. — Non-hematologic toxicity of endometrial cancer
group
Non-hematologic G1 G2 G3 G4 Grade 3-4 (%)
Anorexia 2 2 0 0 0 (0)
Nausea/vomiting 4 4 0 0 0 (0)
Fatigue 5 2 0 0 0 (0)
Diarrhea 1 1 1 0 1 (4.5)
Alopecia 4 1 0 0 0 (0)
Neuropathy 1 1 0 0 0 (0)
Dysgeusia 3 0 0 0 0 (0)
Myalgia 2 0 0 0 0 (0)
ALT/AST 3 1 0 0 0 (0)
Nail change 4 0 0 0 0 (0)
Stomatitis 1 2 0 0 0 (0)
Allergic reaction 1 0 0 1 1 (4.5)
Table 6. — Response rate.
CR PR SD PD NE Response
rate (%)
Ovarian cancer (n=20) 8 3 1 3 1 55.0
Endometrial cancer (n=22) 5 6 1 3 3 50.0
Table 4. — Non-hematologic toxicity of ovarian cancer
group
Non-hematologic G1 G2 G3 G4 Grade 3-4 (%)
Anorexia 1 2 0 0 0 (0)
Nausea/vomiting 3 4 0 0 0 (0)
Fatigue 4 2 0 0 0 (0)
Diarrhea 2 1 0 0 0 (0)
Alopecia 3 1 0 0 0 (0)
Neuropathy 2 1 0 0 0 (0)
Dysgeusia 4 0 0 0 0 (0)
Myalgia 1 0 0 0 0 (0)
ALT/AST 2 1 0 0 0 (0)
Nail change 4 1 0 0 0 (0)
Stomatitis 1 1 0 0 0 (0)
Allergic reaction 2 0 0 0 0 (0)
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inum-based chemotherapy and paclitaxel are also used as
front-line treatment for endometrial carcinoma in many
facilities; however, only few therapies are effective for
patients with these therapies-resistance.
It is hoped that docetaxel will be an alternative anticancer
drug to paclitaxel. This is because docetaxel has 2.5 times
higher effect on microtubules than paclitaxel [27]. Of 15
patients with paclitaxel-resistance ovarian carcinoma, CR
was observed in five cases (33.3%), and PR in three cases
(20.0%) in the present study. In addition, patients that pre-
viously received paclitaxel were excluded in a study previ-
ously reported on advanced or recurrent endometrial
carcinoma [18-20]. In the present study, CR and PR re-
spectively were observed in two patients (28.6%), respec-
tively that previously received paclitaxel in endometrial
carcinoma. Therefore, the present authors consider that a
better effect can be expected from concomitant use of do-
cetaxel and carboplatin.
In the present study, concomitant use of docetaxel and car-
boplatin by biweekly administration for advanced or recur-
rent ovarian carcinoma obtained 55.0% of CR and PR. There
is a phase II trial that administered docetaxel (75 mg/m
2
) and
carboplatin (AUC: 5) every three weeks for recurrent ovar-
ian, peritoneal, and tubal carcinoma as docetaxel plus carbo-
platin therapy [28]. Subjects of this trial were 25 patients with
platinum sensitive recurrent ovarian carcinoma who experi-
enced carboplatin alone or combination therapy of carbo-
platin and other anticancer drug as 9 first line chemotherapy;
a high response rate of 72% was reported. Of these 25 cases,
21 cases received a combination therapy of paclitaxel and
carboplatin; thus, it is considered that docetaxel will be an
effective anticancer drug for recurrent ovarian carcinoma
after therapy of paclitaxel and carboplatin.
Docetaxel has toxicity characteristics different from pa-
clitaxel, although both are taxane agents [27]. Neutropenia
is the most common toxicity of docetaxel. In the present
study, grade 4 neutropenia was found in nine cases
(45.0%) of ovarian carcinomas, and ten cases (45.5%) of
endometrial carcinomas. Strauss et al. reported that grade
3 or worse neutropenia was observed in 60% of patients
in their study that administered docetaxel (75 mg/m
2
) and
carboplatin (AUC: 5) every three weeks in recurrent ovar-
ian carcinomas [28]. Moreover, grade 3 or worse neu-
tropenia were observed in 94% of patients in every
three-week administration of docetaxel (60 mg/m
2
) plus
carboplatin (AUC: 5), as well as febrile neutropenia, which
required postponement of treatment for at least seven days,
was observed in 14% of patients in a phase III trial that
compared docetaxel plus carboplatin and paclitaxel and
carboplatin as a first-line chemotherapy for ovarian carci-
nomas [7]. Also, in a comparison study of three arms in-
cluding every three-week administration of docetaxel plus
cisplatin, docetaxel plus carboplatin, and paclitaxel plus
carboplatin for advanced recurrent ovarian carcinomas,
grade 3 or worse neutropenia was observed in 90% of pa-
tients and febrile neutropenia was observed 6.7% of pa-
tients in the docetaxel plus carboplatin group [29]. For
neurotoxicity, grade 3 motor neuropathy (6.7%) and grade
3 sensory neuropathy (1.3%) were observed in paclitaxel
plus carboplatin group. On the other hand, neuropathy of
grade 3 or worse was not observed in the docetaxel plus
carboplatin group [29]. No neuropathy case of grade 3 or
worse was found in the present study. 
The present results showed that biweekly administration
of docetaxel or carboplatin for advanced and recurrent en-
dometrial and ovarian carcinomas results in acceptable side
effects, favorable response rate, and PFS. It is suggested
that biweekly administration of docetaxel and carboplatin
maybe a front-line chemotherapy for advanced or recurrent
endometrial and ovarian carcinomas. However, a further
randomized phase III study would be required to evaluate
risks and benefits of biweekly administration of docetaxel
and carboplatin.
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Introduction
Breast cancer is one of the most leading causes of deaths
in the world and the second one in western countries [1].
The prevalence of the disease is also increasing in Asian
populations [2]. In 90% metastasized patients, the resist-
ance to routine chemotherapies has been reported [3]. Dif-
ferent epigenetic or genetic factors [4] have been assumed
to be involved in the process of the disease including inhi-
bition in apoptosis and impairment in the repair of DNAs
[5, 6]. The p53 gene, located on the short arm of chromo-
some 17 with 11 exons has been identified for its role to in-
hibit impairments in cycle and growth of cells [7] in
apoptosis, transcription, and senescence [8 ,9]. Several
studies including the authors’ previous study [10] showed
that polymorphism and some mutations in the p53 gene
play roles in changes which lead to malignancy in colorec-
tal [11] breast, lung, and bladder cancers [12, 13]. It has
been suggested that polymorphism in the codon 72 of the
exon 4 of the p53 gene has link to breast cancer. It has two
allelic forms which lead to produce arginine (CGC) and
proline (CCC) in p53 protein respectively [14]. It has been
also reported that the risk of breast cancer has link with ho-
mozygocity of CGC genotype, arginine/arginine phenotype
[15]. In contrast, some studies concluded that there is no
such association between breast cancer and the polymor-
phism in the codon 72 of the p53 gene [16-18]. However,
an association between homozygocity of proline (CCC) and
the prognosis of breast cancer has been reported in Finland
by Tommiska et al. [19].
Controversial results from different parts of the world
may be due to the possible roles for geographical, regional
or race links between the p53 gene polymorphism and the
risk of breast cancer. It is worthy to indicate that recent
studies showed a decrease in the average age to suffer from
breast cancer in Iran [20]. Although life expectancy has
been increased in parallel to decreasing of mortality, the
overall prevalence has been mounted [21]. The present
study therefore, aimed to determine such possible effect of
having a specific polymorphism in codon 72 of p53 gene
including arginine/arginine, proline/proline, or arginine/
proline genotypes on the prevalence status of cancer and as
risk factors in breast cancer.
The authors followed up all patients for 30 months to ex-
amine that if there was any relationship between those poly-
morphic genotypes and survival rates because, to the best
of their knowledge, there is no report in the region of such
research. The prognosis value of determination of such
polymorphisms and their utilization in early diagnosis and
treatment, particularly when younger women are more
prone to this cancer, were also examined.
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Summary
Purpose of investigation: There are controversial findings to establish relationship between genotype polymorphism of codon 72 of
P53 gene, its prognosis value, and survival rate of the patients in breast cancer. For the first time this study has shown such relationship
in Sabzevar, Iran. Materials and Methods: A descriptive analytical case–control study was conducted on 160 people (80 patients and
80 controls). DNA was extracted and codon 72 of the p53 gene was amplified. The genotype of the p53 gene was determined by elec-
trophoresis, samples were sequenced, and all patients were followed up for 30 months. Results: The frequency of heterozygote argi-
nine/proline was 49 (30.6%) and 51(31.9%) in the patients and controls, respectively. Homozygote arginine/arginine had frequency of
29 (18.1%) in the patients while it was 15 (9.4%) in controls. Homozygote of proline/proline was two (1.3%) in the patients and 14 (8.8%)
in controls. The sequencing results were consistent to PCR and electrophoresis results. Conclusions: This is the first study in the region
which shows relationship between genotype polymorphism, survival rate, and its prognosis value in breast cancer. The authors showed
that homozygote proline/proline in controls was significantly higher compared with that in the patients. They may therefore, conclude
that detection of allelic polymorphisms of codon 72 of the p53 gene including arginine/arginine could be a risk factor predisposition for
breast cancer and valuable tool for determining prognosis, progress, and treatment purposes. 
Key words: Breast cancer; Allelic polymorphism; Codon 72.
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Materials and Methods
Patients and controls
The study was a descriptive, analytical case control which was
conducted on 160 samples including 80 patients with breast car-
cinoma and 80 matched healthy controls. The ethical committee
of the university approved the study. After describing the study's
nature, aims and possible benefits for improvement to prevent or
cure the disease a written consent form was given from each in-
volved sample.
For pathological diagnosis of the breast carcinoma, five sec-
tions with five-µm thickness were prepared from each patient. A
peripheral blood sample at 1.5 ml was taken from each healthy
matched control, homogenized, and stored in the tubes containing
0.5 molar ethylene diamine tetra acetic acid (EDTA) at -20ºC.
DNA extraction and PCR
DNA was separately extracted from each patient and control
using standard kit. Codon 72 of the p53 gene was amplified using
two specific primers by PCR technique. Specific primers for pro-
line and arginine were prepared and lyophilized. They were di-
luted using deionized sterilized water to the required
weight/volume based on manufacturer's instructions. The five
mmolar dNTP solution (stock ten mmolar) was used. The se-
quences for proline and arginine primers were as follows re-
spetively:
Forward: 5’GCCAGAGGCTGCTCCCCC3’ 3’
Reverse: 5’CGTGCAAGTCACAGACTT
Forward: 5’ TCCCCCTTGCCGTCCCAA3’ 3’
Reverse: 5’ CTGGTGCAGGGGCCACGC
During the optimized PCR process 59ºC was used for 50 sec-
onds to amplify proline and arginine. The concentrations of ma-
terials used were as follows: DNA at five mM, primers and
chloride magnesium at 0.5 mM, arginine at two mM and proline
at five mM. The exon 4 of the p53 gene containing codon 72 was
amplified in 35 cycles at the same condition for all collected sam-
ples. 
Histopathological experiments
All diagnosed cancerous tissues after surgery were fixed with
10% formalin and renewed after four hours. Tissue passage was
done by a processing tissue device after 24 hours. Sections with
five-µm thickness were prepared for all samples using rotational
microtome. For background staining hematoxylin, eosin, a spe-
cific monoclonal rabbit antihuman PTEN antibody and avidin-bi-
otinolated immunoperoxidase were used. To localize the antigenic
determinants a citrate buffer at 0.9% and hydrogen peroxidase at
3% were added to all samples and kept at 37º C for 30 minutes to
inhibit endogenous peroxidase. After five times washing with
phosphate buffer saline (PBS), streptoavidin conjugated with
horse radish phosphate (HRP) was added to all sections to oxi-
dize diaminobenzidine (DAB) which stained cells to brown.
Grades and stages
For determination of grades and stages, all samples were ex-
amined by two separate pathologists. Microscopy was carried out
using a motic microscope equipped with advanced motic plus
software with both 100 and 400 magnifications [22]. Histological
grading was separately performed by microscopy based on the
three following parameters: mitotic activity, nuclear pleomor-
phism, and the extent of tubule formation. Grades were then pro-
posed in three groups: 1, 2, and 3 [23]. Tumor stages in the breast
cancer were designated in numbers from 0 to 4 when 0 is for in
situ carcinoma and Stages I, II, III, and IV are for the four conse-
quent stages [24].
Electrophoresis
Electrophoresis was briefly set as follows: PCR product at five µl
was mixed with one µl of loading dye and inserted into 1.5%
agarose gel. For DNA staining, ethidium bromide was used and the
results were photographed using gel documentation device. The
genotype for each sample was then identified based on the base
pairs (bp) of each bind compared with the standard marker. 
Sequencing: Before sequencing each DNA sample was prepared
by cutting the selected binds and was then amplified by PCR and
the resultants were then sent to South Korea for sequencing. 
Follow up: To evaluate relationship between the survival rate of
patients with breast cancer and the genotypic mutation character-
istics of codon 72, all patients were followed up for 30 months.
For this purpose the authors contacted close relatives of all pa-
tients at proper intervals to ask and check the status of each one.
Statistics
Data was analyzed using SPSS software version 15. The Pear-
son chi-square and Fisher exact tests were used when required to
explore associations between genotype and histological parame-
ters. Using Kaplan Meier method, survival rate of patients with
Figure 1. — Cross sections (four µm) from healthy controls and pa-
tients. Above: left cancerous, right normal. The following figures
show different grades and metastatic section in the liver. All samples,
normal and cancerous, were stained by H/E for the background and
specific staining using streptoavidine conjugated with HRP which is
able to oxidize (DAB). This staining method colored cells brown so
that they can be distinguished with each other and other components.
The magnification was 100 except for figures showed grades and
metastatic pictures for which 400 magnification scales were utilized.
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different genotypes and groups in higher and lower cancer stages
was explored. Differences were tested by Mantel-Cox log-rank
test. The results were considered to have significant difference
when the p value was < 0.05 through all experiments.
Results
In the present study all 80 cancerous patients were diag-
nosed with a breast carcinoma. The minimum and maxi-
mum ages in patients were 20 and 86 years. In the healthy
controls their ages were between 23 and 80 years. The av-
erage age for patients and controls were 47.22 ± 12.95 and
48.02 ± 12.48 years, respectively. 
Stages
Of 80 patients, 31 (38.8%) cases were in the Stages of
0 (in situ carcinoma) and I who had cancerous cells lim-
ited to one or some lobules and ducts and there was no
sign of metastasis in fatty tissues, lymph nodes or cells
surrounding the location of the carcinoma. There were 33
(41.3%) samples in Stage ІІ. They showed metastasis in
the nearby tissues such as close lymph nodes. The num-
ber in Stage ІІІ was ten (12.5%) with metastatic cells in
the regional lymph nodes. The other six patients had car-
cinoma in Stage ІV and metastasis was observed in three
patients in their lungs, one in her second breast and the
remaining two ones in their liver (Figure 1).
Grades
There were 13 (16.3%) samples with grade 1, 45 (56.3%)
with grade 2, and 22 (27.5%) with grade 3 (Figure 2). Re-
garding the grade and the menopausal age, the results
showed significant differences between women who were
at or less than 45 years old and older than 45 years. For ex-
ample, a significant difference (p < 0.007) was seen be-
tween ten (12.5%) non-menopausal women  and in three
(3.8%) menopausal ones with grade 1. There were 22
(27.5%) non-menopausal and 23 (28.8%) menopausal cases
with grade 2. However, for all women with grade 3, 17
(21.4%) menopausal ones had significantly higher rate (p <
Figure 3. — The PCR products of codon 72 of p53 gene in exon
4 for proline/proline, arginine/arginine and proline/arginine in
samples with breast cancer. The marker ladder was a standard lad-
der of 100 bp. The allele for proline/proline was 177 bp.The allele
for arginine/arginine was 141.
Figure 2. — The association between survival rates and the stages of cancer. For calculation Stages 0 and I were accumulated and des-
ignated as Stage І and the other as ІІ, ІІІ, and ІV. During follow up, the stages of the disease were measured and as expected patients
with higher stages had lesser survival rate. A: Association between survival rates and the stages of the breast cancer. B: Association be-
tween survival rates and genotypes of the breast cancer. Genotype 1 was designated as arginine/proline, genotype 2 was designated as
arginine/arginine, and genotype 3 was designated as proline/proline.
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0.007) compared with five (6.3%) non-menopausal women.
There were no significant differences (p < 0.44) between
the stage of the carcinoma and either non-menopausal or
menopausal situation. 
The association between the survival rates in the patients
with arginine/proline genotype was higher than that in those
who had arginine/arginine genotype. Patients with pro-
line/proline genotype had the lowest survival rate compared
with other checked genotypes (Figure 2).
Genotypic polymorphism
The authors analyzed the frequency and distribution of
different arginine and proline genotypes. Their alleles had
141 and 177 base pairs respectively. The frequency of het-
erogeneous arginine/proline genotype was 49 (30.6%) and
51 (31.9%) in the patients and healthy controls, respec-
tively, with no significant differences. The frequency of
arginine/ arginine was 29 (18.1%) in the cancerous sam-
ples whereas it was 15 (9.4%) in the healthy controls,
which showed a higher rate in the patients compared with
the controls but, there was no significant difference. How-
ever, the frequency of homogeneous proline/proline geno-
type in the healthy controls with 14 (8.8%) cases was sig-
nificantly higher than that in the patients with two (1.3%)
cases (p < 0.001)(Table 1). Below we have brought the
genotypes followed by their consequent stages in accor-
dance with their frequency: proline/proline at Stage ΙV
arginine/arginine at Stage ΙΙΙ, arginine/proline at Stage
ΙΙ<, and Stage Ι, respectively. The results for bands of
arginine and proline alleles are shown in Figure 3.
Sequencing results
The results of sequencing for homozygous arginine/argi-
nine, proline/proline, and heterogenous arginine/arginine
were consistent with the results given by PCR and elec-
trophoresis in the patients and healthy controls (Figure 1).
Moreover, the results of grading and staging were also con-
sistent in terms of having significant or non-significant dif-
ferences between genotypes in the patients and controls
(Figure 4). 
Follow up
Association between the survival rate and the genotypic
mutation characteristics of codon 72 of p53 gene were ex-
amined for all patients. All patients were followed up for 30
consequent months by interval contacts with their closed
relatives. It was expected that patients who were in higher
stages had lesser survival rate compared to those who were
in lower stages. During follow up, 38 patients out of 80 ones
died. Of 38 dead 20 had hemozygote arginine/arginine, 16
had heterozygote arginine/proline, and two patients had pro-
line/proline genotypes. The highest survival rate was ob-
served in patients with arginine/proline genotype compared
with others. The second higher survival rates were for cases
with arginine/arginine whereas two patients with pro-
line/proline genotype had the lowest survival rate among
the examined cases though they were only two cases. 
Discussion
Studies have shown that the risk of breast cancer mortal-
ity may be affected by genetic and epigenetic factors [25]
including polymorphisms in the p53 gene. In this gene
codon 72 on exon 4 have two distinct alleles which encode
arginine (CGC) and proline (CCC), respectively, in the p53
Table 1. — The frequency of the genotype codon 72 of p53
gene expression in the different tumor stages in the cells of
breast cancer and normal tissue. The data were statistically
tested to find any significant differences.
Variables Arg/pro Arg/Arg Pro/Pro Statistical
No. (%) No. (%) No. (%) relationship
Cancer 49 (30.6%) 29 (18.1%) 2 (1.3%) p < 0.001
Normal 51 (31.9%) 15 (9.4%) 14 (8.8%)
Stage of cancer in situ carcinoma p < 0.001
and I 22 (27.5%) 9 (11.5%) 0 (0%)
II 26 (32.5%) 7 (8.8%) 0 (0%)
III 1 (1.3%) 8 (10%) 1 (1.3%)
IV 0 (0%) 5 (6.3%) 1 (1.3%)
Tumor grade p < 0.01
I 7 (8.8%) 6 (7.5%) 0 (0%)
II 34 (42.5%) 11 (13.8%) 0 (0%)
III 8 (10%) 12 (15%) 2 (2.5 %)
Age < 45 55 (34%) 20 (12.5%) 12 (7.5%) p = 0.124
Age > 45 45 (28%) 24 (15%) 4 (2.5%)
Figure 4. — The results for identifying
sequencing of codon 72 polymorphism
of p53 gene. Left above: The figure
shows the genotype CGC which encodes
proline. Right above B: The figure
shows the genotype CCC which encodes
arginine.
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protein structure [26]. The present results showed that in
the healthy people, the homozygote proline/proline was sig-
nificantly higher compared to the patients. In contrast, the
homozygote arginine/arginine genotype in the patients with
breast carcinoma was higher compared with the healthy
controls. The authors also found that there was slightly
higher heterozygote proline /arginine in the healthy people
compared with the patients.
The survival rate in the patients with arginine/proline
genotype was higher than that in those who had argi-
nine/arginine. So, it seems that patients with arginine/argi-
nine had more chance to suffer from cancer. Cases with
proline/proline genotype had the significantly lowest sur-
vival rate compared with other checked genotypes. How-
ever, it may be assumed that, the reason could be the
number of the cases as they were only two. More impor-
tantly they showed the highest stages, one at the stage III
and another one at the stage IV. These findings suggest that
we need to perform more investigations with a bigger sam-
ple size to cover other possibilities. 
The significant association between the grades and the
stages with the genotype was also observed. However, there
was no such association in women regarding menopausal or
non-menopausal status and the distinct genotype. Some
studies in Brazil and Greece were in agreement with the
present results as they reported a significant link between
the presence of arginine/arginine and the risk of the breast
cancer [15]. In contrast, Vijayraman et al. from Maduria
have reported that there was no such link between the argi-
nine/arginine, proline/proline, and arginine/proline geno-
types of p53 gene and the breast cancer [27]. However, it is
worthy to note that in that study, sample size was smaller
than the present. They had only 100 samples (50 patients
and 50 controls) whereas the present authors examined 160
people, including 80 with cancer and 80 that were healthy.
An association between proline/proline genotype for
exon 4 of codon 72 has been shown by a group in Austria
[28] which demonstrated similar findings with the present
results. They also showed that the frequency of heterozy-
gous proline/arginine was close to each other in the can-
cerous and healthy people. However, unlike the present
study, they suggested that proline/proline had a role in
breast cancer. In Japan, it has been also reported that peo-
ple with proline/proline for codon 72 of p53 gene had lesser
life expectancy than those with either proline/arginine or
arginine/arginine genotypes [29]. Again in agreement with
the present results, a study in Saudi Arabia claimed that
there was a positive link between the initiation of the breast
cancer and the arginine/arginine genotype. In addition, they
proposed that there is a possible protective role for argi-
nine/proline genotype [30].
According to above studies, it may be suggested that the
stage status of the disease had more important role in the
survival rate compared to the genotype status (Figure 4).
These controversial results may reflect the possibility of dif-
ferent functionality for genotypic polymorphism of codon
72 which may be influenced by other factors, such as geo-
graphical and regional epigenetic specifications or even
other unknown reasons. Further investigations, therefore,
may be required to clarify and justify such controversies. In
addition, these results are the reason why many studies have
focused on the roles of codon 72 of p53 gene worldwide,
particularly in the case of breast cancer. Similar to the pres-
ent results in another study, Gochhait et al. showed that argi-
nine/arginine genotype was more prevalent in the women
with breast cancer compared with healthy ones [31].
Moving to another insight, it has been also shown that re-
sponses to the breast cancer treatment with anthracycline can
be influenced by polymorphism of codon 72 of p53 gene in
addition to pathological characteristics [25]. In this regard
Wegman et al. in Sweden have reported that patients with
breast cancer who had estrogen receptors and proline allele
had shown better response to tamoxifen against the breast
cancer than those who carried other alleles of codon 72 [32].
They also showed that patients who had arginine/arginine
genotype had the same response to the treatment with either
tamoxifen or non-tamoxifen chemotherapy. Therefore, these
results suggested that lack of proline allele in the patients re-
sulted in the better effective response to non-tamoxifen
chemotherapy [32].Schneider et al. who worked on neck and
head cancers in Germany believed that the role of polymor-
phism of codon 72 of p53 gene is due to its role in apoptosis
in malignant cells. Their study showed that tumors with argi-
nine/arginine were resistant to apoptosis while tumors with
proline/arginine were susceptible to the same apoptosis
process [33]. Like the present results, their study confirmed
the importance of some aspects of oncogenesis for argi-
nine/arginine allele.
Conclusion
Controversial findings in breast cancer studies in different
regions [34] suggested that there are probably regional pat-
terns for the appearing and presence of a particular geno-
type of codon of 72, which plays role in oncogenic
processes. The present authors may assume that, due to the
effect of epigenetic factors in genotypic changes and con-
sequently in different functions, more experimental wider
works are required to identify the genotypic situation of
codon 72 in any area where breast cancer is endemic and
prevalent. The importance of breast cancer, the realty that
there are no sufficient studies to clarify possible roles of
polymorphism in codon 72 in different regions and popula-
tions, and many other controversial results, would encour-
age researchers to design comprehensive studies focusing
on the factors affecting the survival rate, life expectancy,
and related regional factors. These findings may lead to ear-
lier diagnosis and subsequently the findings would be the
best effective prevention and treatment protocols and hence
would lead to less mortality due to breast cancer.
EJGO_4_2016:Layout 1  30-06-2016  11:14  Pagina 497
R. Golmohammadi, M.J. Namazi498
Acknowledgments
This study has been supported financially by Sabzevar
University of Medical Sciences. The authors would also
like to thank Mrs. Narges Valizadeh at the Faculty of Med-
icine Research Laboratory at the Mashhad University of
Medical Sciences for their kind technical assistance.
References
[1] Abdulrahman G.O., Rahman G.A.: “Epidemiology of breast cancer in
Europe and Africa”. J. Cancer. Epidemiol., 2012, 2012, 915610. 
[2] Lam W.W., Fielding R., Ho E.Y.: “Predicting psychological morbid-
ity in Chinese women after surgery for breast carcinoma”. Cancer,
2005, 103, 637.
[3] Longley D.B., Johnston P.G.:”Molecular mechanisms of drug resist-
ance”. J. Pathol., 2005, 205, 275.
[4] Scotto K.W.: “Transcriptional regulation of ABC drug transporters”.
Oncogene, 2003, 47, 7496.
[5] Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., Kim J.C.: “Sig-
nificance of mismatch repair protein expression in the chemotherapeu-
tic response of sporadic invasive ductal carcinoma of the breast”. Breast
J., 2004, 1, 20.
[6] Michor F., Nowak M.A., Iwasa Y.: “Evolution of resistance to cancer
therapy”. Curr. Pharm. Des., 2006, 12, 261.
[7] Reisman D., Takahashi P., Polson A., Boggs K.: “Transcriptional Reg-
ulation of the p53 Tumor Suppressor Gene in S-Phase of the Cell-Cycle
and the Cellular Response to DNA Damage”. Biochem. Res. Int., 2012,
2012, 808934. 
[8] Hofseth L.J., Hussain S.P., Harris C.C.: “p53: 25 years after its dis-
covery”. Trends Pharmacol. Sci., 2004, 4, 177.
[9] Reinhardt H.C., Schumacher B.: “The p53 network: cellular and sys-
temic DNA damage responses in aging and cancer”. Trends Genet.,
2012, 3, 128.
[10] Golmohammadi R., Namazi M.J., Nikbakht M., Salehi M., Derakhshan
M.: “Characterization and Prognostic Value of Mutations in Exons 5
and 6 of the p53 Gene in Patients with Colorectal Cancers in Central
Iran”. Gut Liver, 2013, 7, 295.
[11] Burroni E., Bisanzi S., Sani C., Puliti D., Carozzi F.: “Codon 72 poly-
morphism of p53 and HPV type 16 E6 variants as risk factors for pa-
tients with squamous epithelial lesion of the uterine cervix”. J. Med.
Vitrol., 2013, 1, 83. 
[12] Xu T., Xu Z.C., Zou Q., Yu B., Huang X.E.: “P53 Arg72Pro poly-
morphism and bladder cancer risk--meta-analysis evidence for a link
in Asians but not Caucasians”. Asian Pac. J. Cancer Prev., 2012, 5,
2349.
[13] Papadakis E.N., Dokianakis D.N., Spandidos D.A.: “p53 codon 72
polymorphism as a risk factor in the development of breast cancer”.
Mol. Cell Biol. Res. Commun., 2000, 6, 389.
[14] Donehower L.A.: “p53:guardian AND suppressor of longevity?” Exp.
Gerontol., 2005, 1, 7.
[15] Damin A.P., Frazzon A.P., Damin D.C., Roehe A., Hermes V., Zettler
C., Alexandre C.O.: “Evidence for an association of TP53 codon 72
polymorphism with breast cancer risk”. Cancer Detect. Prev., 2006, 6,
523.
[16] Suspitsin E.N., Buslov K.G., Grigoriev M.Y., Ishutkina J.G., Ulibina
J.M., Gorodinskaya VM, et al.: “Evidence against involvement of p53
polymorphism in breast cancer predisposition”. Int. J. Cancer, 2003, 3,
431.
[17] Mabrouk I., Baccouche S., El-Abed R., Mokdad-Gargouri R., Mosbah
A., Saïd S., et al.: “No evidence of correlation between p53 codon 72
polymorphism and risk of bladder or breast carcinoma in Tunisian pa-
tients”. Ann. N. Y. Acad. Sci., 2003, 1010, 764.
[18] Jiang N., Pan J., Wang L., Duan Y.Z.: “No significant association be-
tween p53 codon 72 Arg/Pro polymorphism and risk of oral cancer”.
Tumour. Biol., 2013, 1, 587.
[19] Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J.,
et al.: “Breast cancer patients with p53 Pro72 homozygous genotype
have a poorer survival”. Clin Cancer Res., 2005, 14, 5098.
[20] Golmohammadi R., Pejhan A.: “The prognostic value of the P53 pro-
tein and the Ki67 marker in breast cancer patients”. J. Pak. Med.
Assoc., 2012, 9, 871.
[21] Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J.: “Cancer
statistics. CA. Cancer”. J. Clin., 2007, 57, 43.
[22] Beckstead J.H.: “A simple technique for preservation of fixation sen-
sitive antigens in paraffin-embedded tissues”. J. Histochem. Cy-
tochem., 1994, 8, 1127.
[23] Sloane J.P., Anderson T.J., Blamey R.W., Brown C.L., Chamberlain
J., Coyne J., et al.: “Pathology reporting in breast cancer screening
2nd ed. National Coordinating group for breast screening pathol-
ogy”. NHSBSP Publication, 1995, 3, 19.
[24] Breast Cancer Org: “Stages of breast cancer”, 2008. Available at:
http://www.breastcancer.org/dia_pict_staging.html
[25] Szkandera J., Absenger G., Dandachi N., Regitnig P., Lax S., Stotz
M., et al.: “Analysis of functional germline polymorphisms for pre-
diction of response to anthracycline-based neoadjuvant chemother-
apy in breast cancer”. Mol. Genet. Genomics, 2012, 9, 755.
[26] Vietri M.T., Riegler G., Ursillo A., Caserta L., Cioffi M, Molinari
A.M.: “p53 codon 72 polymorphism in patients affected with ulcer-
ative colitis”. J. Gastroenterol., 2007, 6, 456.
[27] Vijayaraman K.P., Veluchamy M., Murugesan P., Shanmugiah K.P.,
Kasi P.D.: “p53 exon 4 (codon 72) polymorphism and exon 7 (codon
249) mutation in breast cancer patients in southern region (Madu-
rai) of Tamil Nadu”. Asian. Pac J. Cancer. Prev., 2012, 2, 511.
[28] Proestling K., Hebar A., Pruckner N., Marton E., Vinatzer U.,
Schreiber M.: “The Pro allele of the p53 codon 72 polymorphism is
associated with decreased intratumoral expression of BAX and p21,
and increased breast cancer risk”. PLoS One, 2012, 7, e47325.
[29] Toyama T., Zhang Z., Nishio M., Hamaguchi M., Kondo N., Iwase
H., et al.: “Association of TP53 codon 72 polymorphism and the out-
come of adjuvant therapy in breast cancer patients”. Breast Cancer
Res., 2007, 3, R34.
[30] Al-Qasem A., Toulimat M., Tulbah A., Elkum N., Al-Tweigeri T.,
Aboussekhra A.: “The p53 codon 72 polymorphism is associated
with risk and early onset of breast cancer among Saudi women”.
Oncol. Lett., 2012, 4, 875.
[31] Gochhait S., Bukhari S.I, Bairwa N., Vadhera.S, Darvishi K., Raish
M., et al.: “Implication of BRCA2 -26G>A 5' untranslated region
polymorphism in susceptibility to sporadic breast cancer and its mod-
ulation by p53 codon 72 Arg>Pro polymorphism”. Breast Cancer
Res., 2007, 5, R71.
[32] Wegman P., Stal O., Askmalm M.S., Nordenskjöld B., Rutqvist L.E.,
Wingren S.: “p53 polymorphic variants at codon 72 and the outcome
of therapy in randomized breast cancer patients”. Pharmacogenet.
Genomics, 2006, 5, 347.
[33] Schneider-Stock R., Mawrin C., Motsch C., Boltze C., Peters B.,
Hartig R., “et al”.: “Retention of the arginine allele in codon 72 of the
p53 gene correlates with poor apoptosis in head and neck cancer”.
Am. J. Pathol., 2004, 4, 1233.
[34] He X.F., Su J., Zhang Y., Huang X., Liu Y., Ding D.P., Wang W.,
Arparkorn K.: “Association between the p53 polymorphisms and
breast cancer risk: meta-analysis based on case-control study”.
Breast Cancer Res. Treat., 2011, 130, 517.
Address reprint requests to:
M.J. NAMAZI, M.D.
Department of Microbiology, Immunology and 
Parasitology, Faculty of Medicine
Sabzevar University of Medical Sciences
PO Box 3019
Sabzevar (Iran) 
e-mail: mjnamazi@gmail.com
EJGO_4_2016:Layout 1  30-06-2016  11:14  Pagina 498
Introduction
Cervical carcinoma is the second most common cancer
affecting women’s health worldwide, and more than 80%
of all cervical cancers occur in women in developing
countries [1]. Cervical cancer remains an important pub-
lic health problem in mainland China. In 2005, there were
approximately 58,000 new cervical cancer cases (National
Office for Cancer Prevention and Control et al., 2009) and
about 20,000 deaths [2].
The treatment strategy of cervical carcinoma has been
improved significantly in the past two decades. On the
basis of numerous notable studies in the late 1990s, con-
current irradiation with cisplatinum-based chemotherapy
(CCRT) has been recommended as standard treatment for
local advanced cervical carcinoma (LACC) in most de-
veloped counties in the world [3, 4]. Cisplatin added to
radiation could reduce the relative risk of death from cer-
vical carcinoma by approximately 50% by decreasing
local failure and distant metastasis, and improve overall
survival (OS) by 9%–18% as well [5, 6]. However, the
five-year OS of LACC patients still remains around 70%
[7], and in elderly patients, patients with co-morbid med-
ical conditions, poor performance status (PS), and those
who refused chemotherapy cannot be administered, for
which a different strategy is required to enhance the ef-
fects of radiotherapy given as a single modality of treat-
ment [8]. Moreover, one of the major criticisms raised
against CCRT is the potentially higher risk of complica-
tions, such as hematologic and gastrointestinal toxicities.
Thus, it is still critical to explore a more effective thera-
peutic strategy for further OS improvement of LACC. 
Until now, it is still not clear whether CCRT can provide
a significant advantage for LACCs, eg, Stages III–IVA, in
comparison with pure radiotherapy (RT) or in combina-
tion following radical surgery [9]. A meta-analysis study
demonstrated that survival benefit of CCRT might be re-
stricted to lower stage patients with International Federa-
tion of Obstetricians and Gynaecologists (FIGO) Stage
IB–IIA, IIB having an increase in OS of 10% and 7%, re-
spectively, by CCRT [10]. A retrospective study carried
out in 174 Chinese patients with LACC reported that pre-
operative CCRT achieved outcomes superior to RT alone,
but depending on the pathologic response, tumor size and
lymph-node involvement as major prognostic factors [11].
However, previous studies did not define the incidence,
type, and severity of postoperative complications and long
term efficacy of CCRT in a large series of Chinese LACC
patients. Therefore, the aim of this study was to determine
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Summary
Purpose: To assess the complications and clinical outcomes of concurrent chemoradiotherapy (CCRT) or pure radiotherapy (RT) in
local advanced cervical carcinoma (LACC) patients. Materials and Methods: A retrospective study was carried out in 113 consecu-
tive LACC (FIGO Stage IB2-IIIB) patients, of whom 68 received CCRT; the others received pure RT. Five-year overall survival (OS)
and the incidence, type, and severity of postoperative complications were analyzed. Results: The five-year survival rate for CCRT and
pure RT were 67.7% and 46.8%, respectively (p = 0.018). The incidences of bone marrow suppression and gastrointestinal reaction for
CCRT and pure RT were 100% vs. 88.89% (p < 0.001) and 70.6% vs. 33.33% (p < 0.001). Only 16.18% patients received CCRT de-
veloped chronic radiation enteritis, and 4.35% developed chronic radiation cystitis. While 11.11% patients received pure RT experienced
chronic radiation enteritis (p = 0.449), 4.44% experienced chronic radiation cystitis (p = 0.312). Conclusions: This retrospective study
demonstrated that CCRT followed by radical surgery achieved a better outcome compared with pure RT in LACC patients, but could
apparently rise the incidence and severity of hematologic and gastrointestinal toxicity. 
Key words: Local advanced cervical carcinoma; Concurrent chemoradiotherapy; pure radiotherapy; Complications; Clinical outcome.
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whether CCRT offered a lower incidence of toxic reactions
and better long-term efficacy in comparison with pure RT
in a five-year follow-up retrospective cohort.
Materials and Methods
Patients 
LACC patients who were treated in The Second Hospital of Tian-
jin Medical between January 2007 and January 2009 were recruited
in this study. Inclusion criteria were: (1) Biopsy proven cases of ad-
vanced squamous cell carcinoma of uterine cervix, Stage IB2–IIIB
(as per FIGO 2009 staging); (2) age between 25 and 75 years; (3)
Karnofsky Performance Status (KPS) ≥ 70; (4) adequate bone mar-
row, liver, and renal function (Hb ≥ 10 g/dl; WBC ≥ 3,000/mm
3
,
platelets ≥ 120,000/mm
3
; bilirubin < 2 mg/dl; blood urea nitrogen <
25 mg/dl, creatinine < 1.5 mg/dl); (5) no obvious mental abnormal-
ities, psychological disorder and cognitive impairment; (6) with
complete basic medical records and follow-up information. Exclu-
sion criteria were: (1) age > 75 years or < 25 years; (2) KPS < 70;
(3) pregnancy; (4) history of pelvic surgery, malignancy, exposure to
cytotoxic chemotherapy or radiation; (5) combination of other tumor
or sever chronic illness, such as chronic obstructive pulmonary dis-
ease, coronary heart disease, diabetes; (6) with distant metastasis.
The study was approved by the Institutional Review Board of the
present hospital. Written informed consent was obtained from all of
the patients according to the committee’s regulations.
One hundred thirteen LACC cases who met the eligibility cri-
teria were divided into two groups according to the treatment arm:
68 patients in group A received CCRT, and 45 patients in group B
received pure RT. Baseline patient characteristics were similar and
well-balanced in both groups (Table 1).
Treatment
Both groups received combination of external beam radiation
therapy (EBRT) and intracavitary brachytherapy (ICBT). EBRT
included 6~15 MV of linear accelerator therapy apparatus, and
ICBT included a WD- HDR18 close after installed with Iridium
192 radioactive sources. EBRT included DT 46~50 Gy, 2.0
Gy/times, five times a week, and the radiation field included the
upper bound on the edge between the lumbar spine, lower obtu-
rator under two cm, and with the vaginal invaded scope changes,
the lateral reach derma pelvic most outside diameter 1~2 cm wide,
common iliac, external iliac, and iliac and sacral front and obtu-
rator lymph nodes were involved. All patients received ICBT im-
mediately after completion of EBRT, DT 36~42 Gy, six
Gy/week,once a week to point A (a point two cm lateral to the
center of the uterine canal and two cm above the mucous mem-
brane of the lateral fornix of the vagina in the plane of the uterus).
The CCRT group received RT. Chemotherapy began from the first
day of RT using PF scheme: cisplatin (DDP) 50~70 mg/m
2 
1~2
days, 5 fluorouracil (5-Fu) 750 mg/m
2
, 2~5 days, intravenous drip,
three weeks/times, a total of three times.
Follow-up and toxicity evaluation
Patients were followed up by both the radiation oncologist
and the gynecologist with detailed physical and gynecological
examinations. Patients were followed up every six months from
June 2009 to June 2014. The incidence of bone marrow sup-
pression, gastrointestinal reaction, chronic radiation enteritis,
and chronic radiation cystitis were assessed and recorded. Tox-
icity assessment was performed according to the Radiation Ther-
apy Oncology Group/European Organization for Research and
Treatment for Cancer late-radiation morbidity-scoring scheme
[12].
Statistical analysis
Statistical analysis was performed with SPSS 18.0, χ
2
test were
used for categorical variables, and Mann-Whitney U test was used
to for continuous values. OS was calculated from the date of diag-
nosis to the date of death or the date of the last follow-up. Survival
curves were plotted using the Kaplan-Meier product-limit method,
and differences between survival curves were tested using the log-
rank test. All tests were two-tailed and a p-value < 0.05 was con-
sidered significant.
Table 1. — Comparison of baseline clinical characteris-
tics between the two groups.
Clinical variables Group A Group B p
(n=68) (n=45)
Median age (range) 47.5 (29.3-64.2) 48.6 (31.6-67.8) 0.674
Histotype
Squamous 58 41
Adenocarcinoma 8 4 0.602
Adenosquamous
carcinoma
2 0
FIGO Staging
IB2 21 16
IIB 30 22 0.705
IIIB 17 7
Group A: concomitant chemoradiotherapy; Group B: pure radiotherapy.
FIGO: The International Federation of Gynecology and Obstetrics.
Table 2. — Comparison of the incidence of bone marrow suppression between the two groups (n / %).
Groups Cases Grade 0 Grade I Grade II Grade III Grade IV Total Z p*
Groups A 68 0 (0.00) 12 (17.65) 37 (54.41) 15 (22.06) 4 (5.89) 68 (100)
-4.879 0.000
Groups B 45 54 (11.11) 21 (46.67) 17 (37.78) 2 (4.44) 0 (0.00) 40 (88.89)
Group A: concomitant chemoradiotherapy; Group B: pure radiotherapy. 
*
Mann-Whitney U test.
Table 3. — Comparison of the incidence of gastrointestinal reaction between the two groups (n / %).
Groups Cases Grade 0 Grade I Grade II Grade III Grade IV Total Z p*
Groups A 68 20 (29.4) 20 (29.4) 12 (17.6) 10 (14.7) 6 (8.82) 48 (70.6)
-3.788 0.000
Groups B 45 30 (66.67) 7 (15.56) 5 (11.11) 2 (4.44) 1 (2.22) 15 (33.33)
Group A: concomitant chemoradiotherapy; Group B: pure radiotherapy. 
*
Mann-Whitney U test.
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Results
Hematologic, gastrointestinal, nephrotoxic. and urinary
complications were the most common types of toxicity.
During the observation period, as shown in Table 2, 68
(100%) patients in group A experienced no grade bone mar-
row suppression complications, and 19 (27.94%) of them
had ≥ grade 3 complications. In Group B, the bone marrow
suppression complications occurred in 40 (88.89%) pa-
tients, significantly lower than that of group A (Z = - 4.579,
p < 0.000), and two (4.44%) of them had ≥ grade 3 com-
plications, significantly lower than that of group A (χ
2
=
8.389, p = 0.004).
As shown in Table 3, the incidence rate of gastrointesti-
nal reaction in group A was 70.6% (48/68), significantly
higher than that of group B [33.33% (15/45), Z = - 3.788,
p < 0.000]. The III-IV grade gastrointestinal reaction in
group A was 23.53% (16/68), significantly higher than that
of group B [6.67% (3/45), χ
2
= 4.336, p = 0.037].
Of the 68 patients in group A, only 11 (16.18%) patients
developed early-grade chronic radiation enteritis, and five
(4.35%) patients developed early-grade chronic radiation
cystitis. While in group B, five (11.11%) patients developed
early-grade chronic radiation enteritis, and two (4.44%) pa-
tients developed early-grade chronic radiation cystitis. No
significantly differences were observed between two groups
(Z=-0.799, p = 0.449; Z = - 0.625, p = 0.312, respectively)
(Tables 4 and 5).
No patients were lost during the follow-up; the median fol-
low-up was 52 months in both groups. The overall survival
time was 48.8 months for group A and 39.2 months for group
B. The five-year survival rate of the group A was signifi-
cantly higher than the group B (67.7% vs. 46.8%; χ2 = 5.629,
p = 0.018) (Figure 1).
Discussion
This retrospective study evaluated the prevalence of com-
plications and long term-efficacy of CCRT in a relatively large
sample of Chinese LACC patients. The results demonstrated
that CCRT achieved an outcome superior to pure RT in 113
Chinese patients with LACC, which was consistent with pre-
vious studies [11]. However, the present study found that pre-
operative CCRT was associated with significantly higher
incidence of bone marrow suppression and gastrointestinal re-
action, compared with RT alone, suggesting that CCRT could
increase the hematologic and gastrointestinal toxicity.
CCRT is now the standard treatment in LACC and cisplatin
appears to be the ideal chemotherapeutic agent. Green et al.
[13] analyzed data from 19 randomized trials comprising
4,580 patients and concluded that concomitant chemotherapy
results in improved overall survival and progression-free sur-
vival. However, the absolute survival benefit was 12% max-
imum in early-stage (I and II) disease, and the three-year
overall survival (74%) or five-year overall survival or pro-
gression-free survival (50%–63%) of the standard CCRT
alone were still not satisfactory [14]. In the present study, the
five-year OS rates for patients undergoing CCRT and pure
RT were 67.7% and 46.8%, respectively, suggesting that pre-
operative CCRT achieved better outcome in comparison to
RT alone for LACC with acceptable low nephrotoxic and uri-
Table 4. — Comparison of the incidence of chronic radiation enteritis between the two groups (n / %).
Groups Cases Grade 0 Grade I Grade II Grade III Grade IV Total Z p*
Groups A 68 57 (83.82) 4 (5.89) 5 (7.35) 2 (2.94) 0 (0.00) 11 (16.18)
-0.799 0.449
Groups B 45 40 (88.89) 3 (6.67) 1 (2.22) 1 (2.22) 0 (0.00) 5(11.11)
Group A: concomitant chemoradiotherapy; Group B: pure radiotherapy. 
*
Mann-Whitney U test.
Table 5. — Comparison of the incidence of chronic radiation cystitis between the two groups (n / %).
Groups Cases Grade 0 Grade I Grade II Grade III Grade IV Total Z p*
Groups A 68 63 (92.65) 3 (4.41) 1 (1.47) 1 (1.47) 0 (0.00) 5 (4.35)
-0.625 0.612
Groups B 45 43 (95.56) 1 (2.22) 1 (2.22) 0 (0.00) 0 (0.00) 2 (4.44)
Group A: concomitant chemoradiotherapy; Group B: pure radiotherapy. 
*
Mann-Whitney U test.
Figure 1. — Overall survival by means of the Kaplan–Meier sur-
vival analysis using the Log rank test. The overall survival time
was 48.8 months for group A and 39.2 months for group B. The
five-year survival rate of the group A was significantly higher than
the group B (76.7% vs. 53.3%; χ2 = 5.629, p = 0.018).
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nary toxicity and complications. This study together with pre-
vious studies suggest that a combination of preoperative
CCRT and radical surgery may provide a feasible and effec-
tive treatment for patients with LACC.
In the present study, patients receiving CCRT all experi-
enced bone marrow suppression complications, and 27.94%
had grades 3 and 4 in comparison to RT alone (4.44%, p =
0.004). Morris et al. found that 44% patients receiving pelvic
radiation with concurrent chemotherapy experienced grades
3 and 4 bone marrow suppression complications, while this
only occurred in 3% patients treated with RT alone [15]. In
addition, 70.6% patients receiving CCRT experienced gas-
trointestinal reaction, and 23.53% had grades 3 and 4 in com-
parison to RT alone (6.67%, p = 0.037). Green et al. also
reported that the incidence of gastrointestinal reaction was
significantly higher in CCRT patients compared with RT pa-
tients [16]. Several large cohort and phase-III studies on ex-
clusive CCRT have also described severe late toxicity
ranging from 10% to 18.3 % with a predominant pattern of
intestinal toxicity (13% grades 3–4 complications) and vagi-
nal toxicity (20% grades 3–4 complications) [17, 18]. Inter-
estingly, CCRT treatment showed similar toxicities
compared with the RT treatment in chronic radiation enteri-
tis and cystitis. The chronic radiation enteritis rates follow-
ing radiation therapy range from 10-20%, and 1-10% for
chronic radiation enteritis, depending on the bias of the re-
ports. In the present study, 16.18% patients receiving CCRT
developed chronic radiation enteritis, and 4.35% patients de-
veloped chronic radiation cystitis, and the results were in
agreement with the above reported. Altogether, these studies
suggest that CCRT could apparently rise the incidence and
severity of hematologic and gastrointestinal toxicity, thus
emphasizing the need of a close clinical and radiological
monitoring of patients in postoperative period. 
In conclusion, this retrospective study demonstrated that
CCRT followed by radical surgery achieved a better outcome
compared with pure RT in LACC patients, but could appar-
ently increase the incidence and severity of hematologic and
gastrointestinal toxicities. However, this finding is not con-
clusive due to the small sample size and lack of correlation
analysis of clinical variables with complications, which are
major drawbacks of this study. Moreover, the present authors
indicate that this observation is still a retrospective study,
which might be a limitation along with a lack of sufficiently
balanced numbers of patients. However, these findings warrant
further multicenter investigation in a randomized clinical trial.
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Introduction
Cytochrome P-450 2D6 (CYP2D6) is of great clinical
relevance, because it represents one of the most important
enzymes involved in drug metabolism in general. The gene
encoding this enzyme is highly polymorphic, as 93 alleles
with varying function have been reported. According to the
genotype, pattern individuals can be divided into four phe-
notype groups: ultra-rapid (UMs), extensive (EMs), inter-
mediate (IMs), and poor metabolizers (PMs). UMs carry
three active alleles (duplication or amplification effect);
EMs are characterized by the presence of two functional
alleles (*1, *2, *9); IMs carry only one active allele, while
PMs express two inactive alleles (*3,*4,*5) [1].
In general, Caucasians have a quite higher incidence of the
PM phenotype when compared to other races. The studies
referring to African populations on the other hand show a
wide range of results, with the South-Africans having an in-
cidence of 19%. The lowest frequency is reported within the
Asian population. Allele *3 and mostly *4, both of which are
non-functional, are mainly responsible for the PM pheno-
type among Caucasians in general. On the contrary, these al-
leles are rarely found in the Asian population, explaining the
worldwide lowest frequency of PM status in that group [2].
The role of CYP2D6 in the adjuvant treatment of breast
cancer is crucial, as this enzyme is mainly involved in the
biotransformation of tamoxifen to the potent antiestrogen
endoxifen. The aim of the present study is to estimate the
incidence of CYP2D6*4, in the Greek population and more
precisely within females suffering from breast cancer. De-
spite the numerous existing studies focusing on the inci-
dence of CYP2D6*4 between Caucasians in general, and
among specific European ethnic groups as well, relevant
data referring to the Greek race are missing. This is the first
country-wide study attempting such an epidemiological
screening approach. 
Materials and Methods
A total of 80 unrelated mainland Greek female volunteers par-
ticipated in the study after giving written informed consent. They
were all patients suffering from hormone-sensitive breast cancer,
that were recruited during their primary handling or follow-up
examination at the Second Department of Propaedeutic Surgery
of the Medical School in Athens. The study protocol was ap-
proved by the Ethics Committee of the Kapodistrian University
of Athens Medical School. The patients were informed that the
present study was only scheduled for statistical purposes and that
the outcoming results would not influence their treatment regi-
men. The description of the patient’s characteristics is presented
in Tables 1 and 2.
Purification and polymerase chain reaction/ restriction fragment
length polymorphism (PCR-RFLP) of genomic DNA was derived
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Summary
Background: The incidence of CYP2D6*4 among Caucasians is estimated up to 27%, while it is present in up to 90% of all poor me-
tabolizers within the Caucasian population. The hypothesis under question is whether the presence of one or two non-functioning (null) al-
leles predicts an inferior outcome in postmenopausal women with breast cancer receiving adjuvant treatment with tamoxifen. The aim of
the present study is to estimate the incidence of CYP2D6*4, in the Greek population and more precisely among females suffering from breast
cancer. Materials and Methods: Eighty unrelated mainland Greek female volunteers suffering from hormone-sensitive breast cancer were
recruited during their primary handling or follow-up examination in order to provide samples for purification and polymerase chain reac-
tion/ restriction fragment length polymorphism (PCR-RFLP) of genomic DNA derived from buccal swabs. Results: The incidence of in-
dividuals with at least one present allele*4 within the Hellenic population was estimated to be as high as 30% (n = 24/80), with a 95%
confidence interval of 20% to 40%. From the statistical point of view, it can be securely stated that incidence of *4 among Greek women
is over 20%. The incidence of homozygous carriers of *4 in the present sample occurred in 8.75%, while the incidence of allele*4 haplo-
type occurred in 19.4% (n=160). Conclusion: Although the outcoming results for Greek women are actually in line with existing data for
other European nations, it should be noted, that a routine CYP2D6 testing of women suffering from breast cancer is formally not recom-
mended, as the clinical significance of CYP2D6 phenotype in treatment and outcome of breast cancer remains unclear.
Key words: CYP2D6*4; Breast cancer; Tamoxifen; Caucasian.
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from buccal swabs that was performed. The samples were col-
lected with cotton swabs. The swab was scraped firmly against the
inside of each cheek several times and was set to air dry. All indi-
viduals were informed to avoid consuming food or drink within
30 minutes prior to the collection of the sample. Each dry swab
material was placed in a two-mL micro- centrifuge tube, where
300 μL PBS and 25 μL proteinase K solution was added. It fol-
lowed a mix by vortexing 2x5 seconds and incubation for ten min-
utes at 56°C. The swab was at that point removed and 300 μL
buffer B3 were added. The solution was vigorously vortexed and
the sample was incubated at 70°C for another ten minutes. In order
to adjust the DNA binding conditions 300 μL of 96%-100%
ethanol were added to each sample and the new solution was once
again mixed by vortexing. At that point 600 μL of the samples were
transferred from the two-mL micro-centrifuge tubes into Nucle-
oSpin Tissues Columns and was centrifuged at 12,000 x g for one
minute. The prior added ethanol binds the DNA on to the column
membrane. The flow-through was discarded and the columns were
placed back into the collection tube. The silica membrane was ini-
tially washed after adding 500 μL of buffer BW and centrifuging
for one minute at 4,500 x g. The second wash was performed with
an addition of 600 μL buffer B5 to the column and centrifugation
at 14,000 x g for two minutes. The flow-through was once more
discarded. In order to remove the residual ethanol, the NucleoSpin
Tissue Column were then placed into a new collection tube and
were incubated with an open lid for one to two minutes at 70°C. In
the next step and in order to elute highly pure DNA, the columns
were placed into a 1.5-mL micro-centrifuge tube where 80 mL of
pre-warmed elution buffer BE (70°C) were added. The solution
was incubated for one minute and then centrifuged at 12,000 x g
for one more minute. The quantitative measurement of the amount
of isolated DNA could then be performed with photometry. 
The investigation of the presence of CYP2D6*4 was performed
using PCR-RFLP. For successful PCR, about five μl (200 ng) of
DNA extract and 45 μl of PCR mix - including the two specific
primers- were incubated under specific conditions. The used for-
ward and reverse primers for CYP2D6*4 genotyping had the fol-
lowing nucleotide sequences: GCTTCGCCAACCACTCCG
(CYP2D6-f) and AAATCCTGCTCTTCCGAGGC (CYP2D6-r).
The 45 μl PCR mix contained five μl PCR-buffer w/o Mg, one μl
dNTPs, 1.5 μl MgCl2, one μl of each of the primers 2D6-f and
2D6-r, 0.5 μl Taq-polymerase and 40 μl of H
2
O. Thermocycling
conditions were as follows: initial denaturation at 95°C for five
minutes, 40 cycles of denaturation at 95°C for 30 seconds, an-
nealing at 59°C for 30 seconds, and extension at 72°C for 60 sec-
onds. The terminal elongation was performed at 72°C for five
minutes. If the PCR was successful (PCR product of 334 base
pairs, checked by 2% agarose gel electrophoresis), 15 μl of the
product was diluted with five volumes of distilled water and
stored at 4°C. The PCR-product was then digested using the re-
striction endonuclease BstNI. The final digestion mix contained
Table 1. — Cohort descriptives I.
CYP2D6=*4
Total No Yes
N % N % N %
Grade 14 17.5 11 19.6 3 12.5
I
II 51 63.8 32 57.1 19 79.2
III 15 18.8 13 23.2 2 8.3
Histological type
Papilar 1 1.3 1 1.8 . .
Lobular 8 10 6 10.7 2 8.4
Mixed 2 2.5 2 3.6 . .
Ductal 68 85.0 47 83.9 21 87.5
Hybrid 1 1.3 . . 1 4.2
Table 2. — Cohort descriptives II.
CYP2D6=*4
Total No Yes
ER- status N 80 56 24
Mean 0.7 0.7 0.8
Median 0.8 0.8 0.8
Min 0.2 0.2 0.2
Max 1.0 1.0 1.0
PR-status N 80 56 24
Mean 0.6 0.6 0.7
Median 0.7 0.6 0.7
Min 0.0 0.0 0.0
Max 1.0 1.0 1.0
Age (years) N 80 56 24
Mean 53.6 54.1 52.4
Median 53.0 53.5 50.5
Min 30.0 30.0 40.0
Max 88.0 88.0 75.0
Figure 1. — Gel picture, CYP2D6*4 polymorphism.
Lane 1 – IM genotype (intermediate metaboliser -334, 230, and
104 base pairs).
Lane 2 – EM genotype (extensive metaboliser -230 and 104 base
pairs).
Lane 3 – PM genotype (poor metaboliser -334 base pairs).
Lane 4 – 100 base pair ladder as marker.
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15 μl of PCR product, five μl of NEB buffer, one μl of BstNI,
and 29 μl H
2
O (total mix volume 50 μl) and was incubated at
60°C for one hour. The digestion products were further analyzed
on a 10% acrylamide gel electrophoresis, together with a 100-bp
DNA weight marker. The excepted electrophoresis patterns and
their interpretation are presented in Figure 1.
Statistical analysis
Sample size estimation was based on the assumption that the true
incidence of allele *4 would approximately be 20%. The majority of
the existing literature evidence that the incidence of allele *4 among
healthy Caucasian women ranges from 18% to 21% [3, 4]. Thus
with 80 patients (160 examined alleles), the expected level of con-
fidence would be ± 7%. Asymptotic 95% confidence intervals where
used in order to assess the level of accuracy for the point estimates,
while hypothesis testing was used to test several alternatives.
Results
In the present study, the incidence of individuals with at
least one present allele*4 within the Hellenic population was
estimated to be as high as 30% (n = 24/80), with a 95% con-
fidence interval of 20% to 40%. With this mean, it can be se-
curely stated that incidence of *4 among Greek women is
over 20%. Furthermore, the incidence of homozygous carri-
ers of *4 in the present sample occurred on 8.75% (Tables 3
and 4), while the incidence of allele*4 haplotype occurred in
19.4% (n=160).
Discussion
The main question remaining to be answered is whether
the routine use of CYP2D6 genotyping should be intro-
duced in the adjuvant setting of tamoxifen or not. Focused
on these issues while designing the present study, the sam-
ple consisted exclusively of Greek female patients with hor-
mone-sensitive breast cancer. 
A number of studies have estimated the incidence of
CYP2D6 phenotype and the distribution of CYP2D6 alle-
les within Caucasians. Few of them are restricted to simple
phenotype prediction as summarized in Table 5 [5], while
others have specifically focused on the incidence of al-
lele*4 in various European ethnic groups. 
The activity of the CYP2D6 enzyme can be easily meas-
ured in vivo after the oral administration of a probe drug
that is mainly CYP2D6 metabolized, such as dex-
tromethorphan, debrisoquine or sparteine. The consequent
estimation of the ratio of metabolite to parent drug concen-
tration indicates the CYP2D6 metabolic status [6]. Regard-
ing the detection of CYP2D6*4, it should be mentioned that,
the standard nomenclature of the *4 allele is based on the
presence of the 1846G>A defining variant. Furthermore,
other haplotype variants could also be present [7].
The prevalence of the CYP2D6*4 allele, as estimated in
the present study, complies with the Hardy-Weinberg equi-
librium and is in line with the majority of published results
for other European ethnicities of Caucasian origin. More
precisely, the following frequencies have been reported
among different Caucasian ethnicities: 24.4% - 23% in
Swedes [8, 9], 23.1% - 23,0% in the Polish [10, 11], 22.9%
in Czechs [12], 21.5% in Estonians [13], 19.5% and 20.7%
in Germans [4, 14], 20.0% in Norwegians [15], 18.4% in
Dutch [16], 14.4% - 18.2% in Russians [17, 18], 18.1% and
20.6% in Danish [19, 20], 17.8% in Greeks [21], 16.8% in
Sardinians [22], 15.3% in Italians [23], 14.,9% - 18.6% in
French [24, 25], 1.4% - 14% in Croatians [26, 27], 12.2%,
13.8% and 16.6% in Spanish [28-30] and 11.1% - 12.8% in
Finish [31, 32]. The examined population and the con-
comitant incidence of CYP2D6*4 of the aforementioned
reported studies are presented in Table 6.
Table 3. — CYP2D6 genotyping results.
CYP2D6 n %
*4/*4 7 8,75
wt/*4 17 21.25
wt/wt 56 70.0
Table 4. — Binomial proportion of CYP2D6*4.
Proportion 0.3000
ASE 0.0512
95% lower conf. limit 0.1996
95% upper conf. limit 0.4004
Table 5. — Incidence of poor metabolizers (PM) within
Caucasians [5].
Population PMs (%)
British 8.9
Swiss 10
German 7.7
Polish 8.3
Croatian 3.0
Table 6. — Ethnic studies.
Population n *4 Population n *4 
incidence incidence
(%) (%)
Croatian [27] 200 14.0 Greek [21] 283 17.8
Croatian [26] 144 11.4 Italian [23] 350 15.3
Czech [12] 223 22.9 Norwegian [15] 118 20.0
Danish [19] 240 18.1 Polish [10] 145 23.1
Danish [20] 325 20.6 Polish [11] 300 23.0
Dutch [16] 756 18.4 Russian [18] 290 18.2
Estonian [13] 151 21.5 Russian [17] 204 14.4
Finnish [32] 302 12.8 Sardinian [22] 250 16.8
Finnish [31] 122 11.1 Spanish [30] 290 16.6
French [25] 514 18.6 Spanish [28] 258 12.2
French [24] 171 14.9 Spanish [29] 105 13.8
German [4] 589 20.7 Swedish [8] 281 24.4
German [14] 195 19.5 Swedish [9] 248 23.0
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A special report should be also made on three large stud-
ies that analyzed the allele*4 incidence in multi-ethnic Eu-
ropean cohorts (Table 7). Marez et al. analyzed 672
individuals of European origin and estimated the incidence
of allele*4 to be as high as 18.9%. Further details regard-
ing the sample composition are not available [3]. Similar
results with an allele*4 incidence of 17.2% are also re-
ported in the study of Sistonen et al. performed in a sample
of 157 Europeans individuals [33]. The authors have addi-
tionally reported the respective frequencies in every ethnic
group being part of their cohort. In one further large study
within six populations of the Mediterranean region, the
prevalence of allele*4 occurred in 16%. A further sub-
analysis of the allele*4 frequencies in each ethnic group
has also been reported [34].
Four studies provide data about the incidence of
CYP2D6*4 allele within Caucasians suffering from breast
cancer. Bonanni et al. determined the CYP2D6 genotype
in hysterectomized women participating in the Italian
chemoprevention trial of tamoxifen. The frequency of the
CYP2D6 *4/*4 genotype was statistically significant
higher (9%) in women who developed breast cancer (n=46)
than in the control group (n=136). The authors assumed that
the expression of the inactive allele*4 may consist of a pre-
disposing factor for breast cancer. A strong bias of their
study is due to a lack of group-matching of the follow-up
period and the risk factors associated with breast cancer as
well [35].
Two further studies performed between Spanish individ-
uals are giving conflicting results. Fernandez-Santanter et
al. genotyped 96 breast cancer Spanish patients and com-
pared them to 100 healthy control subjects. The incidence
of allele*4 was 13.5% vs. 22% in patients and controls, re-
spectively. Their results supported a statistically significant
association between wild type CYP2D6 vs. homozygous
*4 genotype and breast cancer risk [36]. This data is con-
flicting with the results of another study among Spanish in-
dividuals published by Ladona et al. Their cohort consisted
of 151 breast cancer patients and 187 healthy controls. The
authors supported an inverse relationship between CYP2D6
activity and breast cancer risk. The prevalence of het-
erozygous CYP2D6 (wt/*4) genotype was higher between
individuals with breast cancer (26.7% vs. 17.2%, p = 0.037)
[37].
Finally, Topic et al. compared the incidence of inactive
allele*4 between breast cancer patients and healthy volun-
teers from Croatia [26]. The prevalence of CYP2D6*4 oc-
curred in 18.4% among breast cancer subjects (28/152
tested alleles) vs. 11.4% among control individuals (33/288
tested alleles). The reported difference was furthermore not
statistically significant, hence no association between
CYP2D6 genotype and breast cancer risk could be safely
supported .
In reference to the Greek population, the only previous
existing study investigating the prevalence of various
CYP2D6 genotypes within healthy Greeks has been pub-
lished by Arvanitidis et al. [21]. In a total of 283 healthy
subjects, 92 were detected to be carriers of the inactive
allele*4. Eight of them were estimated to be homozygous
(3.2%), while the frequency of allele*4 itself occurred in
17.84% (101/566 tested alleles). The present results, al-
though exclusively based on breast cancer patients, are
actually in line with those of Arvanitidis et al, so that no
etiological relationship between CYP2D6 genotype and
breast cancer risk among Greek women could be as-
sumed. The extraction of such a conclusion is actually
not safe and strongly biased, as the two cohorts were
completely and independently analyzed and consisted of
non-matched individuals. 
The present authors refer to a prior review research of
their institution, that evaluates the clinical implication of
the non-functional allele *4 in breast cancer, always in re-
gards to tamoxifen therapy [38]. The results were conflict-
ing and quite inconclusive. Three former reports showed a
favorable outcome in CYP2D6*4 carriers with ER+ breast
cancer. These findings are actually opposed to the basic as-
sumption and could not be supported by any other later
study [39-41].
The great volume of published studies shows a clear
negative relationship between intermediate/poor CYP2D6
metabolizing status and the outcome of ER+ breast can-
cer. This main hypothesis has also been supported from
studies that have exclusively focused on allele*4 alone
[35, 42-45]. Interestingly, the presence of inactive
CYP2D6 alleles and in particular allele*4 has also been
associated with lower circulating serum levels of tamox-
ifen metabolites. In that mean, the benefit of tamoxifen
treatment is strongly limited in this patient group [46, 47].
On the other hand, the acceptance of such a negative im-
pact of allele*4 in the course of breast cancer is not
Table 7. — Multi-ethnic studies.
Population n *4 incidence (%)
European [3] 672 18.9
European [33] 157 17.2
French 25 16.0
French Basque 24 20.8
Sardinian 28 21.4
North Italian 14 14.3
Tuscan 8 18.8
Orcadian 16 12.5
Adygei 17 8.8
Russian 25 20.0
Mediterranean [34] 247 16.0
Sardinian 48 12.5
Central Italians 31 12.9
Alps 28 19.64
Basques 38 21.05
Southern Spaniards 51 17.65
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unique. In a large population study published by Abraham
et al., no association between CYP2D6 phenotypes (al-
lele*4 included) and survival in breast cancer patients
under tamoxifen treatment could be proven. Based on
their results, the authors argued against CYP2D6 testing
in the clinical setting [48].
Although the current recommendations for breast cancer
treatment do not support a CYP2D6 screening prior to ta-
moxifen treatment, the interpretation of every existing re-
sult should be made with respect to the special parameters
of each population.
The estimated incidence of CYP2D6*4 among Greek fe-
males suffering from breast cancer is quite high in com-
parison to previous presented results for other ethnic groups
of Caucasian origin. The present cohort included only
women with hormone positive cancers, in an effort to max-
imize the accuracy of the present results for this patient
group, in which actually the administration of tamoxifen is
absolutely indicated. The outcoming results are in accor-
dance to the Hardy-Weinberg equilibrium and can be con-
sidered as highly reliable given Greece’s consistent and
homogeneous population.
In the present study, the testing for CYP2D6 allele*4 was
performed using germline DNA extracted from hosts’ buc-
cal-derived sample. In a large number of published studies
that doubt about the clinical significance of allele*4 in the
treatment with tamoxifen, the genotyping procedure was
performed at paraffin-fixed cancer tissue. It should be men-
tioned that tumor DNA may show significant differences
from germline DNA due to “loss of heterozygosity” during
cancer progression, a fact that depicts a strong bias of all
these studies.
The cost effectiveness parameter is of high importance,
given the long required time of tamoxifen administration
in relation to the strong financial limitations of the Greek
health system in an area of financial crisis. In patients
where impaired function of CYP2D6 is expected, due to
the presence of one or two *4 alleles, dose adjustment or
other therapy regime should be considered. In patients
which have been found to be intermediate or poor metab-
olizers, caution should be also given in any potential
CYP2D6 inhibitors that may be occasionally co-pre-
scribed due to other medical reasons [49]. If the adminis-
tration of tamoxifen should be continued, dose reduction
or alternative medication for the handling of co-morbidi-
ties might be indicated. Finally, patients that are not likely
to benefit from a treatment with tamoxifen should also not
be exposed to its possible various side and adverse effects
[50, 51].
Conclusion
CYP2D6*4 is the most frequent allele associated with
loss of enzymatic activity among Caucasians. The present
study, performed on an ethnic basis, focused only on
women with hormone-sensitive breast cancer, a patient
group in which the administration of tamoxifen is ab-
solutely indicated. The outcoming results for Greek
women are actually in line to existing data of other Euro-
pean nations. Nevertheless it should be noted, that a rou-
tine CYP2D6 testing of women suffering from breast
cancer is formally not recommended, as the clinical sig-
nificance of CYP2D6 phenotype in treatment and outcome
of breast cancer remains unclear. 
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Introduction
Cervical cancer is the one of most common causes of
cancer-related death in women. Primary treatment currently
includes radical surgery and radiotherapy. However, recent
studies have shown that the curative effect of concurrent
chemoradiotherapy (CCRT) is equivalent to radical surgery
for early stage cervical cancer and more effective than ra-
diation only [1-5].
Although the primary drug choice is cisplatin, paclitaxel
or carboplatin alone has been shown to be efficacious for
CCRT [6-8]. Carboplatin induces the same platinum-DNA
adduct formation as cisplatin, is easy to use, and does not
require hydration [9]; furthermore, it results in lower
nephrotoxicity and emetogenicity than cisplatin. The com-
bination of paclitaxel and cisplatin chemoradiation report-
edly results in only mild toxicity and a good response rate
in patients with locally advanced cervical cancer [10, 11].
The combination of paclitaxel and carboplatin is also ef-
fective as chemotherapy [12, 13], with a good survival rate
[14]; as a result, this combination is used as chemotherapy
for advanced or recurrent cervical cancer in Japan. In
CCRT, these drugs act together as a radiosensitizer as well
as effective chemotherapy. 
The use of CCRT in other cancers has resulted in shorter
treatment durations and improved efficacy in terms of pro-
gression-free survival (PFS), overall survival (OS), toxic-
ity, and complications [15-19]. The present institute utilizes
CCRT with paclitaxel and carboplatin because hydration
and hospitalization are not required, and there are a limited
number of hospital beds in this hospital [20]. However, the
ideal approach for multimodal therapy that includes
chemotherapy and external beam therapy for the treatment
of cervical cancer has not yet been established. It is un-
known if there is increased efficacy against cancer with the
use of two antineoplastic drugs or with the administration
of CCRT. Therefore, the present retrospective study aimed
at evaluating CCRT with paclitaxel and carboplatin in a
large sample of Japanese patients with cervical cancer.
Materials and Methods
With the approval of the Jichi Medical University Institutional
Review Board, the authors retrospectively reviewed the medical
records of patients who received CCRT with paclitaxel and car-
boplatin between September 2006 and June 2012 in the Depart-
ment of Gynecology at the Saitama Medical Center Jichi Medical
University. The need for informed consent was waived because
data were only obtained via retrospective review of records.
Indications for CCRT included patients with International Fed-
eration of Gynecology and Obstetrics (FIGO) Stage IB2-IVB cer-
vical cancer with histopathology of squamous cell carcinoma
(SCC), adenocarcinoma, or adenosquamous carcinoma. Exclu-
sion criteria included previous, partial treatment at another insti-
tution or history of another malignant disease.
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Summary
Purpose of investigation: To determine if concurrent chemoradiotherapy (CCRT) with paclitaxel and carboplatin is effective, con-
venient, and tolerable for cervical cancer treatment. Materials and Methods: The authors retrospectively reviewed the medical records
of 49 patients. Primary outcomes included progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards
model was adjusted for all prognostic factors in the multivariable analysis. Results: Over the median follow-up time of 32 months in a
sample consisting of 87.8% (43/49) squamous cell carcinoma and 12.2% (6/49) adenocarcinoma, two-year PFS and OS rates were
67.2% and 80.9%, respectively. In univariate analyses, stage, histology, performance status, tumor size, and age were significant vari-
ables for OS; only histology was significant in the multivariable analysis. Acute toxicity grade 3 or 4 neutropenia (85.7%), diarrhea
(32.7%), and late toxicity grade 3 or 4 (12.2%) were detected. Conclusions: For cervical cancer treatment, CCRT with paclitaxel/car-
boplatin is satisfactory.
Key words: Uterine cervical neoplasms; Chemoradiotherapy; Paclitaxel; Carboplatin; Survival.
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The following data were collected: age, histopathology, stage,
Eastern Cooperative Oncology Group performance status (PS),
tumor size, number of chemotherapy cycles, toxicities, and tumor
response, which was evaluated according to the Response Evalu-
ation Criteria In Solid Tumors (RECIST) guideline (version 1.1).
PFS and OS were determined as the primary outcomes. PFS was
defined as the interval from the first date of diagnosis to the time
of recurrence, disease progression, or death. PFS data were right-
censored at the time of the last evaluation for patients lost to fol-
low-up. OS was defined as the time from diagnosis to the date of
death and right-censored at the date of the last follow-up visit for
patients who were alive at the end of the study.
Clinical staging was evaluated using pelvic and bimanual rectal
examinations. Tumor diameter was calculated using magnetic res-
onance imaging (MRI). Metastatic survey was conducted by phys-
ical examination, chest radiography, cystoscopy, proctoscopy, and
computed tomography (CT).
All patients receive concurrent weekly paclitaxel, carboplatin,
and radiation therapy as primary treatment in the present institu-
tion. Radiation treatment was administered by external beam pelvic
radiotherapy using the four-field box technique (anteroposterior,
posteroanterior, and two lateral fields) within one week, approxi-
mately, following chemotherapy, when possible. Because the
schedule for radiation is typically fully booked, the number of
chemotherapy cycles prior to radiation was not restricted to avoid
delayed treatment for the cancer patients. A total dose of 45–60
Gy was administered in daily fractions of 1.8–2.0 Gy, five days
per week. At 20–30 Gy, a center split was performed. If patients
were administered high dose-rate brachytherapy, two to four frac-
tions of intracavitary high dose-rate brachytherapy were adminis-
tered in weekly fractions of five to six Gy each to point A, based
on the external os of the uterus, overlap with the external beam, and
tumor volume. The total brachytherapy dose was 12–24 Gy.
The paclitaxel and carboplatin doses were at the treating physi-
cian’s discretion. Paclitaxel was administered at a weekly dose of
60–70 mg/m
2
, with 70 mg/m
2
likely administered to patients with
good PS and general condition. Carboplatin was administered
based on the area under the curve 2, which is the primary method
in the present institute for chemotherapy for cervical cancer [20,
21]. Chemotherapy was administered six to nine times during ir-
radiation or after irradiation; before each cycle, ≥ 1,000 neutrophils
and ≥ 100,000 blood platelets were obtained using growth factors
in cases with neutropenia or leukopenia, respectively, at the treat-
ing physician’s discretion. Patients with hemoglobin levels < 10
g/dL received a red blood cell transfusion before further treatment.
Following completion of the radiation and chemotherapy, pa-
tients were examined by cytology, human papillomavirus (HPV)
testing using Hybrid Capture 2, CT, and MRI. In cases with a lack
of complete response, cytology positive result, or positive HPV
test result following the six to none chemotherapy cycles, addi-
tional chemotherapy was administered.
Response to treatment, using the RECIST guideline (version
1.1), and toxicity were determined at follow-up evaluations. Post-
treatment surveillance was by complete physical examination
every month during the first year, every two months for another
year (year 2), every three months for another year (year 3), and
every six months thereafter. Imaging was obtained by CT every
six to 12 months. Acute hematologic and non-hematologic toxic-
ities were recorded based on the Common Toxicity Criteria (CTC)
Version 4.0. Acute and late gastrointestinal and genitourinary tract
toxicities were recorded using the RTOG/EORTC Late Radiation
Morbidity Scoring Criteria.
The present authors used JMP, version 10.0.0 for statistical
analyses. Demographic variables are reported as mean ± stan-
dard deviation. PFS and OS were analyzed by the Kaplan-Meier
method and compared between age, histopathology, stage, PS,
and tumor size using log-rank tests because of the short study pe-
riod. The Cox proportional hazards model was used to adjust for
all prognostic factors in multivariable analysis, including sur-
vival, stage, tumor histology, PS, and tumor size. For all statisti-
cal tests, a p-value < 0.05 was considered significant.
Results
During the study period, 58 patients underwent radia-
tion. Nine patients were excluded because they received
only radiation, resulting in a sample size of 49 patients
(Figure 1) with a mean age of 57.2 ± 10.5 years (Table 1).
One patient was lost to follow-up at 18 months. The basic
patient characteristics and prevalence of all stages are
shown in Table 1.
There were only eight patients with Stage IVB cervical
cancer (Table 1). All but four patients completed their
chemotherapy; two patients had grade 4 fatigue, one pa-
tient experienced an outbreak of Guillain-Barré syndrome,
and one patient experienced a cerebral infraction. An addi-
tional patient who experienced a cerebral infraction did not
complete the radiation therapy. The total radiation dose was
57.0 ± 8.6 Gy; this included the one patient that did not
complete the radiation therapy.
The follow-up lasted a median 32 months (range, four to
75 months). The Kaplan-Meier estimates for PFS and OS
Figure 1. — Flowchart of enroll-
ment of patients with Stage IB2-IVB
cervical cancer.
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are shown in Figures 2 and 3, respectively; the two-year
PFS and OS rates were 67.2% and 80.9%. The estimated
median PFS and OS rates were 55.1 months and 92.1
months, respectively. Of the patients with a complete or
partial response (Table 2), 31.1% (14/45) of the patients ex-
perienced recurrence (n = 3, local; n = 9, distant; and n = 2,
both local and distant). The distant metastases sites in-
cluded para-aortic lymph nodes (35.7%, 5/14), lungs
(28.6%, 4/14), and the liver (14.3%, 2/14). 
In the univariable analysis, histology, PS, tumor size, and
age were significant (Table 3); however, only histology was
significant in the multivariable analysis (hazard ratio, 6.69;
p = 0.0271) (Table 4). The PFS was 72% for SCC and 33%
for adenocarcinoma.
Acute toxicity grade 3 or 4 neutropenia, anemia, and di-
arrhea were detected in 85.7%, 8.2%, and 32.7% of the pa-
tients, respectively (Table 5). Late toxicity grade 3 or 4 was
detected in 12.2% of the patients. Vaginal fistula occurred
in three patients, and perforation of the sigmoid colon oc-
curred in one patient; all of these patients had a PS of 3.
One patient developed septic shock, but she was treated
with antibiotics and recovered.
Discussion
In the present study, treatment of cervical cancer with
CCRT, including paclitaxel and carboplatin, was satisfac-
tory, with similar response, PFS, and OS rates to those of
previous studies (Table 6) [2, 4, 22], even in patients with
Table 1. — Demographic and clinical characteristics of
patients with Stage IB2-IVB cervical cancer.
Total sample (n = 49)
Age (years) (mean ± SD) 57.2 ± 10.5
Tumor size (cm) (mean ± SD) 60.0 ± 19.2 (range, 22–125)
Stage, n (adenocarcinoma) 49 (6)
IB2 8 (1)
IIA1 0
IIA2 4 (0)
IIB 14 (1)
IIIA 5 (2)
IIIB 7 (0)
IVA 3 (0)
IVB 8 (2)
Lymph node, n
Positive 17
Negative 32
RALS, n
Yes 28
No 21
RALS: remote afterloading system.
Table 2. — Response rate to concurrent chemoradiother-
apy with paclitaxel and carboplatin in patients with Stage
IB2-IVB cervical cancer.
Stage n CR+PR CR PR SD PD
IB2-IIB 24 100 22 (91.7) 2 (8.3) 0 0
IB2-IIB
adenocarcinoma
2 100 1 (50) 1 (50) 0 0
IIIA-IVA SCC 13 92.3 9 (69.2) 3 (23.1) 0 1 (7.7)
IIIA-IVA
adenocarcinoma
2 100 1 (50) 1 (50) 0 0
IVB SCC 6 83.3 3 (50) 1 (16.7) 0 2 (33.3)
IVB
adenocarcinoma
2 100 1 (50) 0 0 1 (50)
Total 49 91.8 37 (75.5) 8 (16.3) 0 4 (8.2)
CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease; SCC: squamous cell carcinoma.
Figure 2. — Kaplan-Meier estimates of progression-free survival
in patients with cervical cancer who underwent concurrent
chemoradiotherapy with paclitaxel and carboplatin.
Figure 3. — Kaplan-Meier estimates of overall survival in pa-
tients with cervical cancer who underwent concurrent chemora-
diotherapy with paclitaxel and carboplatin.
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Stage III-IV cancer [4]. Regarding adverse effects, neu-
tropenia tended to occur more frequently than previously
reported, while gastrointestinal effects were less frequent
[2,4,5,22]. Weekly administration of paclitaxel and carbo-
platin might be tolerable and effective in patients with stage
IB2-IVB cervical cancer.
Similar to the results of the present study, a combination
of paclitaxel and carboplatin has been reported to be effec-
tive chemotherapy [12, 13] as well as acting as a radiosen-
sitizer. A previous in vitro study demonstrated an additive
effect with concomitant paclitaxel and radiation for SCC
[6]. In addition, a phase I study of weekly paclitaxel and
carboplatin with concurrent radiotherapy demonstrated
similar PFS and OS to those of cisplatin [23]. Furthermore,
another member of the taxane family, docetaxel, enhances
the efficacy of antivascular therapy when administered
weekly; in addition, it confers metronomic chemothera-
peutic effects [24]. Therefore, the present treatment may
also function as antivascular therapy. 
Carboplatin can be administered to patients with severe
renal insufficiency [25] and demonstrates lower nephro-
toxicity and emetogenicity than cisplatin [9]. Given the rel-
ative frequency of neutropenia and gastrointestinal effects
in the present study, the authors believe that the regimen
they utilized is suitable for outpatients, without requiring
hospitalization.
PS and chemotherapy have been reported as independ-
ent prognostic factors for survival [26], and there was a
tendency in the present study for PS to be a prognostic
factor for survival. With a good PS, CCRT can be consid-
ered. The combination of taxane and platinum may ex-
tend PFS without affecting quality of life [27].
Furthermore, the therapeutic effects of weekly paclitaxel
and carboplatin are similar to those of cisplatin [28, 29].
Stage IVB cancer tended to be related with poor survival
Table 3. — Relationships between prognostic factors and
cervical cancer patient survival in univariable analyses.
PFS p OS p
Stage 0.0096 0.0017
IB2-IIB 84.6 87.8
IIIA-IVA 53.3 85.1
IVB 37.5 37.5 
Tumor histology 0.0935 0.0061
SCC 71.9 85.6
AdenoCa 33.3 33.3 
PS < 0.0001 0.0006
1 78.8 86.2
2 40 60
3 0 60
Tumor size
≤ 6 cm 76.7 89.5 0.0371 
> 6 cm 52.6 0.013 66.9 
Age (years) 0.654 0.0372 
≤ 60 79.2 89.3
> 60 59 68.2
Intracavitary therapy
Yes 82.1 0.008 88.7
No 47.6 70.2 0.0649
PFS: progression-free survival; OS: overall survival;
SCC: squamous cell carcinoma; AdenoCa: adenocarcinoma;
PS: Eastern Cooperative Oncology Group performance status.
Table 4. — Relationships between prognostic factors and
cervical cancer patient survival in multivariable analysis
Hazard radio 95% CI p
Stage IB2-IIB 1
IIIA-IVA 1.51 0.19–10.88 0.68
IVB 9.93 0.93–129.38 0.0579
Tumor SCC 1
histology AdenoCa 6.69 1.35–35.08 0.0271
PS 1 1
2 5.52 0.69–35.64 0.0994
3 5.34 0.90–38.90 0.0661
Tumor size ≤ 6 cm 1
> 6 cm 1.93 0.43–8.05 0.3733 
Age (years) ≤ 60 1
> 60 3.04 0.66–15.31 0.15
Intracavitary No 1
therapy Yes 0.97 0.11–9.51 0.9784
CI, confidence interval; SCC, squamous cell carcinoma; AdenoCa, adenocar- 
cinoma; PS, Eastern Cooperative Oncology Group performance status.
Table 5. — Incidence and types of acute and late complica-
tions in patients with cervical cancer who underwent con-
current chemoradiotherapy with paclitaxel and carboplatin.
Grade
0 1 2 3 4
Acute
Hematologic (neutropenia) 2 3 9 31 4
Hematologic (anemia) 3 22 20 4 0
Thrombocytopenia 42 6 1 0 0
Non-hematologic (vomiting) 36 8 4 0 1
Non-hematologic (diarrhea) 1 19 13 13 3
Late
Urogenital disorder 34 3 11 1 0
Gastrointestinal disorder 42 0 5 1 1
Lymphedema 49 0 0 0 0
Neuropathy 34 11 1 3 0
Table 6. — Progression-free survival and overall survival
rates reported in previous studies of the use of concurrent
chemoradiotherapy with paclitaxel and carboplatin in cer-
vical cancer.
Reference Progression-free Overall
survival survival
Keys, et al. (1999) [2] 79 85
Eifel, et al. (2004) [4] Not available 73
Whitney, et al. (1999) [22] 57 55
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outcomes in the present study; however, Stage IIIA-IVA
patients may benefit from this CCRT regimen. All of the
patients with recurring Stage IVB cancer died, but pa-
tients with Stage IIIA-IVA cancer survived with additional
treatment. The cancer in these stages (IIIA-IVA) invades
locally, while cancers of higher stages spread principally
through the lymphatic system; therefore, chemotherapy
may be important in these patients [30], and the present
regimen may be useful for treating Stage IVB cervical
cancer [26].
Adverse effects included bone marrow suppression,
with particularly high rates of neutropenia in the present
study. Because the data are retrospective and from clini-
cal practice instead of phase I study, the doses chosen by
the physicians might not reflect the optimal doses; it is
possible that the doses were too high, resulting in toxicity.
The outcomes of a phase I trial were published after these
patients were treated [23]. In addition, 34.7% (17/49) of
the patients were older than 60 years, and the condition
of the patients was particularly poor, with 85.7% (42/49)
of the patients experiencing at least grade 3 neutropenia
and 16.7% (7/49) of the patients with a PS of 2 or 3.
Therefore, future clinical trials are needed to determine
the optimal dose to avoid neutropenia and bone marrow
suppression.
This study has certain limitations. First, because the pres-
ent study was retrospective in nature, randomized con-
trolled trials should be conducted to reduce potential
selection bias in determining PFS and OS. Strict and ap-
propriate protocols should be followed to evaluate adverse
effects. Because of the small number of patients with Stage
IVB cancer, the results might not generalize to patients with
more advanced cancers, and further study should be con-
ducted to gather data in these patients.
The present results indicate that weekly administration
of paclitaxel and carboplatin as part of CCRT might be ef-
fective for the treatment of cervical cancer. The response,
PFS, and OS rates were acceptable, and there were less fre-
quent adverse gastrointestinal effects than previously re-
ported. Future studies should be conducted to compare the
efficacy of cisplatin alone with paclitaxel/carboplatin as
part of CCRT for the treatment of cervical cancer.
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Introduction 
Endocervical adenocarcinoma (ECA) accounts for 15%-
25% of all cervical cancers and the incidence appears to be
increasing. Most ECA exhibit a hybrid of endometrioid and
mucinous features, or even a dominant or pure endometri-
oid or mucinous differentiation, therefore ECA and en-
dometrial adenocarcinoma (EMA), share many common
morphological characteristics. Only when adenocarcinoma
is alone confined to the cervix or the corpus (usually lower
uterine segment), the primary ECA or EMA are readily di-
agnosed. When both the corpus and cervix are involved and
precursor lesions are lacking, determining the primary site
of a uterine adenocarcinoma can be problematic in hys-
terectomy specimens [1]. Many recent publications indi-
cated that most ECA are high-risk human papillomavirus
(hr-HPV)-related tumors, and diffuse/strong p16 expression
can be regarded as a surrogate marker of the presence of hr-
HPV [1, 2]. In contrast, most EMA are considered etiolog-
ically unrelated to HPV infection, and usually show high
levels of vimentin, ER/PR expressions [3-7]. Therefore it is
entirely possible to complete the morphological differential
diagnosis between ECA and EMA. In the present study, the
authors investigated the detection of hr-HPV (16/18) DNA
by in situ hybridization (ISH) and expressions of p16, vi-
mentin, ER, and PR by immunohistochemistry (IHC). Their
aim was to explore a panel of useful markers in differential
diagnosis of primary ECA and EMA.
Materials and Methods
Tissue samples
Thirty-three ECA (22 usual endocervical type, three en-
dometrioid type, three villoglandular type, two intestinal type, two
serous type, one adenosquamous carcinoma) and 31 EMA (27 en-
dometrioid type, four serous type) were collected for this study
from archives (2010-2012) of the Department of Pathology,
Zhongnan Hospital of Wuhan University. The average age of the
patients with ECA was 43.8 years (from 27 to 64), and 53.6 years
for patients with EMA (from 28 to 80).
Detection of HPV DNA 
ISH for hr-HPV (16/18) DNA was performed in all the cases. The
hr-HPV (type 16/18) ISH detection kit was utilized. The procedures
included slice processing, dewaxing and hydration, microwave heat-
ing, hybridization, signal amplification, and chromogenic develop-
ment [7, 8]. Controls included positive tissue sections of cervical
squamous cell carcinoma and negative tissue sections of EMA for hr-
HPV (16/18) DNA detection. Cases with brown precipitation or a
discrete punctate reaction product (when the copies of viruses were
low) in the nucleus were interpreted as positive.
IHC
The expressions of p16, vimentin, ER, and PR were determined
according to the manufacturer’s instruction. Brown staining in cyto-
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Summary
Objective: The aim of this study was to explore a panel of useful markers in differential diagnosis of primary endocervical adenocarci-
noma (ECA) and endometrial adenocarcinoma (EMA). Materials and Methods: Thirty-three ECAs and 31 EMAs were collected and ex-
amined for high-risk human papillomavirus (hr-HPV) (16/18) DNA using in situ hybridization, and for p16, vimentin, ER, PR expression
using immunohistochemistry (IHC). Results: Detection rate of hr-HPV (16/18) DNA in ECA (72.7%, 24/33) was significantly higher than
that in EMA (12.9%, 4/31) (p < 0.01). Twenty-four of 33 (72.7%) cases of ECA, but only five of 31 (16.1%) cases of EMA showed high
expression of p16. Twenty-three of 24 (95.8%) hr-HPV DNA-positive ECA and all four (100.0%) hr-HPV DNA-positive EMA showed high
levels of p16 expression. High expression rates of vimentin (90.3%, 28/31), ER (58.1%, 18/31), and PR (71.0%, 22/31) in EMA were sig-
nificantly higher than those in ECA, respectively (p < 0.01). Conclusion: Detection of hr-HPV DNA combined with immunohistochemi-
cal expressions of p16, vimentin, ER, and PR have important value in differential diagnosis between ECA and EMA.
Key words: hr-HPV DNA; p16; Vimentin; ER/PR; In situ hybridization; Immunohistochemistry; Endocervical adenocarcinoma; En-
dometrial adenocarcinoma.
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plasm/ nucleus (p16), cytoplasm (vimentin) and nucleus (ER, PR)
was accepted as presence of immunoreactivity. The percentage of
positive cells was assessed under ×400 microscopy. The expression
was classified as following grades: (1) -, if none were stained posi-
tive or positive staining cell < 5%; (2) 1+, positive cell occupied 6%-
25%; (3) 2+, 26%-50%; (4) 3+,>50%. - and 1+ were categorized as
low expression, and 2+ and 3+ were scored as high (over) expres-
sion [9]. The cervical squamous cell carcinoma, fibrosarcoma and
breast carcinoma tissue section was used as positive control for p16,
vimentin, and ER/PR, respectively. The PBS solution was used to
replace the primary antibody as negative control.
Statistical analysis
The SPSS 11.0 statistics program was used for data analysis.
The chi-square test was used and p < 0.05 was accepted as statis-
tically significant.
Results
The detection of HPV (16/18) DNA in ECA and EMA
A total of 24 of the 33 (72.7%) ECA were found to be hr-
HPV (16/18) DNA-positive by ISH, but the difference of
detection rate for hr-HPV (16/18) DNA was not significant
in histological subtypes (p > 0.05). Only four of 31(12.9%)
EMA were hr-HPV (16/18) DNA-positive, but detection
rate of hr-HPV (16/18) DNA in serous type (75.0%, 3/4)
was significantly higher than that of endometrioid type
(1/27, 3.7%) (p < 0.01). Statistically, detection rate of hr-
HPV (16/18) DNA in ECA was significantly higher than
that in EMA (p < 0.01) (Table 1) (Figures 1A, 2A).
The expression of p16 and correlation between hr-HPV
DNA detection and expression of p16 in ECA and EMA
Twenty-four of 33 (72.7%) cases showed high expres-
sion of p16 in ECA, but only five of 31 (16.1%) cases in
EMA exhibited high expression of p16. The difference was
significant between the former and the latter (p < 0.01).
Figure 1. — Detection and ex-
pression of hr-HPV (16/18) DNA,
p16, vimentin, and ER in ECA.
(A) The hr-HPV (16/18) DNA de-
tection demonstrate brown punc-
tate positive reaction product
within tumor cell nuclei of ECA.
In situ hybridization ×20. (B) The
p16 staining shows diffuse cyto-
plasmic and nuclear expression in
case of hr-HPV DNA (+) ECA.
Normal endocervical glands
(black arrow) exhibit negative
staining (×10). (C) The vimentin
staining shows negative expres-
sion in ECA. The endometrial
stroma exhibits positive staining
(×10). (D) The ER staining shows
negative expression in ECA. The
endometrial stroma and residual
endocervical glands (black ar-
rows) are visualized as positive
control (×10).
Table 1. — Detection of hr-HPV (16/18) DNA and expres-
sion of p16 in ECA and EMA (n, %).
Group n hr-HPV p16 expression*
DNA (+) Low High
Cervical adenocarcinoma 33 24 (72.7%) 9 (27.3) 24 (72.7)
endocervical type 22 17 (77.3%) 6 (27.3) 16 (72.7)
villoglandular type 3 2 (66.7%) 1 (33.3) 2 (66.7)
endometrioid type 3 2 (66.7%) 0 (0.0) 3 (100.0)
intestinal type 2 2 (100.0%) 0 (0.0) 2 (100.0) 
serous type 2 1 (50.0%) 1 (50.0) 1 (50.0) 
andenosquamous
carcinoma 1 0 (0.0%) 1 (100.0) 0 (0.0)
Endometrial
adenocarcinoma 31 4 (12.9%) 26 (83.9) 5 (16.1)
endometrioid type 27 1 (3.7%) 25 (92.6) 2 (7.4) 
serous type 4 3 (75.0%) 1 (25.0) 3 (75.0)
Total 64 28 (43.8%) 35 (54.7) 29 (45.3)
* - and 1+ were categorized as low expression;
2+ and 3+ were scored as high expression.
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High levels of p16 expression did not correlate with vari-
ous histological subtypes of ECA (p > 0.05), but the rate of
p16 high expression in serous type (75.0%, 3/4) was higher
than that in endometrioid type (7.4%, 2/27) of EMA (p <
0.01) (Table 1) (Figures 1B, 2B).
Twenty-three of 24 (95.8%) hr-HPV DNA-positive
ECA cases showed high expression of p16, but only 1 of
9 (11.1%) hr-HPV DNA-negative ECA cases showed p16
high expression. All 4 (100.0%) hr-HPV DNA-positive
EMA cases presented p16 high expression, but 1 of 27
(3.7%) of hr-HPV DNA-negative EMA cases exhibited
p16 high expression. Regarding the incidence of p16
high-level expression, there was significant difference be-
tween hr-HPV DNA-positive and -negative cases of ECA
(p< 0.05) and EMA (p< 0.01), respectively (Table 2) (Fig-
ure 1B, 2B).
The expression of vimentin, ER, and PR in ECA and EMA
All 33 cases of ECA showed low expression of vimentin
(no detection in 32 cases, weak positive expression in one
case). Twenty-eight of 31 (90.3%) EMA cases presented high
levels of vimentin expression, but difference for high levels
of vimentin expression was significant between endometri-
oid (96.3%, 26/27) and serous type (50.0%, 2/4) of EMA (p
< 0.01). Statistically, the rate of high expression of vimentin
in EMA was higher than that in ECA, and the difference was
dramatic (p < 0.01) (Table 3) (Figure 1C, 2C). 
All 33 cases of ECA showed low expression of ER (no de-
tection in 32 cases and minimal positive expression in one
case). ER High expression rate was 58.1% (18/31) in EMA,
but high expression rate in endometrioid type (18/27, 66.7%)
was higher than that of serous type (0/4, 0.0%) (p < 0.05).
The high expression rate of ER in EMA was evidently higher
than that in ECA (p < 0.01) (Table 3) (Figure 1D).
All 33 cases of ECA exhibited low expression (negative
staining) of PR. High expression rate of PR was 71.0%
(22/31) in EMA, but difference of high expression rate be-
tween endometrioid type (81.5%) and serous type (0.0%)
was significance (p < 0.01). Statistically, the high expres-
sion rate of PR in EMA was significantly higher than that
in ECA (p < 0.01) (Table 3) (Figure 2D).
Discussion
Infection of hr-HPV is the main causative event in the de-
velopment of cervical cancer and hr-HPVs have been detected
Figure 2. — Detection and ex-
pression of hr-HPV (16/18)
DNA, p16, vimentin, and PR in
EMA. (A) The hr-HPV (16/18)
DNA detection demonstrates
brown positive precipitation
within tumor cell nuclei of some
EMA. In situ hybridization ×40.
(B) The p16 protein staining
shows focal positive cytoplasmic
and nuclear expression in case for
hr-HPV DNA(-) EMA (×10). (C)
The vimentin staining shows dif-
fuse cytoplasmic expression in
EMA (×10). (D) The PR staining
shows diffuse positive expression
within tumor cell nuclei of en-
dometrial adenocarcinoma (×10).
Table 2. — Correlation between hr-HPV(16/18) infection
and p16 high expression in ECA and EMA.
Group hr-HPV p16 X
2 p
(16/18) expression
DNA high (n)
detection (n)
ECA +, 24 23 5.13 < 0.05
-, 9 1
EMA +, 4 4 11.2 < 0.01
-, 27 1 
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in up to 99.7% of squamous cell carcinoma [10]. At present,
although infection frequency and viral type of hr-HPV are
distinct in many studies, most ECAs (~90.0%) have been re-
garded as hr-HPV-related tumors. In contrast, infection of hr-
HPV is rarely seen in EMA. Plunkeff et al. found that 78.0%
(39 of 50) ECAs contained hr-HPV DNA, compared with
2.0% (1 of 50) EMAs that was positive for hr-HPV DNA [6].
Hadzisejdć et al. reported that 81 out of 89 (91.0%) tested
positive for hr-HPV DNA in ECA, in which, statistically sig-
nificant predominance of single hr-HPV (type 18) infections
in adenocarcinoma in situ (AIS) and endocervical adenocar-
cinoma (AC) whereas multiple hr-HPV (16/18 type) infec-
tions were more abundant in AC compared with AIS [8]. In
cervical cancer associated with hr-HPV infection, functional
inactivation of Rb by HPV E7 protein results in an accumu-
lation of p16 protein because normally Rb inhibits transcrip-
tion of p16 [10,11]. As a consequence, most ECA exhibit a
diffuse positivity of p16, whereas EMA (especially en-
dometrioid type) is usually negative or there is focal positiv-
ity [3, 5, 12, 13]. Expression of p16 protein is associated with
HPV oncogenic potential in cervical and genital lesions [14].
Thus, p16 protein is also a useful marker to help determine the
tumor origin such as ECA and EMA (endometrioid type). In
the present study, detection rate of hr-HPV (16/18) DNA was
72.7% (24/33) in ECA, compared with 12.9% (4/31) in EMA.
High p16 expression rate of ECA (72.7%, 24/33) was signif-
icantly higher than that of EMA (16.1%, 5/31). The authors
also found that the rate of p16 high expression was 95.8%
(23/24) in hr-HPV-positive cases of ECA, and all four
(100.0%) hr-HPV DNA-positive EMA presented p16 high
expression. The present results and other studies suggest that
hr-HPV DNA detection and p16 expression level could be a
useful adjunct to distinguish between ECA and EMA. There
have been some controversial reports regarding the role of
the p16 protein in the differential diagnosis of ECA and EMA.
Recently, Saad et al. proposed that the expression of p16 in
undifferentiated carcinoma of the uterus does not exclude its
endometrial origin. They found that diffuse/strong positive
staining for p16 was seen in 40/50 (80%) cases of ECA and
14/28 (50%) cases of undifferentiated endometrial carcinoma.
At present, distinguishing between undifferentiated endome-
trial carcinoma and endocervical adenocarcinoma, both of
which share diffuse p16 expression, should rely on simulta-
neous detection of human papilloma virus in the latter [15].
Because most ECAs are hr-HPV-related tumors and the dif-
fuse p16 positivity can be regarded as a surrogate marker of
the presence of hr-HPV, p16 marker is currently the most im-
portant focus of attention and has been most widely applied
in the field of gynecologic pathology [16]. 
Vimentin is an intermediate filament protein normally ex-
pressed in mesenchymal cells, but the aberrant expression of
vimentin can be found in epithelial cancer cells [17]. For a
long time, vimentin is a useful and reliable marker to iden-
tify the primary ECA and EMA (especially endometrioid
type). Azumi et al. have indicated that as a diagnostic
reagent, antibodies to vimentin are of the greatest applica-
tion in the diagnosis of carcinoma of uncertain primary site,
whereas strong co-expression of vimentin and keratin may be
a clue to renal, endometrial, and thyroid carcinomas [18].
Many studies showed that the positive expression rates for
vimentin were significantly different between primary ECA
and EMA [19]. The positive expression rate of vimentin in
the former was approximately 7%-14% compared with 62%-
93% in the latter [20-22]. In the present study, 32 cases did
not have any expression of vimentin and only one case was
weak positive expression in 33 cases of ECA. In contrast,
the high expression rate for vimentin was 90.3% (28/31) in
EMA, especially in EMA of endometrioid type with high ex-
pression rate of 96.3% (26/27). The present research results
strongly suggest that vimentin is indeed a valuable marker in
the differential diagnosis of ECA and EMA.
The endometrium is one principal target tissue of the pitu-
itary-gonadal axis, but has also been recognized as an en-
docrine organ. Human endometrium expresses ER and PR,
which are related to autocrine and paracrine processes that re-
spond to estrogen and progesterone. The ER and PR expres-
Table 3. — Expressions of vimentin, ER, and PR in endocervical and endometrial adenocarcinoma (n, %).
Group n Vimentin expression* ER expression* PR expression*
Low High Low High Low High
Cervical adenocarcinoma 33 33 (100.0) 0 (0.0) 33 (100.0) 0 (0.0) 33 (100.0) 0 (0.0)
endocervical type 22 22 (100.0) 0 (0.0) 22 (100.0) 0 (0.0) 22 (100.0) 0 (0.0)
villoglandular type 3 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0)
endometrioid type 3 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0)
intestinal type 2 2 (100.0) 0 (0.0) 2 (100.0) 0 (0.0) 2 (100.0) 0 (0.0) 
serous type 2 2 (100.0) 0 (0.0) 2 (100.0) 0 (0.0) 2 (100.0) 0 (0.0)
andenosquamous carcinoma 1 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
Endometrial adenocarcinoma 31 3 (9.7) 28 (90.3) 13 (41.9) 18 (58.1) 9 (29.0) 22 (71.0) 
endometrioid type 27 1 (3.7) 26 (96.3) 9 (33.3) 18 (66.7) 5 (18.5) 22 (81.5)
serous type 4 2 (50.0) 2 (50.0) 4 (100.0) 0 (0.0) 4 (100.0) 0 (0.0) 
Total 64 36 (56.3) 28 (43.7) 46 (71.9) 18 (28.1) 42 (65.6) 22 (34.4)
* –and 1+ were categorized as low expression; 2+ and 3+ were scored as high expression.
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sion and distribution pattern may play an important role in
endometrial function and pathogenesis [23]. Therefore, EMA
(especially endometrioid type) is typically hormone-depen-
dent. Many studies reported that the EMA (endometrioid
type) significantly expresses ER and PR. In contrast, ECA
usually have absent or limited expression of ER and PR [1, 7,
22-24]. According to literature, positive expression rates of
ER and PR in EMA were 67% - 97% and 89% - 96%, com-
pared with 4% - 20%, and 4% - 21% in ECA, respectively
[20-22]. The present results show that the high expression
rates of ER and PR were 58.1% and 71.0%, respectively, in
the EMA, and 66.7% and 81.5%, especially in the en-
dometrioid type of EMA. However, ER and PR expressions
were low in ECA (the vast majority did not express), with no
high-expression cases. The high expression rates of ER and
PR in EMA was evidently higher than that in ECA (p < 0.01).
The present results were consistent with what have been re-
ported in the literature.
The present study demonstrated once again that the detec-
tion of hr-HPV DNA combined with immunohistochemical
expressions of p16, vimentin, ER, and PR are useful for dif-
ferential diagnosis between ECA and EMA and clarifying
the origin of uterine adenocarcinomas.
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Introduction
Hydatidiform moles (HMs) are the most common form
of gestational trophoblastic disease (GTD) resulting from
abnormal fertilisation and are characterised by hydropic
swelling of placental villi and trophoblastic hyperplasia.
They are categorised into two distinct entities of partial hy-
datidiform mole (PHM) and complete hydatidiform mole
(CHM), based on morphological, genetic, and clinical fea-
tures. In addition, hydropic abortions (HAs) can mimic
HMs morphologically. Accurately distinguishing HAs from
HMs and PHMs from CHMs is important for appropriate
clinical management, as the risk of persistent GTD is higher
in patients with CHM (10–30%) than with PHM (0.5–5%),
whereas HA is completely benign and not associated with
the risk of persistent GTD [1]. A diagnosis of HM can often
be made based on a morphological assessment alone. How-
ever, there are significant overlaps in the histological fea-
tures between HMs and HAs, as well as between CHMs
and PHMs, causing considerable inter-observer and intra-
observer variability in the diagnosis [2]. 
Genomic imprinting (gene expression based on gametes
of origin) is important for the regulation of implantation
and embryonic development. CHMs are derived exclu-
sively from the paternal genome (androgenetic diploidy),
whereas PHMs contain one maternally derived and two pa-
ternally derived haploid genomes (diandric triploidy), sug-
gesting that both CHM and PHM are the result of abnormal
expression of imprinted genes. The p57 gene is paternally
imprinted and expressed predominantly from the maternal
allele in most tissues. p57 is a potent cell cycle inhibitor
and tumour suppressor, and lack of p57 expression in tro-
phoblastic disease plays a relevant role in its abnormal pro-
liferation and differentiation [3]. 
The c-erbB-2 (also known as Her-2/neu) protein is a
transmembrane tyrosine kinase receptor in the epidermal
growth factor receptor family. This proto-oncogene is in-
volved in activating pathways leading to cell growth and
differentiation. The c-erbB-2 protein is expressed fre-
quently at low levels in a variety of adult epithelial cells;
however, aberrant activation of c-erbB-2 due to amplifica-
tion and/or overexpression can contribute to unrestrained
proliferation and tumour development [4].
CD117, also known as c-kit, is a tyrosine kinase recep-
tor that regulates cell proliferation, apoptosis, adhesion and
chemotaxis. CD117 may be involved in proliferation and
normal differentiation of the placenta during pregnancy
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Summary
Purpose: To explore the utility of p57, c-erbB-2, CD117, and Bcl-2 immunostaining in the differential diagnosis of complete hyda-
tidiform mole (CHM), partial hydatidiform mole (PHM), and hydropic abortion (HA). Materials and Methods: Immunohistochemical
expression of the p57, c-erbB-2, CD117, and Bcl-2 proteins were investigated semi-quantitatively using paraffin-embedded tissue sec-
tions from histologically unequivocal cases of CHM (n = 20), PHM (n = 23), and HA (n = 17). Results: All cases of CHM exhibited a
striking absence of p57 expression. The percentage of positive p57 staining was similar between PHMs (73.9%) and HAs (76.5%) (p
> 0.05). The comparison of c-erbB-2 expression revealed a significantly higher percentage of positive c-erbB-2 staining in CHMs (45%)
compared with that in PHMs (8.7%) and HAs (5.9%) (p = 0.006 and 0.01, respectively). The CD117 expression pattern (immunoreac-
tivity score, percentage of positive cells, and staining intensity) was significantly lower in HAs compared with that in PHMs and CHMs
(p < 0.05 for all). A significantly increased Bcl-2 expression pattern was observed in HAs compared with that in PHMs and CHMs (p
< 0.05 for all). Conclusion: Immunohistochemical examination of p57, c-erbB-2, CD117, and Bcl-2 expression represents a relatively
simple, reliable, and cost-efficient procedure to definitively distinguish among CHM, PHM, and HA.
Key words: Bcl-2; CD117; c-erbB-2; Hydatidiform mole; p57.
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[5]. Overexpression of CD117 has been implicated in the
pathogenesis of numerous tumours including choriocarci-
noma [6].
Apoptosis plays an important role in normal placental
morphogenesis and in the pathogenesis of GTD [7]. Bcl-2,
an anti-apoptotic molecule residing in the mitochondria,
plays a decisive role regulating cell death during embryo-
genesis and normal placental growth, and its dysregulation
has been implicated in several pregnancy disorders [8].
The objectives of this study were to ascertain the ex-
pression patterns of p57, c-erbB-2, CD117, and Bcl-2 in
CHMs, PHMs, and HAs, and to assess the value of these
markers in the dif ferential diagnosis of the three entities.
Materials and Methods
Case selection
Sixty-seven formalin-fixed paraffin-embedded gestational
specimens with hydropic swelling of chorionic villi were re-
trieved from the files of the Department of Pathology, Antalya
Training and Research Hospital between January 2010 and De-
cember 2012 after institutional review board approval. The di-
agnosis of each case (CHM, PHM or HA) was obtained from
the original pathology report. Hematoxylin and eosin-stained
sections of the specimens were reviewed independently by two
pathologists with no knowledge of the specimens’ clinical in-
formation and classified as CHM, PHM or HA according to the
main morphological findings [9]. CHM is characterized by hy-
dropic swelling of villi with central cisterns, circumferential tro-
phoblastic hyperplasia with diffuse and marked atypia, and
trophoblastic inclusions. Morphologic features of PHM include
focal trophoblastic hyperplasia, a dimorphic villous population
with an admixture of hydropic and normal villi, scalloping and
prominent stromal trophoblastic inclusions, and mild tro-
phoblastic atypia. HA is characterized by villous edema without
trophoblastic hyperplasia. Sixty cases were histologically un-
equivocal for CHM (n =20), PHM (n = 23), and HA (n = 17) and
constituted the study group. The remaining seven equivocal
cases were difficult to classify as HA, PHM or CHM because of
mixed histological features and were excluded from the final
statistical analysis. These equivocal cases were subjected to mo-
lecular genotyping. Patient demographic data were obtained
through a chart review. Serum beta-human chorionic go-
nadotropin (β-hCG) levels were measured by a two-site chemi-
luminescence immunoassay based on the direct sandwich
technique. The inter- and intra-assay coefficients of variation
were 4.1% and 1.3%, respectively.
Figure 1. — A) Villi from a complete hydatidiform mole (CHM) demonstrating complete loss of p57 immunostaining of both the villous
cytotrophoblast and stromal cells (magnification, ×100). B) Villi from a partial hydatidiform mole (PHM) demonstrating positive p57 im-
munostaining of both the villous cytotrophoblast and stromal cells (magnification, ×100). C) Bcl-2 protein cytoplasmic staining (strong in-
tensity) is seen in the synctiotrophoblastic and cytrophoblastic cells of PHM (magnification, ×40). D) Lack of Bcl-2 staining is seen in the
CHM synctiotrophoblastic and cytotrophoblastic cells (magnification, ×40). E) CD117 cytoplasmic staining (strong intensity) is seen in the
CHM synctiotrophoblastic and cytotrophoblastic cells (magnification, ×100). F) Lack of CD117 staining is seen in PHM synctiotropho-
blastic and cytotrophoblastic cells (magnification, ×40). G) Negative c-erbB-2 immunostaining in hydropic abortion (magnification, ×200).
H) Positive c-erbB-2 immunostaining of CHM synctiotrophoblastic and cytotrophoblastic cells (magnification, ×40).
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Tissue preparation and evaluation of immunohistochemical stain-
ing
Briefly, four-μm thick, representative sections from formalin-
fixed, paraffin-embedded tissue blocks were obtained in each
case, incubated for 120 minutes at 60°C and then overnight at
37°C. The tissue sections were deparaffinzed in xylene and alco-
hol, rehydrated, washed in a solution buffered with 10% sodium
citrate in a microwave oven (800 W). The slides were left to cool
at room temperature for 20 minutes. Endogenous peroxidase ac-
tivity was blocked using 0.3% hydrogen peroxide, and the slides
were washed in phosphate-buffered saline (PBS; ten mM, pH
7.4). As the primary antibody, mouse monoclonal antibodies
against p57 (clone 25B2; 1:50 dilution), c-erbB-2 (clone 10A7;
1:40 dilution), CD117 (clone 57A5D8, ready to use), and Bcl-2
(clone 3.1; 1:80 dilution) were incubated with the slides for 60
minutes at room temperature, according to the manufacturer’s pro-
tocol. The slides were washed in PBS, and the sections were in-
cubated for 20 minutes with biotinylated secondary antibody. The
chromogenic reaction was performed using 3,3’diaminobenzi-
dine. Then, the sections were washed in distilled water, counter-
stained with hematoxylin and mounted with Entellan. Appropriate
positive and negative controls were run for each case. The evalu-
ation of protein expression was performed independently by two
pathologists (DS and BT). The stained cell types were identified
as either a villous cytotrophoblast, villous intermediate tro-
phoblast, villous syncytiotrophoblast, villous stromal cells or de-
cidual cells. All samples were scored semi-quantitatively. Im-
munohistochemical results were recorded independently of the
original clinicopathological diagnosis. Representative case ex-
amples are illustrated in Figure 1.
On the basis of the staining pattern reported in the literature,
the specimens were interpreted as “positive” for p57 staining
when distinct nuclear staining (> 50%) of villous stromal cells
and cytotrophoblasts was observed. The p57 stain was interpreted
as “negative” when there was no distinct staining or limited nu-
clear staining (< 10%) of villous stromal cells and cytotro-
phoblasts but intermediate trophoblasts and/or maternal decidua
exhibited nuclear expression of p57 (which served as the positive
internal control for all cases). Nuclear expression in villous stro-
mal cells and cytotrophoblasts in the focally positive range (10–
50%) was considered an equivocal result [10]. Syncytio-
trophoblastic cells were used as negative controls.
c-erbB-2 expression was analysed by evaluation of the stain-
ing intensity and the proportion of stained villous trophoblastic
cells as follows: (0): no staining or staining observed in < 10% of
the villous trophoblast cells, (+): weak staining observed in > 10%
of the villous trophoblast cells in part of the cell membrane, (++):
weak to moderate complete membrane staining observed in >
10% of the villous trophoblast cells, and (+++): strong complete
membrane staining observed in > 10% of the villous trophoblast
Figure 2. — Representative
examples of diploid and tri-
ploid histograms produced
by short-tandem repeat am-
plification. A) Three loci
(DXS6854, D18S976, and
D21S1246) each demon-
strate two alleles, consi-
stent with diploidy (two
peaks with approximate 1:1
ratios). B) Three loci
(D13S325, D21S1442, and
DXYS218) each demon-
strate three alleles, consi-
stent with triploidy.
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cells [11]. c-erbB-2 expression was categorised as positive or neg-
ative, and only the score (+++) was considered a positive reac-
tion. Sections of two breast carcinomas known to express
c-erbB-2 served as positive controls.
CD117 and Bcl-2 expression in villous cells was evaluated
using an immunoreactivity score (IRS) as described elsewhere
[12]. The IRS was calculated by multiplying the percentage of
positive cells (PP) by the staining intensity (SI). PP was estimated
by counting ~ 100 cells per slide (×400 magnification) and scored
as follows: 0 = < 5% staining, 1 = 5–25% staining, 2 = 25–50%,
3 = 50–75% staining, and 4 = > 75% staining. The SI was scored
as follows: 0: negative, 1: weakly positive, 2: moderately positive
and 3: strongly positive. Cytoplasmic staining was the criterion
for positive CD117 and Bcl-2 reactions. Sections of a lymph node
with follicular hyperplasia were used as a positive control for Bcl-
2, and sections of a gastrointestinal stromal tumour were used as
a positive control for CD117.
DNA analysis by short tandem repeat (STR) genotyping
DNA extraction was performed on formalin-fixed, paraffin
embedded tissue following a standard procedure using an auto-
mated system. Quantitative fluorescent polymerase chain reac-
tion (QF-PCR) methodology was used to determine the diploidy
status of the extracted DNA. Short-tandem repeat loci were eval-
uated in each sample using the ChromoQuant QF-PCR kit,
which allows for DNA amplification and fluorescence analysis
of 22 loci from different chromosomes and the amelogenin locus
simultaneously. The amplified microsatellite fragment size data
were analysed using ChromoQuant Visualizer STaR ver. 4.03
analysis software. QF-PCR amplification and capillary elec-
trophoresis were performed according to the manufacturer’s in-
structions. Capillary electrophoresis data from villous tissues
were analysed to identify alleles at each locus. For each locus
from which two alleles were identified, the allelic ratio was cal-
culated by dividing the peak height of the longer allele by the
peak height of the shorter allele. Allelic ratios of 0.8–1.4 were
considered consistent with diploidy. Allelic ratios < 0.65 or >
1.8 were considered to be consistent with triploidy. Allelic ratios
that fell between the normal and abnormal ranges were classed
as inconclusive. In addition, loci with three and two alleles iden-
tified were consistent with triploidy and diploidy, respectively
(Figure 2). At least two informative loci were required for the
final interpretation. 
Statistical analysis
The comparison of antibodies among histologically unequivo-
cal cases was assessed using SPSS 18.0 software. The numeric
variable comparison among the three groups was performed using
the Kruskal–Wallis test, and post-hoc comparisons were assessed
using the Mann–Whitney U-test with Bonferroni’s correction.
Categorical data were compared using Pearson’s chi-square test.
All tests were two-sided at a significance level of p < 0.05. 
Results
The age of the 67 patients ranged from 17 to 45 years
(median, 27) with gestational ages of 6–15 weeks (median,
ten). Patients with PHM (median, 26 years) were younger
than those with CHM (median, 29 years), and HA (me-
dian, 31 years). The median gestational age at the time of
diagnosis was nine weeks for the HA cases, 11 weeks for
PHM cases, and ten weeks for CHM cases. All patients
with HMs were followed by clinical examination and
serum β-hCG measurements. After therapeutic evacuation,
one patient with CHM evolved into persistent trophoblas-
tic disease requiring methotrexate therapy. However, the β-
hCG level was negative after six months of therapy. The
average follow-up period in cases of HMs was 12.8
months (range 12–14). 
The comparison of p57, c-erbB-2, CD117, and Bcl-2 ex-
pression in the histologically unequivocal cases is sum-
marised in Table 1. All 20 cases that had been morpho-
Table 1. — Immunohistochemical analysis of p57, c-erbB-2, CD117, and Bcl-2 in hydropic abortions, partial, and com-
plete hydatidiform moles.
Marker expression HA PHM CHM p-value p1-value p2-value p3-value
(n=17) (n=23) (n=20) 
p57 
a
< 0.001 < 0.001 0.999 < 0.001 
Negative 4 (23.5) 6 (26.1) 20 (100) 
Positive 13 (76.5) 17 (73.9) -
c-erbB-2 
a
0.003 0.006 0.999 0.01
Negative 16 (94.1) 21 (91.3) 11 (55.0) 
Positive 1 (5.9) 2 (8.7) 9 (45.0)
CD117 
b
Staining intensity 1.06±0.24 1.78±0.60 2±0.72 < 0.001 0.307 < 0.001 < 0.001 
Percentage of positive cells 1.88±0.70 2.65±0.89 2.75±0.91 0.002 0.857 0.005 0.005 
Immunoreactivity scores 2.06±1.20 5.09±2.81 6.05±3.87 < 0.001 0.651 0.001 < 0.001 
Bcl-2 
b
Staining intensity 2.29±0.77 1.61±0.84 0.75±0.55 < 0.001 0.001 0.014 < 0.001 
Percentage of positive cells 1.35±0.1 0.72±0.21 0.70±0.47 0.005 0.015 0.009 0.005
Immunoreactivity scores 2.29±0.77 1.61±0.84 0.75±0.55 < 0.001 0.001 0.014 < 0.001 
Values are given as 
a
number (%) or 
b
mean ± SD ( standard deviation). If the Kruskal–Wallis test was positive (p < 0.05) then post-hoc analysis was applied.
p, between three groups; p1, between partial and complete hydatidiform mole; p2, between partial hydatidiform mole and hydropic abortion;
p3, between complete hydatidiform mole and hydropic abortion. Adjusted significance level for p1, p2, and p3 = 0.017.
HA: hydropic abortion, PHM: partial hydatidiform mole, and CHM: complete hydatidiform mole.
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logically diagnosed as CHM exhibited a striking lack of p57
positive staining in villous cytotrophoblasts and stromal
cells. Although the percentage of positive p57 staining
tended to be higher in HAs (76.5%) than in PHMs (73.9%),
the difference was not significant (p = 0.999). Maternal de-
cidua and intermediate trophoblasts showed strong p57 ex-
pression in contrast to the syncytiotrophoblast, which
showed complete negativity in all cases regardless of the di-
agnosis.
c-erbB-2 expression was observed in all types of villous
trophoblasts. The villous stromal cells and decidual cells
showed negative immunostaining. A significant between-
group difference was observed in the percentage of posi-
tive c-erbB-2 staining (p = 0.003). Pair-wise comparisons
between the groups revealed a significantly higher per-
centage of positive c-erbB-2 staining in CMs (45%), com-
pared with PHMs (8.7%) and HAs (5.9%) (p = 0.006 and
0.01, respectively). However, no significant difference was
observed between PHMs and HAs (p = 0.999). 
Cells positively expressing CD117 were restricted mostly
to villous trophoblasts, whereas decidual and villous stro-
mal cells showed weak immunostaining. The expression
pattern (SI, PP, and IRS) was significantly lower in HAs
compared with PHMs and CMs, as shown in Table 1. Al-
though the expression pattern tended to be higher in CMs
than in PHMs, the difference was not significant (adjusted
p > 0.017).
Bcl-2 expression was observed in all types of villous tro-
phoblasts. Villous stromal cells and decidual cells showed
negative immunostaining. A significance between-group
difference was observed in the Bcl-2 expression pattern (p
< 0.05). A pair-wise comparison between the groups re-
vealed significantly increased expression in HAs compared
with PHMs and CHMs, and also in PHMs compared with
CHMs (adjusted p < 0.017 for all)
Seven histologically undetermined cases included one
case with a differential diagnosis between HA and PHM,
whereas the other six cases had a differential diagnosis
between PHM and CM (Table 2). DNA analysis by STR
genotyping was performed to refine the histological sub-
types of these cases. Case with a differential diagnosis be-
tween HA and PHM showed positive p57 expression and
cytogenetic diploidy, consistent with a HA. Among the
six cases with a differential diagnosis between PHM and
CM, two cases showed equivocal results for p57 im-
munostaining and cytogenetic triploidy, consistent with
PHM, and the remaining four cases showed negative p57
immunostaining and cytogenetic diploidy, consistent with
CM.
Discussion
Accurate clinical diagnosis is important for distinguish-
ing among CHM, PHM, and HA. A careful microscopic
evaluation of the morphological features observed on
haematoxylin and eosin-stained slides remains the corner-
stone of diagnosis for these three entities. However, classi-
fying HMs based solely on histological appearance can be
extremely difficult, even for an experienced pathologist. In
addition, HAs may exhibit atypical trophoblast prolifera-
tion leading to an erroneous diagnosis of HM. Several an-
cillary techniques have been applied to resolve these
diagnostic problems, including immunohistochemistry,
conventional cytogenetics (karyotyping), flow cytometry,
digital image analysis, fluorescence in situ hybridisation
(FISH), and molecular genotyping [13]. 
The value of an immunohistochemical analysis of the pa-
ternal ly imprinted, maternally expressed p57 gene for im-
prov ing the diagnosis of HMs has been well established.
p57 is a highly specific and sensitive marker for CHM due
to an absence of nuclear staining in villous stromal cells
and cytotrophoblasts [14-16]. The lack of p57 activity in
CHM cases can lead to loss of cell cycle control, resulting
in abnormal proliferation and differentiation of tro-
phoblasts, correlated with histological features such as tro-
phoblastic hyperplasia. In contrast, both PHMs and HAs
contain a maternal chromosomal complement and express
p57. This differential p57 staining pattern is helpful for dis-
tinguishing CHMs from PHMs and HAs. Rare examples of
CHMs displaying aberrant (positive) p57 expression at-
tributable to retention of the maternal copy of chromosome
11 have been reported [17]. Conversely, PHMs with loss of
maternal chromosome 11 may show negative p57 expres-
sion [18]. Several studies have evaluated p57 immunohis-
Table 2. — Molecular genotyping results in the histologically undetermined cases.
Case Clinical impression Morphologic impression p57 staining Genotyping results Final diagnosis 
1 Missed abortion HA vs. PHM Positive Biparental diploidy HA
2 Missed abortion CHM vs. PHM Negative Androgenetic diploidy CHM
3 Incomplete abortion CHM vs. PHM Negative Androgenetic diploidy CHM
4 Incomplete abortion CHM vs. PHM Equivocal Diandric triploidy PHM
5 Hydatidiform mole CHM vs. PHM Equivocal Diandric triploidy PHM
6 Hydatidiform mole CHM vs. PHM Negative Androgenetic diploidy CHM
7 Hydatidiform mole CHM vs. PHM Negative Androgenetic diploidy CHM
HA, hydropic abortion; PHM, partial hydatidiform mole; CHM, complete hydatidiform mole.
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tochemical staining and have revealed high concordance of
the results with morphology, ploidy, and molecular geno-
typing studies [19, 20]. p57 immunostaining can also be
helpful when refining the diagnosis of some morphologi-
cally challenging cases and for detecting androgenetic cell
lines in mosaic/chimeric conception cases [21]. The pres-
ent authors identified loss of p57 expression in all CHM
cases. In the present cases, nearly all p57 staining results
were readily interpretable as negative or positive, with the
exception of two equivocal results encountered in cases
proven to be PHMs by molecular genotyping. The authors
confirmed that p57 is of no value when trying to distinguish
PHM from HA, although it is helpful to distinguish CHM
from PHM and HA, as both conditions show similar p57
expression patterns.
CD117 is a surface marker for embryonic, hematopoi-
etic, and mesenchymal stem cells; it allows cells to re-
main in their undifferentiated state [22]. The interaction
between CD117 with its ligand stem cell factor (SCF)
promotes phosphorylation and activation of intracyto-
plasmic signal cascades essential for embryogenesis,
hematopoiesis, proliferation, and migration of germ cells.
In addition, binding of SCF to CD117 promotes tumour
growth by promoting proliferation and/or by protecting
tumour cells from death. Few studies have investigated
CD117 expression in HMs. Ahmed et al. found that the
CHM trophoblast cells express CD117 with variable in-
tensity and localisation, but no comparison was made
with HAs or with PHMs [23]. A recent study found that
CD117 expression pattern does not differ among CHMs,
PHMs and normal pregnancy [24]. The authors found a
significantly increased CD117 expression pattern in
CHMs and PHMs compared with that in HAs. This find-
ing suggests that over-expression of CD117 may play a
critical role in the aggressive behavior of CHMs.
Bcl-2 is a type of proliferation or maturation-related
marker of trophoblasts that shows decreased expression
along with terminal differentiation and maturation [25].
Previous studies have reported contradictory results in re-
lation to Bcl-2 expression for discriminating molar and
non-molar pregnancies. A study by Fulop et al. demon-
strated significantly stronger Bcl-2 protein expression in
CHMs and choriocarcinoma compared with that in both
normal placentas and PHMs [26]. Al-Bozom showed that
Bcl-2 staining pattern does not differ among CHMs,
PHMs, and HAs [27]. Hussein reported strong Bcl-2 ex-
pression in chorionic villi from first trimester pregnancy
terminations compared with CHMs and PHMs. Author
suggested that the relatively moderate Bcl-2 expression
in partial and CHMs may prevent apoptotic cell death of
these atypical trophoblastic cells, allowing them to ac-
quire a more malignant potential [12]. The present results
demonstrated a significant decrease in Bcl-2 expression
in CHMs and PHMs compared with HAs, inferring an in-
creased apoptotic profile in molar pregnancy. Some of
these discrepancies can be attributed to differences in the
immunohistochemical staining method and the evaluation
of Bcl-2 expression. The present authors propose that the
variations in Bcl-2 expression among CHMs, PHMs, and
HAs may be used as a potential adjunctive diagnostic tool
to discriminate the three entities.
Immunohistochemical analysis of c-erbB-2 overexpres-
sion in HMs has been proposed as a predictor of persistent
trophoblastic disease in several studies. Some authors
found increased c-erbB-2 expression in CHM that pro-
gressed to a gestational trophoblastic tumour compared
with those with spontaneous remission [28, 29]; however,
this finding has not been corroborated [11]. Fulop et al.
found that c-erbB-2 staining was significantly stronger in
cases of CHM and choriocarcinoma compared with normal
placenta and PHM [26]. Bauer et al. reported that high c-
erbB-2 expression in combination with DNA hyperploidy
is associated with more aggressive behavior of the GTD
[30]. The present study is the first attempt to assess the
value of c-erbB-2 expression to distinguish HMs from
HAs. The present results demonstrate a higher percentage
of c-erbB-2 expression in CHMs compared with PHMs,
which supports the more aggressive characteristics of
CHMs. In addition, immunohistochemical staining for c-
erbB-2 provided useful diagnostic information to distin-
guish among CHMs, PHMs, and HAs. 
Previous studies have shown that histological evalua-
tions in combination with techniques that determine DNA
content (ploidy) improve the accuracy of diagnosing
HMs. These ancillary molecular techniques include con-
ventional cytogenetics (karyotyping), flow cytometry,
image analysis, and FISH [31-33]. DNA ploidy analysis
can readily distinguish triploid PHM from diploid con-
ceptions but cannot distinguish between CHM and HA be-
cause both are diploid. The most recent ancillary
technique, molecular genotyping using PCR amplification
of STR loci, allows for determination of both ploidy and
the maternal/paternal contributions of chromosome com-
plements. Unlike karyotyping, molecular genotyping does
not require fresh tissue, as it can be performed on routine
formalin-fixed paraffin-embedded material, making it par-
ticularly suitable for clinical practice. Other ploidy tech-
niques, including FISH, can be performed on fresh
paraffin-embedded tissue but occasionally produce results
that are difficult to interpret because of maternal tissue
contamination. Recent data suggest that molecular geno-
typing may have advantages over other molecular meth-
ods used to distinguish androgenetic diploidy, diandric
triploidy, and biparental diploidy, which are characteristic
of CMs, PHMs and HAs, respectively [34,35]. One study
proposed a diagnostic working algorithm in combination
with molecular genotyping and p57 immunohistochem-
istry to refine the diagnosis of HMs [36]. However, mo-
lecular genotyping methods are technically difficult,
relatively expensive, time consuming, and not universally
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available. Another limitation of genotyping is that mater-
nal decidual tissue free of fetal tissue must be present for
comparison of villous and paternal alleles. In the present
study, STR genotyping was performed on the equivocal
cases reported herein due to mixed histological features
that did not conform to the expected findings for typical
CHMs, PHMs, and HAs, and its use was crucial to deter-
mine the correct diagnosis.
Conclusion
Immunohistochemical examination of p57, c-erbB-2,
CD117, and Bcl-2 expression is a relatively simple, reli-
able, and cost-efficient procedure to definitively distinguish
among CHM, PHM, and HA. However, molecular tech-
niques are still required for evaluating some challenging
cases. 
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Introduction
Cancer is one of the most serious medical problems
threatening human life and ranks as the leading cause of
death. As is well known, many factors that contribute to
cancer occurrence have been reported, such as lifestyle, to-
bacco, alcohol addiction, environment, and so on [1].
Moreover, recent studies indicated that estrogen was asso-
ciated with an increased risk of multiple types of cancer,
especially breast and prostate cancer and may represent a
leading preventable cause of death [2, 3]. Estrogen is me-
diated by the estrogen receptor (ESR), which interacts with
other cell-signaling pathways to influence cell behavior.
There are two major ESR subtypes: ESR1 and ESR2,
which are encoded by two separate genes located on chro-
mosome 6q25.1 and chromosome 14q23.1, respectively [4,
5]. Since ESR2 was identified in 1996 [6], there has been
mounting evidence that the genetic variants in ESR2 gene
have an influence on body weight [7], Alzheimer’s disease,
[8], anorexia nervosa [9], and so on, whereas the speciﬁc
functions of ESR2 in carcinogenesis are not yet known.
Currently, related studies have drawn close attention to
ESR2 polymorphisms (rs3020450, rs4986938, and
rs1256049) which were thought to be associated with the
risk of various cancers, such as breast and prostate cancer,
uterine fibroids, and other cancers; however, the results
were generally inconclusive and inconsistent. The incon-
sistencies in previous studies might be due to small sample
sizes, different research populations, and random errors.
Therefore, the present authors performed a comprehensive
meta-analysis to derive a more precise estimation of the
correlation between these three polymorphisms and the
cancer risks.
Materials and Methods
Identification and selection of eligible studies
The following bibliographic databases were searched by using
the combined words ‘‘ESR2/ERβ/ER-beta/estrogen receptor
beta’’, ‘‘cancer’’ or ‘‘carcinoma’’, ‘‘genetic variation’’ or ‘‘poly-
morphism’’. A comprehensive systematic bibliographic search
was applied through the medical databases PubMed, CNKI, and
WanFang for all publications up to June 2014. The criteria for
acceptance of the studies were as follows: (1) studies evaluated
ESR2 (rs3020450, rs4986938, and rs1256049) gene polymor-
phisms and available cancer risk; (2) case-control studies; (3) the
numbers of the genotype or allele were reported in the article or
could be obtained from authors or other source; (4) available
genotype frequency. Moreover, the studies were eliminated as
follows: (1) case-only studies, case reports, editorials, and review
articles (including meta-analyses); (2) studies without raw data
available; (3) duplicated studies.
Data extraction
Two authors (Wenkai Xia and Weidong Mao) independently
extracted all the data based on the inclusion criteria listed above.
All disagreements regarding eligibility were resolved by discus-
sion with a third author (Qiwen Deng). Any study with incorrect
or inconsistent data was excluded. The following variables were
extracted from each study if available: first author’s last name and
the year of publication, country of subjects, cancer type, geno-
typing method and ethnicity of the population, matching numbers
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of genotyped cases and controls, and polymorphism site (Table
1). If difference and discrepancies were existed after data collec-
tion, discussion was carried out to reach a consensus.
Statistical analysis
Odds ratio (OR) with its 95% confidence intervals (CI) was
calculated to assess the overall association of ESR2 rs3020450,
rs4986938, and rs1256049 polymorphisms with cancer risk. The
pooled ORs were calculated for the risks of carriage of the mu-
tant allele on cancers compared with the wide-type homozygote,
followed by evaluating the risk in the recessive model and dom-
inant model. Stratified analysis was also performed according
to cancer type (endometrial, prostate, breast, and other cancer
groups which combined the cancer types containing less than
two individual studies), source of control and genotyping
method. Chi-square test based Q-statistic test was used to eval-
uate heterogeneity across the studies [10], and was considered
significant if p
heterogeneity
< 0.05. Both fixed-effects (the Man-
tel-Haenszel method) and random effects (the DerSimonian and
Laird method) models were used to pool the results [10]. A
fixed-effect model was employed when no heterogeneity ex-
isted. Otherwise, the random-effect model was employed to pool
the results. Publication bias was applied by funnel plots and the
Egger’s linear regression test. For the controls of each study, the
genotype frequencies of the three polymorphisms of ESR2 were
assessed for Hardy-Weinberg equilibrium using a web-based
program. All statistical tests were performed with STATA ver-
sion 11.0.
Table 1. — Characteristics of studies included in the meta-analysis.
Year Cancer Country Ethnicity Source Genotyping Polymorphism sites Cases Controls
of method
control
2009 Uterine fibroids Germany Caucasian HB PCR-ARMS rs3020450 101 102
2010 Uterine fibroids China Asian HB TaqMan rs4986938, rs1256049 92 193
2010 TGCT Italy Caucasian HB TaqMan rs1256049 234 218
2009 PC France Caucasian HB Taqman rs4986938, rs1256049 382 381
2010 PC Japanese Asian HB Taqman rs1256049 180 177
2007 PC
1
Mix
2
Mix HB Taqman rs3020450, rs4986938, rs1256049 8323 9412
2009 PC USA Caucasian PB TaqMan rs4986938 219 370
2012 PC Iran Asian PB PCR-RFLP rs4986938,rs1256049 162 324
2005 PC China Asian HB TaqMan rs1256049 40 86
2004 PC Japan Asian HB TaqMan rs1256049 136 236
2014 OC Germany Caucasian HB PCR-ARMS rs3020450 184 182
2009 OC USA Mix PB TaqMan rs3020450 147 251
2009 OC USA Caucasian PB TaqMan rs3020450 72 146
2009 OC USA Asian PB TaqMan rs3020450 94 172
2010 LC USA Caucasian PB Taqman rs3020450, rs4986938, rs1256049 1021 826
2011 Melanoma Italy Caucasian HB TaqMan rs4986938 112 195
2012 LC Singapore Asian PB TaqMan rs4986938, rs1256049 702 1578
2009 HCC China Asian HB TaqMan rs4986938, rs1256049 100 100
2012 GBC India Asian HB PCR-LDR rs1256049 410 220
2009 EC Australia Caucasian HB TaqMan rs4986938, rs1256049 191 291
2004 EC USA Caucasian PB Taqman rs1256049 220 661
2013 EC Germany Caucasian HB PCR-ARMS rs3020450 135 135
2013 EC China Asian HB TaqMan rs4986938, rs1256049 60 60
2011 CRC Germany Caucasian HB PCR-ARMS rs4986938 676 669
2010 BTC China Asian PB TaqMan rs4986938, rs1256049 411 786
2009 BC Germany Caucasian HB PCR-ARMS rs3020450 318 318
2006 BC USA Caucasian PB TaqMan rs4986939 88 1272
2007 BC
1
Mix Caucasian PB Taqman rs3020450, rs4986938, rs1256049 5789 7761
2005 BC Sweden Caucasian HB PCR-RFLP rs4986938, rs1256049 723 480
2003 BC China Asian PB PCR-RFLP rs1256049 1113 1209
2009 BC Sweden Caucasian PB Sequencing rs3020450 538 1073
2009 BC Japan Asian PB PCR-LDR rs4986938, rs1256049 388 388
2009 BC Japan Mix PB PCR-LDR rs4986938, rs1256049 458 458
2003 BC Sweden Caucasian HB PCR-RFLP rs4986938, rs1256049 219 238
2009 BC India Asian HB PCR-RFLP rs4986938 248 249
2009 BC Gernany Caucasian PB TaqMan rs4986938, rs1256049 3919 7421
1
Mixed United States and Europe, 
2
Mixed population including Caucasian, Asian, and African.
TGCT: testicular germ cell tumor; OC: ovarian cancer; BTC: biliary tract cancer; BC: breast cancer; CRC: colorectal cancer; EC: endometrial cancer;
HCC: hepatocellular cancer; PC: prostate cancer; LC: lung cancer; GBC: gallbladder carcinoma; PB: population based; HB: hospital based;
PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR-LDR: polymerase chain reaction-ligation detection reaction;
PCR-ARMS: polymerase chain reaction-amplification refractory mutation system.
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Results
Characteristics of studies
This study enrolled 33 eligible papers [2, 12-41] (Figure
1) according to the inclusion criteria. For ESR2 rs3020450
polymorphism, nine studies including 14,369 cases and
17,661 controls were classified into ovarian cancer (two
studies), breast cancer (three studies), and the others, which
were categorized into “other cancers”. Meanwhile, there
were nine studies of Caucasian descendent, two mixed de-
scendent, and one Asian descendent. For ESR2 rs4986938
polymorphism, 20 studies provided available data, 22,833
cases and 30,319 controls included which were classified
into prostate cancer (four studies), lung cancer (two stud-
ies), endometrial cancer (two studies), breast cancer (seven
studies), and others (five studies) which were categorized
into “other cancers”. Meanwhile, these studies with data of
studies of 12 Caucasian descendent, eight of Asian descen-
dent, and two mixed descendent were collected for the
pooled analysis. For ESR2 rs1256049 polymorphism, 22
studies including 22,722 cases and 28,952 controls con-
sisted of Caucasian descendent (12 studies), Asian descen-
dent (13 studies), and mixed descendent provided available
data, which related to prostate cancer (six studies), lung
cancer (two studies), breast cancer (six studies), and other
cancers. Furthermore, the controls of most studies were
population-based and the main genotyping method was
PCR-RFLP (Table 1). 
Main results
For ESR2 rs4986938 polymorphism, subgroup analysis
revealed a low decreased risk for breast cancer in het-
erozygote comparison (AG vs. GG: OR = 0.94, 95% CI:
0.90-1.0, p
heterogeneity
= 0.62) and dominant model com-
parison (AA + AG vs. GG: OR = 0.94, 95% CI: 0.90−0.99,
p
heterogeneity
= 0.285) (Table 2 and Figure 2). In a
stratiﬁed analysis by ethnicity, a decreased risk was ob-
served for Asian descendent (AA vs. GG: OR = 0.56, 95%
CI: 0.39−0.82, p
heterogeneity
= 0.096; AA vs. AG + GG:
OR = 0.76, 95% CI: 0.63−0.92, p
heterogeneity
= 0.065).
Moreover, a decreased risk was observed for Caucasian de-
scendent (AA + AG vs. GG: OR = 0.96, 95% CI:
0.92−1.00, p
heterogeneity
= 0.562). In addition, cancer
type subgroup analysis revealed A allele was associated
with decreased breast cancer (OR = 0.96, 95% CI:
0.93−1.00, p
heterogeneity
= 0.088). 
For ESR2 rs1256049 polymorphism, cancer type’s sub-
group analysis revealed a significant association in the
comparison of homozygote model (AA vs. GG: OR = 3.5,
95% CI: 1.27-9.64, p
heterogeneity
= 0.842), heterozygote
model (AG vs. GG: OR = 1.53, 95% CI: 1.03−2.25,
p
heterogeneity
= 0.305), and dominant model (AA + AG
vs GG: OR = 1.60, 95% CI: 1.09−2.35, p
heterogeneity
=
0.205) in endometrial cancer. Similarly, an increased risk
was observed for the comparison of homozygote model
(AA vs. GG: OR = 1.40, 95% CI: 1.16−4.49, p
heterogene-
ity
= 0.411) with recessive model (AA vs. AG + GG: OR =
1.50, 95% CI: 1.10−2.04, p
heterogeneity
= 0.654) in
prostate cancer (Table 3 and Figure 3). In a stratiﬁed analy-
sis by ethnicity, there was no association between ESR2
rs1256049 and cancer risk. 
For overall analysis, results of pooled analysis revealed
no significant associations between the genotypes of ESR2
rs3020450 polymorphism and cancer risk in all genetic
models (shown in Table 4).
Figure 1. — Flow chart of studies identiﬁed with
criteria according to inclusion and exclusion.
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Table 2. — Stratified analyses of ESR2 rs4986938 polymorphism and cancer risk.
Variables Cases/controls A/A vs. G/G A/G vs. G/G A/A vs. (G/G+G/A) (A/A+G/A) vs. G/G
OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a
Total 22833 / 30319 0.96 (0.9-1.01) 0.109 0.98 (0.94-1.02) 0.178 0.97 (0.92-1.02) 0.245 0.98 (0.94-1.01) 0.07
Cancer type
LC 1565 / 1790 0.96 (0.73-1.26) 0.476 1.04 (0.88-1.23) 0.357 0.97 (0.76-1.24) 0.446 1.03 (0.88-1.20) 0.427
PC 8801 / 10233 0.96 (0.74-1.23)
c
0.026 1.03 (0.97-1.1) 0.305 0.96 (0.75-1.24)
c
0.019 1.03 (0.97-1.09) 0.323
BC 10837 / 16021 0.94 (0.87-1.02) 0.161 0.94 (0.90-1.00)b 0.62 0.96 (0.89-1.03) 0.271 0.94 (0.90-0.99)b 0.285
EC 248 / 346 0.79 (0.46-1.36) 0.444 0.83 (0.57-1.22) 0.639 0.91 (0.58-1.43) 0.444 0.82 (0.57-1.17) 0.506
other 1382 / 1929 0.96 (0.74-1.25) 0.248 0.92 (0.76-1.11) 0.054 0.98 (0.82-1.18) 0.545 0.9 (0.61-1.33) 0.025
c
Ethnicity
Asian 1996 / 3050 0.56 (0.39-0.82)b 0.096 1.01 (0.86-1.19) 0.079 0.76 (0.63-0.92)b 0.065 0.93 (0.70-1.22)c 0.031
Caucasian 18331 / 24521 0.96 (0.90-1.02) 0.752 0.96 (0.92-1.01) 0.616 0.98 (0.92-1.03) 0.931 0.96 (0.92-1.00)b 0.562
Mixed 2506 / 2748 1.16 (0.93-1.45) 0.471 1.10 (0.98-1.24) 0.917 1.12 (0.90-1.39) 0.459 1.11(0.99-1.24) 0.755
LC: lung cancer, PC: prostate cancer, BC: breast cancer, EC: endometrial cancer. 
a p value of Q test for heterogeneity test; b Statistically signiﬁcant results;
c 
Random-effect model was applied when p value for heterogeneity < 0.05, otherwise, ﬁxed-effect model was applied.
Figure 2. — Forest plots of effect estimates for cases and controls of 22 individual studies for rs4986938 stratified by cancer type (AA + GA
vs. GG). For each study, the estimate of OR and its CI is plotted with a box and a horizontal line. Filled diamond pooled OR and its 95% CI.
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Table 3. — Stratified analyses of the ESR2 rs1256049 polymorphism and cancer risk.
Variables Cases/controls A/A vs. G/G A/G vs. G/G A/A vs. (G/G+G/A) (A/A+G/A) vs. G/G
OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a
Total 22673 / 28909 1.07 (0.75-1.54)
c
0 0.93 (0.82-1.06)
c
0 1.12 (0.84-1.48)
c
0 0.94 (0.82-1.08)
c
0
Cancer type
lung cancer 1563 / 1779 1.13 (0.82-1.56) – 1.01 (0.80-1.27) – 1.13 (0.84-1.51) – 1.01 (0.84-1.23) 0.606 
prostate cancer 7796 / 8927 1.40 (1.02-1.91)b 0.411 0.91 (0.73-1.14)c 0.011 1.50 (1.10-2.04)b 0.654 0.98 (0.82-1.18)c 0.048
breast cancer 11652 / 15726 0.47 (0.19-1.13)
c 
0 0.91 (0.73-1.14)
c 
0 0.57 (0.26-1.23)
c
0 0.83 (0.62-1.12)
c
0
endometrial
cancer
471 / 1010 3.50 (1.27-9.64)b 0.842 1.53 (1.03-2.25)b 0.305 1.72 (0.85-3.68) 0.549 1.60 (1.09-2.35)b 0.205
other 1240 / 1510 0.84 (0.27-2.60)
c
0.001 0.72 (0.48-1.09)
c
0.045 0.95 (0.42-2.16)
c
0.01 0.72 (0.45-1.15)
c
0.01
Ethnicity
Asian 4085 / 5191 1.15 (0.88-1.51)
c
0.008 0.89 (0.76-1.04)
c
0.042 1.09 (0.96-1.24) 0.089 0.94 (0.81-1.09)
c
0.022
Caucasian 17401 / 22337 0.23 (0.02-2.39)
c
0 0.93 (0.72-1.19)
c
0 0.34 (0.04-2.93)
c
0 0.86 (0.65-1.15)
c
0
Mixed 458 / 458 1.10 (0.72-1.69) – 1.07 (0.81-1.40) – 1.87 (0.53-6.65) – 1.03 (0.79-1.33) –
Africa 778 / 966 1.87 (0.53-6.65) – 1.00 (0.77-1.31) – 1.07 (0.71-1.61) – 1.07 (0.83-1.08) – 
LC: lung cancer, PC: prostate cancer, BC: breast cancer, EC: endometrial cancer; 
a p value of Q test for heterogeneity test; b Statistically signiﬁcant results;
c 
Random-effect model was applied when p value for heterogeneity < 0.05; otherwise, ﬁxed-effect model was applied.
Figure 3. Forest plots of effect estimates for cases and controls of 25 individual studies for rs4986938 stratified by cancer type (AA vs.
GG). For each study, the estimate of OR and its CI is plotted with a box and a horizontal line. Filled diamond pooled OR and its 95% CI.
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Test of heterogeneity
For overall studies of ESR2 rs1256049 polymorphism, a
significant heterogeneity was apparent among homozygous
comparison (AA vs GG: p
heterogeneity
=0.000), heterozy-
gote comparison (AG vs. GG: p
heterogeneity
=0.000), re-
cessive comparison (AA vs. AG + GG: P
heterogeneity
=0.000), dominant model (AA + AG vs. GG: P
heterogeneity
=0.000)
There was no apparent heterogeneity for overall studies
of ESR2 rs4986938 and ESR2 rs3020450.
Sensitivity analysis and publication bias
Sensitivity analysis was performed to assess the stability
of these results and to find the source of the heterogeneity
by sequential removal of individual eligible study. The re-
sults of sensitivity analysis were obtained after sequentially
excluding each case-control study, indicating the stability of
the results.
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias. The shape of the funnel plot indi-
cated obvious asymmetry in ESR2 rs1256049 heterozygous
model comparison and dominant model comparison (Figure
4A). Thus, Egger’s test was used to provided statistical evi-
dence of funnel plot asymmetry (t = -2.62, p = 0.016) (shown
in Table 5), which suggested the existence of publication bias
in the meta-analysis. To adjust this bias, a trim-and-fill
method mentioned by Duval and Tweedie [42] was utilized
(Figure 4B). As a result, the conclusion with or without the
trim-and-fill method did not change, indicating that the pres-
ent results were statistically robust. While the shapes of the
funnel plots did not reveal any evidence of obvious asym-
Table 4. — Stratified analyses of the ESR2 rs3020450 polymorphism and cancer risk.
Variables Cases/controls A/A vs. G/G A/G vs. G/G A/A vs. (G/G+G/A) (A/A+G/A) vs. G/G
OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a OR (95% CI) p a
Total 16417 / 19956 0.98 (0.92-1.06) 0.557 1.01 (0.97-1.05) 0.57 0.98 (0.91-1.05) 0.465 1.00 (0.96-1.05) 0.696
Cancer type
OC 497 / 751 1.12 (0.72-1.73) 0.148 0.89 (0.59-1.36)
c
0.046 1.07 (0.70-1.63) 0.102 0.94 (0.74-1.19) 0.085
BC 6481 / 8918 0.94 (0.84-1.05) 0.491 1.00 (0.94-1.07) 0.962 0.94 (0.84-1.04) 0.507 0.99 (0.93-1.05) 0.824
PC 8182 / 9224 1.00 (0.90-1.11) 0.818 1.03 (0.97-1.10) 0.612 0.99 (0.90-1.09) 0.929 1.02 (0.96-1.09) 0.614
other cancer 1257 / 1063 1.11 (0.84-1.47) 0.654 0.96 (0.81-1.15) 0.975 1.13 (0.87-1.47) 0.58 0.99 (0.84-1.17) 0.995
Ethnicity
Asian 94 / 172 2.78 (0.87-8.86) – 0.66 (0.38-1.22) – 3.11 (0.99-9.79) – 0.85 (0.50-1.47) –
Caucasian 14128 / 17238 0.98 (0.91-1.06) 0.835 1.01 (0.96-1.06) 0.8 0.97 (0.91-1.05) 0.749 1.00 (0.96-1.05) 0.892
Mixed 2195 / 2546 0.99 (0.81-1.21) 0.126 1.03 (0.91-1.12) 0.077 0.97 (0.80-1.18) 0.186 0.87 (0.55-1.37)
c
0.04
OC: ovarian cancer, PC: prostate cancer, BC: breast cancer; 
a p value of Q test for heterogeneity test; b Statistically signiﬁcant results;
c 
Random-effect model was applied when p value for heterogeneity < 0.05, otherwise, ﬁxed-effect model was applied.
Figure 4. — Begg’s funnel plot of Egger’s test for publication bias
tests for heterozygote comparison in ESR2 rs1256049. Each circle
represents as an independent study for the indicated association.
Log [OR], natural logarithm of OR. Horizontal lines mean effect
size. A: Begg’s funnel plot of publication bias test. B: Begg’s fun-
nel plot of publication bias test after trim-and-fill method.
Table 5. — Egger’s test for three polymorphisms of ESR2.
Polymorphism Egger's Homozygous Heterozygous Recessive Dominant
test
rs3020450 t 0.96 -0.74 1.01 -0.37
p 0.358 0.476 0.337 0.719
rs4986938 t -0.66 -0.37 -0.27 -0.044
p 0.52 0.715 0.788 0.665
rs1256049 t -0.55 -2.62 -0.23 -2.09
p 0.59 0.016 0.824 0.058
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metry in all genetic models of ESR2 rs3020450 and ESR2
rs4986938 polymorphisms (Figures 5, 6). In addition, all
models of ESR2 rs3020450 and ESR2 rs4986938 did not
show any evidence of publication bias (p > 0.05) (Table 5). 
Discussion
Thirty-three studies were identified according to the ac-
ceptance and exclusion criteria to investigate the relation-
ship between the genetic variants in the ESR2 gene and
cancer risk. There was a correlation between estrogens and
cancer risks. Estrogen metabolism was related to vitamin
D, insulin sensitivity, and fat metabolism as well as in-
flammation development which closely linked with cancer
occurrence [43]. Estrogens have significant direct and/or
indirect effects on development and progression of cancer,
in which ESR2 was a key factor [44, 45]. To date, it is
known that the genetic polymorphisms in ESR2 gene lo-
cate on chromosome14 and can change the stability of the
transcript [5, 26, 46]. It was not difficult to observe that this
evidence supported the present results regarding the asso-
ciation between ESR2 rs4986938, rs1256049 and
rs3020450, and cancer occurrence.
As for the ESR2 rs4986938 polymorphism, subgroup
study revealed that there was only a single comparison
model (GA + AA vs. GG) in Caucasian descendent showed
the significant association with cancer risk. Meanwhile, sig-
nificant associations were found in Asian descendent for
the comparison of AA vs. GG and AA vs. GA + GG, which
suggested ethnic differences did not influence the cancer
risk. Significant results of different genetic models, how-
ever, were observed in two descendent, which suggested
that relatively limited study number and small sample size
contributed to the results. Cancer type subgroup analysis
revealed that ESR2 rs4986938 polymorphism was a pro-
tective factor in breast cancer. Recently, several studies
have revealed that ESR2 rs4986938 polymorphism was as-
sociated with cancer risk [16, 26, 28, 31]. However, some
studies did not demonstrate a significant association be-
tween rs4986938 and cancer risk [2, 13, 27, 29]. Inconsis-
tent results might be caused by phytoestrogen intake and
BMI in different descendent which might be critical for ge-
netic effect. In addition, the approach to select participants
and study design should also be taken into account.
As for the ESR2 rs1256049 polymorphism, cancer type
subgroup analysis revealed that there existed a correlation
between ESR2 rs1256049 polymorphism and the risk of
prostate cancer under homozygous (AA vs. GG) model, it
showed the same pattern of results as that under recessive
model (AA vs. AG + GG). Meanwhile, a significant associ-
ation was also observed between ESR2 rs1256049 and en-
dometrial cancer. In the subgroup analysis by ethnicity, no
significant association was associated with cancer risk in any
genetic model. However, the results might be caused by rel-
atively limited study number, only two studies of rs1256049
in subgroup analysis specific to Caucasians [2, 27]. For the
ESR2 rs1256049 polymorphism, due to many conflicted re-
sults [20, 27, 35, 38], further well-designed, unbiased, large
case-control studies need to be performed to confirm these
results.
As for the ESR2 rs3020450 polymorphism, no significant
associations were found in all comparisons. In similarly, three
studies did not show a significant association by comparison
ESR2 rs3020450 with ovarian cancer. In addition, no signif-
icant association was found among uterine fibroids, prostate,
lung, and breast cancer [2, 15, 18, 37]. Therefore, more re-
lated studies need to further clarify the relationship between
ESR2 rs3020450 polymorphism and cancer risk.
Some potential limitations of this meta-analysis should be
acknowledged. First, all the eligible studies the authors
searched were from the database in English and Chinese,
articles with potentially high-quality data that were pub-
Figure 5. — Begg’s funnel plot of the Egger’s test of allele com-
parison for publication bias for AG versus GG in ESR2 rs4986938
polymorphism.
Figure 6. — Begg’s funnel plot of the Egger’s test of allele com-
parison for publication bias for AG versus GG in ESR2 rs3020450
polymorphism.
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lished in other languages were not included in this paper be-
cause of potential medical translation inaccuracies. Second,
though most controls were selected from healthy popula-
tions, there was no uniform definition of controls. Finally,
some potentially suspected factors such as age, sex, living
habits, menstrual history, and environmental factors were
not considered so that the authors’ unadjusted estimates still
need further validation. However, the present meta-analy-
sis had some advantages. First, in order to increase the sta-
tistical power of the meta-analysis significantly, the authors
extracted data from as many different studies as possible.
Second, all case-control studies included in this research met
the authors’ selection criteria well.
In conclusion, the present study demonstrated the rela-
tionship between three polymorphisms of ESR2 and cancer
risk. The result indicated that rs4986938 was associated
with a decreased risk of breast cancer in Caucasians and
Asians, and rs1256049 polymorphism was significantly as-
sociated with prostate cancer and endometrial cancer, while
rs3020450 showed no obvious associations with cancer.
However, further studies based on more comprehensive and
large, stratified population to facilitate evaluation the asso-
ciation between ESR2 and cancer risk are warranted.
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Introduction
Recently, the incidence of cervical adenocarcinoma has
been increasing and the onset age is becoming younger,
approximately accounting for 10%-34% of cervical can-
cer [1]. Cervical glandular intraepithelial neoplasia
(CGIN) is precancerous lesions of adenocarcinoma and is
less understood compared with cervical intraepithelial
neoplasia (CIN). This study was designed to preliminar-
ily evaluate the clinical significance of different methods
in diagnosis of 146 CGIN patients admitted to the pres-
ent institution from 2008 throughout 2011.
Materials and Methods 
Study subject 
A total of 146 patients were diagnosed with CGIN and ad-
mitted to Beijing Obstetrics and Gynecology Hospital between
January 2008 and May 2011. Among them, 117 were surgi-
cally treated with cervical conization, 23 loop electrosurgical
excision procedure (LEEP), and six panhysterectomy. Thirty-
two patients were diagnosed with CGIN by preoperative his-
tological examination and 114 diagnosed with CGIN postop-
eratively including those with CGIN complicated with CIN.
Those subjects complicated with cervical squamous carci-
noma and cervical adenocarcinoma were excluded from this
study. All cases were aged between 22 and 67 years, 41.3
years on average. 
The mean times of pregnancy were 2.5 and of delivery was
1.6. Those with menopause accounted for 15.8% and 84.2% of
premenopausal women. Eighty-eight patients (60.2%) had no
clinical symptoms, 25 cervical contact hemorrhage, 19 abnor-
mal secretion, and nine abnormal vaginal bleeding. All cases
with CGIN were confirmed by pathological examination. 
Methods 
All 146 patients underwent ThinPrep cytologic test (TCT) pre-
operatively. Those with AGC and undesirable transformation zone
further received colposcope and cervical biopsy. Those suspected
with AGC received endocervical curettage (ECC) simultaneously.
Based upon histological examination, cervical conization was sub-
sequently performed as necessary. Another ten patients with non-
cervical lesions were diagnosed with CGIN by postoperative
pathological examination. CGIN refers to glandular neoplasia of
cervix during early stage of infiltration, divided into two levels:
low-grade cervical glandular intraepithelial neoplasia (L-CGIN)
and high-grade cervical glandular intraepithelial neoplasia (H-
CGIN). H-CGIN included in situ adenocarcinoma. 
Classification of CGIN was conducted based upon histolog-
ical and cytological characteristics. Histological manifestations
of H-CGIN resembled in situ adenocarcinoma. L-CGIN was
characterized with certain abnormal changes. H-CGIN referred
to all abnormal alterations. 
Statistical analysis 
SPSS 13.0 statistical software was utilized for data analysis.
Chi-square and paired chi-square tests were performed. P <
0.05 was considered as statistical significance. 
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Summary
Objective: To preliminarily evaluate the clinical significance of different methods in diagnosis of cervical glandular intraepithelial neo-
plasia (CGIN). Materials and Methods: Clinical manifestations, ThinPrep cytologic test (TCT), cervical biopsy, and pathological features
of 106 patients with CGIN admitted to Beijing Obstetrics and Gynecology Hospital between 2008 and 2011 were retrospectively ana-
lyzed. Results: Among 146 cases diagnosed with CGIN, 87 (59.6%) had L-CGIN and 59 (40.4%) H-CGIN. Thirty-seven patients (25.6%)
were found to have simple CGIN and 109 (74.6%) had CGIN complicated with cervical intraepithelial neoplasia (CIN). TCT revealed
atypical glandular cells (AGC) in 20 patients (13.7%), six of whom had L-CGIN (6.9%) and 14 (23.7%) had H-CGIN with statistical sig-
nificance between two groups (p < 0.05). TCT detected AGC in 13 cases (35.1%) with simple CGIN and seven with mixed CGIN (6.4%)
(P<0.05). Endocervical curettage (ECC) revealed AGC abnormality in ten cases (25.6%). Cervical biopsy under colposcope revealed 32
patients (22.9%) had CGIN, including 15 L-CGIN (18.3%), and 17 H-CGIN (29.3%) with no statistical significance (p > 0.05). Among
those diagnosed with CGIN by colposcope-assisted cervical biopsy, 19 (51.4%) had simple CGIN and 13 (11.9%) mixed CGIN (p < 0.05).
Conclusion: Preoperative diagnostic rate of simple CGIN was higher than CGIN complicated with CIN.
Key words: Cervical glandular intraepithelial neoplasia; Endocervical glandular dysplsia; Diagnosis.
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Results 
Types of CGIN 
Among 146 cases of CGIN, 37 (25.6%) had simple
CGIN and 109 (74.4%) mixed CGIN, mainly complicated
with CIN. Eighty-seven (59.6%) were diagnosed with L-
CGIN and 59 (40.4%) with H-CGIN. 
TCT 
TCT revealed signs of AGC in 20 cases (13.7%), includ-
ing six (6.9%) with L-CGIN and 14 (23.7%) H-CGIN; sta-
tistical significance was observed between two groups (p
< 0.05). The detection rate of H-CGIN was significantly
higher than L-CGIN by TCT. Among 37 cases diagnosed
with AGC, 13 (35.1%) had simple CGIN and seven (6.4%)
mixed CGIN with statistical significance (p < 0.05). The
detection rate of TCT in simple CGIN was higher than that
in mixed CGIN. The outcomes of TCT are illustrated in
Table 1.
Comparison of colposcope-assisted cervical biopsy,
ECC, and postoperative cervical pathological examination
results 
Among 146 cases, 140 underwent cervical conization.
Preoperative cervical biopsy revealed 32 (22.9%) CGIN
and 108 (77.1%) were diagnosed with postoperative cervi-
cal conization. These 140 patients received colposcope and
cervical biopsy. Thirty-nine patients with AGC and poor
transformation zone were treated with ECC. ECC revealed
gland cell abnormality in ten cases (25.6%). Thirty-two pa-
tients (22.9%) were diagnosed with cervical biopsy in-
cluding 15 L-CGIN (18.3%) and 17 H-CGIN (29.3%) (χ
2
=
2.339, p > 0.05) Cervical biopsy revealed 19 cases (51.4%)
had simple CGIN and 13 mixed CGIN (11.9%) (χ
2
=
26.259, p < 0.05), as shown in Tables 2 and 3.
Discussion 
CGIN and epidemiological characteristics 
As the precancerous lesions of cervical adenocarcinoma,
the naming and category of CGIN remain debated. In the
USA and other regions, the classification criteria proposed
by International Society of Gynecological Pathologists
were adopted, that is, endocervical glandular dysplasia
(EGD) and in situ adenocarcinoma. In the U.K. and Euro-
pean nations, it is named as cervical glandular intraepithe-
lial neoplasia (CGIN), which is divided into two categories:
low-grade CGIN (L-CGIN) and high-grade CGIN (H-
CGIN). H-CGIN includes in situ adenocarcinoma [2].
Some scholars classified CGIN into CGIN I, II, and III.
However, it is challenging to implement this standard and
the diagnostic reproducibility is low in clinical practice [3].
The European classification criteria of CGIN were adopted
in this study. CGIN is less commonly seen than CIN.
The ratio of cervical adenocarcinoma and squamous car-
cinoma is 1:5, whereas the ratio of precancerous lesions of
these two cancers was 1:80 [4]. The ratio of in situ cancer
and infiltrated cancer was 1:3 for adenocarcinoma and 5.25
: 1 for squamous carcinoma, and 62 (58.5%) were diagnosed
with L-CGIN and 44 (41.5%) with H-CGIN. The age at
onset of CGIN was 39-40 years, 39.89 years on average [5].
The mean age in this study was 41.3 years, basically con-
sistent with previous findings. It is difficult to diagnose
CGIN during early stage. Previous studies demonstrated that
HPV infection is closely correlated with cervical gland le-
sions. HPV 16, 18, and 31 can be detected in over 80% of
patients diagnosed with cervical adenocarcinoma and squa-
mous carcinoma. However, the underlying cause remains
elusive. Previous studies indicated the time of L-CGIN pro-
gressing into H-CGIN was 1.5 to three years [6]. It has been
reported that HPV16 is associated with cervical in situ ade-
nocarcinoma, and HPV18 is associated with advanced cer-
vical adenocarcinoma [7]. In this study, 87 cases (59.6%)
were diagnosed with L-CGIN and 59 (41.5%) H-CGIN. A
majority of cases (60.2%) had no symptoms. Others pre-
sented with clinical symptoms mainly including vaginal se-
cretion abnormality and contact hemorrhage.
Diagnosis of CGIN 
It is a challenging task to diagnose CGIN preoperatively.
A majority of CGIN is diagnosed after cervical biopsy, cer-
vical conization or uterus excision. Previous studies indi-
cated that approximately 46% to 72% of CGIN patients
were diagnosed after excision of CIN lesions [4]. Zhang et
al. reported that 66.7% of CGIN cases were confirmed after
Table 1. — TCT outcomes.
TCT results Cases AGC non-AGC p value
L-CGIN 87 6 81
H-CGIN 59 14 45
< 0.05
Simple CGIN 37 13 24
Mixed CGIN 109 7 102
< 0.05
Table 2. — Cervical biopsy under colposcope in the diag-
nosis of CGIN of different grade
CGIN classification Cases Cervical biopsy under colposcope
CGIN Without CGIN
L-CGIN 82 15 67
H-CGIN 83 17 41
Total 140 32 108 
Table 3. — Relationship between preoperative and post-
operative diagnosis of CGIN
Preoperative diagnosis Cases Postoperative diagnosis
Simple CGIN Mixed CGIN
CGIN 32 19 13
Without CGIN 114 17 96
Total 146 37 109
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treatment of CIN or benign pathological changes. In this
clinical trial, the percentage of postoperative diagnosis of
CGIN was 80.3%, which is consistent with previous find-
ings. It is difficult to diagnose CGIN preoperatively due to
the following reasons: 1) CGIN lesions were mainly dis-
tributed around the cervix and affected the superficial mu-
cosa, recess gland, deep gland, CIN, SCCA, and
adenocarcinoma margins. It is likely to miss diagnosis due
to difficult sampling. 2) CGIN cells, endocervical cells, and
endometrial cells resembled in appearance. It was difficult
to differentiate from cervical squamous epithelial lesions,
possibly leading to misdiagnosis. 3) CGIN is constantly
complicated with CIN. Previous studies reported that up to
90% of non-infiltrated pathological changes were compli-
cated with squamous epithelial CIN [8]. The proportion of
CGIN complicated with CIN was 74.4% in this study. Se-
vere CIN lesions may conceal the pathological changes of
CGIN, mainly characterized with CIN lesions. Therefore, it
is likely to miss the diagnosis of CGIN. 
Diagnostic levels of pathologists 
The Bethesda system (TBS) is widely applied in clinical
screening of cervical pathological changes and significantly
enhances the early diagnosis of cervical squamous epithelial
lesions. However, the positive rate of TBS in screening of
cervical lesions is low and the false-negative rate is high,
which is likely to cause misdiagnosis. In addition, the detec-
tion rate of cervical AGC is equally low ranging from 0.05%
to 2.1% [9]. It has been reported that the sensitivity of TCT
ranged from 32.7% to 48.1%, and the specificity was 69.4%-
94.4% [10]. Zhang et al. demonstrated the sensitivity of TCT
was 33.3% in Chinese population [11]. In this study, merely
13.7% of patients presented with preoperative TCT abnor-
mality, probably due to the majority of CGIN cases compli-
cated with CIN, which affected the accuracy of TCT. The
detection rate of L-CGIN by TCT was 6.9% (6/87) and
23.7% (14/59) for H-CGIN cases with statistical signifi-
cance, suggesting that the positive rate of TCT in screening
of H-CGIN is higher than L-CGIN. TCT remains the only
screening approach of CGIN, whereas the sensitivity is rel-
atively low. However, colposcope-assisted cervical biopsy
and ECC have their own limitations in diagnosis of CGIN. 
It is difficult to collect sampling of the lesions within the
cervix under colposcope. The subjective judgement of the
physicians is also likely to cause miss diagnosis. Addition-
ally, use of ECC fails to collect the samples and the possi-
bility of extracervical lesions could not be excluded. In this
study, 39 patients received ECC, and only ten cases (25.6%)
were found to have AGC, hinting a low preoperative diag-
nostic rate. Previous studies demonstrated that the positive
predictive value of colposcope in diagnosis of squamous
and glandular epithelial lesions was 93.5%, whereas 9.8%
for the diagnosis of glandular epithelial lesions [12]. Other
studies reported that the detection rate of glandular abnor-
mality ranged from 35% to 70% in CGIN patients by col-
poscope-assisted cervical biopsy [9]. In this study, colpo-
scope-assisted biopsy revealed glandular epithelial abnor-
mality in 22.8% of patients and the sensitivity was not high.
No statistical significance was observed in diagnostic rate of
varying degree of CGIN. TCT revealed that those with AGC
should undergo colposcope and cervical biopsy under direct
vision to avoid the miss diagnosis. Cervical conization is of
vital value in the diagnosis of CGIN.
CGIN lesions were distributed in a central and diffusive
pattern, approximately 10% of CGIN lesions were located
above the cervix [13]. Compared with CIN, it is more com-
plex and difficult to diagnose CGIN. TCT and colposcope
examination lack reliability. Cervical conization rather than
cervical biopsy should be performed in diagnosing patients
suspected with cervical glandular diseases. Kietpeerakool
et al. [14] reported that among 51 patients diagnosed with
cervical in situ adenocarcinoma by cervical conization, 22
presented with cervical glandular abnormality, 29 squa-
mous epithelial abnormality, and 9 AGC by colposcope-
assisted biopsy and/or ECC. Thirty-one patients (60.8%)
were suspected with glandular diseases before surgery. Pre-
vious studies demonstrated that pap smear, colposcope-as-
sisted biopsy, and ECC were not suitable for diagnosing
cervical glandular diseases, whereas cervical conization
should be considered. In this study, 140 patients underwent
cervical conization including 32 (22.9%) diagnosed with
glandular lesions preoperatively and 108 confirmed by
pathological diagnosis following cervical conization.
Therefore, cervical conization plays a pivotal role in the di-
agnosis of CGIN.
Preoperative diagnostic rate of simple CGIN higher than
mixed CGIN 
Majority of CGIN patients were complicated with CIN
lesions and the percentage of simple CGIN was relatively
low. CGIN patients complicated with CIN revealed that
they were characterized with squamous epithelial lesions
prior to examination whereas glandular epithelial patho-
logical changes were neglected. Thus, preoperative detec-
tion rate of mixed CGIN was lower than simple CGIN.
Ovanin-Rakic et al. [15] demonstrated that among 123
CGIN cases, 13 had adenocarcinomas in situ of the cervix
(AIS), 18 glandular intraepithelial lesions (GIL) I and II,
58 AIS complicated with squamous epithelial lesions, and
34 AIS complicated with GIL I and II. The detection rate of
simple AIS, GIL I, and II was 61.5% and 22%, significantly
higher compared with 25.9% and 20.6% for mixed cases.
Kietpeerakool et al. [14] reported that 20 (70.4%) among 51
cases with AIS were suspected with simple glandular le-
sions preoperatively, whereas 12 AIS patients (50%) were
complicated with CIN. Preoperative detection rate of sim-
ple AIS was higher than that of mixed AIS. In this study,
TCT revealed the signs of AGC in 37 patients (35.1%) with
simple CGIN, and seven cases (6.4%) with mixed CGIN
with statistical significance (p < 0.05). Thus, the detection
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rate of AGC by TCT in simple CGIN was significantly
higher than mixed CGIN. Thirty-two cases were diagnosed
with CGIN by colposcope-assisted cervical biopsy includ-
ing 19 (51.4%) simple CGIN and 13 (11.9%) mixed CGIN
with statistical significance (p < 0.05), suggesting that it is
much easier to identify simple CGIN than mixed CGIN.
Taken together, it is difficult to preoperatively diagnose
CGIN. TCT remains the only screening approach of CGIN
with relatively low sensitivity. Colposcope, cervical
biopsy/ECC present with a low detection rate of CGIN. For
CGIN patients complicated with CIN, conventional colpo-
scope and endocervical curettage should be performed to
detect AGC. For those suspected with glandular epithelial
abnormality, cervical conization should be performed to
confirm the diagnosis. How to screen and diagnose CGIN
during early stage and before surgery remains a challenge.
Along with the improvement of cervical sampling and cell
molecular diagnosis and deeper understanding of clinical
and pathological physicians, preoperative detection rate of
CGIN is increased, thereby reducing the incidence and
mortality of infiltrated cervical adenocarcinoma.
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Introduction
Very little literature describes the capacity of peritoneal tu-
berculosis to mimic a peritoneal carcinomatosis [1, 2]. An
elevation of CA 125 has been observed in tumoral peritoneal
carcinomatosis, but has also been observed in cases of peri-
toneal tuberculosis. If CA 125 monitoring is well known as
a means to assess response to anti-cancer therapies [3], its
interest is not appreciated for the monitoring of peritoneal
carcinomatosis associated with mycobacterium tuberculosis.
CT-scan is not specific enough for the diagnosis of peritoneal
carcinomatosis and does not allow to distinguish its origin.
PET scan can be useful for diagnosis of peritoneal carcino-
matosis [4] but does not prove the certitude of the diagnos-
tic. Laparoscopy with histological analysis is the only
diagnostic instrument able to provide a clear diagnosis [5].
Case Report
In July 2008, a 51-year-old women who came from Madagascar
and had been living in France for about ten years, presented an im-
portant abdominal volume increase associated only with abdominal
pain. The clinical history of the patient showed that a Bartholin cyst
surgery had been performed in 2003, arterial hypertension con-
trolled with drugs, and that the patient was a heavy smoker (15–20
cigarettes/day). The biological marker CA 125 was highly elevated
(717 KU/L), however, no other biological anomaly was observed.
Ultrasound exploration showed abundant ascites with peritoneal
carcinomatosis and pleural effusion with dilatation of the medi-
astinum. In order to deepen the diagnosis and to expedite treatment,
a CT-scan and ascitic liquid analysis were performed. The CT-scan
showed a peritoneal and bilateral pleural carcinomatosis (Figure
1a), pelvic mass with uterus myomatous confirming the previous ul-
trasound diagnosis (Figure 1b), and a right adrenal mass of six cm,
compatible with adrenocortical primitive neoplasm (Figure 1c). The
biochemical, bacteriological, and cytological ascitic liquid analy-
sis were diagnostically non-contributory, except for the presence of
75% atypical cells.
Because the clinical life status of the patient deteriorated rapidly,
no coelioscopy was performed and a chemotherapy was established
with carboplatin and paclitaxel (six cycles), beginning in August
2008 and ending in November 2008. During chemotherapy, a pri-
mary treatment of neutropenia (granulocyte colony stimulating fac-
tor, GCSF) was administered.
After the sixth cycle of chemotherapy, a control CT-scan showed
a disappearance of abdominal ascites, important reduction of ab-
dominal and pleural carcinomatosis (Figure 1e), and stability of size
of the right adrenal mass (Figure 1f). However, bilateral pulmonary
embolism was diagnosed (Figure 1d). The patient was immediately
treated with anticoagulation therapy (tinzaparin sodium). A PET-
scan realized in December 2008 revealed a suspected abdominal
and pleural fixing, compatible with the conclusion of the CT-scan,
excluding the right adrenal mass (Figure 2a). Monitoring of the bi-
ological marker CA 125 was performed prior to during and fol-
lowing chemotherapy (Figure 3).
Revised manuscript accepted for publication January 26, 2015
7847050 Canada Inc.
www.irog.net
Eur. J. Gynaecol. Oncol. - ISSN: 0392-2936
XXXVII, n. 4, 2016
doi: 10.12892/ejgo3557.2016
Summary
The authors report a case of women, 51-year-old that presented with peritoneal tuberculosis, with concomitant adrenocortical prim-
itive neoplasm, mistaken as peritoneal carcinomatosis, due to the failure of correct histological analysis. In fact, the critical life status,
associated to increases of CA 125, typical imaging of peritoneal carcinomatosis, and presence of 75% atypical cells in ascitic fluid, in-
duced to begin chemotherapy.
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Figure 2. — (a) PET-scan taken in December 2008 showing a suspected tumor abdominal and pleural lesions. This is compatible
with conclusions from the CT-scan, but no suspected fixing imagine corresponds to a right adrenal mass location. (b) PET-scan per-
formed in February 2009 showing an evident response to anti-tubercular therapy comparatively to the one first taken in December
2008.
Figure 1. — A CT-scan performed July 2008, prior to chemotherapy, showing: (a) peritoneal and bilateral pleural carcinomatosis, (b)
an adrenal mass of six cm and (c) pelvic mass with ascites misinterpreted as carcinomatosis. After chemotherapy, the CT-scan of No-
vember 2009 reveals: (d) bilateral pulmonary embolism, (e) unconformity of disappearance of abdominal ascites and reduction of ab-
dominal and pleural carcinomatosis, and (f) size stability of the right adrenal mass.
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As a result of the presence of pleural liquid and as a consequence
of important respiratory symptomatology of the patient, it was de-
cided to perform a pleuroscopy with biopsy in January 2009. The
result of this test was surprising. No tumor cells were found, but
the typical aspect of tuberculosis was revealed. Histological analy-
sis described important necro-inflammation associated with the
presence of numerous epithelioid granulomas and giant-cells; the
Ziehl test was negative, finally no histological evidence of malig-
nancy was identified. In light of this new diagnostic, an anti-tuber-
culosis treatment was initiated in February: isonazide 5 mg/kg,
rinfapicine 9.6 mg/kg, ethambutol 15 mg/kg, and pyrazinamide.
Therefore before the beginning of anti-tubercular treatment, the
breath symptomatology improved . A PET-scan performed in Feb-
ruary 2009 showed an evident response to anti-tubercular therapy
comparatively to the one first made in December 2008 (Figure 2b).
To investigate the right adrenal mass, a study was performed:
potassium 3.6 mmol/L, renin 995 µU/l, urinary aldosterone 144
pmol/L, hypercortisolism (cortisol at 8h 342 nmol/L and 12h 362
nmol/L) with urinary cortisol 936 nmol/24h, ACTH 4.1 ng/l, and
DOC and 18-OH-progesterone were normal. In May 2009, the au-
thors decided to precede with a adrenalectomy that confirmed a hy-
pothesis of adrenocorticol primitive neoplasm. Furthermore, the
abdominal exploration confirmed the absence of peritoneal carcino-
matosis. After adrenalectomy and anti-tuberculosis therapy, the clin-
ical status of the patient improved with reduction of pleural liquid.
Discussion
In this case, the critical condition of the patient associated
with atypical cells present in cytological ascitic liquid moti-
vated rapid initiation of chemotherapy. The fact that the pa-
tient initially responding to this treatment with improvement,
was an additional aspect that led to the erroneous diagnosis of
abdominal carcinomatosis. The decrease of clinical symp-
toms and of CA 125 after chemotherapy was misinterpreted
as confirmation of peritoneal carcinosis. The authors did not
observe a decrease in neutrophils during cytotoxic chemother-
apy because the patient had received routine prophylaxis with
GCSF: peritoneal tuberculosis of the patient has not wors-
ened.
The authors believe that carboplatin and paclitaxel were ef-
ficient against adenocorticocarcinoma [6-8]. Thus, immunod-
eficiency related to adrenal carcinoma was probably reduced,
possibly allowing greater local control of peritoneal tubercu-
losis.
Conclusion
This case reinforces the principle of histological diagnosis
before beginning chemotherapy. The imaging, was not suffi-
cient and can lead to therapeutic errors. Finally, this case il-
lustrates that for certain types of peritoneal carcinomatosis
associated with mycobacterium tuberculosis, disease progres-
sion is slow and can be better controlled for several months in
case of efficient therapy and in situations favoring the tuber-
culosis.
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Figure 3. — Monitoring of the biological marker; CA 125 before
and after chemotherapy.
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Introduction 
Primary vulvar melanomas represent rare entities in the
current bibliography. They account for 7% to 10% of all vul-
var malignancies [1, 2]. Predisposing factors, such as ulcer
formations, former local radiation, presence of HPV lesion,
diabetes mellitus or immunosuppression, play without any
doubt a very important role. Among all the prognostic fac-
tors, tumor size, depth of the invasion, lymphatic status, and
grading, affect the therapeutic management [3]. The treat-
ment of choice, regarding all melanotic lesions, especially
those in the vulvar region, remains a surgical one. In most
cases, wide excision with two- to three-cm margins may re-
place the traditional radical vulvectomy. On the other hand,
in cases of lymphatic infiltration, a bilateral inguinal femoral
lymphadenectomy should be considered. We must never
forget the role of the sentinel node biopsy in order to avoid
the lymphatic dissection. In locally advanced cases poten-
tially requiring an extra-radical management, radiation ther-
apy alone or together with immunotherapy remains a
valuable approach.
Case Report
An 84 year-old Caucasian woman (gravida5, para5) presented
with small amount of fresh bleeding, noted on tissue paper while
patient was wiping herself. This was associated with pain or
trauma. The patient had no history of diabetes, no family history
of endometrial, colorectal or hereditary non-polyposis colorectal
cancer, and she was not taking any exogenous hormones. Her last
smear was at the age of 65 and it was normal. During the afore-
mentioned bleeding period, she did not notice any discoloration or
ulceration in the external genitalia, neither any lump in the lower
abdomen, nor fever or bladder symptoms or significant weight
loss. The physical examination revealed the presence of a black
raised lesion, around 3×2 cm with irregular and distinct borders at
right labium minus and satellite lesions at left labium. The lesions
were non-tender, but bled on touch (Figure 1). According to the
above physical findings, a biopsy became mandatory. The histo-
logical examination revealed a mucosal malignant melanoma,
without B raf-gene (BRFA) V 600 mutation. The CT of the tho-
rax/abdomen/pelvis revealed no evidence of metastatic lesions.
The bone window setting described mild degenerative changes
throughout the lumbar spine. The patient underwent radical ante-
rior vulvectomy and bilateral inguinal-femoral lymphadenectomy.
The histolologic report revealed the presence of ulceration, mi-
totic figures 26 per mm
2
, Breslow’s thickness of 3.0 mm, no signs
of regression or lymphovascular/perineural invasion or mi-
crosatellites. The resection margins were 3.5 mm in situ compo-
nent and the depth was 14 mm. According to American Joint
Commission on Cancer (AJCC) TNM staging system, the lesion
was T3bNxMx.
Postoperatively, the patient underwent cycles of radiotherapy.
During her follow up (ten weeks postoperatively) the physical ex-
amination did not reveal any signs of regression. On the other
hand, a 2×2 cm palpable lymph node at the right inguinal region
was discovered. The ultrasound examination described enlarged
nodes 2×2 cm at the right groin area, with increased vascularity,
consistent with nodal recurrence. The thorax/abdominal/pelvic CT
revealed multiple liver metastasis (largest lesion 18 mm) and two
metastatic lymph nodes (4×3 cm) in the right inguinal region (Fig-
ure 2). The patient underwent cycles of palliative chemotherapy,
followed by cisplatin, carboplatin, and paclitaxel. Unfortunately,
she died within the first year.
Discussion 
Malignant melanoma of the vulva represents the second
most common malignancy of the vulva accounting for a
median rate of 8.5% of all melanoma cases.[4] According
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Summary
Primary melanomas of the vulva are extremely rare, creating obstacles in the differential diagnosis of other epithelial and non-epithelial
malignancies. Due to their rarity, there are only approximately 250 cases reported in the current literature. Vulvar melanomas tend to
relapse locally, as well as develop locoregional and distant metastasis through lymph node and haematic dissemination. The authors de-
scribe a case of an 84-year-old Caucasian female patient, presenting with postmenopausal bleeding, consistent with primary vulvar
melanoma cause, which was successfully diagnosed and treated accordingly. 
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to the current literature, the five-year survival rates for the
vulvar melanoma ranges from 20% to 56% [5]. The pres-
ent report confirms the overall poor prognosis for vulvar
melanomas as noted by Jaramillo et al. [6]. Over a 30-year
period (1973 to 2003), there were only 644 cases of vulvar
melanoma identified within Surveillance Epidemiology and
End Results (SEER) database of the U.S. National Cancer
Institute (NCI) [7]. According to recent studies, the major-
ity (> 85%) of the patients, expressing vulvar melanoma,
are Caucasian [8]. In general though, it is very difficult to
describe the race distribution. Therefore, more studies
should be conducted in the future. Imaging techniques are
essential for the initial evaluation of the lesion. Pelvic MRI
can provide important information regarding the extension
of the local infiltration and can help in the therapeutic map-
ping. In order to distinguish metastatic lesions, a multide-
tector CT or PET/CT is mandatory. Despite the surgical and
adjuvant therapy, many cases of vulvar melanomas are
treated by antiangiogenic therapy [9]. Many clinical trials
suggest the provision of adjuvant interferon-alpha (IFN-a)
regarding the increase of recurrence free survival, but this
seems not to affect the overall survival. Vulvar melanomas
express higher recurrence rate in comparison with other cu-
taneous or mucosal melanomas. The recurrence rate is ap-
proximately 60% [10]. Classical agents concerning doses of
adjuvant therapy consist of platinum/taxane regimens with
a response rate of 20% [11]. New and promising agents tar-
geting the T-cell stimulation represent the future manage-
ment options [12].
Conclusion
According to the recent bibliography, vulvar melanomas
represent rare entities. In many cases the prognosis and the
overall survival rates are poor. Multidisciplinary coopera-
tion in order to establish the ultimate management mapping
becomes mandatory. 
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Figure 1. — Primary melanoma of the vulva.
Figure 2. — Abdominal CT showing the liver metastasis ‘A’, with
the arrow pointing to the lesion.
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Introduction 
Pure ovarian choriocarcinoma is one of the extremely rare
ovarian cancers, which is classified as either gestational or
non-gestational origin [1-3]. Gestational choriocarcinoma
(GCO) contains at least one paternal compliment in the
genes, but non-gestational choriocarcinoma (NGCO) arises
from an ovarian germ cell tumors or epithelial tumor.
NGCO can consist of pure trophoblasts or be mixed by germ
cell tumor, containing immature teratomas, dysgerminomas,
and polyembryomas. Thus, NGCO contains no paternal
contribution to the genome [4]. NGCO is known to be re-
sistant to single-agent chemotherapy and has poor progno-
sis compared to GCO [5]. Although it is important to
distinguish each type of choriocarcinoma, it is difficult to
distinguish between the two types by routine histologic, ul-
trastructural, or immunohistochemical examination in post-
menarche women [1, 2]. A few cases have been reported
where DNA polymorphism analysis was utilized to diag-
nose NGCO. Recently, the laparoscopic approach in early-
stage ovarian cancer has markedly improved [6]. In this
paper, the authors report a case of NGCO diagnosed by
DNA polymorphism analysis after hand-assisted laparo-
scopic surgical (HALS) staging and the long-term clinical
outcome.
Case Report
A 41-year-old woman with gravida 2, para 2 was admitted to
Ulsan university hospital because of solid adnexal mass and vagi-
nal bleeding of during one month prior. She did not have remark-
able medical history but underwent two cesarean sections. Vital
signs and laboratory findings were unremarkable. The authors
checked tumor markers for malignancy evaluation. It showed that
the serum beta-human chorionic gonadotropin (β-hCG) titer was
increased at 1,400 mIU/ml (normal range, 0-3 mIU/ml). Other
tumor markers were not remarkable; alpha fetoprotein (AFP) was
2.1 ng/ml (normal < 20 ng/ml), carcinoembryonic antigen (CEA)
was 1.3 ng/ml (normal < 2 ng/ml), carbohydrate antigen 125
(CA125) was 13.9 U/ml (normal < 45 U/ml), and carbohydrate
antigen 19-9 (CA19-9) was 8.3 U/ml (normal < 37 U/ml). Trans-
vaginal sonograms and abdominopelvic computed tomography
(APCT) showed a large well-capsulated round mass (109.3×98.6
mm) arising from the right adnexa (Figure 1-A). The large mass
was suspected to be a malignant tumor based on radiologic re-
ports. Chest CT, mammography, duodenofibroscopy, and
colonoscopy were performed but there were no meaningful find-
ings. The endometrial biopsy was performed and a diffuse decid-
ual reaction was reported. For the preliminary diagnosis of ovarian
cancer, she underwent HALS staging operation. A 12-mm trocar
for telescope was inserted through the umbilicus and two five-
mm trocars were inserted on LLQ and RLQ areas. A four-cm
transverse incision was made on the suprapubic area, where fas-
ciotomy was performed, and peritoneum was incised. A flexible
wound retractor was inserted through the extended suprapubic in-
cision. The abdomen and pelvis were carefully explored and pal-
pated using laparoscopic vision and direct palpation, respectively.
During laparoscopic exploration, the tumor was observed to be
well-encapsulated in the pelvic area and there was no evidence of
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Summary
Non-gestational choriocarcinoma (NGCO) is a rare primary ovarian cancer with poor prognosis. It is important to distinguish it
from gestational ovarian choriocarcinoma (GCO), because there are different treatment options. However, it is difficult to distinguish
the two types by routine histologic, ultrastructural, or immunohistochemical examination. The authors present NGCO in a 41-year-
old woman, which was confirmed by DNA polymorphism analysis. All tested microsatellite markers had identical DNA profiles
with the same allelic sizes between tumor and normal myometrium of the patient, indicating that both tissues originated from the same
person. The results confirmed that the tumor was non-gestational in origin. Although the tumor was large, the authors performed hand-
assisted laparoscopic surgical (HALS) staging. After three cycles of combination chemotherapy and surgery, the patient has not had
any evidence of disease 48 months after treatment. This case demonstrates the usefulness of HALS staging and DNA polymorphism
analysis in NGCO.
Key words: DNA polymorphism analysis; Hand-assisted laparoscopy; Non-gestational choriocarcinoma; Ovary.
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Figure 1. — A) Imaging study of non-gestational
choriocarcinoma arising in the ovary. Transvaginal
sonogram (A-1) and abdomino-pelvic computed to-
mography (A-2). A 11-cm well-defined complex cys-
tic tumor arising from right adnexa; multiple uneven
internal septa with a focus of small solid component
B) Surgical view of hand-assisted laparoscopic sur-
gical staging (HALS): preparation view (B-1) and la-
paroscopic view (B-2).
Figure 2. — A) Microscopic findings of non-gesta-
tional choriocarcinoma arising in the ovary showing
a biphasic arrangement of syncytiotrophoblastic (A-
1) and cytotrophoblastic tumor cells (A-2) (H&E
×200); strong immunopositivity for β-hCG in the
syncytiotrophoblastic component (A-3; β-hCG im-
munostain ×200); positive immunostain for cyto- ker-
atine in the tumor cell (A-4; cytokeratine
immunostain ×200).
B) DNA microsatellite markers profile comparison
between normal myometrium and tumor tissue. The
patient was homozygous for three markers (D5S346,
BAT26, and BAT25) and heterozygous for two mark-
ers (D17S250 and D2S123) in both the tumor and
normal myometrial tissues. Note that the DNA pro-
filing patterns of the normal and tumor tissues were
identical at all markers tested, indicating that both tis-
sues were from the same person. Thus, this tumor was
of a non-gestational origin.
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metastasis. After right salpingo-ophorectomy was performed, the
specimen was removed through a wound retractor while using an
endoscopic pouch to prevent the spillage of tumor content. The
frozen section was suspected to be a type a choriocarcinoma. The
authors performed laparoscopic assisted vaginal hysterectomy
(LAVH), left salpingo-ophorectomy, omentectomy, pelvic and
para-aortic lymph node dissection, appendectomy, and multiple
biopsies (paracolic gutter and pelvic peritoneum). Optimal de-
bulking was achieved with no macroscopic residual tumor (Fig-
ure 1-B).
Microscopically, the tumor was composed of pleomorphic
biphasic arrangement with cytotrophoblasts and syncytiotro-
phoblasts admixed with hemorrhage and necrotic tissue. The syn-
cytiotrophoblasts were strongly immunopositive for β-hCG and
cytokeratin staining (Figure 2-A). The tumor was intact with the
ovarian surface.
DNA profiling was performed between normal myometrium
and ovarian tumor to determine the genetic origins of the chorio-
carcinoma. The authors used selected a consensus panel of five
microsatellite markers: BAT25, BAT26, D5S346, D17S250, and
D2S123. These markers are highly polymorphic microsatellite
markers used for diagnosing hereditary non-polyposis colorectal
cancer (HNPCC). The authors conducted multiplex polymerase
chain reaction (PCR) for markers with different amplification
sizes and analyzed the results using the GeneScan 3.1 software
package. The present patient was homozygous for three markers
(D5S346, BAT 26, and BAT25) and heterozygous for two mark-
ers (D17S250 and D2s123) in both normal myometrial tissue and
the tumor. DNA profiling patterns showed the same allelic sizes
of all tested microsatellite markers between tumor and myome-
trial tissues (Figure 2-B). As a result, a pure NGCO of the ovary,
Stage Ia (FIGO staging system) was confirmed in pathological re-
ports. 
Postoperatively, the patient was treated with bleomycin, etopo-
side, and cisplatin (BEP) adjuvant combination chemotherapy
every 28 days for three cycles. The serum β-hCG level decreased
to 28.7 mIU/ml five days after surgery, and was within the normal
range after one cycle of chemotherapy. The patient recovered well
after surgery and was treated with three cycles of chemotherapy
without any complications. The patient has shown no signs of re-
currence 48 months after completing  chemotherapy. 
Discussion 
Primary ovarian choriocarcinoma is a very rare type of
ovarian cancer, with an incidence rate of 0.008 per 100,000
women-year in United States [7]. Ovarian choriocarcinoma
is classified based on its origin as gestational or non-gesta-
tional. GCO arises from an  ovarian pregnancy or metasta-
sis from regressed or occult primary gestational
choriocarcinoma in the  genital tract, as in the uterus [3, 8].
NGCO arises from germ cell differentiation in trophoblast
structures and coexist with other malignant germ cell com-
ponents [3, 8]. In general, GCO is treated with a single
chemo-agent but NGCO is treated with regimen of multi-
ple chemo-agents, including vincristine, actinomycin-D,
cyclophosphamide (VAC), BEP, and etoposide, methotrex-
ate, actinomycin-D, cyclophosphamide, oncovine (EMA-
CO). Compared to GCO, NGCO is more likely to
metastasize to the lymphatic system and spread within ab-
dominal cavity, and has worse prognosis [8]; however, Lan-
zhou et al. suggested that the five-year survival rate was
79.4% in patients who underwent adjuvant multiple drug
chemotherapy [9]. Bao et al. reported that the prognosis of
NCGO is related with whether or not they received adju-
vant multiple drug chemotherapy [2]. Here, the authors re-
port a patient with NCGO who was treated with BEP
regimen after curative surgery and has had a disease-free
survival of 48 months. 
DNA polymorphism analysis is a useful method to dis-
tinguish between GCO and NGCO [10].However, a review
of the literature only found five cases where DNA poly-
morphism analysis was used to diagnose NGCO (Table 1). 
NGCO can be diagnosed with histological finding in pa-
tients who are sexually immature, who have never had sex-
ual intercourse, or are postmenopausal [8]. However it is
difficult to differentiate the two subtypes by histological
finding, particularly in patients of reproductive age and in
pure choriocarcinoma tumors without the other components
of germ cell tumors. Thus the DNA polymorphism analy-
sis would be a more useful method in women of childbear-
ing age. For DNA polymorphism analysis, there is no
consensus as to how many microsatellite markers are
needed for diagnosis. Tsujioka et al. reported that they
could diagnose NGCO using only two or three microsatel-
lite markers [10]. Yamamoto et al. suggested that DNA
analysis using more microsatellite markers facilitates a
more accurate diagnosis, so they performed DNA analysis
with 15 loci [11]. Koo et al. assayed eight microsatellite
markers for identification of the tumor origins [3]. In this
study, DNA polymorphism analysis was performed using
three homozygous markers (D5S346, BAT26, and BAT25)
and two heterozygous markers (D17S250 and D2S123) in
both the tumor and normal myometrial tissues. These five
markers were reliable for evaluating the origin of the pri-
mary tumor. Thus, the present authors suggest that five
markers for DNA analysis may be a reliable number for di-
agnosis of NGCO. Further consensus for how many mark-
ers are needed to accurately diagnose NGCO are needed. 
In a comparative study between laparoscopic and la-
parotomic approach for early-stage ovarian cancer, Ghezzi
et al. reported that there was no significantly difference in
postoperative complications, upstaging effects, appropriate
lymph node retrieval, disease-free survival, and overall sur-
vival between the two different approaches. They recom-
mended a laparoscopic approach for the standard surgical
staging for early-stage ovarian cancer [6]. In 28 cases of la-
paroscopic approach for early-stage malignant non-epithe-
lial ovarian tumors, Shim et al. reported that laparoscopic
approach could achieve good results, even for tumors
greater than five cm and those that require aggressive
lymph node dissection [12]. In the present study, the ovar-
ian tumor featured was well-encapsulated, intact, large
(about 11cm), and there was no sign of metastasis based on
preoperative radiologic findings. The present authors per-
formed HALS staging operation for the patient. They
EJGO_4_2016:Layout 1  30-06-2016  11:15  Pagina 551
S.H. Ahn, H.J. Roh, H.J. Cho, S.G. You, S.H. Lee, Y.S. Kwon552
Table 1. — Details of 48 Cases of non-gestational choriocarcinoma of ovary (our case included).
Author Age
(years)
Chief
complaints
Tumor
Characteristics
Tumor 
side
Surgery Stage hCG
(min/mL)
Diagnostic method Chemotherapy
regimen
Outcome
1 Simard 1937 17 NS NS Right RO IIB Elevated History, histology None DOD 4 months
2 Backus & Griffi n 1941 13 NS NS NS TAH BSO IIB NS History, histology None DOD 6 months
3 Oliver & Horne 1948 11 Pain in abdomen Large, necrotic
hemorrhagic
Right RSO IIB Elevated History, histology None DOD 4 months
4 Groeber 1963 13 NS NS Left LO IA NS History, histology None DOD 4 months
5 Dehaan 1965 7 Pain in abdomen 12cm Right RSO IA 200 History, histology None NED 19 months
6 Hay & Stewart 1969 13 Pain in abdomen 8cm, necrotic
hemoperitoneum
Right RSO IC Elevated History, histology MTX NED 15 months
7 Panayotou et al. 1971 12 Pain in abdomen 10.5cm, necrotic
hemorrhagic
Left TAH BSO I Elevated History, histology MTX DOD 5 months
8 Smith et al. 1973 7 NS NS NS YES, NS NS NS History, histology MAC NED 8 months
9 Shah et al. 1974 14 Lump in abdomen 25cm, necrotic
hemoperitoneum
Right Autopsy II NS History, histology NS DOD
10 Adelman et al. 1975 1 NS NS NS USO NS NS History, histology MAC NED
11 Gerbie et al. 1975 16 NS NS Left LSO IV NS History, histology MTX NED 11 years
12 Gerbie et al. 1975 17 NS NS Right RO IA NS History, histology MTX Act-D NED 6 years
13 Gerbie et al. 1975 17 NS NS Left LSO III NS History, histology MAC NED 1 year
14 Stevens et al. 1979 19 Pain in abdomen Large Left TAH BSO IV 160 (urine) History, histology MTX Act-D DOD 10 days
15 Piver & Lurain 1979 NS NS NS NS NS IC Elevated History, histology MTX Act-D NED 8 months
16 Creasman et al. 1979 NS NS NS NS BSO III NS History,histology MAC NED 54 months
17 Vance & Greisinger
1985 
9 Pain in abdomen 14cm, friable
hemoperitoneum
Right RO IC Elevated History, histology PVB NED 6 months
18 Axe et al. 1985 6 Vaginal bleeding Friable, hemoperitoneum Right RO IC NS History, histology None NED 10 years
19 Axe et al. 1985 11 Pain in abdomen Friable, hemorrhagic Right RO I Elevated History, histology None DOD
20 Raju et al. 1985 16 Fever, dysuria 18cm, necrotic 
hemoperitoneum
Right Autopsy IV NS History, histology NS DOD
21 Sengupta & Everett 1987 11 NS NS NS UO NS NS History, histology NS NS
22 Pippitt et al. 1988 NS NS NS NS UO NS NS History, histology VAB-VI NED 9 months
23 Spingler et al. 1990 20 Pain in abdomen Ruptured tumor NS YES, NS NS NS History, histology NS DOD
24 Gribbon et al. 1992 NS NS NS NS YES, NS NS Elevated History, histology NS DOD 4 months
25 Gribbon et al. 1992 11 NS NS NS YES, NS IIC Elevated History, histology NS NED 1 year
26 Brown et al. 1993 11 NS NS NS USO NS NS History, histology NS NED 32 months
27 Trigueros et al. 1995 21 NS 24cm Right TAH BSO III 200,000 History, histology PVB NED 4 years
28 Arima et al. 1995 26 NS NS NS NS NS NS DNA analysis NS NS
29 Arima et al. 1995 21 NS NS NS NS NS NS DNA analysis NS NS
30 Chou et al. 1997 39 NS 20cm Left TAH BSO IV 71,885 History, histology Carboplatin
Etoposide
Ifosfamide
NED 17 months
31 Gungor et al. 1999 16 Pelvic pain NS NS TAH Bilateral ovarian 
wedge resection
NS 20,000 History, histology EMA-CO DOD 6 months
32 Inaba et al. 2000 12 Irregular Bleeding 11cm, ruptured Right RSO LOC III 25,000 History, histology PEB(high dose) NED 3 years
33 Goswami et al. 2001 18 Pain in abdomen 10x12cm, friable Left LSO ROC IA 88,385 History, histology MAC NED 5 months
34 Tsujioka et al. 2003 19 Pain in abdomen 9cm Left LSO IV 200,000 DNA analysis EMA-CO NED
35 Ozdemir et al. 2004 13 Pain in abdomen 7x8cm, ruptured Right RSO NS 91,028 History, histology MAC NED 9 months
36 Corakci et al. 2005 22 Pain in abdomen 8cm Right RSO IA 15,050 History, histology PEB NED
37 Koo et al. 2006 33 Vaginal bleeding 10x14cm, ruptured TAH BSO NS 185,000 History, histology MAC NED 18 months
38 Yamamoto et al. 2007 19 Vaginal bleeding 6.8cm Left LSO IA 206,949 DNA analysis MEA NED 12 months
39 Roghaei et al. 2007 47 Pain in abdomen
Vaginal bleeding
10cm Left TAH BSO partial-
omentectomy
IV 970 History, histology EMA-CO NED 12 months
40 Bao Kong et al. 2009 10 Pain in abdomen 15x13cm, ruptured Left LSO IC 7,957 History, histology PVB NED 2 months
41 Sung Hye Park
et al. 2009 
55 Pelvic pain, dry cough 6x5cm Right TAH BSO IV 64,838 History, histology BEP NED 20 months
42 Narges Izadi Mood
et al. 2009 
31 Pain in abdomen 7x7cm Right RSO I 1,000 History, histology EMA-CE NED 7 years
43 Narges Izadi Mood
et al. 2009 
32 Vaginal spooting 13x11cm Left TAH BSO
 infracolic-omentectomy
IIA 5,500 History, histology BEP NED 5 years
44 Lin Lv et al. 2011 48 Vaginal bleeding 18x15cm, friable TAH BSO PLND 
PALNS
omentectomy 
appecdectomy
III 7,664 History, histology BEP NED 1 year
45 Pedro Exman
et al. 2013 
24 General weakness 12x10cm Left TAH BSO 
omentectomy
IV 675,713 DNA analysis Neo-adjuvant 
BEP
NS
46 Youn jin Choi
et al. 2013 
33 Pain in abdomen
Vaginal bleeding
5x4cm, ruptured Left LO ROC peritoneal 
mass biopsy
III 17,763 History, histology EMA NED 5 years
47 Eun Jin Heo et al. 2014 12 Vaginal bleeding 4x4cm Left LSO partial 
omentectomy multiple 
peritoneal biopsy
IA 20,257 History, histology BEP NED 14 months
48 Present case 40 Vaginal bleeding 11x10cm Right LAVH BSO PLND 
PALND omentectomy
appendectomy
IA 1,400 DNA analysis BEP NED 4 years
Note. NS, not stated; NED, no evidence of disease; DOD, death of disease. TAH, total abdominal hysterectomy; LAVH, laparoscopic assisted vaginal hysterectomy; BSO, bilateral 
salpingo-oophorectomy; RSO; right salpingo-oophrectomy; LSO, left salpingo-oophrectomy; UO, unilateral oophorectomy; RO, right oophorectomy; LO, left oophorectomy; 
ROC, right ovarian cystectomy; LOC, left ovarian cystectomy; PLND, pelvic lymph node dissection; PALNS, para-aortic lymph node sampling; PALND, para-aortic lymph 
node dissection; MTX, methotrexate; Act-D, actinomycin D; MAC, methotrexate, actinomycin-D, chlorambucil; VBP, vinblastine, bleomycin, cisplatin; VAB-VI, vinblastine, 
bleomycin, cisplatin, actinomycin D, cyclophosphamide; PEB, cisplatin, etoposide, bleomycin; EMA-CO, etoposide, methotrexate, actinomycin D, cyclophosphamide, 
vincristine; MEA, methotrexate, etoposide, dactinomycin; BEP, bleomycin, etoposide, cisplatin; EMA-CE, etoposide, methotrexate, actinomycin D, cisplatin, etoposid.
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achieved a good surgical result without any complications,
such as tumor spillage. For well-encapsulated large ovarian
tumor without rupture or metastasis, a laparoscopic ap-
proach could be one of the good staging options for early
stage ovarian cancer. 
In conclusion, NGCO is a very rare, and more resistant to
single-agent chemotherapy than that of gestational origin.
Thus, it is important to differentiate between gestational and
non-gestational origin using DNA polymorphism analysis for
selection of chemotherapy in post-menarche women. In early-
stage ovarian cancer, HALS staging may be a good treatment
option for large ovarian tumors. Based on diagnosis of surgery
and DNA analysis, combination chemotherapy may be im-
portant in improving the prognosis of a patient.  
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Introduction
Vulvar tumours constitute 3-5% of gynaecologic malig-
nancies and compose < 1% of all malignancies in women
[1]. Majority of the vulvar tumours are squamous carcino-
mas. Vulvar mucinous adenocarcinomas are extremely rare
regardless of being primary or metastatic. Primary mucinous
tumours of vulva may arise from Bartholin’s glands, sweat
glands, sebaceous glands, mesonephric remnants, ectopic
breast tissue or in association with entero-cutaneous fistulas
[2, 3]. Presence of signet ring cells in a tumour at genito-uri-
nary site is highly suggestive for a metastatic lesion possibly
from a gastro-intestinal origin [4, 5]. Here the authors pres-
ent a case of signet ring cell mucinous adnenocarcinoma of
the vulva with an undetermined primary origin. 
Case Report
A 62-years-old woman presented with spotting and with a his-
tory of two vaginal births. Her medical history was unremarkable
except for total abdominal hysterectomy and bilateral salpingo-
oophorectomy performed in 2001 due to uterine fibroids. Her
physical examination revealed an irregularly contoured rough
nodule with a diameter of three centimetres on the medial side of
right labium major. Speculum examination revealed a normal ap-
pearing vaginal vault. Transvaginal ultrasonography did not
demonstrate a pelvic pathology. Pap smear was normal and tu-
mour markers including CA 125, CA 19-9, CA 15-3, CA 72-4,
and CEA were within normal limits (4.4 U/ml, 3 U/ml, 16.5 U/ml,
2.28 U/ml, and 0.38 ng/ml respectively). An excisional biopsy
was performed. Pathologic examination revealed a mucinous ade-
nocarcinoma with signet ring cells. The tumour was observed to
invade dermis, extending trough the epidermis, and causing
micro-ulcerations on stratified squamous epithelium of vulvar
skin (Figure 1). Signet ring cells observed within the mucinous
lakes (Figure 2A), stained positive for mucicarmine. Surgical mar-
gins of the resected specimen were free from tumoral cells. Im-
munohistochemical staining was performed. Tumour cells were
extensively stained with CK20 (Figure 2B), CDx2, MUC2. Focal
areas of staining were observed with CK7 and MUC5AC. MUC1
GCDFP-15 stains were negative for the specimen. Further inves-
tigations were performed to detect the possible primary site of the
tumour considering the staining pattern, particularly for a gas-
trointestinal site tumour. Colonoscopic and gastro-duedonoscopic
examinations were normal. Mammography did not demonstrate
any suspicious lesions. PET-CT was unremarkable except for a
mildly increased uptake compatible for inflammatory response
(SUV max: 1.9) at the site of vulvar biopsy. Toraco-abdomino-
pelvic CT did not demonstrate any pathologic lesions but a hae-
mangioma with a diameter of 11 mm within liver. 
A decision was made to perform expectant management. Mon-
itoring included systemic physical examination, pelvic examina-
tion, vaginal vault smear, serum tumour marker level assessment,
mammography, colonoscopy, and gastro-duedonoscopy. After two
years of uneventful follow-up, patient presented with erythema-
tous swelling at right thigh and pain on right aspect of pelvis.
Pelvic examination revealed a rough reddish nodule with irregular
contours measuring approximately 3×4 cm. Lower extremity ve-
nous Doppler examination did not reveal any signs of deep venous
thrombosis or venous insufficiency. Serum levels of CA125, CA
19-9, and CEA were found within normal range. Pelvic MRI re-
vealed irregularly contoured mass originating from right labium
major, extending to distal portion of urethra and vaginal orifice,
and infiltrating through pelvic floor muscles. Right para-iliac and
inguinal lympadenopathy with subcutaneous edema in favour of
extra-capsular lymphatic spread and nodular lesions at right iliac
bone and right lateral side of sacral bone indicating metastasis were
also demonstrated by pelvic MRI. These findings were considered
as a recurrence of previously diagnosed malignancy and
chemotherapy regimen consisting in carboplatin and paclitaxel was
started. After six cycles of chemotherapy, PET-CT imaging demon-
strated a physiological spread of F-18 FDG throughout the body.
Colonoscopic, gastro-duedonoscopic examinations, mammogra-
phy, and serum tumour marker levels were normal as well. The pa-
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Primary mucinous carcinoma of the vulva
with signet ring cells deriving from the cloaca
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Summary
Vulvar neoplasias are rarely encountered lesions at female genital tract, regardless if they are primary or metastatic. Presence of
signet ring cells in a tumour at female genito-urinary tract is highly suggestive of a metastatic lesion particularly from a gastrointesti-
nal tumour. Here the authors present a case of vulvar carcinoma with signet ring cells with an undetermined primary site possibly orig-
inating from embryonic cloaca. 
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tient is disease-free at 41 months after the diagnosis and 12 months
after completion of the chemotherapic regimen.
Discussion 
Metastatic tumours of the vulva constitute only 5-8% of
all vulvar malignancies. Vulvar metastases generally indi-
cate a widespread primary disease and are usually consid-
ered as a preterminal event. The duration of survival
changes in cases with metastatic vulvar lesions is in respect
of the primary malignancy. Majority of these cases are re-
ported to have disseminated diseases when diagnosed to
have vulvar metastases. The overall mean survival rate of
the women that have malignancies with vulvar metastases
was estimated as 35.6 months subsequent to the diagnosis
of metastatic vulvar lesions [1]. Most common extra-geni-
tal primary sites of vulvar metastasis were reported as
breast carcinoma and gastro-intestinal system tumours [6].
In this case, any possible primary site of vulvar tumour was
unable to be demonstrated despite all attempts. Systemic
physical examinations, pelvic examinations, serum tumour
marker levels, vaginal vault smears, PET-CT, mammogra-
phies, colonoscopies, and gastro-duedonoscopies were all
normal at initial investigation, as well as the follow-up vis-
its even at the time of recurrence that was occurred two
years after the local excision.
Primary mucinous carcinomas of the vulva may arise
from ectopic breast tissue, Bartholin’s glands, sweat glands,
sebaceous glands, mesonephric remnants or in association
with entero-cutaneous fistulas [2,3]. 
Normally vulva includes some mammary-like tissue as
a derivative of milk-lines. However, there are few number
of reported adenocarcinoma cases derived from this ectopic
mammary tissue. These usually form glandular structures
and exhibit oestrogen or progesterone receptor positivity
[7-10]. Although signet ring cells could be seen in breast
cancer in rare cases [11] immunohistochemical features of
the present case were not consistent with a carcinoma de-
rived from breast tissue. 
Primary carcinoma of Bartholin’s gland constitutes 2-7%
of all vulvar malignancies and adenocarcinomas comprise
nearly 40% of Bartholin’s gland carcinomas [12]. There are
some criteria described for the definitive diagnosis of
Bartholin gland carcinoma, such as demonstration of tran-
sition from normal Bartholin gland tissue to neoplastic tis-
sue, histologically compatible localization of tumour with
the origin of Bartholin’s gland, and no evidence of other
primary tumour [13]. In the present case there was no tran-
sition observed between normal Bartholin gland tissue and
neoplastic tissue. Tumour margins were not connected with
Bartholin’s gland. 
Figure 1. — Infiltration of tumour cells in stratified squamous ep-
ithelium causing ulceration.
Figure 2. — A) Epithelial cells
appearing as signet ring cells
within the mucinous lakes. B)
Staining of tumour cells with
CK20 reside within the muci-
nous lakes and spread through
the epidermis.
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Immunohistochemical staining features of the tumour in-
dicated that this tumour may not be derived from glandu-
lar heterotopias. In glandular heterotopias of vulva, cells
stain positively for CK7, CD-X2 and CEA, but negatively
for CK20 [14]. Extensive staining with CK20 in the setting
of focal staining with CK7 in the present case strongly sug-
gests that a glandular heterotopia is unlikely and the lesion
might be secondary to metastasis, possibly from gastroin-
testinal system. Moreover tumour cells have not stained
with GCDFP 15, excluding the possibility of extra-mam-
mary Paget disease. 
Primary vulvar carcinomas originating from cloacal rem-
nants have been published in a handful of reports that are
summarized at Table 1 [2, 15-25]. These tumours are known
to have glandular structures, could be continuous with epi-
dermis and may cause focal ulcerations. Signet ring cells
could be observed in the tumours derived from cloacal ori-
gin, however a primary mucinous tumour of the vulva with
signet ring cells derived from cloacal remnants is an excep-
tionally rare occurrence and has not been reported before.
The tumour in the present case might be derived from em-
bryonic remnants of cloaca at vulvar region. On the other
hand, the present patient has a history of two vaginal births
with right mediolateral episiotomy and rectal mucosa could
be involved in the course of episiotomy repair. In any case,
origin of this tumour deemed to be closely related with cloaca. 
Limited number of reports about this issue indicates a rel-
atively indolent course and favourable prognosis in these
types of tumours [24]. Less aggressive surgeries like local
wide excision instead of radical vulvectomy could be curative
in these tumours, particularly in the cases with negative sur-
gical margins [16, 17] and in the absence of any clinical sus-
picion for metastasis to regional lymph nodes or distant sites. 
Cormio et al. [22] reported two cases of vulvar cancer with
cloacogenic origin. One of these cases was found to have
disseminated colon cancer 36 months after surgical treatment
of vulvar disease and the other case was found to have a dys-
plastic polyp at colon 39 months after vulvar surgery. The
present authors have performed colonoscopy and gastro-due-
donoscopy at follow-up visits. In their opinion, dissimilar
with other types of vulvar cancer, performing colonoscopy
and gastro-duedonoscopy in primary cloacogenic vulvar
tumor follow-up, seems reasonable unless otherwise proven
by future studies. 
Table 1. — Summary of the clinical presentation, management, and outcomes of reported vulvar adenocarcinoma cases
with cloacogenic origin
Author Age Vulvar Other clinical Treatment Inguinal- Distant Prognosis
(years) lesion findings femoral metastasis
LNM
Tiltman et al. [15] 50 NA NA Modified RV+ BL IFLND Yes No 12 months DFF
Kennedy et al. [16] Case 1: 54 Case 1: RV+BIFLND Case1: 120 months
Case 2: 63
NA NA
Case 2: Wide LE
No No
Case 2: 48 months DFF
Ghamande et al. [2] 67 1.2 cm No RV+BIFLND No No 17 months DFF
Willen et al. [17] 57 1 cm No Wide LE No No 26 months DFF
Zaidi et al. [18] 43 4 cm No Modified RV+BILND No No 18 months DFF
Rodriguez et al. [19] 69 1,5 cm No Wide LE - No 36 months DFF
Liu et al. [ 20] 49 1.8 cm Inguinal LAP Wide LE+ BILND No No 24 months DFF
Dubé et al. [21] 58 2 cm No RHV+ ULIFLND No No 16 months DFF
Case 1: metastatic colon cancer
Cormio et al. [22] Case 1: 58
NA NA
Case 1: RHV+BLIFLND
No No
36 months after treatment
Case 2: 42 Case 2: RV+BLIFLND Case 2: 39 months DFF +
dysplastic polyp in sigmoid colon
Karkouche et al. [23] LE (recurrence after 6 months)
31 NR NR
LE for recurrence
- - 15 months DFF
Inguinal LAP+
Chibbar et al. [24]
49
1 cm lower vaginal Chemo-radiation
Yes Yes DOD 27 months later
(multiple) involvement+ Punch biopsy+BLIFLND
lung metastasis
Musella et al. [25]
Inguinal LAP+ Neoadjuvant CT
57 5 cm Lower vaginal Radical vulvectomy+ Yes No 4 months DFF
involvement ULIFLND
Present case 62 3 cm No Wide LE - No Recurrence after 24 months
Recurrence: Recurrence: Recurrence: Recurrence: Recurrence:  
4 cm extensive spread chemotherapy yes yes
12 months DFF after recurrence
RV: radical vulvectomy; RHV: radical hemivulvectomy; LE: local excision; LAP: lymphadenopathy; LNM: lymph node metastasis;
BIFLND: bilateral inguinal-femoral lymph node dissection; ULIFLND: unilateral inguinal-femoral lymph node dissection;
BILND: bilateral inguinal lymph node dissection; DFF: disease-free follow-up; DOD: died of disease; NA: not available; NR: not reported.
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In the present case, the malignancy had relapsed after two
years. Invasion of pelvic floor muscles, involvement of lymph
nodes with extra-capsular spread and pelvic bone metastasis
were detected. These factors indicate an unfavourable prog-
nosis. This recurrence could be classified as FIGO Stage IVA
if considered to be a primary vulvar tumour. However, de-
spite these unfavourable prognostic factors, the disease seems
to respond unpredictably well to carboplatin-paclitaxel regi-
men, similar to the case reported by Musella et al. [25]. A vul-
var tumour with > two cm diameter and confined to the vulva
or perineum was classified as T
1b
N
0
M
0 
according to TNM
classification and all patients with tumours larger than two
cm require a thorough inguinal-femoral lymphadenectomy
[26]. However a thorough inguinal-femoral lymphadenec-
tomy is associated with long-term morbidities and should be
avoided whenever the survival will not be compromised by
omission of this procedure. Depending on the scarce data
about this rare occurrence, considering the indolent course of
this tumour, and the probable susceptibility to chemotherapy
as indicated by limited number of reports in literature, future
treatment of these patients might include more limited sur-
geries (for example to avoid the possible long-term morbidi-
ties associated with the groin dissection), if efficiency of a
narrow surgery in preventing relapses is demonstrated to be
similarly successful to wide surgeries in reliable studies that
will be conducted for this aspect. However, without doubt,
this issue should be clarified by studies with large number of
cases prior shifting to a more conservative surgical approach
and without support of reliable evidence limited surgeries
should not be considered as safe and effective. 
In conclusion, although the current evidence is not suffi-
cient to reliably recommend a modality of treatment due to
rarity of this kind of tumours, primary mucinous tumors of
the vulva with a cloacal origin could have relatively good
prognosis even if they include signet ring cells and might re-
spond well to chemotherapy regimens comprising carbopatin
and paclitaxel.
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Introduction
Carcinoma of the cervix is one the most common malig-
nancy associated with pregnancy. According to the literature
its frequency is estimated at approximately 1.2−10.6 cases
per 10,000 pregnancies in different populations, while in
Poland the frequency of this cancer is estimated from 1/1,370
to 1/2,500 of pregnancies [1, 2], in which 69−83% of inva-
sive carcinomas associated with pregnancy is at Stage I. Ac-
cording to histological classification, 81−87% of them are
recognised as squamous cell carcinoma and 7−15% of them
are recognised as adenocarcinoma [3]. The mean age of pa-
tients suffering from cervical cancer is from 31 to 35 years.
The most common symptoms of cervical cancer like spot-
ting, and pain can be disguised by pregnancy, due to the fact
that they may be interpreted as the symptoms associated with
pregnancy. It is important to be aware of the fact that carci-
noma of the cervix is usually asymptomatic, especially in the
early stages [2, 4, 5]. For these reasons obtaining of cervical
smear in pregnancy should be a routine procedure carried
out during the first visit to a gynaecologist. Diagnostic pro-
cedures used for detecting cervical cancer in pregnant
women are similar to those used for diagnosis of this cancer
in unpregnant patients. Main diagnostic procedures include:
cervical cytology, colposcopy, and biopsy [6].
Treatment of cervical cancer associated with pregnancy
depends on the stage of the cancer and on the gestational
age. The choice of the best time for surgery or look and
wait management depends not only on the stage of preg-
nancy but also on the clinical and histopathological char-
acteristics, the depth of invasion, and the grade of tumor’s
differentiation [2]. This decision should be made jointly by
patient and her doctor. Finally the patient’s choice of
method of treatment must be made based on very accurate
information [7]. The expedited treatment is recommended
before 20 weeks of gestation, while after this time the treat-
ment can be postponed until the fetus reaches lung maturity
[4, 8]. Due to immaturity of the fetal’s lungs during the first
half of pregnancy, the primary treatment of Stage Ib and
IIa of cancer is extended hysterectomy and lymphadenec-
tomy. In this case the delay of the treatment might be a life-
threatening situation. The primary treatment of early stages
of cervical cancer in advanced pregnancy is a cesarean sec-
tion accompanied by expedited adjuvant therapy - the
Wertheim-Meigs extended hysterectomy combined with ra-
diotherapy. 
According to current state of research on cervical carci-
noma, planned delay of treatment does not worsen the prog-
nosis. At present it does not seem to be confirmed that
pregnancy is causing the progression of the disease [9].
However, the decision about the delay of treatment until
the fetus is potentially able to live outside the uterus is usu-
ally made by the patient. During this time pregnant woman
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Summary
Carcinoma of the cervix is the most common malignancy associated with pregnancy. The frequency of cervical cancer is estimated
to range from 1/1,200 to 1/10,000 pregnancies. The symptoms of cervical cancer are not specific and can be mistaken as frequent symp-
toms associated with other pathologies of pregnancy. The diagnostic procedure is similar to the one which should be proposed to un-
pregnant women. The treatment of cervical cancer depends on gestational age. The final treatment and further prognosis is carried out
after delivery. The authors present the case of a 35-year-old woman at 34 weeks of gestation diagnosed with Stage IB cervical cancer.
Treatment was delayed until fetal maturity and an elective cesarean section was performed at 36 weeks’ gestation, followed by a radi-
cal hysterectomy, bilateral salpingo-oophorectomy, and a pelvic lymphadenectomy. Patient underwent adjuvant radiochemotherapy and
brachytherapy. Recurrence of neoplastic process was found after one year.
Key words: Cervical cancer; Pregnancy; Total hysterectomy.
Fast and unfavorable course of invasive cancer of the uterine
cervix associated with pregnancy despite of a typical treatment.
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remains under strict observation in order to detect possible
progression of the cancer and to institute the treatment after
taking into account the level of fetal lung maturity [2].
The prognosis in cervical cancer in pregnant women is
not much different from that in unpregnant patients and it
mainly depends on the stage of the disease. The overall
five-year survival rate for cervical carcinoma in pregnant
and unpregnant women is almost the same and the differ-
ence is not statistically significant (87.5% of women diag-
nosed with Stage Ib and 69.9% of women with Stage IIa
survive their disease at least five years) [7]. The impact of
pregnancy on the progression of cervical cancer is still dis-
putable. It is believed that inhibition of cell-mediated im-
munity and high level of estrogens may have unfavourable
impact on cancer growth. However, the majority of re-
searches indicate that, as far as dysplasia, preinvasive and
microinvasive cancer is concerned, the course of the dis-
ease among pregnant women is slow and pregnancy does
not influence prognosis and overall survival rate in inva-
sive cancer [10]. The treatment depends on the stage of the
disease, weeks of gestation, general condition of the preg-
nant woman, and her attitude towards termination of preg-
nancy. It should be also conducted interdisciplinary and
individually selected [4, 9, 11, 12].
Case Report
A 35-year-old multipara at 36 weeks of gestation in her third
pregnancy was admitted to I Department of Obstetrics and Gy-
naecology of the Medical Centre of Postgraduate Education in
Warsaw on 11
th
of May 2009 in order to finish the pregnancy fol-
lowed by Wertheim-Meigs radical hysterectomy.
The patient at 27 weeks of gestation was previously admitted on
9
th 
of March 2009 to the Department of Pathology of Pregnancy
Municipal Hospital due to gestational diabetes mellitus (GDM
G1). In her past obstetric history, she had two pregnancies which
were physiological and finished at term. During the stay she was
informed about diabetes diet and the rules of glycemic control. In
consequence of the fact that she did not have a recent cytology
result (last Pap test 2007 – the second group) and abnormalities on
speculum examination, she was additionally recommended to
have cervical cytology carried out. The patient was discharged
from the hospital with saved and live pregnancy. On 20
th
of March
2009 the cervical cytology was performed. The test revealed high
grade squamous intraepithelial lesion (HGSIL) according to the
Bethesda System 2001 and a colposcopy was ordered. It was car-
ried out on 14
th
of April 2009 and confirmed the result of Pap test.
The result of the colposcopy biopsy from 15
th
of April 2009 was
carcinoma palnoepitheliale akeratodes infiltrans colli uteri.
Before surgery she was informed about the disease and treat-
ment possibilities and she consented to proposed treatment. On
admission, speculum examination revealed as follows: oversized
ectocervix, cervical ectropion which was partly covered with nor-
mal epithelium, ulceration four cm in diameter limited to the an-
terior lip, and purulent excretion from endocervical canal. USG
examination revealed longitudinal lie, vertex presentation, mean
gestational age 37 weeks, estimated fetal weight 3,150 grams, an-
terior placenta, and normal amount of amniotic fluid. 
MRI of lesser pelvis performed on 14
th
of May 2009 revealed
rotated and off-center cervix, diameter: four cm and unclear
stroma. In the left lateral side of the cervix and in the anterior lip
there were two focuses with a high signal on T2-weight images
which sizes were as follows: 7×5×26×9 mm. If all clinical find-
ings were in accordance, it could be invasive malignancy limited
to the cervix. There were no signs of invasion into parametrium
and vagina. The ovaries were moved by oversized uterus beyond
the examined area. Obliteration of the nearest adipose tissue was
probably the result of edema and impaired venous circulation due
to pregnancy. The lymph nodes enlargement in this area was not
observed. 
The patient was qualified to cesarean section, hysterectomy
with ovaries (on her request), and pelvic lymphadenectomy. On
15
th
of May 2009 cesarean section was performed using the supra-
pubic transverse incision. Female infant was delivered 3,520/54,
Apgar 10. Afterwards there was performed the Wertheim-Meigs
total hysterectomy with ovaries and upper part of the vagina and
pelvic lymphadenectomy. A drain in the peritoneal cavity and in
the obturator cavity was left. Estimated blood loss: 800–1,000 ml.
The perioperative course was uncomplicated and there was no
need of transfusion. On 20
th
of May 2009 the patient and her baby
were discharged from the hospital in a state of good health.
Histopathological examination obtained on 27
th
of May 2009
revealed that macroscopically the cervix was 6.5 cm length and
five cm in diameter. An ulceration 4.5 cm in diameter and 0.2 cm
in depth could be observed within whole surface of the cervix. In
the scope of the posterior lip of the cervix and the external os,
there was a white tissue of tumor which constituted up to 90% of
the cervical wall and stretched 2.5 cm into cervical canal. The
vaginal cuff was 2.5 cm in width without invasion. The dimen-
sions of uterine corpus were 14×13×11 cm, and there were no
pathological changes. The fallopian tubes and ovaries were with
no pathological changes. Microscopically: carcinoma planoep-
itheliale microcellulare precipuae akeratodes colli uteri. There was
observed an invasion of the tumor into the cervix but not into the
uterine isthmus. Right parametrium was almost without patho-
logical changes. The left one: in the scope of one vessel there were
emboli consisted of carcinoma cells. The vaginal cuff had normal
appearance. The common iliac lymph node on the right side: in
three nodes subcapular metastases were observed. The obturator
lymph nodes on the left side: in three nodes there was an inflam-
mation. The internal iliac lymph nodes on the right side were with-
out significant changes. The internal iliac lymph nodes on the left
side: in one lymph node there could be observed metastasis which
filled up to 50% of its volume. There were no pathological
changes in the left common iliac lymph nodes, the right obturator
lymph nodes, and the right internal iliac lymph nodes.
The patient was referred to the Oncological Centre in Warsaw
due to adjuvant therapy. She underwent radiotherapy of the pelvis.
The dose of radiation was 4,500 cGy/g/d.fr.180 cGy/g and addi-
tionally there was a boost on the left external iliac lymph nodes
performed in a dose of 1,500 cGy/g/d.fr.60 cGy/g. The treatment
course lasted 33 days. During radiotherapy the patient received
five courses of chemotherapy – DDP – 65 mg. From 5
th
to 19
th
of
October 2009 she underwent brachytherapy HDR located in the
top of the vagina in a dose of 22.5 Gy in three fractions up to 0.5
cm depth. The treatment tolerance was good.
In January 2010 CT examination of the abdomen and true pelvis
revealed a solid tumor in the abdominal wall with dimensions of
40×60×43 mm. It was situated in the right rectus abdominal mus-
cle on the level of the iliac crest. It was probably a metastasis. The
patient was hospitalised from 7
th
to 12
th
of February 2010 in I De-
partment of Obstetrics and Gynaecology of the Medical Centre
of Postgraduate Education in Warsaw where she underwent a re-
section of the tumor. Histopathological examination confirmed
the presence of carcinoma planoepitheliale’s metastases. The pa-
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tient was again admitted to the Department because of recurrence
of the disease with vomit and severe pain in the area of pubis sym-
physis. Physical examination on admission revealed a disruption
of wound in low pole and presence of purulent excretion was ob-
tained which revealed numerous colonies of Escherichia coli.
Sonography showed heterogenous area (sizes 25×20 mm)
stretched to the abdominal wall. The abdominal X-rays performed
in a sitting position revealed numerous fluid levels in a small and
large intestine which indicated obstruction. Surgeon was asked
for consultation due to suspicion of a fistula of large intestine and
the symptoms of obstruction. The patient was qualified to parental
nutrition. Rectal culture was also ordered. It revealed a large
growth of Escherichia coli and Enterococcus faecalis. She was
prescribed cefuroxime 3×1.5 g iv., metronidazole 3×500 mg iv.,
diclofenac 100 m 2×1 susp per rectum, nadroparin 0.3 ml sc, and
morphine as analgesic. 
PET–CT examination (March 24, 2010) which was performed
out of hospital showed three small tumors up to 5.5 mm in the
right lung, however no accelerated metabolic activity was ob-
served. Apart from that there were no changes in the lungs. The
thoracic lymph nodes were not enlarged. A large lesion was ob-
served in the abdominal wall from S2 level to pubic symphysis
(71.3 mm). Its largest transverse size (at the level of the top of hip
joint) was 62.3×43.5 mm. The lesion revealed accelerated meta-
bolic activity, SUV max 14.5. It did not invade the urinary blad-
der. There were single implants shown in the peritoneum. The
lymph nodes were not enlarged. There were no focal lesions ob-
served in the liver, spleen, and in the kidneys. Probably, as a re-
sult of inflammation, the accelerated metabolic activity in the
stomach’s and duodenum’s walls was observed. CT examination
(April 7, 2010) revealed an infiltration into peritoneum, omen-
tum, and abdominal wall below a postoperative scar. In the lesion
area was observed widened intestinal loop over this lesion with
symptoms of subobstruction. The lesion stretched to the urinary
bladder which front wall was altered and thickened.
Laboratory tests were collected according to the special proce-
dure for patient suffering from cancer. Morphology (April 15,
2001): leukocytes – 10.2 K/ul, erythrocytes – 3.02 M/uL, hemo-
globin – 8.31 g/dl. Other blood tests: urea – 22 mg/dl, creatinine
– 0.8 mg/dl, protein – 6.6 G/DL, glucose – 119 mg/dl, albumin
3.2 g/dl, iron 21 ug/dl, CRP – 193 mg/l, ALAT – 22 IU/l, ASPAT
– 15 IU/l, and LDH – 51 IU/l. 
Because of worsening patient’s state of health, the fistula of
large intestine and the mechanical obstruction as the result of can-
cer recurrence, the patient was referred for the surgery. On 22
nd 
of
April 2010 she underwent partial resection of small intestine,
colon, and resection of malignancy situated in the true pelvis and
abdominal wall which was not radical. The ileum was repaired
end-to-end and the transverse colon was repaired end-to-side. A
proximal colonostomy, appendicectomy, and drainage of the small
intestine were performed . During perioperative period two units
of PRBCs and two units of FFP were transfused. 
The results of laboratory test which was performed after sur-
gery: morphology (April 22, 2010): leukocytes – 16.7 K/ul, ery-
throcytes – 3.86 M/uL, and hemoglobin – 10.8 g/dl. Other blood
tests: urea – 18 mg/dl, creatinine – 0.5 mg/dl, protein – 5.3 g/dL,
and albumin – 2.1 g/dl. 
The patient was discharged from the hospital and was referred
to the Oncological Center in Warsaw due to adjuvant radiotherapy
and chemotherapy, however she did notcontinue the therapy. A
few months later she was admitted to the I Department of Ob-
stetrics and Gynaecology of the Medical Centre of Postgraduate
Education again due to the worsening of her state of health and en-
terocutaneous fistula. This delay of the proper treatment may have
been responsible for this unfavourable course of disease. She was
referred to alternative continuance of the chemotherapy in the On-
cological Center in Warsaw but she was disqualified from
chemotherapy trials because of the worsening state of health and
the stage of the cancer. Patient died in September 2010.
Discussion
Extended radical hysterectomy is a treatment of choice in
case of Stage Ib cervical carcinoma associated with preg-
nancy. The aim of this treatment is the total resection of
cancer and also the assessment of disease stage. The col-
lected material allows to conduct histopathological exami-
nation. The result of this examination is important to make
the decision concerning the relevant treatment – radiother-
apy or chemotherapy. The extended radical Wertheim-
Meigs hysterectomy is an extensive surgery and it is
associated with a high risk of complications. The compli-
cations’ frequency oscillates from several to 70% [9]. The
complications are usually as follows: damage of the nerv-
ous system structures and ligaments that maintain the nor-
mal position of the uterus, damage of parametrium, vesical,
and perirectal venous plexuses, as well as venous plexus of
the obturator cavity, damage of the ureter, urinary bladder
and large arteries and veins during resection of the pelvic,
and para-aortic lymph nodes [9]. The frequency of these
intraoperative complications is estimated from 0% to 16%
[13]. The intraoperative mortality is assessed from 0% to
2% [8]. The frequency of postoperative complications oc-
curring among patients who have undergone Wertheim-
Meigs hysterectomy is quite common [9]. The peculiarity
of Wertheim-Meigs hysterectomy and its range cause
higher and additional risk of complication among pregnant
women who are treated because of cervical cancer. At the
same time, adjuvant therapy may also caused some com-
plication, for example the intestinal injury which concerned
in the present patient. These can be divided into early and
late radiation complications. Early severe complications
can be observed in 1.1% of patients whereas early moder-
ate radiation complications occur in 41% of patients. More-
over they are more frequent among patient treated with
surgery and adjuvant radiotherapy than in patients treated
with radiotherapy alone. The second risk factor is the time
between surgery and radiotherapy, especially when it is less
than four weeks [14]. The pregnancy is a state which con-
stitutes additional risk of complications [7]. The lesser
pelvis of pregnant women is highly vascularised and the
performing of such extensive surgery followed by cesarean
section is associated with even higher risk for patient than
mentioned above. The high level of perimetrium’s and
perivaginal’s vascularisation among pregnant women is
connected with higher risk of intraoperative and postoper-
ative complications in connection with unpregnant women.
During preparation for the surgery it is very important to
perform MRI examination which allow to assess the stage
of the disease. In spite of high risk of complications, ex-
tended radical hysterectomy is the only known surgery
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which may save both mother’s and child’s life. The prog-
nosis depends on the stage of the disease, patient’s age,
state of health, socio-economic status, as well as the level
of medical knowledge and technical opportunities of the
hospital [2, 4, 8, 15]. Identification of the full list of pre-
dictor factors, doctors’ appropriate knowledge, and experi-
ence allow choosing the best treatment procedure. The
decision should always be taken after consultation with the
patient. She must be informed about advantages and dis-
advantages of the proposed treatment and possible conse-
quences for the infant because of preterm delivery. During
pregnancy, woman is more often examined than ever be-
fore. The proper diagnosis before pregnancy is a very im-
portant prognostic factor. The prognosis is better if the
diagnosis is known at early pregnancy because of the pos-
sibility for immediate treatment. The diagnosis in advanced
pregnancy is usually associated with higher stage of the dis-
ease and higher risk of recurrence and complication which
may lead to patient’s death [15]. 
According to Polish Gynecological Society Guidelines,
all women should begin cervical cancer screening three
years after they begin having vaginal intercourse, but no
later than when they are 25-years-old. Screening should
be conducted every year with a regular Pap test. Women
who have normal Pap test results and do not have any ad-
ditional risk factors of cervical cancer may get screened
every three years. Women older than 30 who have had
three normal Pap test results in a row or women after total
hysterectomy may also get screened every three years.
Every year examination is required for women who have
HIV infection, oncogenic HPV types infection, and those
who are taking immunosuppressive drugs [16]. Moreover
Polish Gynecological Society recommends performing
Pap test before conception if the last Pap test has been per-
formed over six months earlier and/or during first antena-
tal appointment with a gynecologist [17]. These guidelines
had been followed by the present team, but it did not pro-
tect the patient before the development of invasive cancer.
In different countries, cervical cancer screening programs
are similar to this performed in Poland. Usually, it is rec-
ommended to begin cervical cancer screening at 20-30
years and extending to 60-65 years, at a three- or five-year
intervals [18]. The duration of progression from a precan-
cerous phase to cervical cancer is quite long, and it is es-
timated to occur at ten to 12 years [19]. The progression of
disease in the present authors’ patients is surprisingly fast
and it may dispute their current knowledge regarding
tumor biology during pregnancy, especially in the third
trimester. Unfortunately, the management guidelines for
these patients remain unclear. Some authors have recom-
mended that maximum delay of treatment may be 12
weeks for Stage Ib1 tumors and six weeks for Stage Ib2
tumors [20]. According to French recommendations for
management of pregnant patients with invasive cancer, in
case of Stage Ib2 cancer diagnosed after 22 weeks of ges-
tation, the acceptable delay in treatment should be less then
six to eight weeks [21]. However, in other studies the delay
of definitive treatment of Stage Ib of disease only for four
and six weeks led to patients’ death [22]. 
The present patient was admitted to the hospital because
of gestational diabetes mellitus. There were abnormalities
observed on speculum examination. It is controversial why
colposcopy or at least a cervical cytology during her first
hospitalization was not carried out. These tests could ac-
celerate the diagnosis of cancer. In this case the time be-
tween the first hospitalization and the histopathological
examination’s result was about 40 days. The result of her
previous Pap test was the second group. Usually the pro-
gression to cancer is slower than two years. The reason of
this unexpected fast progression might be false negative re-
sult of cervical cytology. It should be remembered that the
sensitivity of cervical cytology is only about 70-80%. The
second reason of this situation might be the fact that preg-
nancy is a state which helps the development of cervical
cancer via two mechanisms. First is the fact that higher vas-
cularisation of lesser pelvis is probably responsible for
faster progression of the disease and metastases. Moreover
changes in the activity of immune system may weaken the
immune response. It may be considered whether the preg-
nancy should be terminated after 34 weeks of gestation
after the previous steroid therapy. Many researchers claim
that after this time infant’s life expectancy is similar to that
which occurs among full-term infants [21, 23-26]. It should
be also obligatory to perform a Pap test in the first trimester
of pregnancy regardless of last cytology result. If there are
any doubts, a colposcopy should be performed.
As long as we do not have clear recommendations about
the management of cervical cancer during pregnancy, this
tumor will still remain a clinical challenge. Apart from this,
treatment of these women in specialistic hospitals and has-
tening of diagnostic procedures, particularly during third
trimester, seems to be reasonable. Verification of screening
scheme during pregnancy should be also considered, espe-
cially in a group with additional risk of cancer develop-
ment.
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Introduction
Lipomas are ordinarily benign tumors [1, 2]. In vast ma-
jority, lipomas are small and usually do not enlarge expe-
ditiously [3]. Moreover, in most cases, their appearance is
sporadic, with no known cause. Although lipomas may
occur in any part of the body and are composed mainly of
fat tissue [4], they rarely develop in the breast causing di-
agnostic dilemma [5]. It is well known that mammography
and ultrasonography are often the two basic imaging tools
in case of breast diseases [6] and by extension when a pal-
pable mass is found. However, often these tools are not ca-
pable to distinguish a lipoma from other conditions. The
unusual case of a right breast giant lipoma prompted the
idea of writing this report mainly because of its extremely
challenging size and due to the difficulty in differential di-
agnosis with the use of the available imaging techniques. 
Case Report
A 62-year-old female came to REA hospital in Athens with a
complaint of chest asymmetry of the right breast increasing at the
connection of the pectoralis muscle. This symptom appeared a
few two to three months prior. Clinical examination showed a pal-
pable, movable, and painless mass in the right breast, without the
presence of nipple discharge or axillary lymphadenopathy. The
laboratory dosage of CEA and CA 15-3 were normal.
Ultrasonography revealed breast tissue involution (ACR 1).
Moreover, a radiolucent mass (lipid tissue), two cm in diameter,
close to major thoracic muscle was observed, and the muscle ap-
peared thinner. Furthermore, the ultrasound showed that in the
center of the mass there were three lipid cysts in contact with a di-
ameter of four cm. In the additional work-up with shear wave elas-
tography (SWE), the area presented a low mean value (17.0 kPa)
and SWE-Ratio (1.23). Consequently, the ultrasound findings
were mostly compatible with lipid mass (lipoma) or liposarcoma
and areas with cystic necrosis.
The findings from digital mammography were classified into
the BIRADS-2 category. It is noteworthy that mammography de-
tected a scattered fibroglandular tissue, especially in upper outer
quadrant of the breast. Additionally, mammography confirmed all
the aforementioned findings from the ultrasound examination.
Compared with the previous mammogram, there was no signifi-
cant change in the radiographic appearance, except from the lesion
in the right pectoralis major muscle.
Breast magnetic resonance imaging (MRI) exam was per-
formed at axial, sagittal, and coronal planes, before and after the
intravenous gadolinium contrast enhancement. According to the
findings, there was a lesion consisting mainly of fat tissue under
the right major pectoralis muscle. In the center of this lesion, a
secondary multilobulated lesion approximately four cm in diam-
eter, was recognized. This secondary lesion appeared with high
intensity T1 signal and medium-to-low signal on T2-weighted im-
ages, while intravenous contrast injection showed linear periph-
eral enhancement. The differential diagnosis of this image was
between accessory breast, lipomatosis or lipoma under the major
pectoralis muscle, containing an area of fat necrosis. Neverthe-
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Summary
Lipomas are the most frequent mesenchymal tumors consisting of mature fat cells and are usually benign. They represent approxi-
mately 4-5% of all benign tumors that occur in human body. They can sometimes present very large sizes in their localization and are
referred to as “giant lipomas”. In this article, the authors report an unusual case of a right breast giant lipoma causing diagnostic dilemma.
A 62-year-old woman was referred to the present hospital with a complaint of a sudden chest asymmetry of the right breast increasing
at the connection of the pectoralis muscle. Ultrasonography revealed breast tissue involution (ACR 1). Specifically, the ultrasound find-
ings were mostly compatible with lipid mass (lipoma) and areas with cystic necrosis. The findings from digital mammogram were not
conclusive compared with ultrasound examination. Moreover, the results from the breast MRI were contradictory and other diagnosis
was evinced. The patient underwent wide-surgical excision and reconstruction and had an excellent postoperative issue. According to
the final histopathological examination, the tumor measured 17 cm and was covered by a thin membranous capsule. Furthermore, it had
the appearance and composition of adipose tissue. In conclusion, according to the authors’ view, this case is rare due to its challenging
size and the difficulty in differential diagnosis. 
Key words: Breast lipoma; Giant lipoma; Rare breast lump; Benign breast tumor.
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Figure 1. — Drawing of the surgical scars.
Figure 3. — Wide-surgical excision and incision of the subcuta-
neous fat.
Figure 5. — Removal of lipoma.
Figure 2. — Mammographic view (MLO and CC) with the hook
wire.
Figure 4. — Incision of the pectoralis muscle.
Figure 6. — Giant breast lipoma.
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less, the last case was the most probable one. There was no area
of abnormal enhancement that indicated invasive lesion of the
breast after the intravenous gadolinium contrast injection. More-
over, there was no axillary adenopathy bilaterally. 
Despite the probable benign condition, the patient was advised
to have it removed by surgical procedure. The first step of the
surgery was the exact location of the breast abnormality with the
usage of a fine hook wire preoperatively (Figures 1, 2). The pa-
tient underwent wide-surgical excision under general anesthesia
(Figures 3-5). An arcuate incision of lump was performed in the
upper external quadrant of the right breast along the Langer’s
lines. After opening the subcutaneous tissue, the authors discov-
ered that the major pectoralis muscle was very thin and dislo-
cated. They opened with electrical scalpel the muscle
longitudinally and the lump appeared and was grasped out from
the scar. A precise hemostasis was performed and reconstruction
of the defect was made with local gland flaps (Takeda technique).
The surgical cavity was drained with a negative pressure aspira-
tion (wound vac). The result from the frozen section was nega-
tive for malignancy and specifically the specimen was diagnosed
as lipoma and liponecrosis (Figures 6-8). According to the final
histopathological examination, the tumor measured 17×14×8 cm
with a total weight of 1,789 grams and covered by a thin mem-
branous capsule (Figures 9-12). Furthermore, it had the appear-
ance and composition of adipose tissue. The patient had an
excellent postoperative performance status and was discharged
the same day.
Discussion
Lipomas are the most frequent mesenchymal tumors
consisting of mature fat cells and are usually benign,
well- circumscribed, and encapsulated [5, 7]. The inci-
dence of lipomas ranges from approximately 10% to 16%
in case of mesenchymal tumors [1, 8-10] and also, rep-
Figure 7. — Lipoma measuring 17 cm.
Figure 9. — Breast lipoma H&E ×25.
Figure 8. — Excised specimen.
Figure 10. — Area of connective tissue lined by foamy histiocytes
×25.
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resent 4-5% of all benign tumors that occur in human
body [11]. Owing to the limited information in the liter-
ature concerning lipoma occurring in breast tissue, the
exact incidence of breast lipoma remains a subject of in-
tense controversy [11]. Moreover, the etiology of lipoma
development is not completely understood [4, 12]. It is
worthwhile to note that lipoma may affect all people in-
dependent of their sex and age. As an example, there are
several case reports that describe breast lipoma develop-
ment in men [10]. Moreover, at times the patients may
have more than one lipoma in their body and this is due
to a genetic condition, which is known as familial multi-
ple lipomatosis [4]. Lipomas are also known to develop
in children, as shown by a study which conducted by
Greek scientists [13], but its occurrence in this popula-
tion is rare. 
Giant breast lipomas are defined as tumors that have a
diameter of at least ten cm in one dimension or weight of
more than 1,000 grams [1,9-11]. Giant breast lipomas have
rarely been reported in the literature and for this reason the
present case report is rare due to the challenging tumor size.
Owing to the normal fatty composition of the breast, breast
lipoma may cause diagnostic uncertainty [5, 14]. Thus, dif-
ficulties in differentiation from other breast lesions are
often encountered [1, 8]. The differential diagnosis of
lipoma includes benign conditions: hamartoma, hematoma,
haemangioma, angiomyolipoma, cyst, abscess, fat necro-
sis, fibroadenoma, accessory breast tissue, and malignant
breast conditions: liposarcoma and carcinomas, also mis-
call breast conditions: as phyllodes tumor [5, 6, 9, 15, 16]. 
The data of the literature are in accordance that there is
almost no risk of subsequent malignant transformation as-
sociated with lipomas [1, 2, 4]. However, if lipomas are >
ten cm they could contain sarcomas tissue and for this rea-
son biopsy is required [12]. 
Undoubtedly, breast ultrasound and mammography are
the two basic tools for the differential diagnosis of breast
lumps [6, 9]. MRI can sometimes assist in difficult situa-
tions. However, the final diagnosis is made by core or
“open excisional biopsy” [2]. It is noteworthy that in case
of a clinical diagnosis of lipoma, a biopsy is required if the
suspected lipoma causes symptoms as pain, movement re-
striction, and rapid enlargement or soft consistence [4]. 
The standard and definitive treatment of a lipoma should
be surgical excision [12, 17, 18]. It is noteworthy, that some
published scientific studies indicated that in some cases the
endoscopic-assisted suction of lipomas with the usage of an
ultrasonic scalpel may offer a better and a less invasive sur-
gical result [19, 20]. After surgery, the most common com-
plications are seroma, hematoma, infection, and scars [4].
Also, other modalities of treatment can be proposed: lipo-
suction is an effective alternative treatment of giant lipomas
as  shown by two studies [5, 21] and has been associated with
good cosmetic results [11]. Despite the fact that Raemdonck
et al. demonstrated that there is a high percentage of recur-
rence after liposuction in comparison to surgical excision
[22], a more recent study by Al-basti et al. reported that there
was no sign of recurrence after liposuction in a six-year post-
operative follow up [23]. However, this technique needs to
be improved due to its side effects [11]. Another alternative
treatment of lipomas is “chemical lysis” by subcutaneous in-
jection of deoxycholate which creates lysis of the adipose
tissue [24]. However, further studies are essential before this
treatment can be routinely recommended [4]. 
Although successful excision leads to an excellent prog-
nosis [1], follow-up is necessary due to the possibility of
relapse after a few years [11]. In conclusion, despite the be-
nign behavior of lipoma, because of the symptomatology,
it is necessary to remove it in order to obtain final
histopathological results.
Figure 11. — Chronic inflammatory infiltrate and foamy histio-
cytes (H&E ×50).
Figure 12. — Area of liponecrosis (H&E ×25).
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Introduction
Benign metastasizing leiomyoma (BML) is an obscure
condition in which metastatic benign smooth muscle le-
sions in the lungs, lymph nodes, or abdomen appear to
be derived from leiomyoma of the uterus. Because of its
rarity and uncertainty, making proper differential diag-
nosis from malignant tumors is still challenging. Here,
the authors present a rare case of BML of the lungs with
metabolic activity on 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET), in which needle
biopsy of the uterus was efficient to make a decision on
further treatment. 
Case Report
A 51-year-old premenopausal asymptomatic woman was re-
ferred to the present hospital due to abnormal shadows on a chest
X-ray. She had a history of myomectomy at age 35. Chest com-
puted tomography (CT) revealed more than 30 multiple nodules
in both lungs (Figure 1), and metastatic lung cancer was highly
suspected. PET-CT with FDG was performed to identify the pri-
mary carcinoma site and find any other metastatic lesions. PET-
CT showed high FDG uptake on the uterus. The maximum
standardized uptake value (SUVmax) on the uterus was 24.7,
whereas on the lung lesions it was 2.5 (Figure 2). On magnetic
resonance imaging (MRI) of the pelvis, an enlarged uterus and
multiple round nodules were found (Figure 3). With these imag-
ing investigations, the authors considered uterine sarcoma as the
origin of the lung metastasis. 
The treatment strategy for advanced uterine sarcoma is still
controversial. The present authors’ policy for uterine sarcoma
with unresectable metastasis is combined chemotherapy. To
make pathological confirmation, therefore, bronchoscopic
biopsy of lung nodules was performed. This revealed estrogen
receptor-positive spindle cells; however, it was not possible to
confirm BML or sarcoma. The authors then performed trans-ab-
dominal needle biopsy of the uterus. This showed spindle cells
as well and was compatible with leiomyoma. Finally, the diag-
nosis of BML of the lungs was made. With this diagnosis of
BML, total hysterectomy and bilateral salpingo-oophorectomy
were performed.
Discussion
Here, the present authors found two important clinical is-
sues. BML of the lungs can show metabolic activity on
FDG-PET-CT, and uterine needle biopsy is useful for the
proper diagnosis of this condition. First, BML of the lungs
can show metabolic activity on FDG-PET-CT. Nowadays,
FDG-PET-CT has become an accepted tool and plays an
important role to distinguish malignant from benign tu-
mors. For the evaluation of pulmonary malignancy, the sen-
sitivity of FDP-PET-CT is about 90% with a specificity of
around 78% [1]. With regards to SUVmax in the pulmonary
nodules, SUVmax greater than 2.5 is suspicious for malig-
nancy in the appropriate clinical settings [2, 3].
To the best of the present authors’ knowledge, only four
cases of BML with FDG-PET-CT findings have been re-
ported in the English literature [4-6]. The SUVmax was
from negative to 2.2 in those prior cases. A case with
SUVmax 2.2 had open thoracotomy carried out for the
pathological confirmation [5]. Compared to these four
cases, the current case showed relatively high FDG avidity
in the lung nodules. Furthermore, the excessively high
SUVmax in the uterus made it difficult to exclude that the
metastatic lung cancer originated from the uterine sarcoma.
In addition, it is well known that leiomyoma of the uterus
show high SUVmax on FDG-PET-CT [7-9]. Nishizawa et
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Summary
Benign metastasizing leiomyoma (BML) is a rare condition that affects other organs out of the uterus. Recently, a few case reports
in which 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used to distinguish the malignancy have been
published. Here, the authors present a case of BML with metabolic activity on PET, in which needle biopsy of the uterus was efficient
to make diagnosis. 
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Figure 1. — Chest CT showing multi-
ple round nodules of various sizes in
both lungs.
Figure 2. — FDG uptake on
PET-CT. SUVmax on the
lung lesions is 2.5 (a, b),
whereas on the uterus it is
24.7 (c, d).
Figure 3. — T2-weighted
MRI revealing an enlarged
uterus and multiple round
nodules. Comparison of a
nodule by PET-CT (a) with
MRI (b).
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al. reported a FDG-PET-CT screening in 1,357 healthy
women, and found an SUVmax larger than 3.0 in 10% of
the leiomyomas in premenopausal women, and 1.2% in
postmenopausal women[10].
Another prospective study showed 17% of leiomyomas had
SUVmax higher than 2.5; however, only 1.6% had one larger
than 5.0 [11] The reason for high FDG uptake in leiomyomas
is suggested to be related to the high levels of glycogen in a
myomatous uterus, the increased blood fraction, and the pro-
liferation of the smooth muscle cells due to increased meta-
bolic need [7]. The SUVmax in sarcomas is supposed to be
significantly higher than in leiomyomas, but its limits to dif-
ferentiate these two neoplasms are still uncertain [12]. In the
present case, SUVmax on the uterus was extremely high, as
in benign leiomyoma, up to 24.7. Microscopically, surgically
removed uterine tumors had moderately greater cellularity
than the surrounding myometrium (Figure 4). Retrospec-
tively, the present authors conclude that these pathological
findings could account for the high SUVmax. Second, uter-
ine needle biopsy is useful for the proper diagnosis of this
condition. With only imaging evaluation, preoperative dis-
tinction of uterine sarcoma from leiomyoma is sometimes dif-
ficult. Especially because the current case was suspected for
malignancy with metastatic lung cancer, pathological confir-
mation was essential to make the clinical decision on further
treatment. Needle biopsies are frequently performed on solid
tumors in other organs such as the prostate, breasts or liver,
however, its utility for uterine tumors has not achieved wide-
spread acceptance. Two prospective studies of uterine needle
biopsy have been published so far [13, 14]. Kawamura et al.
analyzed 435 patients with ‘myoma-like’ nodules by MRI, in
which seven had uterine sarcoma. Combined histopathologic
findings of transcervical needle biopsy and MRI, gave sensi-
tivity and specificity with respect to distinguishing uterine
sarcoma from leiomyoma of 100% and 98.6%, respectively
[13]. Tamura et al. described that in 63 cases of uterine tu-
mors determined by MRI, 12 were diagnosed as malignant
by needle biopsy, and 51 cases were benign. Among these 51
patients, one was diagnosed as having a low-grade endome-
trial stromal sarcoma post-surgically. They found the sensi-
tivity and specificity of the needle biopsy were 91.7% and
100%, respectively, and concluded this may be a reliable pre-
operative diagnostic procedure for uterine tumors with sus-
picious malignancy [14]. 
The present authors performed ultrasound-assisted trans-
abdominal needle biopsy of a uterine tumor that had high
FDG avidity. It revealed spindle cells without atypia and
absence of coagulative tumor cell necrosis (Figure  4). With
these pathological findings, the diagnosis of BML of the
lungs was finally made.
In conclusion, BML of the lung can show metabolic ac-
tivity on FDG-PET-CT, and uterine needle biopsy is useful
for the proper diagnosis of this condition. Further reports
should be accumulated to determine whether BML with
FDG avidity may be more common than previously
thought, and whether needle biopsy may be useful to make
proper decisions in such cases.
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Introduction
Lymphomas of the genital tract are uncommon. Some
cases reported in literature demonstrate the possibility of
the primary onsetting of lymphomas in the genital tract,
usually presenting as B-cell lymphomas and sometimes
multifocal lymphomas [1]. In only four cases, a lymphoma
was found in endometrial polyps to the best of the present
authors’ knowledge [2-5].
Herein, a case of a primary B-cell lymphoma arising in
an endometrial polyp is reported in order to improve the
knowledge about this exceptional situation.
Case Report
A non-menopausal women, aged 53 years, presented to her own
gynecologist to check menstrual irregularities and spotting. Her
personal history was uneventful. The gynecologist performed a gy-
necological examination, a specular examination, a pap smear, and
an ultrasonographic transvaginal scan. No abnormalities were
found at the gynecological examination, at the specular examina-
tion, and at pap smear. The ultrasonographic transvaginal scan re-
sulted in aspecific endometrial irregularity. Therefore, the patient
was counseled to plan a hysteroscopy, to better understand the
bleeding site in endometrium. The hysteroscopy was made with a
Bettocchi hysteroscope, allowing endometrial biopsies or in-office
operative procedures. The hysteroscopist detected two endome-
trial polyps and a cervical polyp. The hysteroscopic endometrial
pattern was proliferative and normal, and the tubal orifices were
normal. The endometrial polyps were both at isthmic level of the
endometrium on the posterior wall of the uterus. In one of them, a
necrotic area on the apex was detected as the bleeding site. All the
polyps, both cervical and endometrial, were removed with 2.5
French forceps of the Bettocchi hysteroscope, by tractioning them
from the base. This technique avoids polyps’ morcellation and im-
proves pathological diagnosis [6].
Unexpectedly, the histological examination showed that the apex
of the bleeding polyp was infiltrated by atypical lymphoid cells, with
large nucleus, along with multiple nucleoli and frequent mitosis (Fig-
ure 1). The lesion was two mm across the largest diameter. The im-
munohistochemical analysis demonstrated that the neoplastic cells
were positive for CD20 and Bcl-6, and negative for CD3, CD5,
CD10, CD23, Bcl-2, CD30, and Alk-1. The Ki67 proliferative index
was 95%. Based on these finding and after a careful review of the
slides, the diagnosis of a B-cell high-grade lymphoma was done.
The patient was urgently referred to hematological evaluation.
Thus, a total body positron emission tomography (PET), a total
body computerized tomography with contrast, a colonoscopy, and
bone marrow sampling were performed. All these examinations
excluded lymphatous localizations. Therefore, a primary local-
ization of the B-cell lymphoma in the endometrium was strongly
suspected. A laparothomic hysterectomy with annessectomy and
regional lymphadenectomy was performed for staging and treat-
ing the disease. The pathological examination resulted in a nor-
mal pattern of the uterus, ovaries, and nodes. Therefore, it was
concluded that the primary localization of the B-cells lymphoma
was in the endometrial polyp. The postoperative course of the
patient was uneventful. No other therapies were scheduled. Pa-
tient is fine at 18 months follow-up.
Discussion
To date, four other cases of lymphomas in endometrial
polyps were reported [2-5]. In the case of Rittenbach et al.
[2], large atypical lymphoid cells with immunophenotypic
pattern of B-cell lymphoma were found in bioptic frag-
ments of an endometrial polyp protruding from cervical os.
The pattern of B-cell lymphoma within the polyp was con-
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Summary
A non-menopausal women underwent gynecological evaluation for spotting and menstrual irregularities. After first line gynecolog-
ical assessments, the patient underwent office hysteroscopy. By using an in-office technique, two isthmic endometrial polyps and one
cervical polyp were removed. One endometrial polyp was found to harbor a B-cell high-grade lymphoma just on the apex (found to be
necrotic). The following staging examinations and the pathological assessment of the endometrium, the uterus, the adnexa, and the lym-
phatic regional nodes did not find any localization of the lymphoma. No additional treatments were done. The patient is alive and dis-
ease-free at 18 months follow-up.
Key words: Endometrial polyp; B-cell lymphoma; Hysteroscopy.
EJGO_4_2016:Layout 1  30-06-2016  11:15  Pagina 572
U. Indraccolo, R. Ranaldi, M. Mirabile, R. Centurioni 573
firmed after total hysterectomy, because uterus, en-
dometrium, and another endometrial polyp were not in-
volved in the disease. Histological signs of chronic
inflammation in the polyp did not involve malignancy, two
leiomyomatas, and adenomyosis were also described. No
antitumor therapy was done. After three years from surgery,
patients was free from disease.
In the case of Annibali et al. [3], a B-cell MALT-type
lymphoma was found after endometrial polyp removal. No
other surgery and therapy was done and the patient was free
from disease at 24 months follow-up.
More recently, Xia et al. [4] reported a case of a large in-
travascular B-cell lymphoma within an endometrial polyp.
With just the removal of the polyp, the patient is alive at
ten months follow-up. However, by reading the Xia et al.
case [4], one can understand a diffusion of the disease at
the time of endometrial polyp removal.
Additionally, Guldrís et al. [5] reported a primary diffuse
non-Hodgkin B-cell lymphoma in an endometrial polyp
and in endometrium. The disease was reported in two lym-
phatic nodes as well. A combined chemotherapy and ra-
diotherapy were performed and remission was reported at
18 months follow-up. 
The present case shares some similarities with the cases
of Rittenbach et al. [2] and Annibali et al. [3]. In both
cases, the neoplasm was confined to endometrial polyps,
and seemed to have a favorable prognosis. However, in
the present case, there was a large B-cell non Hodgkin
lymphoma, like the one of Rittenbach et al. [2]. The Rit-
tenbach et al, [2] case and the case presented here under-
went both hysterectomy. The surgical removal of the
uterus (and, in the present case, of the adnexa and of the
lymphatic nodes) excluded the diffusion of the neoplasm
to other sites of the genital tract. No additional therapies
Figure 1. — Upper: the excised
polyp contains an area of in-
creased cellularity (circle, H&E,
×20). Bottom left: at higher mag-
nification, the area is composed of
blastic lymphoid cells (H&E,
×400). Bottom right: The neoplas-
tic cells show strong and diffuse
CD20 positivity (CD20, ×250).
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were done, with good prognosis. Overall, endometrial pri-
mary lymphoma may onset like a polypoid lesion [1] or
may associate to endometrial polyps [7]. Therefore, it
should be recommended to quickly remove all the en-
dometrial polyps and then the uterus in order to reach a di-
agnosis. It could be speculated that the endometrial polyp
removal may be the first line surgical treatment for a lo-
calized primary B-cell non-Hodgkin lymphoma of the en-
dometrial polyp. Moreover, tricks for improving the
pathological assessment should be used. The in-office
hysteroscopic procedure proves to be effective for both
the pathological examination and a quick first line surgi-
cal therapy.
In conclusion, endometrial polyps may exceptionally har-
bor primitive B-cell non-Hodgkin lymphomas. The patho-
genesis and the treatment of such exceptional situation
needs further investigations, but a two-step surgical ap-
proach (polypectomy and hysterectomy) could be effective
in the localized cases. The present authors recommend to
report cases of lymphomas arising in endometrial polyps,
due to the need of understanding the best treatment to
schedule for such an exceptional condition.
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Introduction
Ovarian cancer is associated with the highest mortality
rate of all gynaecological malignancies in developed regions
of the world and is the eighth most common type of cancer
world-wide [1]. Epithelial ovarian cancers account for 90%
of ovarian cancers. Ovarian clear cell carcinoma is a distinct
subtype of epithelial ovarian cancer and often presents as a
pelvic mass at FIGO Stage I or II disease [2-3]. Unfortu-
nately ovarian clear cell carcinomas are associated with
higher rates of recurrence and subsequent higher mortality
rates compared with other epithelial ovarian cancers [4].
Epithelial ovarian cancers generally metastasise by di-
rect seeding of the peritoneal cavity. Extra-peritoneal
metastases occur in less than 40% of patients and in these
cases, metastases to pleura, lung, and liver are well-recog-
nised sites of distant ovarian cancer spread [5-6]. Subcuta-
neous nodules are a rarely encountered site of distant
metastasis, occurring in about 3.5% of epithelial ovarian
cancers [5]. The majority of subcutaneous metastases occur
as a single nodule at the level of the umbilicus, known as
the Sister Mary Joseph nodule, which is thought to occur
secondary to direct peritoneal spread [5]. 
Subcutaneous metastases from solid tumours occur at a
rate of 10%, most frequently from breast cancer and
melanoma [7]. The diagnosis of subcutaneous metastases
is commonly associated with extranodal metastatic disease
and a poor prognosis [7]. In ovarian cancer, the median
survival time from diagnosis of skin metastasis is nine
months [7].
The authors present a case of a woman who presented
with multiple anterior abdominal wall subcutaneous nod-
ules confirmed to be metastatic ovarian clear cell carci-
noma, and discuss the clinical implications of this finding. 
Case Report
A 46-year-old female patient presented with a left ovarian mass,
which was an incidental finding on a routine general examina-
tion. At the time of initial diagnosis, there was a large complex
cystic mass arising from the left ovary on computerised tomogra-
phy (CT). The Ca125 level was within the normal range at 20
U/ml. The patient underwent a total abdominal hysterectomy and
left salpingo-oophorectomy, left pelvic lymph node dissection,
and left para-aortic node sampling. She had previously had a right
salpingo-oophorectomy. She was diagnosed with FIGO Stage 1C1
ovarian clear cell adenocarcinoma based on comprehensive stag-
ing. The left ovarian cystic mass was densely adherent to the
pelvic peritoneum, pelvic side wall, uterus and rectum, and rup-
tured intraoperatively. Peritoneal washings were negative and
there was no evidence of lymph node spread (0/11 lymph nodes
positive). She was managed postoperatively with six cycles of
chemotherapy with carboplatin and paclitaxel and no radiother-
apy. A CT scan postoperatively demonstrated no evidence of dis-
tant metastases.
Four years after the initial diagnosis, the patient presented with
intermittent abdominal pain and mild abdominal distension. A
restaging CT demonstrated a left pelvic sidewall mass, which was
confirmed to be ovarian clear cell carcinoma by fine needle
biopsy. This was initially managed with three cycles of carbo-
platin and six weeks of radiotherapy. The carboplatin was ceased
after the third cycle due to an anaphylactoid reaction. The fol-
lowing year a positron emission tomography (PET)-CT scan
demonstrated that the left pelvic sidewall mass had increased in
size. This was managed surgically, with a laparotomy, removal of
an omental nodule, and division of adhesions. After a period of
nine months, the patient presented with persistent vague abdom-
inal symptoms, however a PET scan demonstrated no evidence
of disease recurrence and the Ca125 level remained within the
normal range.
At age 52, two months after this PET scan, and five years after
the initial diagnosis, the patient noted a number of “lumps” in her
abdominal skin and on examination there were multiple subcuta-
neous nodules in the anterior abdominal wall. A magnetic reso-
nance imaging (MRI) scan demonstrated five new subcutaneous
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Summary
Skin metastasis is a rare form of ovarian carcinoma spread and is associated with widespread disease and a poor prognosis. The au-
thors present a case of a patient, with a past history of ovarian clear cell carcinoma, who presented with subcutaneous nodules as the
first sign of recurrent metastatic disease.
Key words: Ovarian cancer; Ovarian clear cell carcinoma; Skin metastasis; Subcutaneous nodule; Case report.
EJGO_4_2016:Layout 1  30-06-2016  11:15  Pagina 575
J. Wade, S. Armon, O.M. McNally576
nodules (Figure 1), confirmed to be metastatic ovarian clear cell
carcinoma on fine needle biopsy (Figure 2). A repeat PET scan
demonstrated widespread metastatic disease in the liver and
omentum. The Ca125 level was 193 U/ml. The patient was treated
with two cycles of carboplatin and gemcitabine chemotherapy. A
CT scan following these two cycles demonstrated progression of
disease and the Ca125 level had risen to 2,400 U/ml; and therefore
the chemotherapy regime was changed to liposomal doxorubicin.
At the time of this report, the patient had received six cycles of
chemotherapy with liposomal doxorubicin. The Ca125 had fallen
to 300 U/ml and a CT scan demonstrated stable disease.
Discussion
Ovarian cancer is associated with the highest mortality
of all gynaecological cancers [8]; and therefore gaining a
greater understanding of the pathophysiology of ovarian
Figure 2. — Histopathology of subcutaneous nodule demonstrating features consistent with ovarian clear cell carcinoma, including
Hobnailed appearance of tumour cells, cytoplasmic clearing, eosinophilic stromal cores in papillae, and papillary and glandular archi-
tecture. Haematoxiline and Eosin staining. Magnification a) ×5; b) ×10; c) ×20.
Figure 1. — a), b), c) MRI im-
ages demonstrating five new
subcutaneous nodules in the an-
terior abdominal wall. The
largest nodule is to the right of
the midline scar below the um-
bilicus in the subcutaneous fat,
indicated with the arrow. There
are four left-sided smaller nod-
ules. d) In diffusion weighted im-
aging (DWI) all of the nodules
demonstrate restricted diffusion
and enhancement.
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cancer is of upmost importance. Ovarian clear cell carci-
nomas, a subtype of epithelial ovarian cancers, typically
present early in the disease process, however disease re-
currence is common and often fatal [2]. Metastasis from
ovarian cancer occurs predominantly by direct extension
into the peritoneal cavity and dissemination via the peri-
toneal fluid [9]. Studies have found that approximately
30-38% of patients with epithelial ovarian cancer develop
distant metastases [5-6]; and the presence of distant site
metastases, including liver, lung, and pleural are associ-
ated with poor prognosis. As discussed in this paper, dis-
tant metastases to skin are very rare [5]. 
The pathophysiology contributing to skin metastases re-
mains unclear. The majority of cases reporting skin metas-
tases detail nodules in surgical sites and laparoscopic port
sites, suggesting direct seeding may be an important fac-
tor [5, 10]. This case study details five subcutaneous nod-
ules in the anterior abdominal wall, not associated with a
surgical incision site. A recent case study has also pre-
sented the finding of subcutaneous nodules in the chest
wall associated with metastasis from epithelial ovarian
cancer [11]. This suggests that direct peritoneal spread
may not be the only factor contributing to metastases to
skin and likely lymphatic or haematogenous spread may
be involved. Previous studies have shown that lymphatic
invasion of ovarian tumours is associated with metastases
to lymph nodes, small bowel, lung, and liver [12]. Further
investigation is required to identify the underlying mech-
anism contributing to subcutaneous metastases from ovar-
ian carcinoma.
Skin and other distant metastases occur at late stages
and are associated with disseminated disease, as was the
finding in this case. Management options at this late stage
are unclear; however palliative approaches have been sug-
gested to be appropriate [5, 13]. Surgical resection of the
subcutaneous nodules has also been proposed to increase
survival time [14]; although this may not be suitable in
the setting of widespread disease [13]. 
Oncologists should be aware of subcutaneous nodules
as a presentation of ovarian cancer recurrence and inves-
tigate any new development of subcutaneous nodules ac-
cordingly.
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Introduction
Vulvar melanoma in situ is rare. Like oral mucosal
melanomas, vulvar in situ lesions are considered precur-
sors of invasive melanoma and the progression is often
multifocal [1]. The majority of vulvovaginal melanomas
present with relatively advanced tumors while in situ le-
sions alone are not usually recognized [2,3]. The vulvo-
vaginal junction at the introitus is a high risk site for vaginal
and vulvar melanoma. The intraoperative management re-
quires accurate and complete assessment of lesions that ex-
tend both laterally and in depth in melanoma in situ [4]. It
is not generally appreciated that melanoma of the vulva and
vagina have more in common with mucosal melanomas
such as those in mouth, which appear to be biologically dif-
ferent to cutaneous melanoma [5]. Approximately 3% of
all melanomas diagnosed in women are located within the
genital tract, predominantly affecting the vulva, followed
by vaginal melanoma [6]. Vulvar melanoma represent less
than 1% of all melanomas. Moreover it is the second most
common vulvar malignancy, as it represents from 3.4% to
10% of cases among vulvar neoplasms [7]. Melanoma in
situ in about 20-45% of cases does not present any clinical
symptoms [8]. Amelanotic melanoma of the vulva is ex-
tremely rare; in a recent review, less than 10% were found
to lack pigmentation [9]. In this paper, the authors present
a rare case of amelanotic melanoma of the vulva, without
any clinical symptoms recognized in random check up for
uterine prolapse.
Case Report 
A 71-year-old woman with a rectocele presented in 2005. In the
last period she had various complaints: gradually increasing lower
bowel pain and defecator dysfunction without any fecal inconti-
nence. The following previous operations were reported: a) a total
hysterectomy with bilateral adnexectomy, b) cholecystectomy,
and c) once umbilical hernia operation, at 30, ten, and three years
ago, respectively. The gynaecological and transvaginal examina-
tions were unremarkable. Blood chemistry showed no abnormal-
ity. Accidentally a small nodular lesion was observed in the left
labia majora. Macroscopically the features of the lesion were nor-
mal without any colour changes with a size to 0.4 cm. The phys-
ical examination detected a vulvar mass, 6×2×2 mm in size,
without asymmetry irregular borders. No ulcers or bleeding was
detected. Moreover no presenting clinical symptoms in vulva area
were referred. For rectocele repair the woman underwent a pos-
terior colporrhaphy and a vulva-biopsy. The ill-defined dermal le-
sion with extension into subcutaneous tissue was noted. The intra-
and postoperative course was uneventful. The extracted material
from left labia was submitted for a histopathological examination.
Histological examination revealed an in-situ malignant melanoma
without any evidence of invasive disease. The tumor was com-
posed of large neoplastic cells with abnormal, hyperchromatic nu-
clei, having abundant eosinophilic, often clear, cytoplasm (Figure
1). The lesion lacked melanin, necrosis or haemorrhage. There
were, however, focal areas of melanocytic dysplasia of various
degrees. A scattered mononuclear cell infiltrate was noted in the
superficial dermis. Immunohistochemically, tumour cells stained
positively for HMB-45, Melan A, and S-100 protein. (Figure 2).
The above described immunohistochemically findings revealed
the diagnosis of primary amelanotic melanoma [10, 11]. The
tumor was totally excised with adequate and histological tumor
free margins. Seven days later after vulva biopsy, a magnetic res-
onance imaging did not show any metastases. Two weeks later
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Summary
Amelanotic malignant melanoma of the vulva is extremely rare. The authors describe here a case of amelanotic malignant melanoma
of the vulva, occurring in a 71-year-old woman without any clinical symptoms. The woman had a small nodular lesion in the left labia
majora. Local excision was performed. Histological examination revealed an in situ malignant melanoma without any evidence of in-
vasive disease. All suspicious lesions in the vulva region, even if there are no clinical symptoms, should be biopsied, and if an in-situ
melanoma is identified, partial or total vulvectomy should be considered. 
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the patient underwent a partial vulvectomy. Histological exami-
nation of the surgical margins were again optimal tumor-free. The
patient will have the first follow up examination six months post-
operatively.
Discussion 
Vulvar melanomas are usually pigmented or character-
ized by a painful or bleeding identified mass. The term ame-
lanotic melanoma includes true amelanotic lesions with no
pigmentation and melanomas with minimal residual pig-
mentation [12]. Most reported cases of amelanotic
melanoma are metastatic, however they have been cases of
amelanotic melanoma of primary lesion [13, 14]. The radi-
ological diagnostic procedures which are used for confir-
mation of amelanotic melanoma, as computed tomography,
magnetic resonance imaging, ultrasound, and proctoscopy
are not specific to all cases of amelanotic melanoma, be-
cause approximately 30% them lack pigmentation. Only a
histopathological examination can confirm an amelanotic
melanoma. Histopathologically in primary lesions are found
nested and single growth of atypical melanocytes in the sur-
rounding mucosa and immunohistochemical markers as S-
100, HMB-45, Melan A, and microphthalmia associated
transcription factor. The primary modality of treatment is
surgery [11, 15].
In this case a woman with a small nodular region in the
left labia majora was presented. No pigmentation and no
clinical symptoms as ulcers or bleeding were detected. The
patient underwent a partial vulvectomy with tumor-free sur-
gical margins. It is also important to mention that in the re-
cent literature, only a few cases of amelanotic vulvar
melanomas have been published and none of these have
been found at such an early stage [10]. Furthermore other
studies referred to ulcerated lesions of the vulvar region
that was not observed in the present case. It is possible that
the present authors found the lesion in a very early stage. In
a recent study, only two cases of vulvar melanoma were di-
agnosed in situ and none was amelanotic [7]. A case of
amelanotic melanoma of the vulva is referred by Baderca et
al., which was not in situ [16].
The treatment of the vulvar melanoma is local excision
with tumor free margins. Many studies found no differ-
Figure 1. — Amelanotic vulvar melanoma in stu.
Figure 2. — Tumour cells stained positively HMB-45, Melan A,
and S-100 protein.
Table 1. — Invasive amelanotic melanomas of vulva: treatment modalities.
Shetty K.J. et al., 2012 [18] 23 years Mass 5×6 cm Inoperable/radiotherapy Mass, odour, bleeding
Baderca F.L. et al., 2008 [16] 78 years Inner site right labium majus Hemi vulvectomy, resection of 
5×2 cm clitoris/polychemotherapy Pruritus, swelling, bleeding
Oiso N. et al., 2010 [14] 80 years 20 mm left labium majus Excision of the tumor Ulcerated nodule
An J. et al., 2009 [10] 60 years 2 cm left labium minus Radical vulvectomy and bilateral Ulcer, bleeding, 
inguinal lymphadenectomy. burning discomfort
Ulmer A. et al., 1996 [19] 60 years Left labium Hemi vulvectomy, resection of Pruritus, bleeding
Hoffman U. et al., 1995 [20] 55 years 1.3 cm right labium majus clitoris, resection of the tumor Nodular tumor
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ences between radical rejection of the lesion with total vul-
vectomy and lymphadenectomy and more conservative
techniques [17]. The present authors decided to perform a
partial vulvectomy although the tumour was totally excised
from the first time with adequate and histological free mar-
gins. 
It is concluded that vulvar malignant melanoma is a rare
and aggressive tumour. Standardized treatment of patients
with malignant melanoma of the vulva is required for de-
finitive treatment. Surgery should be performed in accor-
dance with the accepted standards for cutaneous melanoma,
however no treatment recommendations exist due to the
rarity of this disease. The ABCDE scheme (asymmetry,
border, irregularities, colour variation, diameter > five mm.
enlargement or evaluation of colour change, shape, or
symptoms) is very useful for early melanoma recognition
[10]. All suspicious pigmented or unusually thick lesions
in the vulva region should be biopsied for histopathologi-
cal evaluation. The depth of these lesions is critical. Table
1 presents cases of invasive amelanotic melanoma and
treatment modalities [18-20]. However current literature
research has not referred any other case of amelanotic
melanoma vulva in situ.
The gynaecologist should take into consideration that le-
sions of the vulva could be suspicious for melanoma even
when there is no melanin pigmentation and no clinical
symptoms. Amelanotic melanoma may present in a great
variety of clinical features and should be considered in the
different diagnosis of any nonpigmented lesion located in
uncommon position of the vulva. Local excision and partial
vulvectomy is recommended for patients with malignant
melanoma in situ of the vulva. Therefore, the importance of
self-examination and early diagnosis of melanoma of the
vulva should be emphasized, and accurate inspection of the
vulva should be indispensable during routine gynaecolog-
ical examination. Any lesion in vulva should be considered
likely to be a melanoma. Standardized documentation of
clinical and histopathological parameters is needed for
grouping of cases for future comparative studies. 
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Introduction
Gynandroblastoma is an extremely rare tumour consist-
ing of female-type sex-cord stromal tumour cells and male-
type sex-cord stromal tumour cells, and each of these
components accounts for at least 10% or more of the mass.
These lesions usually present with adult-type granulosa
cells and Sertoli cells in young adults [1] and often induce
signs of masculinization and feminization due to the effects
of tumour-producing sex hormones, such as estradiol and
testosterone.
Although convalescence after tumour excision is thought
to be associated with a good prognosis, gynandroblastoma
is usually borderline malignant. In addition, there are cur-
rently no large-scale studies available regarding the prog-
nosis of this disease, and late-onset recurrence and
subsequent death may occur in some cases [2].
The authors herein report a case of gynandroblastoma in-
volving the longest disease-free period.
Case Report
A 66-year-old woman with mild lower abdominal pain for a
month presented to this hospital. Her gynaecological history was
unremarkable (G5P3, menopause at age 48). She had asthma and
had undergone cholecystectomy at age 48. She did not smoke or
consume alcohol. Her general condition was stable (conscious-
ness, clear; pulse rate, 78 per minute; body temperature, 36.8°C;
body mass index, 27.8 kg/m
2
) except for a mildly high blood pres-
sure at 190/80 mmHg. She did not present evidence of feminiza-
tion or masculinization.
On physical examination, an elastic-hard mass, the size of a new-
born’s head (11 cm), was palpable with tenderness in the middle of
the lower abdomen. The uterus was enlarged for her age at 10×6 cm,
the endometrium was thickened at two cm, and a solid-cystic mass
measuring ten cm in diameter presented as a right adnexal lesion on
transvaginal ultrasound. Magnetic resonance imaging (Figure 1)
showed that the solid part had a relatively high intensity, whereas
the cystic part showed a mixture of low-and high-intensity features
on a T2W1 image. Additionally, a nutrient vessel of the tumour from
the uterus was suspected. Thoraco-abdominal computed tomogra-
phy revealed no apparent metastasis or enlarged lymph nodes. The
complete blood count and biochemistry tests results that the param-
eters were within the normal range, although CA-125 (52.2 U/ml)
and serum estradiol (146 pg/ml) levels were slightly elevated. En-
dometrial curettage, performed for endometrial thickness prior to la-
parotomy, led to a diagnosis of atypical endometrial hyperplasia.
She underwent surgery after the diagnosis of right ovarian tumour,
which was suspected to be a granulose cell tumour.
Accumulated yellowish serous ascites (600 ml) were submitted
for cytological analysis, and the result was negative. The uterus,
left adnexa, and intestines were adhesion-free, but the enlarged right
ovary, the size of a new-born’s head, strongly adhered to the
retroperitoneum. Because of the ascites and adhesion, a malignant
tumour was suspected. Therefore, simple hysterectomy and bilateral
adnexectomy were performed. The authors did not pathologically
diagnose the tumour during surgery.
The right ovarian tumour had an 11-cm diameter and 450-gram
weight. It was elastic-hard with a mostly smooth surface, although
papillary structure was observed in some areas. Macroscopic ex-
amination of the excised surface of the tumour revealed a yellow-
ish solid component with bleeding, necrosis, and various sized cysts
containing serous liquid. There were some protrusions on the cyst
wall. Endometrial thickness was apparent, but no noticeable my-
ometrial proliferation was observed (Figure 2). 
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Summary
Gynandroblastoma, an extremely rare ovarian tumour that usually consists of both Sertoli stromal cell and granulosa cell tumours,
often produces both androgenic and estrogenic effects. The authors herein report a case of gynandroblastoma with the longest disease-
free period reported to date. A 66-year-old woman without metrorrhagia or hirsutism presented with abdominal pain and slightly elevated
serum estradiol levels. Her uterus was enlarged, and endometrial curettage performed to reduce endometrial thickness prior to laparotomy
led to a diagnosis of atypical endometrial hyperplasia. She was diagnosed of ovarian tumour. The pathology report revealed that the right
ovarian tumour was a “gynandroblastoma”. Such lesions are classified as borderline malignant. Postoperative adjuvant therapy was not
administered in this case because only a few recurrent or fatal cases have been reported. The lesion was classified as pT1aN0M0 according
to Union for International Cancer Control (UICC). The patient is alive and has been disease-free for 77 months post-surgery.
Key words: Gynandroblastoma; Sex cord; Stromal cell tumours; Granulosa cell tumor; Sertoli cell tumour.
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Histologically, the tumour comprised of two different elements
(Figures 3 and 4): “granulosa cell tumour,” which shows charac-
teristic features such as Call-Exner bodies (Figure 3c), nuclei with
folds and grooves (Figure 3d), microfollicular pattern (Figure 3e),
trabecular architecture, and insular formation, and “Sertoli cell tu-
mour” with its typical tubular formation, such as hollow tubules
(Figure 3f) and immature tubules (Figure 3g). Eighty percent of
the tumour was granulosa cell tumour and the remaining 20% was
Sertoli cell tumour (Figure 4). Tumour cells were immunoreac-
tive for inhibin, cytokeratin AE1/AE3, progesterone receptor, and
calretinin in both granulosa and Sertoli cell tumour elements.
Based on these findings, the tumour was diagnosed as a gynan-
droblastoma. Thickened endometrium histologically showed sim-
ple endometrial hyperplasia, and no remarkable findings were
observed in the left ovary.
Figure 2. — Macroscopic findings of the excised specimen. 
Figure 1. — Magnetic
resonance imaging
showing a solid com-
ponent with a rela-
tively high intensity,
whereas the cystic
part shows a mixture
of low-and high-in-
tensity features on a
T2W1 image
Figure 3. — Pathological findings. (a) Macroscopic findings of the excised surface of the tumour after formalin fixation. (b) Haema-
toxylin and Eosin staining of the portion of the tumour seen in the red frame in (a). (c) Call-Exner bodies of the granulosa cell tumour.
(d) Nuclear groove of tumour cells of the granulosa cell tumour. (e) Microfollicular pattern of the granulosa cell tumour. (f) Hollow
tubules of the Sertoli cell tumour. (g) Immature tubules of the Sertoli cell tumour.
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After surgery, the patient and her family were provided infor-
mation on gynandroblastoma. Although the patient was informed
of the possible benefits of adjunctive therapy that the treatment
of choice for borderline tumours, the patient decided to undergo
follow-up without adjunctive treatment. Written informed con-
sent was obtained from the patient. She has been healthy without
any relapse of the tumour during the 77 months of follow-up post-
surgery.
Discussion
Embryologically, Sertoli cells and Leydig cells are
thought to develop from primitive embryonic marrow, and
granulosa cells develop only from cortex sex cords [3, 4].
The exact origin of gynandroblastomas is unknown. Some
reports state that gynandroblastoma is a simultaneous tu-
morigenic transformation of marrow and cortex. In con-
trast, it has also been reported that gynandroblastomas
develop from undifferentiated gonadal mesenchymal cells
that have the potential to differentiate into both sexes.
Macroscopically, gynandroblastoma is a solid tumour
with cystic formation, and the colour of the division sur-
face is white or flavedo. The size of the tumour ranges from
two to 20 cm [5]. When masculinization and feminization
exist simultaneously, gynandroblastoma can be clinically
suspected; however, the diagnosis of gynandroblastoma
using only the symptoms is sometimes difficult because of
the opposing effects of each hormone. The differential di-
agnoses include granulosa cell tumours, Sertoli-stromal cell
tumours, small cell carcinoma, endometrial stromal sar-
coma, and endometrioid adenocarcinoma.
In the present case, the patient did not have metrorrhagia
or signs of masculinization, and her serum estradiol levels
were slightly elevated. Her uterus was enlarged for her age.
The major complaint of abdominal pain led to the diagno-
sis of ovarian tumour, and granulosa cell tumour was sus-
pected because of the presence of atypical endometrial
hyperplasia resulting from the high serum estradiol levels.
Since there are not many long-term follow-up studies,
the present authors suggest careful observation of patients
with such tumours. The patient received treatment and un-
derwent long-term follow-up at this hospital; however,
more such cases are required to accumulate evidence.
Conclusion
Granulosa and Sertoli cell tumours are categorised as
being borderline malignant. The prognosis of both tumours
is generally excellent, although a few lesions display ma-
lignant biologic behaviour. The current patient has re-
mained healthy without any relapse of the tumour for 77
months of follow-up after surgery. Since gynandroblastoma
is a rare tumour, careful follow-up is important in order to
determine the biologic behaviour of such lesions.
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Figure 4. — Distribution of granulosa cell tumour and Sertoli cell
tumour in the histologic section.
EJGO_4_2016:Layout 1  30-06-2016  11:15  Pagina 583
Introduction
Pregnancies consisting of a live fetus accompanying a
hydatiform mole are uncommon and comprise one in
22,000–100,000 pregnancies [1]. Among them, the preg-
nancies resulting in viable fetuses are extremely rare,
often due to the development of maternal complications,
including preeclampsia and vaginal bleeding. The risk
for gestational trophoblastic neoplasm is another con-
cern because of the delayed evacuation of the molar tis-
sue. [2]
In this paper, the authors present a case of complete
mole hydatiform (CHM) with a live co-twin fetus
(CHMLF) resulting in the delivery of a healthy male in-
fant with the partial regression of the molar tissue and the
decline of serum beta human chorionic gonadotropin (β-
hCG) during the pregnancy.
Case Report
A 25-year-old woman, gravida 2, para 1, at 22 weeks’ gesta-
tion was referred to the present institution on suspicion of CHM
and CHMLF. Her previous medical history was unremarkable
and her obstetric history included one term vaginal birth. She
had no problems with the pregnancy except for slight vaginal
bleeding and mild hyperemesis by that time. Ultrasound exam-
ination revealed a live fetus with normal placenta and adjacent
to the placenta a well-defined multi-cystic snowstorm-like mass
which was compatible with CMH. This cystic area measured
12.5×7 cm (Figure 1). The amount of amniotic fluid was nor-
mal and there were no signs of growth retardation or fetal anom-
alies. The serum level of β-hCG was > 10,000 IU/ml. CHMLF
was strongly suspected. The risk of possible maternal compli-
cations, fetal malformations, and subsequent malign transfor-
mation were explained and the couple was counseled for
termination, but they chose to continue this pregnancy and de-
clined any invasive prenatal testing to confirm the karyotype of
the fetus. During the expectant management there were no major
maternal complications (thyrotoxiosis, preeclampsia, anemia).
Serial ultrasound examinations performed at two-week intervals,
demonstrated normal fetal growth and a reduction in size of the
molar tissue. Recurrent vaginal spotting continued in the second
and third trimester. On the last ultrasound, molar tissue was ob-
served thoroughly small on one side of the uterus. At 36 weeks,
a cesarean section was performed because of vaginal bleeding,
and a 2,630-gram male infant with an Apgar score of 9 and 10
at one and five minutes was delivered. The placenta and grape-
like mass were removed manually. The pathologic examination
of the placenta revealed 6.5×4 cm focal area which was com-
patible with CMH (Figure 2). 
Immunohistochemical stains with the P57KIP2 anti-body
were helpful in the differential diagnosis of complete hydatiform
moles. Expression of P57KİP2, a paternally imprinted gene, is
either absent or low in trophoblast in cases of complete moles in
contrast to diffuse staining in partial moles and non-molar pla-
centas. In present case, the villous stromal cells and cytotro-
phoblastic cells did not show P57KIP2 immunoreactivity, while
the intermediate trophoblastic cells were positive (Figure 3) [3].
The karyotype in cultured cells from the molar area was diploid.
The serum β-hCG level was 3,912 IU/ml at the delivery and pa-
tients followed by weekly serum β-hCG measurement. β-hCG
levels decreased gradually. At second month of postpartum pe-
riod the patient’s β-hCG persisted at the levels of 56 and 60
IU/ml. Metotrexate with leucovorin rescue treatment was started
and β-hCG level returned to normal after third course. No evi-
dence of persistent gestational trophoblastic disease (PTD) was
found at first year of postpartum period. 
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Summary
Pregnancies resulting in viable fetuses are extremely rare in accompanying a hydatiform mole, often due to the development of ma-
ternal complications, including preeclampsia and vaginal bleeding. The risk for gestational trophoblastic neoplasm is another concern
because of the delayed evacuation of the molar tissue. In this paper, the authors present a case of complete mole hydatiform with a live
co-twin fetus (CHMLF) resulting in the delivery of a healthy male infant with the partial regression of the molar tissue and the decline
of serum beta human chorionic gonadotropin (β-hCG) during the pregnancy. In the management of CHMLF, each patient must be con-
sidered individually and eligible patients can be followed in the absence of serious maternal complications. Serial ultrasound examina-
tions and close clinical and laboratory surveillance of the mother are certainly indicated.
Key words: Complete mole hydatiform; Twin pregnancy; Gestational trophoblastic neoplasm.
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Discussion 
The CHMLF is a relatively uncommon event with a
quoted range of incidence from one in 10,000 to one in
100,000 pregnancies [4]. Most of these cases either aborted
or resulted in stillbirth and only a few with a living new-
born. There are, overall, about 200 cases of twin pregnancy
with CHMF documented to date in the literature and only
30 cases of twin pregnancy with CHMF resulting in a live
birth documented in detail in the literature. [5]
Clinicians and parents with CHMLF cases encounter a
clinical dilemma, as they have to decide between continu-
ation or immediate termination of the pregnancy. The prob-
lems in the management of CHMLF involve the risks of
fetal abnormality, malignant trophoblastic change, and se-
vere maternal complications [6, 7]. The rate of pregnancy
termination due to maternal complications is different in
various reports. Fishman et al. [8] reported their termina-
tion rate as 71% because of maternal complications. This
high rate may be due to spontaneous abortions and in-
trauterine deaths in their series. Conversely Sebire et al. [9]
reported that only 4% of the pregnancies were terminated
because of maternal complications.
As with the singleton molar pregnancies, some clinical
criteria of aggressivity for the mother, such as maternal age,
parity, uterine size, serum level of β-hCG before evacua-
tion, signs of preeclampsia, and the existence of theca lutein
cysts have been studied, but none of them predict progres-
sion to PTD [10]. Bristow et al. compared the clinical fea-
tures of CHM in which the fetus remained viable and the
pregnancies terminated or ended in stillbirth. In the non-vi-
able group, the peak serum level of β-hCG was higher, and
uterine height was greater than expected. In viable molar
cases, the trophoblast was less aggressive or progressed to
spontaneous degeneration. Spontaneous intrauterine fetal
death appears to be very common in CHM with a live co-
twin, mostly before 24 weeks [11].
The risk for PTD in the CHMLF cases is not higher than
the risk in single molar pregnancies. Bristow et al. [11] re-
ported that PTD occurs in 68.4% of CHMLF gestations de-
livered before fetal viability and 28.6% of those resulting in
a living fetus. They concluded that the advanced gestational
age required to produce a viable, surviving fetus is not an
independent risk factor for the development of PTD. Sev-
eral studies have shown that the risk level does not change
with advanced gestational age [12, 13].
Marcorelles et al. [14] suggested that there are two types
of spontaneous evolutions during the second trimester of
pregnancy: either the molar part becomes quiescent, allow-
Figure 1. — Ultrasound photograph at 22 weeks’ gestation show-
ing complete hydatiform mole (upper part) and normal placenta
with a fetus. The molar tissue was 12.7×7 cm.
Figure 2. — Macroscopic photograph of the placenta (15×17 cm)
and the molar tissue 6.5×4 cm.
Figure 3. — p57KIP2 immunostaining of a complete hydatiform
mole. The villous stromal cells and cytotrophoblastic cells do not
show p57KIP2 immunoreactivity, while the intermediate tro-
phoblastic cells were positive for p57.
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ing the pregnancy to continue, or it continues to grow ex-
tensively, leading to fetal death and maternal complications. 
In the present case during the follow up, no maternal and
fetal complications were observed and the pregnancy ended
with the delivery of a live baby. The molar tissue regressed
and the size of it decreased significantly during the preg-
nancy (partial regression). After delivery, patients were fol-
lowed by serial β-hCG measurement; when the β-hCG
levels persisted patients were diagnosed as gestational tro-
phoblastic neoplasia (GTN). Because the patients were
evaluated as low risk GTN, single-agent methotrexate treat-
ment was administered. Negative β-hCG level was
achieved and no recurrence was detected during a one-year
period. In the present authors’ opinion, in the management
of CHMLF each patient must be considered individually
and eligible patients can be followed in the absence of se-
rious maternal complications. Serial ultrasound examina-
tions and close clinical and laboratory surveillance of the
mother are certainly indicated.
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Introduction
The presence of adnexal masses during pregnancy ranges
from 1:81 to 1:2,500 pregnancies, but only 3% of these masses
are malignant [1]. A Krukenberg tumor is an ovarian adeno-
carcinoma metastasis from a primary malignancy of the gas-
trointestinal tract, with 76% originating from the stomach, and
it accounts for 1~2% of all ovarian tumors [2]. The incidence
of gastric cancer in pregnant women was only 0.016% even in
Japan where a high rate of gastric cancers was reported [3];
hence Krukenberg tumor during pregnancy is even rarer.
The patient with Krukenberg tumor can be pregnant be-
cause the ovary still has a part of the normal cortex and hence
does not affect ovulation. A Krukenberg tumor with preg-
nancy is so uncommon and due to the lack of treatment guide-
lines, it is easily misdiagnosed, thus presenting a challenge
for the physician. The authors present a case report of a
woman 29-weeks pregnant patient with massive bilateral
Krukenberg tumors, which was misdiagnosed as subserous
myoma preoperatively and ovarian stromal tumor intraoper-
atively. The aim was to provide clinicians with the clinical
manifestations of this rare case and provide some information
about better clinical diagnosis and treatment of the disease.
Case Report
A 26-year-old nulliparous woman with preeclampsia was referred
to the Obstetrics Department at 29
+2
weeks of gestation, with com-
plaints of intermittent headache and dizziness over the past three
weeks and clouded vision for one day. She complied with her ante-
natal schedule well and generally had no abnormalities detected dur-
ing the course of pregnancy until recently. At eight weeks of
gestation, progesterone treatment was once given because of vagi-
nal bleeding. Small red acne on the skin of the neck and the chest
which was androgenized body feature was observed since she was
pregnant. She denied any past medical problems and was not taking
any medications prior to her pregnancy. Additionally, she denied the
use -of tobacco, alcohol, or illicit drugs. The family history was non-
contributory.
The physical exam found her blood pressure to be 160/120 mmHg
and it indicated a gravid uterus at around 28 weeks of gestation.
Lower limbs had slight edema. A gynecological examination re-
vealed no clitoral enlargement. Laboratory findings showed normal
electrolytes. Hemoglobin was 135 g/L and platelets were 379×10
9
/L.
Urine analysis revealed no evidence of leucocytes and blood. How-
ever, the quantitative 24-hour urine collection for protein was 0.78
grams (normal level during pregnancy is 0-0.3 grams/24 hours). Car-
cinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9)
levels were normal, while the cancer antigen 125 (CA 125) was
found to be elevated at 92.49 U/ml (normal range: 0-39 U/ml) and
alphafetoprotein (AFP) was 79.19 ng/ml (normal range: 0-20 ng/ml).
Circulating levels of testosterone were elevated to 10.91 ng/ml (nor-
mal range: 0.06-0.82 ng/ml), while other hormones such as estra-
diol and aldosterone were in the normal range. 17-OH-progesterone
was 4.96 μg/L (normal range: 0.40-1.02 μg/L).
An ultrasound revealed a normal fetal intrauterine pregnancy but
detected a heterogeneous solid mass mimicking a subserous myoma
originated from uterus, with regular echogenic margin and a tex-
ture, 11.3×9.4×6.8 cm in size, just the back of the cervix, without
ascites (Figure 1A). The blood flow signals were seen in the mass.
The image was so similar to that of a subserosal myoma that the
authors did not perform further imaging studies such as CT or MRI.
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Summary
Krukenberg tumor with pregnancy is rare but it is a challenge for treatment and diagnosis. The authors report a case of a 29-week preg-
nant patient with a massive bilateral Krukenberg tumor which was misdiagnosed as myoma preoperatively and as ovarian stromal tumor
intraoperatively. Prenatally the woman was asymptomatic except for preeclamptic symptoms, but red acne on the skin and elevated
testosterone were observed. Pelvic ultrasound detected a heterogeneous solid mass mimicking a subserous myoma. The deterioration
of preeclampsia prompted a cesarean section, but the neonate died nine days after he was born. A bilateral adnexal mass was found and
considered as stromal tumor by frozen section because of luteinization of the stroma. The final pathology showed low differentiation
adenocarcinoma of ovary, which was confirmed by gastric biopsies. The patient had undergone chemotherapy 16 times without surgi-
cal debulking and she was in generally well 1.5-year follow-up.
Key words: Ovary; Krukenberg tumor; Pregnancy; Virilization; Subserous myoma.
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The patient with preeclampsia was stabilized with magnesium
sulfate and anti-hypertensive therapy, monitoring for maternal and
fetal well-being. One week later, the patient experienced abdomi-
nal distension and blood pressure increased to 180/128 mm/Hg, and
ultrasound showed ascites about 2,000 ml and lactate dehydroge-
nase (LDH) was up to 407 U/L (normal range: 40-250 U/L). Urine
analysis revealed quantitative 24-hour urine collection for protein
to be 12.56 grams.The deterioration of preeclampsia prompted the
decision of termination of pregnancy.
Cesarean section was conducted under spinal anesthesia and one
1,100-gram male fetus was born with Apgar scores 9 and 9 at one
and five minutes and was then admitted to the neonatal intensive care
unit. There were no neonatal apparent anomalies but the neonate de-
veloped respiratory distress syndrome that was treated with surfac-
tant. However, his situation was getting worse and at last family gave
up the treatment, and nine days after he was born, the newborn died.
After the closure of the uterus during operation, the patient was found
to have a bilateral adnexal mass measuring 12 cm in its greatest di-
ameter of the right ovary and 5 cm for the left (Figure 1B). The right
ovary biopsy was processed for frozen section investigation, which
was considered sclerosis stromal tumor (Figure 2A). Frozen section
for the left ovary biopsy was also subsequently considered a stromal
tumor. Palpation of the upper abdomen showed macroscopically nor-
mal liver, spleen, peritoneum, omentum, small and large intestines,
but the greater curvature of the stomach was found to be a bit stiff,
which suggested a primary gastric cancer. Although the gynecologist
doubted a Krukenberg tumor during exploration, intraoperative
pathological examination indicated there was no lesion for malig-
nancy. Therefore the authors decided neither to remove the ovaries
and nor to enlarge the operation, and the next suggested therapy was
to be given after the final pathologic result and gastric examination.
The final pathology showed low differentiation adenocarcinoma
of bilateral ovary, which was confirmed with numerous mucin-filled
signet-ring cells and several intestinal-type glands, and indicated a
possible metastasis from a gastric origin (Figure 2B). This was fur-
ther supported by the immunochemistry results. The tumor was im-
Figure 1 — A) Ultrasound show-
ing a heterogeneous solid mass
mimicking a subserous myoma,
measuring 11.3×9.4×6.8 cm. B)
During cesarean section, pres-
ence of a bilateral adnexal
masses measures 12 cm in its
greatest diameter in the right
ovary, and 5 cm in the left.
Figure 2 — A) Intraoperative
frozen section of the ovary
biopsy showing small groups of
signet-ring cells scattered in the
stroma, which is remarkably
luteinized and misdiagnosed as a
sclerosis stromal tumor (H&E,
×400). B) Paraffin section of the
ovary (final pathology) showing
the tumor tissue composed of nu-
merous mucin-filled signet-ring
cells and several intestinal-type
glands. (H&E, ×400).
Figure 3 — A) Esophagogastro-
duodenoscopy showing mucosal
fold thickening on the non-peri-
staltic stomach wall along the
greater curvature. B) Gastric
biopsy shows a poorly differen-
tiated adenocarcinoma in the
lamina propria of stomach. The
tumor is characterized by signet-
ring cells, tubular glands, and
solid tubules (H&E, ×400).
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munoreactive to CK7 and CK20, which suggested a gastro- pancre-
atobiliary origin. Based on the intraoperative exams, an esopha-
gogastroduodenoscopy was performed, which revealed patchy areas
of erythema and mucosal fold thickening on the non-peristaltic stom-
ach wall along the greater curvature (Figure 3A). Multiple biopsies
were obtained that showed the presence of a poorly differentiated
adenocarcinoma in the lamina propria of stomach (Figure 3B).
Ten postoperative days later, the patient was discharged from the
hospital after recovery of the preeclampsia. Since she was diag-
nosed as having Stage IV gastric cancer, palliative chemotherapy
was scheduled. Then the patient had undergone chemotherapy 16
cycles without surgical debulking and she was generally well when
the authors had performed a 1.5-year follow-up.
Discussion
Generally, a Krukenberg tumor is usually considered as an
advanced presentation of gastric cancer, although less than
one-third of the primary sites were appendix, colon, breast,
small intestine, rectum, gallbladder, and urinary bladder [4].
The special tumor has different clinical manifestations and
the patients usually present with symptoms related to ovar-
ian involvement such as abdominal pain and distention [4].
However, the remainders of patients present with non-spe-
cific gastrointestinal complaints or are asymptomatic.
Kiyokawa et al. performed an analysis of 120 Krukenberg
tumors and found that the dominated clinical presentation
was usually abdominal swelling or pain, while 17 patients
had abnormal vaginal bleeding. Ascites was present in 43%
of the cases. Sixty-three percent of the tumors were docu-
mented to be bilateral [5]. However, during pregnancy the
diagnosis of Krukenberg tumor poses a challenge because of
its extremely rare incidence [1, 6-10]. Moreover, gastric can-
cer often presents with some symptoms such as nausea and
vomiting, which are common experiences during pregnancy,
affecting most of pregnant women. The abdominal pain and
distention can be explained by pregnancy, ovarian masses,
and ascites. So pregnancy easily masks the symptoms of re-
currence and delays the diagnosis and treatment. In this case,
the main presentation was typical preeclampsia symptoms
such as high blood pressure, edema, proteinuria, and dizzi-
ness. Another important reason why the authors did not di-
agnose gastric cancer earlier was because she had no known
risk factors for gastrointrstinal malignancies. She was just a
26-year-old and had no known H. pylori infection and non-
smoker status. Furthermore, she was largely asymptomatic of
features suggesting upper gastrointestinal malignancy. 
Ultrasonography and MRI are essential in the workup for
imaging of adnexal masses during pregnancy. Certain sono-
graphic findings can indicate a Krukenberg tumor. Usually
abdominal and pelvic ultrasonography and MRI reveal bilat-
eral and solid ovarian masses, but cystic masses can also
occur. In pregnancy, the echo structure of Krukenberg tumor
was homogeneously hyperechoic and abundant vasculariza-
tion and a main vessel with a tree-shaped structure on the color
Doppler examination was observed [11]. However, it may be
confused with other adnexal masses, such as teratomas and
corpus luteum cysts, which are more common during preg-
nancy. At times, ovarian neoplasm should be identified with
a subserosal uterine myoma with pedicle [12], because the
sonographic texture of the myoma has a solid mass and reg-
ular echogenic margin. In the present case, despite undergo-
ing multiple ultrasound scans, no pelvic abnormalities and
adnexal masses had been detected until the third trimester of
pregnancy. Perhaps the reason was the mask of enlargement
of the uterus with pregnancy. Unfortunately, the ovarian tumor
was misdiagnosed as subserous myoma, which allowed cli-
nicians to ignore the further examination of the mass. 
To predict ovarian cancer during pregnancy, the role of
tumor markers remains controversial. Firstly, it is infrequent
that pregnancy associated pelvic masses are malignant. Sec-
ondly, with gestational age the interpretation of these tumor
markers should vary. Several of the tumor markers used to
diagnose ovarian cancers are difficult to interpret during
pregnancy, because oncofetal antigens are often involved in
biological functions associated with fetal development, dif-
ferentiation, and maturation [13]. So the authors thought mild
increase of CA 125 and AFP in this case had low sensitivity
and specificity for ovarian tumor. Interestingly, the patient
presented some signs of virilization after she was pregnant.
Those virilizing symptoms during pregnancy could be eas-
ily attributed to an androgen secreting pregnancy luteoma or
endocrine diseases such as adrenal hyperplasia. However,
many cases of virilization and hirsutism of mother in asso-
ciation with Krukenberg tumors during pregnancy have been
reported in literature [5, 7, 9, 14], although it is still unclear
why some Krukenberg ovarian tumors lead to androgen
overproduction as presented in this case. The present patient
was a rare case, but the authors did not recognize that the
sign of virilization was presentation of ovarian metastatic
tumor. Therefore, it should be emphasized that an important
manifestation of the Krukenberg tumor with pregnancy is
virilization by the hormone production, although only a small
percentage of patients have endocrine manifestations.
Krukenberg tumors are sometimes misdiagnosed as Sertoli
cell or Sertoli-Leydig cell tumors by the submitting pathol-
ogist, particularly when a prominent tubular component and
luteinization of the stroma, sometimes accompanied by vir-
ilization, are encountered [5]. In this case, the tumor was re-
garded as ovarian stromal neoplasm through rapid frozen
pathologic examination. The reason of misdiagnosis was due
to a large number of luteinized stromal cells which could se-
cret hormones including testosterone in the ovary (Figure
2A). Histologically, Krukenberg tumor often consist of
mucus-producing glandular structures, small solid nests, and
numerous signet-ring cells surrounded by partly luteinized
ovarian stroma [15]. However, Sertoli and Sertoli-Leydig
cell tumors are rarely bilateral, and although large empty
rounded lipid vacuoles may be present, particularly in Sertoli
cells, signet-ring cells containing mucin are not encountered
[5]. The present patient with virilization revealed a stromal
luteinization, and androgenizing hormone production re-
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sulted from development of luteinized stroma in Krukenberg
tumors. Elevated serum levels of hCG are thought to be the
cause of the stromal luteinization of tumors during preg-
nancy, and the hCG dependence of virilizing Krukenberg tu-
mors during pregnancy has been documented by both in vitro
and in vivo hormonal studies [5].
An important factor that affects fetal survival is metastatic
potential of the cancer of fetus [16]. Placental metastasis is
a high risk factor for fetal metastasis. In order to avoid neona-
tal adverse outcomes, pathologic examination of the placenta
is needed and the newborns should be followed up closely
once placental metastasis is found [17]. In the present case,
the placental tissue was not made a pathologic examination,
so the authors still do not know whether the neonatal death
was due to fetal metastasis.
Because of the rarity of Krukenberg tumor with pregnancy,
there is insufficient information in the literature regarding
guidance for appropriate treatment and management. Multi-
disciplinary team approach is absolutely the way to manag-
ing such a rare and difficult disease, including preoperative
and intraoperative diagnosis and treatment. It was suggested
that following a diagnosis of malignancy in pregnancy, the
patient should be promptly transferred to a regional cancer
facility that was equipped with a linked obstetrics and neona-
tal unit [6]. In spite of this, the overall prognosis of Kruken-
berg tumor is often poor if the primary tumor is found after
metastasis to the ovaries, and even worse, if the primary
tumor remains undetected [4, 8]. Jaspers et al. reported that
the three-year survival rate was 8%, although this had less of
an impact on fetal survival [18]. Outside of pregnancy,
Krukenberg tumors had a median survival of 14 months [4].
However, possible early detection with debulking surgery,
and aggressive targeted chemotherapy might improve the
survival of these patients [19]. Fortunately, the patient in the
present case was still alive after 16 months and she was
treated with more than 16 cycles of chemotherapy.
Conclusion
Krukenberg tumor is rare during pregnancy and the patient
may present with non-specific gastrointestinal complaints or
are asymptomatic. Virilization by the hormone production
perhaps is an important manifestation of the tumor with preg-
nancy. The physicians should be suspicious of the presence
of such tumor in young pregnant women with enlarged
ovaries and virilization.
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